Methods of using interleukin-3 (IL-3) mutant polypeptides for ex-vivo expansion of hematopoietic stem cells
Granted 12 Nov 2002 · 2 office actions
Current assignee: Pharmacia Corporation · originally Pfizer
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Joseph Polazzi, Maire Helena Caparon, Kumnan Paik, John Patrick McKearn +7 · Examiner: Gary L. Kunz · AU 1647 · TC 1600
Life of the application
11 dated eventsAbstract
The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at both the N- and C-termini. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins and methods for using them. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems. Included in the present invention are deletion mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus, and from 1 to 15 amino acids (a.a.119 to 133) have been deleted from the C-terminus, and which also contain amino acid substitutions in the polypeptide. These hIL-3 multiple mutation polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile.
Description
100 parts›This application is a continuation of U.S. application…
This application is a continuation of U.S. application Ser. No. 08/411,796, filed Apr. 6, 1995, now U.S. Pat. No. 5,677,149; which entered the U.S. national stage under 35 USC §371 from PCT/US93/11198, filed Nov. 22, 1993; which is a continuation-in-part of U.S. application Ser. No. 07/981,044, filed Nov. 24, 1992, now abandoned.
This is a continuation-in-part of U.S. application Ser. No. 07/981,044 filed Nov. 24, 1992 which is incorporated herein by reference.
›FIELD OF THE INVENTION
The present invention relates to mutants or variants of human interleukin-3 (hIL-3) which contain one or more amino acid substitutions and which may have portions of the native hIL-3 molecule deleted. These hIL-3 single and multiple mutation polypeptides retain one or more activities of native hIL-3 and may also show improved hematopoietic cell-stimulating activity and/or an improved activity profile which may include reduction of undesirable biological activities associated with native hIL-3.
›BACKGROUND OF THE INVENTION · 1 of 2
Colony stimulating factors (CSFs) which stimulate the differentiation and/or proliferation of bone marrow cells have generated much interest because of their therapeutic potential for restoring depressed levels of hematopoietic stem cell-derived cells. CSFs in both human and murine systems have been identified and distinguished according to their activities. For example, granulocyte-CSF (G-CSF) and macrophage-CSF (M-CSF) stimulate the in vitro formation of neutrophilic granulocyte and macrophage colonies, respectively while GM-CSF and interleukin-3 (IL-3) have broader activities and stimulate the formation of both macrophage, neutrophilic and eosinophilic granulocyte colonies. IL-3 also stimulates the formation of mast, megakaryocyte and pure and mixed erythroid colonies.
Because of its ability to stimulate the proliferation of a number of different cell types and to support the growth and proliferation of progenitor cells, IL-3 has potential for therapeutic use in restoring hematopoietic cells to normal amounts in those cases where the number of cells has been reduced due to diseases or to therapeutic treatments such as radiation and chemotherapy.
Interleukin-3 (IL-3) is a hematopoietic growth factor which has the property of being able to promote the survival, growth and differentiation of hematopoietic cells. Among the biological properties of IL-3 are the ability (a) to support the growth and differentiation of progenitor cells committed to all, or virtually all, blood cell lineages; (b) to interact with early multipotential stem cells; (c) to sustain the growth of pluripotent precursor cells; (d) to stimulate proliferation of chronic myelogenous leukemia (CML) cells; (e) to stimulate proliferation of mast cells, eosinophils and basophils; (f) to stimulate DNA synthesis by human acute myelogenous leukemia (AML) cells; (g) to prime cells for production of leukotrienes and histamines; (h) to induce leukocyte chemotaxis; and (i) to induce cell surface molecules needed for leukocyte adhesion.
Mature human interleukin-3 (hIL-3) consists of 133 amino acids. It has one disulfide bridge and two potential glycosylation sites (Yang, et al., CELL 47:3 (1986)).
Murine IL-3 (mIL-3) was first identified by Ihle, et al., J. IMMUNOL. 126:2184 (1981) as a factor which induced expression of a T cell associated enzyme, 20-hydroxysteroid dehydrogenase. The factor was purified to homogeneity and shown to regulate the growth and differentiation of numerous subclasses of early hematopoietic and lymphoid progenitor cells.
In 1984, cDNA clones coding for murine IL-3 were isolated (Fung, et al., NATURE 307:233 (1984) and Yokota, et al., PROC. NATL. ACAD. SCI. USA 81:1070 (1984)). The murine DNA sequence coded for a polypeptide of 166 amino acids including a putative signal peptide.
The gibbon IL-3 sequence was obtained using a gibbon cDNA expression library. The gibbon IL-3 sequence was then used as a probe against a human genomic library to obtain a human IL-3 sequence.
Gibbon and human genomic DNA homologues of the murine IL-3 sequence were disclosed by Yang, et al., CELL 47:3 (1986). The human sequence reported by Yang, et al. included a serine residue at position 8 of the mature protein sequence. Following this finding, others reported isolation of Pro 8 hIL-3 cDNAs having proline at position 8 of the protein sequence. Thus it appears that there may be two allelic forms of hIL-3.
Dorssers, et al., GENE 55:115 (1987), found a clone from a human cDNA library which hybridized with mIL-3. This hybridization was the result of the high degree of homology between the 3′ noncoding regions of mIL-3 and hIL-3. This cDNA coded for an hIL-3 (Pro 8 ) sequence.
U.S. Pat. Nos. 4,877,729 and 4,959,455 disclose human IL-3 and gibbon IL-3 cDNAs and the protein sequences for which they code. The hIL-3 disclosed has serine rather than proline at position 8 in the protein sequence.
Clark-Lewis, et al., SCIENCE 231:134 (1986) performed a functional analysis of murine IL-3 analogues synthesized with an automated peptide synthesizer. The authors concluded that the stable tertiary structure of the complete molecule was required for full activity. A study on the role of the disulfide bridges showed that replacement of all four cysteines by alanine gave a molecule with {fraction (1/5000)}th the activity as the native molecule. Replacement of two of the four Cys residues by Ala(Cys 79 , Cys 140 →Ala 79 , Ala 140 ) resulted in an increased activity. The authors concluded that in murine IL-3 a single disulfide bridge is required between cysteines 17 and 80 to get biological activity that approximates physiological levels and that this structure probably stabilizes the tertiary structure of the protein to give a conformation that is optimal for function. (Clark-Lewis, et al., PROC. NATL. ACAD. SCI. USA 85:7897 (1988)).
International Patent Application (PCT) WO 89/00598 discloses gibbon- and human-like IL-3. The hIL-3 contains a Ser 8 →Pro 8 replacement. Suggestions are made to replace Cys by Ser, thereby breaking the disulfide bridge, and to replace one or more amino acids at the glycosylation sites.
EP-A-0275598 (WO 88/04691) illustrates that Ala 1 can be deleted while retaining biological activity. Some mutant hIL-3 sequences are provided, e.g., two double mutants, Ala 1 →Asp 1 , Trp 13 →Arg 13 (pGB/IL-302) and Ala 1 →Asp 1 , Met 3 →Thr 3 (pGB/IL-304) and one triple mutant Ala 1 →Asp 1 , Leu 9 →Pro 9 , Trp 13 →Arg 13 (pGB/IL-303).
WO 88/05469 describes how deglycosylation mutants can be obtained and suggests mutants of Arg 54 Arg 55 and Arg 108 Arg 109 Lys 10 might avoid proteolysis upon expression in Saccharomyces cerevisiae by KEX2 protease. No mutated proteins are disclosed. Glycosylation and the KEX2 protease activity are only important, in this context, upon expression in yeast.
WO 88/06161 mentions various mutants which theoretically may be conformationally and antigenically neutral. The only actually performed mutations are Met 2 →Ile 2 and Ile 131 →Leu 131 . It is not disclosed whether the contemplated neutralities were obtained for these two mutations.
›BACKGROUND OF THE INVENTION · 2 of 2
WO 91/00350 discloses nonglycosylated hIL-3 analog proteins, for example, hIL-3 (Pro 8 Asp 15 Asp 70 ), Met 3 rhul-3 (Pro 8 Asp 15 Asp 70 ); Thr 4 rhuL-3 (Pro 8 Asp 15 Asp 70 ) and Thr 6 rhuIL-3 (Pro 8 Asp 15 Asp 70 ). It is said that these protein compositions do not exhibit certain adverse side effects associated with native hIL-3 such as urticaria resulting from infiltration of mast cells and lymphocytes into the dermis. The disclosed analog hIL-3 proteins may have N termini at Met 3 , Thr 4 , or Thr 6 .
WO 90/12874 discloses cysteine added variants (CAVs) of IL-3 which have at least one Cys residue substituted for a naturally occurring amino acid residue.
›SUMMARY OF THE INVENTION
The present invention relates to recombinant human interleukin-3 (hIL-3) variant or mutant proteins (muteins). These hIL-3 muteins contain amino acid substitutions and may also have amino acid deletions at either/or both the N- and C-termini. Preferably, these mutant polypeptides of the present invention contain one to three amino acids which differ from the amino acids found at the corresponding positions in the native hIL-3 polypeptide. The invention also relates to pharmaceutical compositions containing the hIL-3 muteins, DNA coding for the muteins, and methods for using the muteins. Additionally, the present invention relates to recombinant expression vectors comprising nucleotide sequences encoding the hIL-3 muteins, related microbial expression systems, and processes for making the hIL-3 muteins using the microbial expression systems.
The present invention includes mutants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus and/or from 1 to 15 amino acids have been deleted from the C-terminus, and in which from one to three amino acid substitutions have been made. Preferred muteins of the present invention are those in which amino acids 1 to 14 have been deleted from the N-terminus, or amino acids 126 to 133 have been deleted from the C-terminus, and which both also contain from one to three amino acid substitutions in the polypeptide sequence. These hIL-3 multiple mutation polypeptides may have biological activities similar to or better than hIL-3 and, in some cases, may also have an improved side effect profile, i.e., some muteins may have a better therapeutic index than native hIL-3. The present invention also provides muteins which may function as IL-3 antagonists or as discrete antigenic fragments for the production of antibodies useful in immunoassay and immunotherapy protocols. In addition to the use of the hIL-3 mutant polypeptides of the present invention in vivo, it is envisioned that in vitro uses would include the ability to stimulate bone marrow and blood cell activation and growth before infusion into patients.
Antagonists of hIL-3 would be particularly useful in blocking the growth of certain cancer cells like AML, CML and certain types of B lymphoid cancers. Other conditions where antagonists would be useful include those in which certain blood cells are produced at abnormally high numbers or are being activated by endogenous ligands. Antagonists would effectively compete for ligands, presumably naturally occurring hemopoietins including and not limited to IL-3, GM-CSF and IL-5, which might trigger or augment the growth of cancer cells by virtue of their ability to bind to the IL-3 receptor complex while intrinsic activation properties of the ligand are diminished. IL-3, GM-CSF and or IL-5 also play a role in certain asthmatic responses. An antagonist of the IL-3 receptor may have utility in this disease by blocking receptor-mediated activation and recruitment of inflammatory cells.
›BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is the human IL-3 gene for E. coli expression (pMON5873), encoding the polypeptide sequence of natural (wild type) human IL-3 [SEQ ID NO:128], plus an initiator methionine, as expressed in E. coli , with the amino acids numbered from the N-terminus of the natural hIL-3.
FIG. 2 : ClaI to NsiI Replacement Fragment. FIG. 2 shows the nucleotide sequence of the replacement fragment used between the ClaI and NsiI sites of the hIL-3 gene. The codon choice used in the fragment corresponds to that found in highly expressed E. coli genes (Gouy and Gautier, 1982). Three new unique restriction sites, EcoRV, XhoI and PstI were introduced for the purpose of inserting synthetic gene fragments. The portion of the coding sequence shown encodes hIL-3 amino acids 20-70.
FIGS. 3A and 3B shows the nucleotide and amino acid sequence of the gene in pMON5873 with the sequence extending from NcoI through HindIII. The codon choices used to encode amino acids 1-14 and 107-133 correspond to that found in highly expressed E. coli genes.
FIG. 4 shows the construction of the plasmid vector pMON5846 which encodes [Met-(1-133) hIL-3 (Arg 129 )].
FIG. 5 shows the construction of the plasmid vector pMON5847 (ATCC 68912) which encodes [Met-(1-133) hIL-3 (Arg 129 )].
FIG. 6 shows the construction of plasmid vector pMON5853 which encodes [Met-(15-133) hIL-3 (Arg 129 )].
FIG. 7 shows the construction of the plasmid vector pMON5854 which encodes [Met-(1-133) hIL-3 (Arg 129 )].
FIG. 8 shows the DNA sequence and resulting amino acid sequence of the lamB signal peptide.
FIG. 9 shows the construction of the plasmid vector pMON5978 which encodes Met-Ala-(15-125) hIL-3.
FIG. 10 shows the construction of the plasmid vector pMON5988 which encodes Met-Ala(15-125) hIL-3.
FIG. 11 shows the construction of the plasmid vector pMON5887 which encodes Met-(1-125) hIL-3.
FIG. 12 shows the construction of pMON6457 which encodes (15-125) hIL-3; it contains the araBAD promoter and the lamB signal peptide fused to the variant hIL-3 amino acids 15-125.
FIG. 13 shows the construction of pMON6458; it contains the araBAD promoter and the lamb signal peptide fused to the variant hIL-3 amino acids 15-125.
FIG. 14 shows the construction of pMON6467 in which the bases encoding amino acids 35-40 of hIL-3 were deleted using site-directed PCR mutagenesis methods. pMON6467 was used as the template for the generation of single amino acid variants at positions 35-40 of hIL-3.
FIG. 15 shows the construction of single amino acid substitutions at position 35 of hIL-3 using site-directed PCR mutagenesis methods. The mutagenesis results in 20 different single amino substitutions, which is referred to as a “library”, at position 35 of hIL-3.
›DETAILED DESCRIPTION OF THE INVENTION · 1 of 20
The present invention relates to muteins of human interleukin-3 (hIL-3) in which amino acid substitutions have been made at from one to three positions in the amino acid sequence of the polypeptide and to hIL-3 muteins which have substantially the same structure and substantially the same biological activity. Preferred muteins of the present invention are (15-125) hIL-3 deletion mutants which have deletions of amino acids 1 to 14 at the N-terminus and/or 126 to 133 at the C-terminus and which both also have from one to three amino acid substitutions in the polypeptide and muteins having substantially the same structure and substantially the same biological activity. As used herein human interleukin-3 corresponds to the amino acid sequence (1-133) as depicted in FIG. 1 and (15-125) hIL-3 Corresponds to the 15 to 125 amino acid sequence of the hIL-3 polypeptide. Naturally occurring variants of hIL-3 polypeptide amino acids are also included in the present invention (for example, the allele in which proline rather than serine is at position 8 in the hIL-3 polypeptide sequence) as are variant hIL-3 molecules which are modified post-translationally (e.g. glycosylation).
The present invention also includes the DNA sequences which code for the mutant polypeptides, DNA sequences which are substantially similar and perform substantially the same function, and DNA sequences which differ from the DNAs encoding the muteins of the invention only due to the degeneracy of the genetic code.
Included in the present invention are novel mutant human interleukin-3 polypeptides comprising a polypeptide having the amino acid sequence of native human interleukin-3 wherein amino acids 126 to 133 have been deleted from the C-terminus of the native human interleukin-3 polypeptide and amino acids 1 to 14 have been deleted from the N-terminus of the native human interleukin-3 polypeptide and, in addition, polypeptides of the present invention also have one to three amino acid substitutions in the polypeptide sequence. The muteins of the present invention can have from one to three amino acid substitutions in the hIL-3 polypeptide chain and, in addition, can have deletions of amino acids at the N-terminus and/or the C-terminus.
Also included in the present invention are the DNA sequences coding for the muteins of the present invention; the oligonucleotide intermediates used to construct the mutant DNAs; and the polypeptides coded for by these oligonucleotides. These polypeptides may be useful as antagonists or as antigenic fragments for the production of antibodies useful in immunoassay and immunotherapy protocols.
The mutant hIL-3 polypeptides of the present invention may also have methionine, alanine, or methionine-alanine residues inserted at the N-terminus.
The present invention includes hIL-3 mutant polypeptides of the formula I:
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
[SEQ ID NO:15]
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
80 85 90
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
95 100 105
Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
110 115 120
Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe
125 130
wherein
Xaa at position 17 is Ser, Lys, Gly, Asp, Met, Gln, or Arg:
Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 19 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;
Xaa at position 20 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
Xaa at position 21 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;
Xaa at position 22 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val or Gly;
Xaa at position 23 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Ser, or Arg;
Xaa at position 24 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Thr, Phe, Gly, Arg, Ala, or Trp;
Xaa at position 27 is Leu, Gly, Arg, Thr, Ser, or Ala;
Xaa at position 28 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;
Xaa at position 29 is Gln, Asn, Leu, Pro, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro, Leu, Gln, Ala, Thr, or Glu:
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;
Xaa at position 35 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;
Xaa at position 36 is Asp, Leu, or Val;
Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 38 is Asn, or Ala;
Xaa at position 40 is Leu, Trp, or Arg;
Xaa at position 41 is Asn, Cys, Arg, Leu, His, Met, or Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, Ile, Met or Ala;
Xaa at position 43 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;
Xaa at position 44 is Asp, Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala or Pro;
Xaa at position 45 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, Ser, Ala, Ile, Glu or His;
Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;
Xaa at position 47 is Ile, Gly, Val, Ser, Arg, Pro, or His;
Xaa at position 48 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;
Xaa at position 49 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;
Xaa at position 50 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;
›DETAILED DESCRIPTION OF THE INVENTION · 2 of 20
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 52 is Asn, His, Arg, Leu, Gly, Ser, or Thr;
Xaa at position 53 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met;
Xaa at position 54 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His , Ala or Leu;
Xaa at position 55 is Arg, Thr, Val, Ser, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;
Xaa at position 57 is Asn or Gly;
Xaa at position 58 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;
Xaa at position 59 is Glu Tyr, His, Leu, Pro, or Arg;
Xaa at position 60 is Ala, Ser, Pro, Tyr, Asn, or Thr;
Xaa at position 61 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;
Xaa at position 62 is Asn His, Val, Arg, Pro, Thr, Asp, or Ile;
Xaa at position 63 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;
Xaa at position 64 is Ala, Asn, Pro, Ser, or Lys;
Xaa at position 65 is Val, Thr, Pro, His, Leu, Phe, or Ser;
Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 67 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;
Xaa at position 68 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;
Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;
Xaa at position 70 is Asn, Leu, Val, Trp, Pro, or Ala;
Xaa at position 71 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;
Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;
Xaa at position 74 is Ile, Met, Thr, Pro, Arg, Gly, Ala;
Xaa at position 75 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu:
Xaa at position 76 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;
Xaa at position 77 is Ile, Ser, Arg, Thr, or Leu;
Xaa at position 78 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;
Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;
Xaa at position 80 is Agn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;
Xaa at position 81 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;
Xaa at position 82 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;
Xaa at position 83 is Pro, Ala, Thr, Trp, Arg, or Met;
Xaa at position 84 is Cys, Glu, Gly, Arg, Met, or Val;
Xaa at position 85 is Leu, Asn, Val, or Gln;
Xaa at position 86 is Pro, Cys, Arg, Ala, or Lys;
Xaa at position 87 is Leu, Ser, Trp, or Gly;
Xaa at position 88 is Ala, Lys, Arg, Val, or Trp;
Xaa at position 89 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;
Xaa at position 90 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;
Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;
Xaa at position 92 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;
Xaa at position 93 is Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;
Xaa at position 94 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro;
Xaa at position 95 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile, or Tyr;
Xaa at position 96 is Pro, Lys, Tyr, Gly, Ile, or Thr;
Xaa at position 97 is Ile, Val, Lys, Ala, or Asn;
Xaa at position 98 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;
Xaa at position 99 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;
Xaa at position 100 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro;
Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu, or Gln;
Xaa at position 102 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;
Xaa at position 103 is Asp, or Ser;
Xaa at position 104 is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;
Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 106 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;
Xaa at position 108 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala or Pro;
Xaa at position 109 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;
Xaa at position 110 is Lys, Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, or Trp;
Xaa at position 111 is Leu, Ile, Arg, Asp, or Met;
Xaa at position 112 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;
Xaa at position 113 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val or Asn;
Xaa at position 114 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;
Xaa at position 115 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;
Xaa at position 116 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;
Xaa at position 117 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;
Xaa at position 118 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;
Xaa at position 119 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;
Xaa at position 120 is Asn, Ala, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;
and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 with the proviso that when Xaa at position 22 is Leu, and/or Xaa at position 34 is Gly or Glu, and/or Xaa at position 44 is Ala, and/or Xda at position 46 is Lys or Ala, and/or Xaa at position 50 is Lys, and/or Xaa at position 59 is Pro or Arg, and/or Xaa at position 63 is Lys, and/or Xaa at position 75 is Gly or Arg, and/or Xaa at position 94 is Pro, and/or Xaa at position 98 is Arg, and/or Xaa at position 106 is Lys, and/or Xaa at position 110 is Ala or Glu, and/or Xaa at position 111 is Met, then there must be at least one additional substitution besides the ones indicated.
Included in the present invention are (1-133) hIL-3 mutant polypeptides of the Formula II:
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
(SEQ ID NO:16)
1 5 10 15
Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa
›DETAILED DESCRIPTION OF THE INVENTION · 3 of 20
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa
35 40 45
Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa
50 55 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75
Xaa Xaa Leu Xaa kaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa
80 85 90
Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa
95 100 105
Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa
110 115 120
Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe
125 130
wherein
Xaa at position 17 is Ser, Gly, Asp, Met, or Gln; Xaa at position 18 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 19 is Met, Phe, Ile, Arg, or Ala;
Xaa at position 20 is Ile or Pro;
Xaa at position 21 is Asp or Glu;
Xaa at position 21 is Ile, Val, Ala, Leu, or Gly;
Xaa at position 24 is Ile, Val, Phe, or Leu;
Xaa at position 25 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 26 is His, Phe, Gly, Arg, or Ala;
Xaa at position 28 is Lys, Leu, Gln, Gly, Pro, or Val;
Xaa at position 29 is Gln, Asn, Leu, Arg, or Val;
Xaa at position 30 is Pro, His, Thr, Gly, or Gln;
Xaa at position 31 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro, Leu, Gln, Ala, or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 36 is Asp or Leu;
Xaa at position 37 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 38 is Asn or Ala;
Xaa at position 41 is Asn, Cys, Arg, His, Met, or Pro;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, Val or Arg;
Xaa at position 44 is Asp or Glu;
Xaa at position 45 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn, Glu, Ser, or Trp;
Xaa at position 46 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Gly;
Xaa at position 47 is Ile, Val, or His;
Xaa at position 49 is Met, Asn, or Asp;
Xaa at position 50 is Glu, Thr, Ala, Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 52 is Asn or Gly;
Xaa at position 53 is Leu, Met, or Phe;
Xaa at position 54 is Arg, Ala, or Ser;
Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, Val or Lys;
Xaa at position 59 is Glu, Tyr, His, Leu, or Arg;
Xaa at position 60 is Ala, Ser, Asn, or Thr;
Xaa at position 61 is Phe or Ser;
Xaa at position 62 is Asn, Val, Pro, Thr, or Ile;
Xaa at position 63 is Arg, Tyr, Lys, Ser, His, or Val;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val, Thr, Leu, or Ser;
Xaa at position 66 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 67 is Ser, Phe, Val, Gly, Asn, Ile, or His:
Xaa at position 68 is Leu, Val, Ile, Phe, or His;
Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 70 is Asn or Pro;
Xaa at position 71 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;
Xaa at position 72 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
Xaa at position 73 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro;
Xaa at position 74 is Ile or Met;
Xaa at position 75 is Glu, Gly, Asp, Ser, or Gln;
Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or Asp;
Xaa at position 77 is Ile, Ser, or Leu;
Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;
Xaa at position 80 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;
Xaa at position 81 is Leu, or Val;
Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 83 is Pro, Ala, Thr, Trp, or Met;
Xaa at position 85 is Leu or Val;
Xaa at position 87 is Leu or Ser;
Xaa at position 88 is Ala, Arg, or Trp;
Xaa at position 89 is Thr, Asp, Glu, His, Asn, or Ser;
Xaa at position 90 is Ala, Asp, or Met;
Xaa at position 91 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;
Xaa at position 92 is Pro or Ser;
Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser or Thr;
Xaa at position 96 is Pro or Tyr;
Xaa at position 97 is Ile, Val, or Ala;
Xaa at position 98 is His, Ile, Asn, Asp, Ala, Thr, Leu, Arg, Gln, Glu, lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 99 is Ile, Leu, Val, or Phe;
Xaa at position 100 is Lys, Leu, His, Arg, Ile, Gln, Pro, or Ser;
Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu or Tyr;
Xaa at position 102 is Gly, Glu, Lys, or Ser;
Xaa at position 104 is Trp, Val, Tyr, Met, or Leu;
Xaa at position 105 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 106 is Glu, Ser, Ala, or Gly;
Xaa at position 108 is Arg, Ala, Gln, Ser or Lys;
Xaa at position 109 is Arg, Thr, Glu, Leu, Ser, or Gly;
Xaa at position 112 is Thr, Val, Gln, Glu, His, or Ser;
Xaa at position 114 is Tyr or Trp;
Xaa at position 115 is Leu or Ala;
Xaa at position 116 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;
Xaa at position 117 is Thr, Ser, or Asn;
Xaa at position 119 is Glu, Ser, Pro, Leu, Thr, or Tyr;
Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;
and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 with the proviso that when Xaa at position 34 is Gly or/and Xaa or position 46 is Lys or Ala or/and Xaa at position 59 is Arg and/or Xaa at position 63 is Lys and/or Xaa at position 75 is Gly and/or Xaa at position 98 is Arg then there must be at least one additional substitution besides the ones indicated.
›DETAILED DESCRIPTION OF THE INVENTION · 4 of 20
Included in the present invention are (1-133) hIL-3 mutant polypeptides of the Formula III:
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
(SEQ ID NO:17)
1 5 10 15
Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa
35 40 45
Xaa Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa
50 55 60
Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu
65 70 75
Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala
80 85 90
Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa
95 100 105
Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa
110 115 120
Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe
125 130
wherein
Xaa at position 17 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 18 is Asn, His, or Ile;
Xaa at position 19 is Met or Ile;
Xaa at position 21 is Asp or Glu;
Xaa at position 23 is Ile, Ala, Leu, or Gly;
Xaa at position 24 is Ile, Val, or Leu;
Xaa at position 25 is Thr, His, Gln, or Ala;
Xaa at position 26 is His or Ala;
Xaa at position 29 is Gln, Asn, or Val;
Xaa at position 30 is Pro, Gly, or Gln;
Xaa at position 31 is Pro, Asp, Gly, or Gln;
Xaa at position 32 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 33 is Pro or Glu;
Xaa at position 34 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 35 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 37 is Phe, Ser, Pro, or Trp;
Xaa at position 38 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 44 is Asp or Glu;
Xaa at position 45 is Gln, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys;
Xaa at position 46 is Asp, Phe, Ser, Thr, Ala, Asn Gln, Glu, His, Ile, Lys, Tyr, Val or Cys;
Xaa at position 50 is Glu, Ala, Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 54 is Arg or Ala;
Xaa at position 54 is Arg or Ala;
Xaa at position 55 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val or Lys;
Xaa at position 60 is Ala or Ser;
Xaa at position 62 is Asn, Pro, Thr, or Ile;
Xaa at position 63 is Arg or Lys;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val or Thr;
Xaa at position 66 is Lys or Arg;
Xaa at position 67 is Ser, Phe, or His;
Xaa at position 68 is Leu, Ile, Phe, or His;
Xaa at position 69 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 71 is Ala, Pro, or Arg;
Xaa at position 72 is Ser, Glu, Arg, oz Asp;
Xaa at position 73 is Ala or Leu;
Xaa at position 76 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;
Xaa at position 77 is Ile or Leu;
Xaa at position 79 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;
Xaa at position 80 is Asn, Gly, Glu, or Arg;
Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 83 is Pro or Thr;
Xaa at position 85 is Leu or Val;
Xaa at position 87 is Leu or Ser;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 95 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser or Thr;
Xaa at position 96 is Pro or Tyr;
Xaa at position 97 is Ile or Val;
Xaa at position 98 is His, Ile, Asn, Leu, Ala, Thr, Arg, Gln, Lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 99 is Ile, Leu, or Val;
Xaa at position 100 is Lys, Arg, Ile, Gln, Pro, or Ser;
Xaa at position 101 is Asp, Pro, Met, Lys, His, Thr, Pro, Asn, Ile, Leu or Tyr;
Xaa at position 104 is Trp or Leu;
Xaa at position 105 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 106 is Glu or Gly;
Xaa at position 108 is Arg, Ala, or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 112 is Thr, Val, or Gln;
Xaa at position 114 is Tyr or Trp;
Xaa at position 115 is Leu or Ala;
Xaa at position 116 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;
Xaa at position 122 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 123 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;
and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 with the proviso that when Xaa at position 22 is Leu, and/or Xaa at position 34 is Gly or Glu, and/or Xaa at position 44 is Ala, and/or Xaa at position 46 is Lys or Ala, and/or Xaa at position 50 is Lys, and/or Xaa at position 59 is Pro or Arg, and/or Xaa at position 63 is Lys, and/or Xaa at position 75 is Gly or Arg, and/or Xaa at position 94 is Pro, and/or Xaa at position 98 is Arg, and/or Xaa at position 106 is Lys, and/or Xaa at position 110 is Ala or Glu, and/or Xaa at position 111 is Met, then there must be at least one additional substitution besides the ones indicated. and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3 with the proviso that when Xaa at position 34 is Gly and/or Xaa at position 46 is Lys or Ala, and/or Xaa at position 63 is Lys, and/or Xaa at position 98 is Arg, then two or three of the amino acid designated by Xaa are different from the corresponding amino acids of the native (1-133) human interleukin-3.
›DETAILED DESCRIPTION OF THE INVENTION · 5 of 20
Included in the present invention are (1-133) hIL-3 mutant polypeptides of the Formula IV:
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
[SEQ ID NO:18]
1 5 10 15
Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa Xaa
20 25 30
Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa
35 40 45
Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala
50 55 60
Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu
65 70 75
Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala
80 85 90
Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa
95 100 105
Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa
110 115 120
Xaa Xaa Xaa Gln Gln Thr Thr Leu Ser Leu Ala Ile Phe
125 130
wherein
Xaa at position 17 is Ser, Gly, Asp, or Gln;
Xaa at position 18 is Asn, His, or Ile;
Xaa at position 23 is Ile, Ala, Leu, or Gly;
Xaa at position 25 is Thr, His, or Gln;
Xaa at position 26 is His or Ala;
Xaa at position 29 is Gln or Asn;
Xaa at position 30 is Pro or Gly;
Xaa at position 32 is Leu, Arg, Asn, or Ala;
Xaa at position 34 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr, or Met;
Xaa at position 35 is Leu, Ala, Asn, or Pro;
Xaa at position 29 is Asn or Ala;
Xaa at position 42 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 45 is Gln, Val, Met, Leu, Ala, Asn, Glu, or Lys;
Xaa at position 46 is Asp, Phe, Ser, Ala, Gln, Glu, His, Val or Thr;
Xaa at position 50 is Glu Asn, Ser or Asp;
Xaa at position 51 is Asn, Arg, Pro, Thr, or His;
Xaa at position 55 is Arg, Leu, or Gly;
Xaa at position 56 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;
Xaa at position 62 is Asn, Pro, or Thr;
Xaa at position 64 is Ala or Asn;
Xaa at position 65 is Val or Thr;
Xaa at position 67 is Ser or Phe;
Xaa at position 68 is Leu or Phe;
Xaa at position 69 is Gln, Ala, Glu, or Arg;
Xaa at position 76 is Ser, Val, Asn, Pro, or Gly;
Xaa at position 77 is Ile or Leu;
Xaa at position 79 is Lys, Asn, Met, Arg, Ile, or Gly;
Xaa at position 80 is Asn, Gly, Glu, or Arg;
Xaa at position 82 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 87 is Leu or Ser;
Xaa at position 88 is Ala or Trp;
Xaa at position 91 is Ala or Pro;
Xaa at position 93 is Thr, Asp, or Ala;
Xaa at position 95 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
Xaa at position 98 is His, Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Leu;
Xaa at position 99 is Ile or Leu;
Xaa at position 100 is Lys or Arg;
Xaa at position 101 is Asp, Pro, Met, Lys, Thr, His, Pro, Asn, Ile, Leu or Tyr;
Xaa at position 105 is Asn, Pro, Ser, Ile or Asp;
Xaa at position 108 is Arg, Ala, or Ser;
Xaa at position 109 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 112 is Thr or Gln;
Xaa at position 116 is Lys, Val, Trp, Ala, His, Phe, Tyr or Ile;
Xaa at position 117 is Thr or Ser;
Xaa at position 120 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 121 is Ala, Ser, Ile, Pro, or Asp;
Xaa at position 122 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;
Xaa at position 123 is Ala, Met, Glu, Ser, or Leu;
and which can additionally have Met- preceding the amino acid in position 1; and wherein from 1 to 14 amino acids can be deleted from the N-terminus and/or from 1 to 15 amino acids can be deleted from the C-terminus; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3.
Preferred polypeptides of the present invention are (15-125) hIL-3 mutant polypeptides of the Formula V:
Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
[SEQ ID NO:19]
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
80 85 90
Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
95 100 105
Xaa Xaa Xaa Xaa Gln Gln
110
wherein
wherein
Xaa at position 3 is Ser, Lys, Gly, Asp, Met, Gln, or Arg;
Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 5 is Met, Phe, Ile, Arg, Gly, Ala, or Cys;
Xaa at position 6 is Ile, Cys, Gln, Glu, Arg, Pro, or Ala;
Xaa at position 7 is Asp, Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser or Val;
Xaa at position 8 is Glu, Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val, or Gly;
Xaa at position 9 is Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Ser, or Arg;
Xaa at position 10 is Ile, Gly, Val, Arg, Ser, Phe, or Leu;
Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 12 is His, Thr, Phe, Gly, Arg, Ala, or Trp;
Xaa at position 13 is Leu, Gly, Arg, Thr, Ser, or Ala;
Xaa at position 14 is Lys, Arg, Leu, Gln, Gly, Pro, Val or Trp;
Xaa at position 15 is Gln, Asn, Leu, Pro, Arg, or Val;
Xaa at position 16 is Pro, His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys;
Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 18 is Leu, Val, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro, Leu, Gln, Ala, Thr, or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, Ile or Met;
Xaa at position 21 is Leu, Ala, Gly, Asn, Pro, Gln, or Val;
Xaa at position 22 is Asp, Leu, or Val;
Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 24 is Asn, or Ala;
Xaa at position 26 is Leu, Trp, or Arg;
Xaa at position 27 is Asn, Cys, Arg, Leu, His, Met, Pro;
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Lys, Asn, Thr, Leu, Val, Glu, Phe, Tyr, Ile or Met;
›DETAILED DESCRIPTION OF THE INVENTION · 6 of 20
Xaa at position 29 is Glu, Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly or Ser;
Xaa at position 30 is Asp, Ser, Leu, Arg, Lys, Thr,Met, Trp, Glu, Asn, Gln, Ala or Pro;
Xaa at position 31 is Gln, Pro, Phe, Val, Met, Leu, Thr, Lys, Asp, Asn, Arg, Ser, Ala, Ile, Glu, His or Trp;
Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, Ile, Val or Gly;
Xaa at position 33 is Ile, Gly, Val, Ser, Arg, Pro, or His;
Xaa at position 34 is Leu, Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, Val or Asn;
Xaa at position 35 is Met, Arg, Ala, Gly, Pro, Asn, His, or Asp;
Xaa at position 36 is Glu, Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, Phe, Met or Gln;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 38 is Asn, His, Arg, Leu, Gly, Ser, or Thr;
Xaa at position 39 is Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, Met, or;
Xaa at position 40 is Arg, Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala or Leu;
Xaa at position 41 is Arg, Thr, Val, Ser, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, Phe, Leu, Val or Lys;
Xaa at position 43 is Asn or Gly;
Xaa at position 44 is Leu, Ser, Asp, Arg, Gln, Val, or Cys;
Xaa at position 45 is Glu Tyr, His, Leu, Pro, or Arg;
Xaa at position 46 is Ala, Ser, Pro, Tyr, Asn, or Thr;
Xaa at position 47 is Phe, Asn, Glu, Pro, Lys, Arg, or Ser;
Xaa at position 48 is Asn, His, Val, Arg, Pro, Thr, Asp, or Ile;
Xaa at position 49 is Arg, Tyr, Trp, Lys, Ser, His, Pro, or Val;
Xaa at position 50 is Ala, Asn, Pro, Ser, or Lys;
Xaa at position 51 is Val, Thr, Pro, His, Leu, Phe, or Ser;
Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 53 is Ser, Ala, Phe, Val, Gly, Asn, Ile, Pro, or His;
Xaa at position 54 is Leu, Val, Trp, Ser, Ile, Phe, Thr, or His;
Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu;
Xaa at position 56 is Asn, Leu, Val, Trp, Pro, or Ala;
Xaa at position 57 is Ala, Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn;
Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, or Arg;
Xaa at position 60 is Ile, Met, Thr, Pro, Arg, Gly, Ala;
Xaa at position 61 is Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, or Leu;
Xaa at position 62 is Ser, Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp;
Xaa at position 63 is Ile, Ser, Arg, Thr, or Leu;
Xaa at position 64 is Leu, Ala, Ser, Glu, Phe, Gly, or Arg;
Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;
Xaa at position 66 is Asn, Trp, Val, Gly, Thr, Leu, Glu, or Arg;
Xaa at position 67 is Leu, Gln, Gly, Ala, Trp, Arg, Val, or Lys;
Xaa at position 68 is Leu, Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, Tyr, Phe, Ile, Met or Val;
Xaa at position 69 is Pro, Ala, Thr, Trp, Arg, or Met;
Xaa at position 70 is Cys, Glu, Gly, Arg, Met, or Val;
Xaa at position 71 is Leu, Asn, Val, or Gln;
Xaa at position 72 is Pro, Cys, Arg, Ala, or Lys;
Xaa at position 73 is Leu, Ser, Trp, or Gly;
Xaa at position 74 is Ala, Lys, Arg, Val, or Trp;
Xaa at position 75 is Thr, Asp, Cys, Leu, Val, Glu, His, Asn, or Ser;
Xaa at position 76 is Ala, Pro, Ser, Thr, Gly, Asp, Ile, or Met;
Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, Asp, or His;
Xaa at position 78 is Pro, Phe, Arg, Ser, Lys, His, Ala, Gly, Ile or Leu;
Xaa at position 79 iS Thr, Asp, Ser, Asn, Pro, Ala, Leu, or Arg;
Xaa at position 80 is Arg, Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala or Pro;
Xaa at position 81 is His, Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, Trp, Phe, Ile or Tyr;
Xaa at position 82 is Pro, Lys, Tyr, Gly, Ile, or Thr:
Xaa at position 83 is Ile, Val, Lys, Ala, or Asn;
Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, Val, Lys, Arg, Tyr or Pro;
Xaa at position 85 is Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, or His;
Xaa at position 86 is Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, Pro;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, Ala, Gly, Ile, Leu or Gln;
Xaa at position 88 is Gly, Leu, Glu, Lys, Ser, Tyr, or Pro;
Xaa at position 89 is Asp, or Ser;
Xaa at position 90 Is Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, Phe, or Gly;
Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 92 is Glu, Ser, Ala, Lys, Thr, Ile, Gly, or Pro;
Xaa at position 94 is Arg, Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro;
Xaa at position 95 is Arg, Thr, Pro, Glu, Tyr, Leu, Ser, or Gly;
Xaa at position 96 is Lys, Asn, Thr, Leu, Gln, Arg, His, Glu, Ser, Ala or Trp;
Xaa at position 97 is Leu, Ile, Arg, Asp, or Met;
Xaa at position 98 is Thr, Val, Gln, Tyr, Glu, His, Ser, or Phe;
Xaa at position 99 is Phe, Ser, Cys, His, Gly, Trp, Tyr, Asp, Lsy, Leu, Ile, Val or Asn;
Xaa at position 100 is Tyr, Cys, His, Ser, Trp, Arg, or Leu;
Xaa at position 101 is Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met;
Xaa at position 102 is Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile;
Xaa at position 103 is Thr, Ser, Asn, Ile, Trp, Lys, or Pro;
Xaa at position 104 is Leu, Ser, Pro, Ala, Glu, Cys, Asp, or Tyr;
Xaa at position 105 is Glu, Ser, Lys, Pro, Leu, Thr, Tyr, or Arg;
Xaa at position 106 is Asn, Ala, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;
and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding native amino acids of (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.
Included in the present invention are (15-125) hIL-3 mutant polypeptides of the Formula VI:
Asn Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa
[SEQ ID NO:20]
1 5 10 15
›DETAILED DESCRIPTION OF THE INVENTION · 7 of 20
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa
20 25 30
Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60
Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa
65 70 75
Xaa Xaa Xaa Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa
80 85 90
Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa
95 100 105
Xaa Xaa Xaa Xaa Gln Gln
110
wherein
Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 4 is Asn, His, Leu, Ile, Phe, Arg, or Gln;
Xaa at position 5 is Met, Phe, Ile, Arg, or Ala;
Xaa at position 6 is Ile or Pro;
Xaa at position 7 is Asp, or Glu;
Xaa at position 9 is Ile, Val, Ala, Leu, or Gly;
Xaa at position 10 is Ile, Val, Phe, or Leu;
Xaa at position 11 is Thr, His, Gly, Gln, Arg, Pro, or Ala;
Xaa at position 12 is His, Phe, Gly, Arg, or Ala;
Xaa at position 14 is Lys, Leu, Gln, Gly, Pro, or Val;
Xaa at position 15 is Gln, Asn, Leu, Arg, or Val;
Xaa at position 16 is Pro, His, Thr, Gly, or Gln;
Xaa at position 17 is Pro, Asp, Gly, Ala, Arg, Leu, or Gln;
Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro, Leu, Gln, Ala, or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 22 is Asp or Leu;
Xaa at position 23 is Phe, Ser, Pro, Trp, or Ile;
Xaa at position 24 is Asn or Ala;
Xaa at position 27 is Asn, Cys, Arg, His, Met, or Pro;
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg;
Xaa at position 30 is Asp, or Glu:
Xaa at position 31 is Gln, Val, Met, Leu, Thr, Lys, Ala, Asn Glu, Ser or Trp;
Xaa at position 32 is Asp, Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Gly;
Xaa at position 33 is Ile, Val, or His;
Xaa at position 35 is Met, Asn, or Asp;
Xaa at position 36 is Glu, Thr, Ala, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 38 is Asn or Gly;
Xaa at position 39 is Leu, Met, or Phe;
Xaa at position 40 is Arg, Ala or Ser;
Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, Val or Lys;
Xaa at position 45 is Glu, Tyr, His, Leu, or Arg;
Xaa at position 46 is Ala, Ser, Asn, or Thr;
Xaa at position 47 is Phe or Ser;
Xaa at position 48 is Asn, Val, Pro, Thr, or Ile;
Xaa at position 49 is Arg, Tyr, Lys, Ser, His, or Val;
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val, Thr, Leu, or Ser;
Xaa at position 52 is Lys, Ile, Arg, Val, Asn, Glu, or Ser;
Xaa at position 53 is Ser, Phe, Val, Gly, Asn, Ile, or His;
Xaa at position 54 is Leu, Val, Ile, Phe, or His;
Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 56 is Asn or Pro;
Xaa at position 57 is Ala, Met, Pro, Arg, Glu, Thr, or Gln;
Xaa at position 58 is Ser, Glu, Met, Ala, His, Asn, Arg, or Asp;
Xaa at position 59 is Ala, Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro;
Xaa at position 60 is Ile or Met;
Xaa at position 61 is Glu, Gly, Asp, Ser, or Gln;
Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, Gly, or Asp;
Xaa at position 63 is Ile, Ser, or Leu;
Xaa at position 65 is Lys, Thr, Gly, Asn, Met, Arg, Ile, or Asp;
Xaa at position 66 is Asn, Val, Gly, Thr, Leu, Glu, or Arg;
Xaa at position 67 is Leu, or Val;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 69 is Pro, Ala, Thr, Trp, or Met;
Xaa at position 71 is Leu or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala, Arg, or Trp:
Xaa at position 75 is Thr, Asp, Glu, His, Asn, or Ser;
Xaa at position 76 is Ala, Asp, or Met;
Xaa at position 77 is Ala, Pro, Ser, Thr, Phe, Leu, or Asp;
Xaa at position 78 is Pro or Ser;
Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser or Thr;
Xaa at position 82 is Pro or Tyr;
Xaa at position 83 is Ile, Val, or Ala;
Xaa at position 84 is His, Ile, Asn, Leu, Asp, Ala, Thr, Arg, Gln, Glu, Lys, Met, per, Tyr, Val or Pro;
Xaa at position 85 is Ile, Leu, Val, or Phe;
Xaa at position 86 is Lys, Leu, His, Arg, Ile, Gln, Pro or Ser;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu or Tyr;
Xaa at position 99 is Gly, Glu, Lys, or Ser;
Xaa at position 90 is Trp, Val, Tyr, Met, or Leu;
Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 92 is Glu, Ser, Ala, or Gly;
Xaa at position 94 is Arg, Ala, Gln, Ser or Lys;
Xaa at position 95 is Arg, Thr, Glu, Leu, Ser, or Gly;
Xaa at position 98 is Thr, Val, Gln, Glu, His, or Ser;
Xaa at position 100 is Tyr or Trp;
Xaa at position 101 is Leu or Ala;
Xaa at position 102 is Lys, Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, Phe, Tyr or Ile;
Xaa at position 103 is Thr, Ser, or Asn;
Xaa at position 105 is Glu, Ser, Pro, Leu, Thr, or Tyr;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Lys, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;
and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.
Included in the present invention are (15-125) hIL-3 mutant polypeptides of the Formula VII:
Asn Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa
[SEQ ID NO:21]
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa
20 25 30
›DETAILED DESCRIPTION OF THE INVENTION · 8 of 20
Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu
35 40 45
Xaa Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile
50 55 60
Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr
65 70 75
Ala Xaa Pro Xaa Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa
80 85 90
Xaa Xaa Phe Xaa Xaa Lys Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu
95 100 105
Xaa Xaa Xaa Xaa Gln Gln
110
wherein
Xaa at position 3 is Ser, Gly, Asp, Met, or Gln;
Xaa at position 4 is Asn, His, or Ile;
Xaa at position 5 is Met or Ile;
Xaa at position 7 is Asp or Glu;
Xaa at position 9 is Ile, Ala, Leu, or Gly;
Xaa at position 10 is Ile, Val, or Leu;
Xaa at position 11 is Thr, His, Gln, or Ala;
Xaa at position 12 is His or Ala;
Xaa at position 15 is Gln, Asn, or Val;
Xaa at position 16 is Pro, Gly, or Gln;
Xaa at position 17 is Pro, Asp, Gly, or Gln;
Xaa at position 18 is Leu, Arg, Gln, Asn, Gly, Ala, or Glu;
Xaa at position 19 is Pro or Glu;
Xaa at position 20 is Leu, Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 21 is Leu, Ala, Asn, Pro, Gln, or Val;
Xaa at position 23 is Phe, Ser, Pro, or Trp;
Xaa at position 24 is Asn or Ala;
Xaa at position 28 is Gly, Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met Tyr or Arg;
Xaa at position 30 is Asp or Glu;
Xaa at position 31 is Gln, Val, Met, Leu, Thr, Ala, Asn, Glu, Ser or Lys;
Xaa at position 32 is Asp, Phe, Ser, Thr, Ala, Asn, Gln, Glu, His, Ile, Lys, Tyr, Val or Cys;
Xaa at position 36 is Glu, Ala, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Met, Pro, Ser, Thr, or His;
Xaa at position 40 is Arg or Ala;
Xaa at position 41 is Arg, Thr, Val, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val or Lys;
Xaa at position 46 is Ala or Ser;
Xaa at position 48 is Asn, Pro, Thr, or ale;
Xaa at position 49 is Arg or Lys;
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val or Thr;
Xaa at position 52 is Lys or Arg;
Xaa at position 53 is Ser, Phe, or His;
Xaa at position 54 is Leu, Ile, Phe, or His;
Xaa at position 55 is Gln, Ala, Pro, Thr, Glu, Arg, or Gly;
Xaa at position 57 is Ala, Pro, or Arg;
Xaa at position 58 is Ser, Glu, Arg, or Asp;
Xaa at position 59 is Ala or Leu;
Xaa at position 62 is Ser, Val, Ala, Asn, Glu, Pro, or Gly;
Xaa at position 63 is Ile or Leu;
Xaa at position 65 is Lys, Thr, Asn, Met, Arg, Ile, Gly, or Asp;
Xaa at position 66 is Asn, Gly, Glu, or Arg;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 69 is Pro or Thr;
Xaa at position 71 is Leu or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Thr, Asp, Ser, Pro, Ala, Leu, or Arg;
Xaa at position 81 is His, Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser or Thr;
Xaa at position 82 is Pro or Tyr;
Xaa at position 83 is Ile or Val;
Xaa at position 84 is His, Ile, Asn, Ala, Thr, Leu, Arg, Gln, Lys, Met, Ser, Tyr, Val or Pro;
Xaa at position 85 is Ile, Leu, or Val;
Xaa at position 86 is Lys, Arg, Ile, Gln, Pro, or Ser;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Thr, Asn, Ile, Leu or Tyr;
Xaa at position 90 is Trp or Leu;
Xaa at position 91 is Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His;
Xaa at position 92 is Glu, or Gly;
Xaa at position 94 is Arg, Ala, or Ser;
Xaa at position 95 iS Arg, Thr, Glu, Leu, or Ser;
Xaa at position 98 is Thr, Val, or Gln;
Xaa at position 100 is Tyr or Trp;
Xaa at position 101 is Leu or Ala;
Xaa at position 102 is Lys, Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr or Ile;
Xaa at position 103 is Thr or Ser;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Asn, Pro, Asp, or Gly;
Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys;
Xaa at position 109 is Ala, Met, Glu, His, Ser, Pro, Tyr, or Leu;
which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (15-125) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.
Included in the present invention are (15-125) hIL-3 mutant polypeptides of the Formula VIII:
Asn Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa
[SEQ ID NO:22]
1 5 10 15
Xaa Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp
20 25 30
Xaa Xaa Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu
35 40 45
Ala Phe Xaa Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile
50 55 60
Glu Xaa Xaa Leu Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr
65 70 75
Ala Xaa Pro Xaa Arg Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp
80 85 90
Xaa Glu Phe Xaa Xaa Lys Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu
95 100 105
Xaa Xaa Xaa Xaa Gln Gln
110
wherein
Xaa at position 3 is Ser, Gly, Asp, or Gln;
Xaa at position 4 is Asn, His, or Ile;
Xaa at position 9 is Ile, Ala, Leu, or Gly;
Xaa at position 11 is Thr, His, or Gln;
Xaa at position 12 is His or Ala;
Xaa at position 15 is Gln or Asn;
Xaa at position 16 is Pro or Gly;
Xaa at position 18 is Leu, Arg, Asn, or Ala;
Xaa at position 20 is Leu, Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr or Met;
Xaa at position 21 is Leu, Ala, Asn, or Pro;
Xaa at position 24 is Asn or Ala:
Xaa at position 28 is Gly, Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr or Arg;
Xaa at position 31 is Gln, Val, Met, Leu, Ala, Asn, Glu or Lys;
Xaa at position 32 is Asp, Phe, Ser, Ala, Gln, Glu, His, Val or Thr;
Xaa at position 36 is Glu, Asn, Ser or Asp;
Xaa at position 37 is Asn, Arg, Pro, Thr, or His;
Xaa at position 41 is Arg, Leu, or Gly;
Xaa at position 42 is Pro, Gly, Ser, Ala, Asn, Val, Leu or Gln;
Xaa at position 48 is Asn, Pro, or Thr;
›DETAILED DESCRIPTION OF THE INVENTION · 9 of 20
Xaa at position 50 is Ala or Asn;
Xaa at position 51 is Val or Thr;
Xaa at position 53 is Ser or Phe;
Xaa at position 54 is Leu or Phe;
Xaa at position 55 is Gln, Ala, Glu, or Arg;
Xaa at position 62 is Ser, Val, Asn, Pro, or Gly;
Xaa at position 63 is Ile or Leu;
Xaa at position 65 is Lys, Asn, Met, Arg, Ile, or Gly;
Xaa at position 66 is Asn, Gly, Glu, or Arg;
Xaa at position 68 is Leu, Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, Thr, Tyr or Val;
Xaa at position 73 is Leu or Ser;
Xaa at position 74 is Ala or Trp;
Xaa at position 77 is Ala or Pro;
Xaa at position 79 is Thr, Asp, or Ala;
Xaa at position 81 is His, Pro, Arg, Val, Gly, Asn, Ser or Thr;
Xaa at position 84 is His, Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, Tyr, Val or Leu;
Xaa at position 85 is Ile or Leu;
Xaa at position 86 is Lys or Arg;
Xaa at position 87 is Asp, Pro, Met, Lys, His, Pro, Asn, Ile, Leu or Tyr;
Xaa at position 91 is Asn, Pro, Ser, Ile or Asp;
Xaa at position 94 is Arg, Ala, or Ser;
Xaa at position 95 is Arg, Thr, Glu, Leu, or Ser;
Xaa at position 98 is Thr or Gln;
Xaa at position 102 is Lys, Val, Trp, or Ile;
Xaa at position 103 is Thr, Ala, His, Phe, Tyr or Ser;
Xaa at position 106 is Asn, Pro, Leu, His, Val, or Gln;
Xaa at position 107 is Ala, Ser, Ile, Pro, or Asp;
Xaa at position 108 is Gln, Met, Trp, Phe, Pro, His, Ile, or Tyr;
Xaa at position 109 is Ala, Met, Glu, Ser, or Leu;
and which can additionally have Met- or Met-Ala- preceding the amino acid in position 1; and wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (1-133)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.
In Formulas V, VI, VII and VIII the Asn in position 1 corresponds to the Asn in position 15 of native hIL-3 and positions 1 to 111 correspond to positions 15 to 125 in the native hIL-3 sequence shown in FIG. 1 .
Also included in the present invention are polypeptides of the following formula (IX):
1 5 10
[SEQ ID NO:129]
(Met) m -Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr
15 20
Ser Trp Val Asn Cys Ser Xaa Met Ile Asp Glu Ile Ile
25 30 35
Xaa His Leu Lys Xaa Pro Pro Xaa Pro Leu Leu Asp Xaa
40 45 50
Asn Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Met Glu
55 60
Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa Arg
65 70 75
Ala Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa
80 85
Ile Leu Xaa Asn Leu Xaa Pro Cys Leu Pro Xaa Ala Thr
90 95 100
Ala Ala Pro Xaa Arg His Pro Ile Xaa Ile Lys Xaa Gly
105 110 115
Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Thr Phe Tyr Leu
120 125
Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu
130
Ser Leu Ala Ile Phe
wherein m is 0 or 1; Xaa at position 18 is Asn or Ile; Xaa at position 25 is Thr or His; Xaa at position 29 is Gln, Arg, or Val; Xaa at position 32 is Leu, Ala, or Asn; Xaa at position 37 is Phe, Pro, or Ser; Xaa at position 42 is Glu, Ala, or Ser; Xaa at position 45 is Gln, Val, or Met; Xaa at position 51 is Asn or Arg; Xaa at position 55 is Arg, Leu, or Thr; Xaa at position 59 is Glu or Leu; Xaa at position 60 is Ala or Ser; Xaa at position 62 is Asn or Val; Xaa at position 67 is Ser, Asn, or His; Xaa at position 69 is Gln or Glu; Xaa at position 73 is Ala or Gly; Xaa at position 76 is Ser or Ala; Xaa at position 79 is Lys or Arg; Xaa at position 82 is Leu, Glu, or Val; Xaa at position 87 is Leu or Ser; Xaa at position 93 is Pro or Ser; Xaa at position 98 is His, Ile, or Thr; Xaa at position 101 is Asp or Ala; Xaa at position 105 is Asn or Glu; Xaa at position 109 is Arg or Glu; Xaa at position 116 is Lys or Val; Xaa at position 120 is Asn, Gln, or His; Xaa at position 123 is Ala or Glu; wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.
Polypeptides of the present invention include those (15-125) hIL-3 muteins of the following formula (X):
1 5 10
[SEQ ID NO:130]
(Met m -Ala n )p-Asn Cys Ser Xaa Met Ile Asp Glu Ile Ile
15 20
Xaa His Leu Lys Xaa Pro Pro Xaa Pro Leu Leu Asp Xaa
25 30 35
Asn Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu Met Glu
40 45
Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa Arg
50 55 60
Ala Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa
65 70 75
Ile Leu Xaa Asn Leu Xaa Pro Cys Leu Pro Xaa Ala Thr
80 85
Ala Ala Pro Xaa Arg His Pro Ile Xaa Ile Lys Xaa Gly
90 95 100
Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Thr Phe Tyr Leu
105 110
Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln
wherein m is 0 or 1; n is 0 or 1; p is 0 or 1; Xaa at position 4 is Asn or Ile; Xaa at position 11 is Thr or His; Xaa at position 15 is Gln, Arg, or Val; Xaa at position 18 is Leu, Ala, or Asn; Xaa at position 23 is Phe, Pro, or Ser; Xaa at position 28 is Glu, Ala, or Ser; Xaa at position 31 is Gln, Val, or Met; Xaa at position 37 is Asn or Arg; Xaa at position 41 is Arg, Leu, or Thr; Xaa at position 45 is Glu or Leu; Xaa at position 46 is Ala or Ser; Xaa at position 48 is Asn or Val; Xaa at position 53 is Ser, Asn, or His; Xaa at position 55 is Gln or Glu; Xaa at position 59 is Ala or Gly; Xaa at position 62 is Ser or Ala; Xaa at position 65 is Lys or Arg; Xaa at position 68 is Leu, Glu, or Val; Xaa at position 73 is Leu or Ser; Xaa at position 79 is Pro or Ser; Xaa at position 84 is His, Ile, or Thr; Xaa at position 87 is Asp or Ala; Xaa at position 91 is Asn or Glu; Xaa at position 95 is Arg or Glu; Xaa at position 102 is Lys or Val,; Xaa at position 106 is Asn, Gln, or His; Xaa at position 109 is Ala or Glu;
›DETAILED DESCRIPTION OF THE INVENTION · 10 of 20
wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native (15-125)human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.
The present invention includes polypeptides of Formula IX and Formula X above wherein from one to three of the amino acids designated by Xaa are different from the corresponding amino acids of native human interleukin-3 or native (15-125) human interleukin-3; or a polypeptide having substantially the same structure and substantially the same biological activity.
“Mutant amino acid sequence,” “mutant protein” or “mutant polypeptide” refers to a polypeptide having an amino acid sequence which varies from a native sequence or is encoded by a nucleotide sequence intentionally made variant from a native sequence. “Mutant protein,” “variant protein” or “mutein” means a protein comprising a mutant amino acid sequence and includes polypeptides which differ from the amino acid sequence of native hIL-3 due to amino acid deletions, substitutions, or both. “Native sequence” refers to an amino acid or nucleic acid sequence which is identical to a wild-type or native form of a gene or protein.
Human IL-3 can be characterized by its ability to stimulate colony formation by human hematopoietic progenitor cells. The colonies formed include erythroid, granulocyte, megakaryocyte, granulocytic macrophages and mixtures thereof. Human IL-3 has demonstrated an ability to restore bone marrow function and peripheral blood cell populations to therapeutically beneficial levels in studies performed initially in primates and subsequently in humans (Gillio, A. P., et al. (1990); Ganser, A., et al. (1990); Falk, S., et al. (1991). Additional activities of hIL-3 include the ability to stimulate leukocyte migration and chemotaxis; the ability to prime human leukocytes to produce high levels of inflammatory mediators like leukotrienes and histamine; the ability to induce cell surface expression of molecules needed for leukocyte adhesion; and the ability to trigger dermal inflammatory responses and fever. Many or all of these biological activities of hIL-3 involve signal transduction and high affinity receptor binding. Mutant polypeptides of the present invention may exhibit useful properties such as having similar or greater biological activity when compared to native hIL-3 or by having improved half-life or decreased adverse side effects, or a combination of these properties. They may also be useful as antagonists. hIL-3 mutant polypeptides which have little or no activity when compared to native hIL-3 may still be useful as antagonists, as antigens for the production of antibodies for use in immunology or immunotherapy, as genetic probes or as intermediates used to construct other useful hIL-3 muteins. Since hIL-3 functions by binding to its receptor(s) and triggering second messages resulting in competent signal transduction, hIL-3 muteins of this invention may be useful in helping to determine which specific amino acid sequences are responsible for these activities.
The novel hIL-3 mutant polypeptides of the present invention will preferably have at least one biological property of human IL-3 or of an IL-3-like growth factor and may have more than one IL-3-like biological property, or an improved property, or a reduction in an undesirable biological property of human IL-3. Some mutant polypeptides of the present invention may also exhibit an improved side effect profile. For example, they may exhibit a decrease in leukotriene release or histamine release when compared to native hIL-3 or (15-125) hIL-3. Such hIL-3 or hIL-3-like biological properties may include one or more of the following biological characteristics and in vivo and in vitro activities.
One such property is the support of the growth and differentiation of progenitor cells committed to erythroid, lymphoid, and myeloid lineages. For example, in a standard human bone marrow assay, an IL-3-like biological property is the stimulation of granulocytic type colonies, megakaryocytic type colonies, monocyte/macrophage type colonies, and erythroid bursts. Other IL-3-like properties are the interaction with early multipotential stem cells, the sustaining of the growth of pluripotent precursor cells, the ability to stimulate chronic myelogenous leukemia (CML) cell proliferation, the stimulation of proliferation of mast cells, the ability to support the growth of various factor-dependent cell lines, and the ability to trigger immature bone marrow cell progenitors. Other biological properties of IL-3 have been disclosed in the art. Human IL-3 also has some biological activities which may in. some cases be undesirable, for example the ability to stimulate leukotriene release and the ability to stimulate increased histamine synthesis in spleen and bone marrow cultures and in vivo.
Biological activity of hIL-3 and hIL-3 mutant proteins of the present invention is determined by DNA synthesis by human acute myelogenous leukemia cells (AML). The factor-dependent cell line AML 193 was adapted for use in testing biological activity.
One object of the present invention is to provide hIL-3 muteins and hIL-3 deletion muteins with one or more amino acid substitutions in the polypeptide sequence which have similar of improved biological activity in relation to native hIL-3 or native (15-125) hIL-3.
The present invention includes mutant polypeptides comprising minimally amino acid residues 15 to 118 of hIL-3 with or without additional amino acid extensions to the N-terminus and/or C-terminus which further contain from one to three or more amino acid substitutions in the amino acid sequence of the polypeptide. It has been found that the (15-125) hIL-3 mutant is more soluble than is hIL-3 when expressed in the cytoplasm of E. coli , and the protein is secreted to the periplasm in E. coli at higher levels compared to native hIL-3.
When expressed in the E. coli cytoplasm, the above-mentioned mutant hIL-3 polypeptides of the present invention may also be constructed with Met-Ala- at the N-terminus so that upon expression the Met is cleaved off leaving Ala at the N-terminus. These mutant hIL-3 polypeptides may also be expressed in E. coli by fusing a signal peptide to the N-terminus. This signal peptide is cleaved from the polypeptide as part of the secretion process. Secretion in E. coli can be used to obtain the correct amino acid at the N-terminus (e.g., Asn 15 in the (15-125) hIL-3 polypeptide) due to the precise nature of the signal peptidase. This is in contrast to the heterogeneity often observed at the N-terminus of proteins expressed in the cytoplasm in E. coli.
›DETAILED DESCRIPTION OF THE INVENTION · 11 of 20
The hIL-3 mutant polypeptides of the present invention may have hIL-3 or hIL-3-like activity. For example, they may possess one or more of the biological activities of native hIL-3 and may be useful in stimulating the production of hematopoietic cells by human or primate progenitor cells. The hIL-3 muteins of the present invention and pharmaceutical compositions containing them may be useful in the treatment of conditions in which hematopoietic cell populations have been reduced or destroyed due to disease or to treatments such as radiation or chemotherapy.
hIL-3 muteins of the present invention may also be useful as antagonists which block the hIL-3 receptor by binding specifically to it and preventing binding of the agonist.
One potential advantage of the (15-125) hIL-3 muteins of the present invention, particularly those which retain activity similar to or better than that of native hIL-3, is that it may be possible to use a smaller amount of the biologically active mutein to produce the desired therapeutic effect. This may make it possible to reduce the number of treatments necessary to produce the desired therapeutic effect. The use of smaller amounts may also reduce the possibility of any potential antigenic effects or other possible undesirable side effects. For example, if a desired therapeutic effect can be achieved with a smaller amount of polypeptide it may be possible to reduce or eliminate side effects associated with the administration of native IL-3 such as the stimulation of leukotriene and/or histamine release. The hIL-3 muteins of the present invention may also be useful in the activation of stem cells or progenitors which have low receptor numbers. Pharmaceutical compositions containing hIL-3 muteins of the present invention can be administered parenterally, intravenously, or subcutaneously.
In variants which contain an additional cysteine the presence of the cysteine permits the labeling of the protein with ricin which permits targeting ricin and other toxins or tracers using a sulfhydryl linkage to the hIL-3 receptor.
As another aspect of the present invention, there is provided a novel method for producing the novel family of human IL-3 muteins. The method of the present invention involves culturing a suitable cell or cell line( which has been transformed with a vector containing a DNA sequence coding for expression of a novel hIL-3 mutant polypeptide. Suitable cells or cell lines may be bacterial cells. For example, the various strains of E. coli are well-known as host cells in the field of biotechnology. Examples of such strains include E. coli strains JM101 [Yanish-Perron, et al. (1985)] and MON105 [Obukowicz, et al. (1992)]. Various strains of B subtilis may also be employed in this method. Many strains of yeast cells known to those skilled in the art are also available as host cells for expression of the polypeptides of the present invention.
Also suitable for use in the present invention are mammalian cells, such as Chinese hamster ovary cells (CHO). General methods for expression of foreign genes in mammalian cells are reviewed in; Kaufman, R. J. (1987) High level production of proteins-in mammalian cells, in Genetic Engineering, Principles and Methods , Vol. 9, J. K. Setlow, editor, Plenum Press, New York. An expression vector is constructed in which a strong promoter capable of functioning in mammalian cells drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally fused to the coding region for the hIL-3 variant. For example, plasmids such as pcDNA I/Neo, pRc/RSV, and pRc/CMV (obtained from Invitrogen Corp., San Diego, Calif.) can be used. The eukaryotic secretion signal peptide coding region can be from the hIL-3 gene itself or it can be from another secreted mammalian protein (Bayne, M. L. et al. (1987) Proc. Natl. Acad. Sci. USA 84, 2638-2642). After construction of the vector containing the hIL-3 variant gene, the vector DNA is transfected into mammalian cells. Such cells can be, for example, the COS7, HeLa, BHK, CHO, or mouse L lines. The cells can be cultured, for example, in DMEM media (JRH Scientific). The hIL-3 variant secreted into the media can be recovered by standard biochemical approaches following transient expression 24-72 hours after transfection of the cells or after establishment of stable cell lines following selection for neomycin resistance. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature, 2:620-625 (1981), or alternatively, Kaufman et al, Mol. Cell. Biol. , 5(7):1750-1759 (1985) or Howley et al., U.S. Pat. No. 4,419,446. Another suitable mammalian cell line is the monkey COS-1 cell line. A similarly useful mammalian cell line is the CV-1 cell line.
Where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g. Miller et al, Genetic Engineering, 8:277-298 (Plenum Press 1986) and references cited therein. In addition, general methods for expression of-foreign genes in insect cells using Baculovirus vectors are described in: Summers, M. D. and Smith, G. E. (1987)—A manual of methods for Baculovirus vectors and insect cell culture procedures, Texas Agricultural Experiment Station Bulletin No. 1555. An expression vector is constructed comprising a Baculovirus transfer vector, in which a strong Baculovirus promoter (such as the polyhedron promoter) drives transcription of a eukaryotic secretion signal peptide coding region, which is translationally fused to the coding region for the hIL-3 variant polypeptide. For example, the plasmid pVL1392 (obtained from Invitrogen Corp., San Diego, Calif.) can be used. After construction of the vector carrying the hIL-3 variant gene, two micrograms of this DNA is cotransfected with one microgram of Baculovirus DNA (see Summers & Smith, 1987) into insect cells, strain SF9. Pure recombinant Baculovirus carrying the hIL-3 variant is used to infect cells cultured, for example, in Excell 401 serum-free medium (in Biosciences, Lenexa, Kans.). The hIL-3 variant secreted into the medium can be recovered by standard biochemical approaches.
›DETAILED DESCRIPTION OF THE INVENTION · 12 of 20
Another aspect of the present invention provides plasmid DNA vectors for use in the method of expression of these novel hIL-3 muteins. These vectors contain the novel DNA sequences described above which code for the novel polypeptides of the invention. Appropriate vectors which can transform microorganisms capable of expressing the hIL-3 muteins include expression vectors comprising nucleotide sequences coding for the hIL-3 muteins joined to transcriptional and translational regulatory sequences which are selected according to the host cells used.
Vectors incorporating modified sequences as described above are included in the present invention and are useful in the production of the hIL-3 mutant polypeptides. The vector employed in the method also contains selected regulatory sequences in operative association with the DNA coding sequences of the invention and capable of directing the replication and expression thereof in selected host cells.
The present invention also includes the construction and expression of (15-125)human interleukin-3 muteins having one or more amino acid substitutions in secretion vectors that optimize accumulation of correctly folded, active polypeptide. While many heterologous proteins have been secreted in E. coil there is still a great deal of unpredictability and limited success (Stader and Silhavy 1990). Full-length hIL-3 is such a protein, where attempts to secrete the protein in E. coli resulted in low levels of secretion. Secretion of the variant (15-125) hIL-3 mutant polypeptides of the present invention as a fusion with a signal peptide such as lamB results in correctly folded protein that can be removed from the periplasm of E. coli by osmotic shock fractionation. This property of the variant (15-125) hIL-3 muteins allows for the direct and rapid screening for bioactivity of the secreted material in the crude osmotic shock fraction, which is a significant advantage. Furthermore, it provides a means of using the (15-125) hIL-3 muteins to conduct structure activity relationship (SAR) studies of the hIL-3 molecule. A further advantage of secretion of (15-125) hIL-3 muteins fused to the lamb signal peptide is that the secreted polypeptide has the correct N-terminal amino acid (Asn) due to the precise nature of the cleavage of the signal peptide by signal peptidase, as part of the secretion process.
The (15-125) hIL-3 muteins of the present invention may include hIL-3 polypeptides having Met-, Ala- or Met-Ala- attached to the N-terminus. When the muteins are expressed in E. coli , polypeptides with and without Met attached to the N-terminus are obtained. The methlonine can in some cases be removed by methionine aminopeptidase.
Amino terminal sequences of some of the hIL-3 muteins made in E. coli were determined using the method described by Hunkapillar et al., (1983). It was found that hIL-3 proteins made in E. coli from genes encoding Met-(15-125) hIL-3 were isolated as Met-(15-125) hIL-3. Proteins produced from genes encoding Met-Ala-(15-125) hIL-3 were produced as Ala-(15-125) hIL-3. The N-termini of proteins made in the cytoplasm of E. coli are affected by posttranslational processing by methionine aminopeptidase (Ben-Bassat et al., 1987) and possibly by other peptidases.
One method of creating the preferred hIL-3 (15-125) mutant genes is cassette mutagenesis [Wells, et al. (1985)] in which a portion of the coding sequence of hIL-3 in a plasmid is replaced with synthetic oligonucleotides that encode the desired amino acid substitutions in a portion of the gene between two restriction sites. In a similar manner amino acid substitutions could be made in the full-length hIL-3 gene, or genes encoding variants of hIL-3 in which from 1 to 14 amino acids have been deleted from the N-terminus and/or from 1 to 15 amino acids have been deleted from the C-terminus. When properly assembled these oligonucleotides would encode hIL-3 variants with the desired amino acid substitutions and/or deletions from the N-terminus and/or C-terminus. These and other mutations could be created by those skilled in the art by other mutagenesis methods including; oligonucleotide-directed mutagenesis [Zoller and Smith (1982, 1983, 1984), Smith (1985), Kunkel (1985), Taylor, et al. (1985), Deng and Nickoloff (1992)] or polymerase chain reaction (PCR) techniques [Saiki, (1985)].
Pairs of complementary synthetic oligonucleotides encoding portions of the amino terminus of the hIL-3 gene can be made and annealed to each other. Such pairs would have protruding ends compatible with ligation to NcoI at one end. The NcoI site would include the codon for the initiator methionine. At the other end of oligonucleotide pairs, the protruding (or blunt) ends would be compatible with a restriction site that occurs within the coding sequence of the hIL-3 gene. The DNA sequence of the oligonucleotide would encode sequence for amino acids of hIL-3 with the exception of those substituted and/or deleted from the sequence.
The NcoI enzyme and the other restriction enzymes chosen should have recognition sites that occur only once in the DNA of the plasmid chosen. Plasmid DNA can be treated with the chosen restriction endonucleases then ligated to the annealed oligonucleotides. The ligated mixtures can be used to transform competent JM101 cells to resistance to an appropriate antibiotic. Single colonies can be picked and the plasmid DNA examined by restriction analysis and/or DNA sequencing to identify plasmids with mutant hIL-3 genes.
One example of a restriction enzyme which cleaves within the coding sequence of the hIL-3 gene is ClaI whose recognition site is at codons 20 and 21. The use of ClaI to cleave the sequence of hIL-3 requires that the plasmid DNA be isolated from an E. coli strain that fails to methylate adenines in the DNA at GATC recognition sites. This is because the recognition site for ClaI, ATCGAT, occurs within the sequence GATCGAT which occurs at codons 19, 20 and 21 in the hIL-3 gene. The A in the GATC sequence is methylated in most E. coli host cells. This methylation prevents ClaI from cleaving at that particular sequence. An example of a strain that does not methylate adenines is GM48.
›DETAILED DESCRIPTION OF THE INVENTION · 13 of 20
Interpretation of Activity of Single Amino Acid Mutants in IL-3 (15-125)
As illustrated in Tables 6 and 9, there are certain positions in the IL-3 (15-125) molecule which are intolerant of substitutions, in that most or all substitutions at these positions resulted in a considerable decrease in bioactivity. There are two likely classes of such “down-mutations”: mutations that affect overall protein structure, and mutations that interfere directly with the interaction between the IL-3 molecule and its receptor. Mutations affecting the three-dimensional structure of the protein will generally lie in the interior of the protein, while mutations affecting receptor binding will generally lie on the surface of the protein. Although the three-dimensional structure of IL-3 is unknown, there are simple algorithms which can aid in the prediction of the structure. One such algorithm is the use of “helical wheels” (Kaiser, E. T. & Kezdy, F. J., Science, 223:249-255 (1984)). In this method, the presence of alpha helical protein structures can be predicted by virtue of their amphipathic nature. Helices in globular proteins commonly have an exposed hydrophilic side and a buried hydrophobic side. As a broad generalization, in globular proteins, hydrophobic residues are present in the interior of the protein, and hydrophilic residues are present on the surface. By displaying the amino acid sequence of a protein on such a “helical wheel” it is possible to derive a model for which amino acids in alpha helices are exposed and which are buried in the core of the protein. Such an analysis of the IL-3 (15-125) molecule predicts that the following helical residues are buried in the core:
M19, I20, I23, I24, L27, L58, F61, A64, L68, A71, I74, I77, L78, L81, W104, F107, L111, Y114, L115, L118.
In addition, cysteine residues at positions 16 and 84 are linked by a disulfide bond, which is important for the overall structure or “folding” of the protein. Finally, mutations which result in a major disruption of the protein structure may be expressed at low level in the secretion system used in our study, for a variety of reasons: either because the mis-folded protein is poorly recognized by the secretion machinery of the cell; because mis-folding of the protein results in aggregation, and hence the protein cannot be readily extracted from the cells; or because the mis-folded protein is more susceptible to degradation by cellular proteases. Hence, a block in secretion may indicate which positions in the IL-3 molecule which are important for maintenance of correct protein structure.
In order to retain the activity of a variant of IL-3, it is necessary to retain both the structural integrity of the protein, and retain the specific residues important for receptor contact. Hence it is possible to define specific amino acid residues in IL-3 (15-125) which must be retained in order to preserve biological activity.
Residues predicted to be important for interaction with the receptor: D21, E22, E43, D44, L48, R54, R94, D103, K110, F113.
Residues predicted to be structurally important: C16, L58, F61, A64, I74, L78, L81, C84, P86, P92, P96, F107, L111, L115, L118.
The hIL-3 muteins of the present invention may be useful in the treatment of diseases characterized by a decreased levels of either myeloid, erythroid, lymphoid, or megakaryocyte cells of the hematopoietic system or combinations thereof. In addition, they may be used to activate mature myeloid and/or lymphoid cells. Among conditions susceptible to treatment with the polypeptides of the present invention is leukopenia, a reduction in the number of circulating leukocytes (white cells) in the peripheral blood. Leukopenia may be induced by exposure to certain viruses or to radiation. It is often a side effect of various forms of cancer therapy, e.g., exposure to chemotherapeutic drugs and of infection or hemorrhage. Therapeutic treatment of leukopenia with these hIL-3 mutant polypeptides of the present invention may avoid undesirable side effects caused by treatment with presently available drugs.
The hIL-3 muteins of the present invention may be useful in the treatment of neutropenia and, for example, in the treatment of such conditions as aplastic anemia, cyclic neutropenia, idiopathic neutropenia, Chdiak-Higashi syndrome, systemic lupus erythematosus (SLE), leukemia, myelodysplastic syndrome and myelofibrosis.
Many drugs may cause bone marrow suppression or hematopoietic deficiencies. Examples of such drugs are AZT, DDI, alkylating agents and anti-metabolites used in chemotherapy, antibiotics such as chloramphenicol, penicillin and sulfa drugs, phenothiazones, tranquilizers such as meprobamate, and diuretics. The hIL-3 muteins of the present invention may be useful in preventing or treating the bone marrow Suppression or hematopojetic deficiencies which often occur in patients treated with these drugs.
Hematopoietic deficiencies may also occur as a result of viral, microbial or parasitic infections and as a result of treatment for renal disease or renal failure, e.g., dialysis. The hIL-3 muteins of the present invention may be useful in treating such hematopoietic deficiency.
The treatment of hematopoietic deficiency may include administration of the hIL-3 mutein of a pharmaceutical composition containing the hIL-3 mutein to a patient. The hIL-3 muteins of the present invention may also be useful for the activation and amplification of hematopoietic precursor cells by treating these cells in vitro with the muteins of the present invention prior to injecting the cells into a patient.
Various immunodeficiencies e.g., in T and/or B lymphocytes, or immune disorders, e.g., rheumatoid arthritis, may also be beneficially affected by treatment with the hIL-3 mutant polypeptides of the present invention. Immunodeficiencies may be the result of viral infections e.g. HTLVI, HTLVII, HTLVIII, severe exposure to radiation, cancer therapy or the result of other medical treatment. The hIL-3 mutant polypeptides of the present invention may also be employed, alone or in combination with other hematopoietins, in the treatment of other blood cell deficiencies, including thrombocytopenia (platelet deficiency), or anemia. Other uses for these novel polypeptides are in the treatment of patients recovering from bone marrow transplants in vivo and ex vivo, and in the development of monoclonal and polyclonal antibodies generated by standard methods for diagnostic or therapeutic use.
›DETAILED DESCRIPTION OF THE INVENTION · 14 of 20
Other aspects of the present invention are methods and therapeutic compositions for treating the conditions referred to above. Such compositions comprise a therapeutically effective amount of one or more of the hIL-3 muteins of the present invention in a mixture with a pharmaceutically acceptable carrier. This composition can be administered either parenterally, intravenously or subcutaneously. When administered, the therapeutic composition for use in this invention is preferably in the form of a pyrogen-free, parenterally acceptable aqueous solution. The preparation of such a parenterally acceptable protein solution, having due regard to pH, isotonicity, stability and the like, is within the skill of the art.
The dosage regimen involved in a method for treating the above-described conditions will be determined by the attending physician considering various factors which modify the action of drugs, e.g. the condition, body weight, sex and diet of the patient, the severity of any infection, time of administration and other clinical factors. Generally, a daily regimen may be in the range of 0.2-150 μg/kg of non-glycosylated IL-3 protein per kilogram of body weight. This dosage regimen is referenced to a standard level of biological activity which recognizes that native IL-3 generally possesses an EC 50 at or about 10 picoMolar to 100 picoMolar in the AML proliferation assay described herein. Therefore, dosages would be adjusted relative to the activity of a given mutein vs. the activity of native (reference) IL-3 and it would not be unreasonable to note that dosage regimens may include doses as low as 0.1 microgram and as high as 1 milligram per kilogram of body weight per day. In addition, there may exist specific circumstances where dosages of IL-3 mutein would be adjusted higher or lower than the range of 10-200 micrograms per kilogram of body weight. These include co-administration with other CSF or growth factors; co-administration with chemotherapeutic drugs and/or radiation; the use of glycosylated IL-3 mutein; and various patient-related issues mentioned earlier in this section. As indicated above, the therapeutic method and compositions may also include co-administration with other human factors. A non-exclusive list of other appropriate hematopoietins, CSFs and interleukins for simultaneous or serial co-administration with the polypeptides of the present invention includes GM-CSF, CSF-1, G-CSF, Meg-CSF, M-CSF, erythropoietin (EPO), IL-1, IL-4, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, LIF, B-cell growth factor, B-cell differentiation factor and eosinophil differentiation factor, stem cell factor (SCF) also known as steel factor or c-kit ligand, or combinations thereof. The dosage recited above would be adjusted to compensate for such additional components in the therapeutic composition. Progress of the treated patient can be monitored by periodic assessment of the hematological profile, e.g., differential cell count and the like.
Materials and Methods for hTL-1 Mutein Expression in E. coli
Unless noted otherwise, all specialty chemicals were obtained from Sigma Co., (St. Louis, Mo.). Restriction endonucleases, T4 poly-nucleotides kinase, E. coli DNA polymerase I large fragment (Klenow) and T4 DNA ligase were obtained from New England Biolabs (Beverly, Mass.) or Boehringer Mannheim (Indianapolis, Ind.). All chemicals and enzymes were used according to manufacturer's directions.
Escherichia coli Strains
Strain JM101: delta (pro lac), supE, thi, F′ (traD36, proAB, lacI-Q, lacZdeltaM15) (Messing, 1979). This strain can be obtained from the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. 20852, accession number 33876. MON 105 (W3110 rpoH358) (Obukowicz, et al., 1992) is a derivative of W3110 (Bachmann, 1972) and has been assigned ATCC accession number 55204. Strain GM48: dam-3, dcm-6, gal, ara, lac, thr, leu, tonA, tsx (Marinus, 1973) was used to make plasmid DNA that is not methylated at the sequence GATC.
Genes and Plasmids
The gene used for hIL-3 production in E. coli was obtained from British Biotechnology Incorporated, Cambridge, England, catalogue number BBG14. This gene is carried on a pUC based plasmid designated pP0518. The human IL-3 gene sequence is from Yang, et al. (1986).
The plasmids used for production of hIL-3 in E. coli contain genetic elements whose use has been described (Olins et al., 1988; Olins and Rangwala, 1990). The replicon used is that of pBR327 [(Bolivar et al. (1977); Soberon et al., 1980] which is maintained at a copy number of about 50 in the cell (Covarrubias, et al., (1981)). A gene encoding the beta-lactamase protein is present on the plasmids. This protein confers ampicillin resistance on the cell. This resistance serves as a selectable phenotype for the presence of the plasmid in the cell.
Intracellular Expression Plasmids
For cytoplasmic (intracellular) expression vectors the transcription promoter was derived from the recA gene of E. coli (Sancar et al., 1980). This promoter, designated precA, is contained on 72 base pairs (bp) BglII, BamHI fragment which includes the RNA polymerase binding site and the lexA repressor binding site (the operator). This segment of DNA provides high level transcription that is regulated even when the recA promoter is on a plasmid with the pBR327 origin of replication (Olins et al., 1988) incorporated herein by reference.
Secretion Expression Plasmids
In secretion expression plasmids the transcription promoter was derived from the ara B, A. and D genes of E. coli (Greenfield et al., 1978). This promoter is designated pAraBAD and is contained on a 323 base pair SacrII, BglII restriction fragment. The lamB secretion leader (Wong et al., 1988, Clement et al., 1981) was fused to the N-terminus of the hIL-3 gene at the recognition sequence for the enzyme NcoI (5′CCATGG3′). The hIL-3 genes used were engineered to have a HindIII recognition site (5′AAGCTT3′) following the coding sequence of the gene. Downstream of the gene is a 550 bp fragment containing the origin of replication of the single stranded phage f1 [Olins and Rangwala (1989)].
›DETAILED DESCRIPTION OF THE INVENTION · 15 of 20
These hIL-3 variants were expressed as a fusion with the lamB signal peptide operatively joined to the araBAD promoter (Greenfield, 1978) and the g10-L ribosome binding site (Olins et al. 1988). The signal peptide is removed as part of the secretion process. The processed form was selectively released from the periplasm by osmotic shock as a correctly folded and fully active molecule. Secretion of (15-125) hIL-3 was further optimized by using low inducer (arabinose) concentration and by growth at 30° C. These conditions resulted in lower accumulation levels of unprocessed lamB signal peptide (15-125) hIL-3 fusion, maximal accumulation levels of processed (15-125) hIL-3 and selective release of (15-125) hIL-3 by osmotic shock fractionation. The use of a tightly regulated promoter such as araBAD from which the transcription level and hence the expression level can be modulated allowed for the optimization of secretion of (15-125) hIL-3.
The ribosome binding site (RBS) used is that from gene 10 of phage T7 (Olins et al., 1988). This is encoded in a 100 base pair (bp) fragment placed adjacent to precA. In the plasmids used herein, the recognition sequence for the enzyme NcoI (5′CCATGG3′) follows the g10-L RBS. It is at this NcoI site that the hIL-3 genes are joined to the plasmid. It is expected that the nucleotide sequence at this junction will be recognized in mRNA as a functional start site for translation (Olins et al., 1988). The hIL-3 genes used were engineered to have a HindIII recognition site (5′AAGCTT3′) following the coding sequence of the gene. Downstream of the gene is a 550 base pair fragment containing the origin of replication of the single stranded phage f1 (Dente et al., 1983; Olins, et al., 1990) both incorporated herein by reference. A plasmid containing these elements is pMON2341. Another plasmid containing these elements is pMON5847 which has been deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 under the accession number ATCC 68912.
Synthesis of Oligonucleotides
oligonucleotides were synthesized by the cyanoethyl method (Addam et al. 1983, McBride, et al. 1983, Sinba et al., 1984) on Nucleotide Synthesizer model 380A or 380B from Applied Biosystems, Inc. (Foster City, Calif.). Some oligonucleotides were purchased from Genosys Biotechnologies Inc. (The Woodlands, Tex.) or Midland Certified Reagent Co. (Midland, Tex.). The degenerate oligonucleotides were synthesized by machine mixing an equal molar ratio of the desired nucleosides in the condensation reaction at degenerate positions. Oligonucleotides were purified by polyacrylamide gel electrophoresis at concentrations from 12-20% (19:1 crosslinked) in 0.5×Tris borate (TBE) buffer (0.045 M Tris, 0.045 M boric acid, 1.25 mM EDTA) as described by Atkinson (1984) . The Oligonucleotides were desalted by passage through a Nensorb 20 column obtained from DuPont/New England Nuclear (Boston, Mass.) using a PREP Automated Sample Processor obtained from DuPont, Co. (Wilmington, Del.).
Quantitation of Synthetic Oligonucleotides
Synthetic oligonucleotides were resuspended in water (100 μl) and quantitated by reading the absorbance at 260 nm on a Beckman DU40 Spectrophotometer (Irvine, Calif.) using a one centimeter by one millimeter quartz cuvette (Maniatis, 1982). The concentration was determined using an extinction coefficient of 1×10 4 (Voet et al., 1963; Mahler and Cordes, 1966). The oligonucleotide was then diluted to the desired concentration.
Quantitation of synthetic DNA fragments can also be achieved by adding 10 to 100 picomoles of DNA to a solution containing kinase buffer (25 mM Tris pH 8.0, 10 mM MgCl 2 , 10 mM DTT and 2 mM spermidine). To the reaction mix is added ATP to 20 micromolar, ATP radiolabeled at the gamma phosphate (5000-10,0000 dpm/pmol) and 5 units of T4 polynucleotide kinase. Radiolabelled material is obtained from New England Nuclear (Boston, Mass.). The 10 microliter mixture is incubated at 37° C. for one hour. A 1 microliter aliquot of the mixture is chromatographed on DEAE paper (DE81 from Whatman) in 0.35 M ammonium bicarbonate. The counts that remain at the origin are used to determine the concentration of the synthetic DNA.
Recombinant DNA Methods
Isolation of plasmid DNA from E. coli cultures was performed as described (Birnboim and Doly, 1979). Some DNAs were purified by Magic™ miniprep columns, available from Promega (Madison, Wis.).
Purified plasmid DNA was treated with restriction endonucleases according to manufacturer's instructions. Analysis of the DNA fragments produced by treatment with restriction enzymes was done by agarose or polyacrylamide gel electrophoresis. Agarose (DNA grade from Fisher, Pittsburgh Pa.) was used at a concentration of 1.0% in a Tris-acetate running buffer (0.04 M Tris-acetate, 0.001M EDTA). Polyacrylamide (BioRad, Richmond Calif.) was used at a concentration of 6% (19:1 crosslinked) in 0.5×Tris-borate buffer (0.045 M Tris, 0.045 M boric acid, 1.25 mM EDTA), hereafter referred to as PAGE.
DNA polymerase I, large fragment, Klenow enzyme was used according to manufacturer's instructions to catalyze the addition of mononucleotides from 5′ to 3′ of DNA fragments which had been treated with restriction enzymes that leave protruding ends. The reactions were incubated at 65° C. for 10 minutes to heat inactivate the Klenow enzyme.
The synthetic oligonucleotides were made without 5′ or 3′ terminal phosphates. In cases where such oligonucleotides were ligated end to end, the oligonucleotides were treated at a concentration of 10 picomoles per microliter with T4 polynucleotide kinase in the following buffer: 25 mM Tris, pH 8.0, 10 mM MgCl 2 , 10 mM dithiothreitol, 2 mM spermidine, 1 mM rATP. After incubation for 30 minutes at 37° C., the samples were incubated at 65° C. for five minutes to heat inactivate the kinase.
Synthetic Gene Assembly
The (15-125) hIL-3 gene was divided into four regions separated by five convenient restriction sites. In each of the four regions synthetic oligonucleotides were designed so that they would anneal in complementary pairs, with protruding single stranded ends “or blunt ends” and when the pairs were properly assembled would result in a DNA sequence that encoded a portion of the hIL-3 gene. Amino acid substitutions in the hIL-3 gene were made by designing the oligonucleotides to encode the desired substitutions. The complementary oligonucleotides were annealed at concentration of 1 picomole per microliter in ligation buffer plus 50 mM NaCl. The samples were heated in a 100 ml beaker of boiling water and permitted to cool slowly to room temperature. One picomole of each of the annealed pairs of oligonucleotides were ligated with approximately 0.2 picomoles of plasmid DNA, digested with the appropriate restriction enzymes, in ligation buffer (25 mM Tris pH 8.0, 10 mM MgCl 2 , 10 mM dithiothreitol, 1 mM ATP, 2 mM spermidine) with T4 DNA ligase obtained from New England Biolabs (Beverly, Mass.) in a total volume of 20 μl at room temperature overnight.
›DETAILED DESCRIPTION OF THE INVENTION · 16 of 20
DNA fragments were isolated from agarose gels by intercepting the restriction fragments on DEAE membranes from Schleicher and Schuell (Keene, N.H.) and eluting the DNA in 10 mM Tris, 1 mM EDTA, 1 M NaCl at 55° C. for 1 hour, according to manufacturer's directions. The solutions containing the DNA fragment were concentrated and desalted by using Centricon 30 concentrators from Amicon (W. R. Grace, Beverly Mass.) according to the manufacturer's directions. Ligations were performed at 15° C. overnight, except as noted, in ligation buffer (66 mM Tris pH 7.5, 6.6 mM MgCl 2 , 1 mM dithiothreitol, 0.4 mM ATP) with T 4 ligase obtained from New England Biolabs (Beverly, Mass.).
Polymerase Chain Reaction
Polymerase Chain Reaction (hereafter referred to as PCR) techniques (Saiki, 1985) used the reagent kit and thermal cycler from Perkin-Elmer Cetus (Norwalk, Conn.). PCR is based on a thermostable DNA polymerase from Thermus aquaticus . The PCR technique is a DNA amplification method that mimics the natural DNA replication process in that the number of DNA molecules doubles after each cycle, in a way similar to in vivo replication. The DNA polymerase mediated extension is in a 5′→3′ direction. The term “primer” as used herein refers to an oligonucleotide sequence that provides an end to which the DNA polymerase can add nucleotides that are complementary to a nucleotide sequence. The latter nucleotide sequence is referred to as the “template”, to which the primers are annealed. The amplified PCR product is defined as the region comprised between the 5′ ends of the extension primers. Since the primers have defined sequences, the product will have discrete ends, corresponding to the primer sequenCes. The primer extension reaction was carried out using 20 picomoles (pmoles) of each of the oligonucleotides and 1 picogram of template plasmid DNA for 35 cycles (1 cycle is defined as 94° C. for one minute, 50° C. for two minutes and 72° C. for three minutes). The reaction mixture was extracted with an equal volume of phenol/chloroform (50% phenol and 50% chloroform, volume to volume) to remove proteins. The aqueous phase, containing the amplified DNA, and solvent phase were separated by centrifugation for 5 minutes in a microcentrifuge (Model 5414 Eppendorf Inc, Fremont Calif.). To precipitate the amplified DNA the aqueous phase was removed and transferred to a fresh tube to which was added 1/10 volume of 3M NaOAc (pH 5.2) and 2.5 volumes of ethanol (100% stored at minus 20° C.). The solution was mixed and placed on dry ice for 20 minutes. The DNA was pelleted by centrifugation for 10 minutes in a microcentrifuge and the solution was removed from the pellet. The DNA pellet was washed with 70% ethanol, ethanol removed and dried in a speedvac concentrator (Savant, Farmingdale, N.Y.). The pellet was resuspended in 25 microliters of TE (20 mM Tris-HCl pH 7.9, 1 mM EDTA). Alternatively the DNA was precipitated by adding equal volume of 4M NH 4 OAc and one volume of isopropanol [Treco, (1989)]. The solution was mixed and incubated at room temperature for 10 minutes and centrifuged. These conditions selectively precipitate DNA fragments larger than ˜20 bases and were used to remove oligonucleotide primers. One quarter of the reaction was digested with restriction enzymes [Higuchi, (1989)] and on completion heated to 70° C. to inactivate the enzymes.
Two Step Site-directed PCR Mutagenesis
Single amino acid substitution variants were created at positions 17-123 of hIL-3 in two site-directed mutagenesis steps by PCR (Bauer et al. manuscript in preparation).
The single amino acid substitution variants at positions 94-105 of hIL-3 were created as described below. In the first mutagenesis step plasmid DNA, containing the hIL-3 gene (amino acids 15-125), was the template in the PCR reaction. The DNA sequence of one of the oligonucleotide primers was designed to replace 12 base in the hIL-3 gene (15-125) with 12 bases encoding two translation stop codons (5′TAATAA3′), followed. by the recognition sequence (5′GTCGAC3′) restriction enzyme SalI. This 12 base sequence was substituted in the hIL-3 gene following the codon for amino acids 93, 97 and 101. Plasmids containing these mutagenized genes served as the templates for the second mutagenesis step.
In the second mutagenesis step, the 12 base substitution introduced in the first mutagenesis step, was replaced using a 32 fold degenerate oligonucleotide. The degenerate oligonucleotides were synthesized by machine mixing an equal molar ratio of the desired nucleosides in the condensation reaction at degenerate positions. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon. The other bases in the oligonucleotides corresponded to the hIL-3 sequence. The degenerate oligonucleotides theoretically contain 32 different codons, encoding all 20 amino acids and one translation stop codon, at a single position. At the other 9 bases the DNA sequence was restored to encode the native hIL-3 protein sequence. This pool of single amino acid substitutions at a single position is referred to as a “library”. This two step PCR site-directed mutagenesis approach was used to facilitate the identification of single amino acid substitution variants by differential DNA hybridization.
The single amino acid substitution variants at positions 17-93 and 106-123 of hIL-3 (15-125) were created as described below. In the first mutagenesis step plasmid DNA, containing the hIL-3 gene (15-125), was the template in the PCR reaction. The DNA sequence of one of the oligonucleotide primers was designed to delete 18 bases in the hIL-3 gene that encode the following amino acids; 17-22, 23-28, 29-34, 35-40, 41-46, 47-52, 53-58, 59-64, 65-70, 71-76, 77-82, 83-88, 88-93, 106-111, 112-117 and 118-123. Plasmids containing these deletion genes served as the templates for the second mutagenesis step.
In the second mutagenesis step the 18 base deletion, created in the first mutagenesis step, was restored using a 32 fold degenerate oligonucleotide. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon. The other bases in the oligonucleotides corresponded to the hIL-3 sequence. The degenerate oligonucleotides theoretically contain 32 different codons, encoding all 20 amino acids and one translation stop codon, at a single position. At the other 9 bases the DNA sequence was restored to encode the native hIL-3 protein sequence. This pool of single amino acid substitutions at a single position is referred to as a “library”. This two step PCR site-directed mutagenesis approach was used to facilitate the identification of single amino acid substitution variants by differential DNA hybridization.
›DETAILED DESCRIPTION OF THE INVENTION · 17 of 20
Recovery of Recombinant Plasmids from Ligation Mixes and Transformation of E. coli Cells with Recombinant Plasmid DNA
E. coli JM101 cells were made competent to take up DNA. Typically, 20 to 100 ml of cells were grown in LB medium to a density of approximately 150 Klett units and then collected by centrifugation. The cells were resuspended in one half culture volume of 50 mM CaCl 2 and held at 4° C. for one hour. The cells were again collected by centrifugation and resuspended in one tenth culture volume of 50 mM CaCl 2 . DNA was added to a 150 microliter volume of these cells, and the samples were held at 4° C. for 30 minutes. The samples were shifted to 42° C. for one minute, one milliliter of LB was added, and the samples were shaken at 37° C. for one hour. Cells from these samples were spread on plates containing ampicillin to select for transformants. The plates were incubated overnight at 37° C. Single colonies were picked and grown in LB supplemented with ampicillin overnight at 37° C. with shaking. From these cultures DNA was isolated for restriction analysis.
Typically plasmids were constructed, using methods described herein or by references cited herein, as follows except as noted in examples included herein. DNA fragments were purified from agarose or polyacrylamide gels. Purified DNA fragments were ligated and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin containing plates. Plasmid DNA was isolated from a single colony grown in LB Broth and screened by restriction analysis for the desired construct and sequenced to determine that the DNA sequence was correct.
Culture Media
LB medium (Maniatis et al., 1982) was used for growth of cells for DNA isolation. M9 minimal medium supplemented with 1.0% casamino acids, acid hydrolyzed casein, Difco (Detroit, Mich.) was used for cultures in which recombinant hIL-3 was produced. The ingredients in the M9 medium were as follows: 3g/liter KH 2 PO 4 , 6 g/l Na 2 HPO 4 , 0.5 g/l NaCl, 1 g/l NH 4 Cl, 1.2 mM MgSO 4 , 0.025 mM CaCl 2 , 0.2% glucose (0.2% glycerol with the AraBAD promoter), 1% casamino acids, 0.1 ml/l trace minerals (per liter 108 g FeCl 3 . 6H 2 O, 4.0 g ZnSO 4 .7H 2 O, 7.0 CoCl 2 .2H 2 O, 7.0 g Na 2 MoO 4 .2H 2 O, 8.0 g CuSO 4 .5H 2 O, 2.0 g H 3 BO 3 , 5.0 g MnSO 4 .H 2 O, 100 ml concentrated HCl). Bacto agar from Difco was used for solid media and ampicillin (Polycillin-N from Bristol-Meyers, Evansville, Ind.) was added to both liquid and solid LB media at 200 micrograms per milliliter.
DNA Sequence Analysis
The nucleotide sequencing of plasmid DNA was performed using a Genesis 2000 sequencer obtained from DuPont (Wilmington, Del.) according to the methods of Prober et al. (1987) and Sanger et al. (1977). Some DNA sequences were determined using Sequenase™ polymerase according to the protocol of its supplier, U.S. Biochemicals (Cleveland, Ohio).
Production of Recombinant hIL-3 Muteins in E. coli with Vectors Employing the recA Promoter
E. coli strains harboring the plasmids of interest were grown at 37° C. in M9 plus casamino acids medium with shaking in a Gyrotory water bath Model G76 from New Brunswick Scientific (Edison, N.J.). Growth was monitored with a Klett Summerson meter (green 54 filter), Klett Mfg. Co. (New York, N.Y.). At a Klett value of approximately 150, an aliquot of the culture (usually one milliliter) was removed for protein analysis. To the remaining culture, nalidixic acid (10 mg/ml) in 0.1 N NaOH was added to a final concentration of 50 μg/ml. The cultures were shaken at 37° C. for three to four hours after addition of nalidixic acid. A high degree of aeration was maintained throughout the bacterial growth in order to achieve maximal production of the desired gene product. The cells were examined under a light microscope for the presence of retractile bodies (RBs). One milliliter aliquots of the culture were removed for analysis of protein content.
Production of Recombinant hITL-3 Proteins from the AraBAD Promoter in E. coli
E. coli strains harboring the plasmids of interest were grown at 30° C. with shaking in M9 medium plus casamino acids and glycerol. Growth was monitored with a Klett Summerson calorimeter, using a green 54 filter. At a Klett value of about 150, an aliquot of the culture (usually one milliliter) was removed for protein analysis. To the remaining culture, 20% arabinose was added to a final concentration of 0.05%. The cultures were shaken at 30° C. for three to four hours after addition of arabinose. A high degree of aeration was maintained throughout the bacterial growth in order to achieve maximal production of the desired gene product. One milliliter aliquots of the culture were removed for analysis of protein content.
Secretion and Osmotic Shock
Three hour post induction samples were fractionated by osmotic shock [Neu and Heppel (1965)]. The Klett value of the cultures was determined and 1 ml of cells were centrifuged in a Signa mierocentrifuge (West Germany) model 202MK in 1.5 mls snap top microcentrifuge tubes for 5 minutes at 10,000 rpm. The cell pellet was resuspended very gently by pipeting in a room temperature sucrose solution (20% sucrose w/v, 30 mM Tris-Hcl pH7.5, 1 mM EDTA), using 1 μl/1 Klett unit. Following a 10 minute incubation at room temperature, the cells were centrifuged for 5 minutes at 10,000 rpm. The sucrose fraction was carefully removed from the cell pellet. The cell pellet was then resuspended very gently by pipeting in ice cold distilled water, using 1 μl/1 Klett unit. Following a 10 minute incubation on ice, the cells were centrifuged for 5 minutes at 12,000 rpm. The water fraction was carefully removed. Equal volumes of the sucrose and water fractions were pooled and aliquoted to provide samples for ELISA and biological activity screening.
Analysis of Protein Content of E. coli Cultures Producing hTL-3 Mutant Polypeptides
Bacterial cells from cultures treated as described above were collected from the medium by centrifugation. Aliquots of these cells were resuspended in SDS loading. buffer (4×: 6 g SDS, 10 ml beta-mercaptoethanol, 25 ml upper Tris gel stock (0.5 M Tris HCl pH 6.8, 0.4% SDS) brought to 50 ml with glycerol, 0.2% bromophenol blue was added) at a concentration of one microliter per Klett unit. These samples were incubated at 85° C. for five minutes and vortexed. Five or ten microliter aliquots of these samples were loaded on 15% polyacrylamide gels prepared according to the method of Laemmli (1970). Protein bands were visualized by staining the gels with a solution of acetic acid, methanol and water at 5:1:5 (volume to volume) ratio to which Coomassie blue had been added to a final concentration of 1%. After staining, the gels were washed in the same solution without the Coomassie blue and then washed with a solution of 7% acetic acid, 5% methanol. Gels were dried on a gel drier Model SE1160 obtained from Hoeffer (San Francisco, Calif.). The amount of stained protein was measured using a densitometer obtained from Joyce-Loebl (Gateshead, England). The values obtained were a measure of the amount of the stained hIL-3 protein compared to the total of the stained protein of the bacterial cells.
›DETAILED DESCRIPTION OF THE INVENTION · 18 of 20
Western Blot Analysis of hTL-3 Muteins Made in E. coli
In some E. coli cultures producing hIL-3, the level of accumulation of the hIL-3 protein is lower than 5% of total bacterial protein. To detect hIL-3 produced at this level, Western blot analysis was used. Proteins from cultures induced with nalidixic acid or arabinose. were run on polyacrylamide gels as described above except that volumes of sample loaded were adjusted to produce appropriate signals. After electrophoresis, the proteins were electroblotted to APT paper, Transa-bind, Schleicher and Schuell (Keene, N.H.) according to the method of Renart et al. (1979). Antisera used to probe these blots had been raised in rabbits, using peptides of the sequence of amino acids 20 to 41 and 94 to 118 of hIL-3 as the immunogens. The presence of bound antibody was detected with Staphylococcal protein A radiolabeled with 125 I, obtained from New England Nuclear (Boston, Mass.).
Fractionation of E. coli Cells Producing hIL-3 Proteins in the Cytoplasm
Cells from E. coli cultures harboring plasmids that produce hIL-3 muteins were induced with nalidixic acid. After three hours, the hIL-3 muteins accumulated in refractile bodies. The first step in purification of the hIL-3 muteins was to sonivate cells. Aliquots of the culture were resuspended from cell pellets in sonication buffer: 10 mM Tris, pH 8.0, 1 mM EDTA, 50 mM NaCl and 0.1 mM PMSF. These resuspended cells were subjected to several repeated sonication bursts using the microtip from a Sonicator cell disrupter, Model W-375 obtained from Heat Systems-Ultrasonics Inc. (Farmingdale, N.Y.). The extent of sonication was monitored by examining the homogenates under a light microscope. When nearly all of the cells had been broken, the homogenates were fractionated by centrifugation. The pellets, which contain most of the refractile bodies, are highly enriched for hIL-3 muteins.
Methods: Extraction, Refolding and Purification of Interleukin-3 (IL-3) Muteins Expressed as Refractile Bodies in E. coli.
Extraction of refractile bodies (RB's):
For each gram of RB's (and typically one gram is obtained from a 300 ml E. coli culture), 5 ml of a solution containing 6M guanidine hydrochloride (GnHCl), 50 mM 2-N-cyclohexylaminoethanesulfonic acid (CHES) pH 9.5 and 20 mM dithiothreitol (DTT) was added. The RB's were extracted with a Bio-Homogenizer for 15-30 seconds and gently rocked for 2 hours at 5 degrees centigrade (5° C.) to allow the protein to completely reduce and denature.
Refolding of the IL-3 Muteins
The protein solution was transferred to dialysis tubing (1000 molecular weight cut-off) and dialyzed against at least 100 volumes of 4M GnHCl-50 mM CHES pH 8.0. The dialysis was continued overnight at 5° C. while gently stirring. Subsequently dialysis was continued against at least 100 volumes of 2M GnHCl-50 mM CHES pH 8.0 and dialyzed overnight at 5° C. while gently stirring.
Purification of the IL-3 Muteins
The protein solution was removed from the dialysis tubing and acidified by the addition of 40% acetonitrile (CH 3 CN)-0.2% trifluoroacetic acid (TFA) to a final concentration of 20% CH 3 CN-0.1% TFA. This was centrifuged (16,000×g for 5 minutes) to clarify and the supernatant was loaded onto a Vydac C-18 reversed phase column (10×250 mm) available from Vydac (Hesperia, Calif.) previously equilibrated in 20% CH 3 CN-0.1% TFA. The column was eluted with a linear gradient (0.2% CH 3 CN/minute) between 40-50% CH 3 CN-0.1% TFA at a flow rate of 3 ml/minute while collecting 1.5 ml fractions. The fractions were analyzed by polyacrylamide gel electrophoresis (SDS-PAGE) and the appropriate fractions pooled. The pooled material was dried by lyophilization or in a Speed Vac concentrator. The dry powder was reconstituted with 10 mM ammonium bicarbonate pH 7.5, centrifuged (16,000×g for 5 minutes) to clarify and assayed for protein concentration by the method of Bradford (1976) with bovine serum albumin as the standard. Such protein can be further analyzed by additional techniques such as, SDS-PAGE, electrospray mass spectrometry, reverse phase HPLC, capillary zone electrophoresis, amino acid composition analysis, and ELISA (enzyme-linked immunosorbent assay).
hIL-3 Sandwich ELISA
IL-3 protein concentrations were determined using a sandwich ELISA based on an affinity purified polyclonal goat anti-rhIL-3. Microtiter plates (Dynatech Immulon II) were coated with 150 μl goat-anti-rhIL-3 at a concentration of approximately 1 μg/ml in 100 mM NaHCO3, pH 8.2. Plates were incubated overnight at room temperature in a chamber maintaining 100% humidity. Wells were emptied and the remaining reactive sites on the plate were blocked with 200 μl of solution containing 10 mM PBS, 3% BSA and 0.05% Tween 20, pH 7.4 for 1 hour at 37° C. and 100% humidity. Wells were emptied and washed 4× with 150 mM NaCl containing 0.05% Tween 20 (wash buffer). Each well then received 150 μl of dilution buffer (10 mM PBS containing 0.1% BSA, 0.01% Tween 20, pH 7.4), containing rhIL-3 standard, control, sample or dilution buffer alone. A standard curve was prepared with concentrations ranging from 0.125 ng/ml to 5 ng/ml using a stock solution of rhIL-3 (concentration determined by amino acid composition analysis). Plates were incubated 2,5 hours at 37° C. and 100% humidity. Wells were emptied and each plate was washed 4× with wash buffer. Each well then received 150 μl of an optimal dilution (as determined in a checkerboard assay format) of goat anti-rhIL-3 conjugated to horseradish peroxidase. Plates were incubated 1.5 hours at 37° C. and 100% humidity. Wells were emptied and each plate was washed 4× with wash buffer. Each well then received 150 ul of ABTS substrate solution (Kirkegaard and Perry). Plates were incubated at room temperature until the color of the standard wells containing 5 ng/ml rhIL-3 had developed enough to yield an absorbance between 0.5-1.0 when read at a test wavelength of 410 nm and a reference wavelength of 570 nm on a Dynatech microtiter plate reader. Concentrations of immunoreactive rhIL-3 in unknown samples were calculated from the standard curve using software supplied with the plate reader.
›DETAILED DESCRIPTION OF THE INVENTION · 19 of 20
AML Prolifpraton Assay for Bioactive Human Interleukkin-3
The factor-dependent cell line AML 193 was obtained from the American Type Culture Collection (ATCC, Rockville, Md.). This cell line, established from a patient with acute myelogenous leukemia, is a growth factor dependent cell line which displayed enhanced growth in GM/CSF supplemented medium (Lange, B., et al., (1987); Valtieri, M., et al., (1987). The ability of AML 193 cells to proliferate in the presence of human IL-3 has also been documented. (Santoli, D., et al., (1987)). A cell line variant was used, AML 193 1.3, which was adapted for long term growth In IL-3 by washing out the growth factors and starving the cytokine dependent AML 193 cells for growth factors for 24 hours. The cells were then replated at 1×10 5 cells/well in a 24 well plate in media containing 100 U/ml IL-3. It took approximately 2 months for the cells to grow rapidly in IL-3. These cells were maintained as AML 193 1.3 thereafter by supplementing tissue culture medium (see below) with human IL-3.
AML 193 1.3 cells were washed 6 times in cold Hanks balanced salt solution (HBSS, Gibco, Grand Island, N.Y.) by centrifuging cell suspensions at 250×g for 10 minutes followed by decantation of supernatant. Pelleted cells were resuspended in HBSS and the procedure was repeated until six wash cycles were completed. Cells washed six times by this procedure were resuspended in tissue culture medium at a density ranging from 2×10 5 to 5×10 5 viable cells/ml. This medium was prepared by supplementing Iscove's modified Dulbeccols Medium (IMDM, Hazleton, Lenexa, Kans.) with albumin, transferrin, lipids and 2-mercaptoethanol. Bovine albumin (Boehringer-Mannheim, Indianapolis, Ind.) was added at 500 μg/ml; human transferrin (Boehringer-Mannheim, Indianapolis, Ind.) was added at 100 μg/ml; soybean lipid (Boehringer-Mannheim, Indianapolis, Ind.) was added at 50 μg/ml; and 2-mercaptoethanol (Sigma, St. Louis, Mo.) was added at 5×10 −5 M.
Serial dilutions of human interleukin-3 or human interleukin-3 variant protein (hIL-3 mutein) were made in triplicate series in tissue culture medium supplemented as stated above in 96 well Costar 3596 tissue culture plates. Each well contained 50 gl of medium containing interleukin-3 or interleukin-3 variant protein once serial dilutions were completed. Control wells contained tissue culture medium alone (negative control). AMM 193 1.3 cell suspensions prepared as above were added to each well by pipetting 50 μl (2.5×10 4 cells) into each well. Tissue culture plates were incubated at 37° C. with 5% CO 2 in humidified air for 3 days. On day 3, 0.5 μCi 3 H-thymidine (2 Ci/mM, New England Nuclear, Boston, Mass.) was added in 50 μl of tissue culture medium. Cultures were incubated at 37° C. with 5% CO 2 in humidified air for 18-24 hours. Cellular DNA was harvested onto glass filter mats (Pharmacia LKB, Gaithersburg, Md.) using a TOMTEC cell harvester (TOMTEC, Orange, Conn.) which utilized a water wash cycle followed by a 70% ethanol wash cycle. Filter mats were allowed to air dry and then placed into sample bags to which scintillation fluid (Scintiverse II, Fisher Scientific, St. Louis, Mo. or BetaPlate Scintillation Fluid, Pharmacia LKB, Gaithersburg, Md.) was added. Beta emissions of samples from individual tissue culture wells were counted in a LKB Betaplate model 1205 scintillation counter (Pharmacia LKB, Gaithersburg, Md.) and data was expressed as counts per minute of 3 H-thymidine incorporated into cells from each tissue culture well. Activity of each human interleukin-3 preparation or human interleukin-3 variant preparation was quantitated by measuring cell proliferation ( 3 H-thymidine incorporation) induced by graded concentrations of interleukin-3 or interleukin-3 variant. Typically, concentration ranges from 0.05 pM-10 5 pM are quantitated in these assays. Activity is determined by measuring the dose of interleukin-3 or interleukin-3 variant which provides 50% of maximal proliferation [EC 50 =0.5× (maximum average counts per minute of 3 H-thymidine incorporated per well among triplicate cultures of all concentrations of interleukin-3 tested - background proliferation measured by 3 H-thymidine incorporation observed in triplicate cultures lacking interleukin-3]. This EC 50 value is also equivalent to 1 unit of bioactivity. Every assay was performed with native interleukin-3 as a reference standard so that relative activity levels could be assigned.
Relative biological activities of some IL-3 muteins of the present invention are shown in Table 1. The Relative Biological Activity of IL-3 mutants is calculated by dividing the EC 50 of (1-133) hIL-3 by the EC 50 of the mutant. The Relative Biological Activity may represent the average of replicate assays.
The following assay is used to measure IL-3 mediated sulfidoleukotriene release from human mononuclear cells.
IL-3 Mediated Sulfidoleukotriene Release from Human Mononuclear Cells
Heparin-containing human blood was collected and layered onto an equal volume of Ficoll-Paque (Pharmacia #17-0840-02) ready to use medium (density 1.077 g/ml.). The Ficoll was warmed to room temperature prior to use and clear 50 ml polystyrene tubes were utilized. The Ficoll gradient was spun at 300× g for 30 minutes at room temperature using a H1000B rotor in a Sorvall RT6000B refrigerated centrifuge. The band containing the mononuclear cells was carefully removed, the volume adjusted to 50 mls with Dulbecco's phosphate-buffered saline (Gibco Laboratories cat. #310-4040PK), spun at 400×g for 10 minutes at 40° C. and the supernatant was carefully removed. The cell pellet was washed twice with HA Buffer [20 mM Hepes (Sigma # H-3375), 125 mM NaCl (Fisher # S271-500), 5 mM KCl (sigma # P-9541), 0.5 mM glucose (Sigma # G-5000), 0.025% Human Serum Albumin (Calbiochem #126654) and spun at 300×g, 10 min., 4° C. The cells were resuspended in HACM Buffer (HA buffer supplemented with 1 mM CaC12 (Fisher # C79-500) and 1 mM MgC12 (Fisher # M-33) at a concentration of 1×106 cells/ml and 180 μl were transferred into each well of 96 well tissue culture plates. The cells were allowed to acclimate at 37° C. for 15 minutes. The cells were primed by adding 10 μls of a 20× stock of various concentrations of cytokine to each well (typically 100000, 20000, 4000, 800, 160, 32, 6.4, 1.28, 0 fM IL3). The cells were incubated for 15 minutes at 37° C. Sulfidoleukotriene release was activated by the addition of 10 μl of 20×(1000 nM) fmet-leu-phe (Calbiochem #344252) final concentration 50 nM FMLP and incubated for 10 minutes at 37° C. The plates were spun at 350×g at 4° C. for 20 minutes. The supernatants were removed and assayed for sulfidoleukotrienes using Cayman's Leukotriene C4 EIA kit (Cat. #420211) according to manufacturers' directions. Native (15-125) hIL-3 was run as a standard control in each assay.
›DETAILED DESCRIPTION OF THE INVENTION · 20 of 20
Native hIL-3 possesses Considerable inflammatory activity and has been shown to stimulate synthesis of the arachidonic acid metabolites LTC 4 , LTD 4 , and LTE 4 ; histamine synthesis and histamine release. Human clinical trials with native hIL-3 have documented inflammatory responses (Biesma, et al., BLOOD, 80:1141-1148 (1992) and Postmus, et al., J. CLIN. ONCOL., 0:1131-1140 (1992)). A recent study indicates that leukotrienes are involved in IL-3 actions in vivo and may contribute significantly to the biological effects of IL-3 treatment (Denzlinger, C., et al., BLOOD, 81:2466-2470 (1993))
Some muteins of the present invention may have an improved therapeutic profile as compared to native hIL-3 or (15-125) hIL-3. For example, some muteins of the present invention may have a similar or more potent growth factor activity relative to native hIL-3 or (15-125) hIL-3 without having a similar or corresponding increase in the stimulation of leukotriene or histamine. These muteins would be expected to have a more favorable therapeutic profile since the amount of polypeptide which needs to be given to achieve the desired growth factor activity (e. g. cell proliferation) would have a lesser leukotriene or histamine stimulating effect. In studies with native hIL-3, the stimulation of inflammatory factors has been an undesirable side effect of the treatment, Reduction or elimination of the stimulation of mediators of inflammation would provide an advantage over the use of native hIL-3.
Some muteins of the present invention may have antigenic profiles which differ from that of native hIL-3. For example, in a competition ELISA with an affinity purified polyclonal goat anti-hIL-3 antibody, native hIL-3 significantly blocked the binding of labeled hIL-3 to polyclonal anti-hIL-3 antibody. Some polypeptides of the present invention, particularly those with several amino acids differing from those of native hIL-3, fail to block the binding of hIL-3 to anti-hIL-3 antibody.
Table 2 lists the sequences of some oligonucleotides used in making the muteins of the present invention.
Table 3 lists the amino acid sequence of native (15-125) hIL-3 (Peptide #1) and the amino acid sequences of some mutant polypeptides of the present invention. The sequences are shown with the amino acid numbering corresponding to that of native hIL-3 [FIG. 1 ].
Polypeptides corresponding to SEQ ID NOS. 15, 16, 17, 18 and 129 comprising (1-133) hIL-3 containing one or more amino acid substitutions can be made using the procedures described above and in the following examples by starting with the appropriate oligonuctiotides and then constructing the DNA encoding the polypeptide and expressing it in an appropriate host cell. In a similar manner polypeptides which correspond to SEQ ID NOS. 19, 20, 21, 22 and 130 and contain one or more amino acid substitutions and wherein from 1 to 14 amino acids have been sequentially deleted from the N-terminus, or from 1 to 15 amino acids have been deleted from the C-terminus or deletions of amino acids have been made from both the N-terminus and the C-terminus can also be made by following the procedures described above and in the following examples, beginning with the appropriate starting materials.
Additional details may be found in U.S. patent application Ser. No. 07/981,044 filed Nov. 24, 1992, now abandoned which is hereby incorporated by reference in its entirety.
Additional details may be found in co filed U.S. patent application Ser. No. 08/411,795 which is hereby incorporated by reference in its entirety.
All references, patents or applications cited herein are incorporated by reference in their entirety.
Further details known to those skilled in the art may be found in T. Maniatis, et al., Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory (1982) and references cited therein, incorporated herein by reference in its entirety; and in J. Sambrook, et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory (1989) and references cited therein, incorporated herein by reference in its entirety.
The following examples will illustrate the invention in greater detail although it will be understood that the invention is not limited to these specific examples.
Amino acids are shown herein by standard one letter or three letter abbreviations as follows:
Various other examples will be apparent to the person skilled in the art after reading the present disclosure without departing from the spirit and scope of the invention. It is intended that all such other examples be included within the scope of the appended claims.
›REFERENCES · 1 of 2
Adams, S. P., Kavka, K. S., Wykes, E. J., Holder, S. B. and Galluppi, G. R. Hindered Dialkyamino Nucleoside Phosphate reagents in the synthesis of two DNA 51-mers. J. Am. Chem. Soc., 105, 661-663 (1983).
Atkinson, T. and Smith, M., in Gait, M. J., Oligonucleotide Sythesis (1984) (IRL Press, Oxford England).
Bachmann, B., Pedigrees of some mutant strains of Escherichia coli K-12, Bacteriological Reviews, 3:525-557 (1972).
Bayne, M. L., Expression of a synthetic gene encoding human insulin-like growth factor I in cultured mouse fibroblasts. Proc. Natl. Acad. Sci. USA 84, 2638-2642 (1987).
Ben-Bassat, A., K. Bauer, S-Y. Chang, K. Myambo, A. Boosman and S. Ching. Processing of the initiating methionine from proteins: properties of the Escherichia coli methionine aminopeptidase and its gene structure. J. Bacteriol., 169: 751-757 (1987).
Biesma, B. et al., Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood, 80:1141-1148 (1992).
Birnboim, H. C. and J. Doly. A rapid alkaline extraction method for screening recombinant plasmid DNA. Nucleic Acids Research, 7(6): 1513-1523 (1979).
Bradford, M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding, Analytical Biochemistry, 72: 248-254 (1976).
Clark-Lewis, I., L. E. Hood and S. B. H. Kent. Role of disulfide bridges in determining the biological activity of interleukin 3, Proc. Natl. Acad. Sci.,USA, 85: 7897-7901 (1988).
Clement, J. M. and Hofnung, M. Gene sequence of the receptor, an outer membrane protein of E. coli K12. Cell, 27: 507-514 (1981).
Covarrubias, L., L. Cervantes, A. Covarrubias, X. Soberon, I. Vichido, A. Blanco, Y. M. Kupersztoch-Portnoy and F. Bolivar. Construction and characterization of new cloning vehicles. V. Mobilization and coding properties of pBR322 and several deletion derivates including pBR327 and pBR328. Gene 13: 25-35 (1981).
Deng, W. P. & Nickoloff, J. A. Site-directed mutagenesis of virtually any plasmid by eliminating a unique site. Anal. Biochem. 200:81 (1992).
Dente, L., G. Cesareni and R. Cortese, pEMBL: A new family of single stranded plasmids, Nucleic Acids Research, 11: 1645-1655 (1983).
Dunn, J. J. and Studier, F. W., Complete nucleotide sequence of bacteriophage T7 DNA and the locations of T7 genetic elements. J. Mol. Biol. 166:477-535 (1983).
Falk, S., G. Seipelt, A. Ganser, O. G. Ottmann, D. Hoelzer, H. J. Stutte and K. Hubner. Hematopathology 95: 355 (1991).
Fling, M. E., et al. Nucleotide sequence of the transposon Tn7 gene encoding an aminoglycoside-modifying enzyme, 3″(9)-O-nucleotidyltransferase. Nucl. Acids Res. 13:7095-7106 (1985).
Ganser, A., A. Lindemann, G. Seipelt, O. G. Ottmann, F. Herrmann, M. Eder, J. Frisch, G. Schulz, R. Mertelsmann and D. Hoelzer. Effects of Recombinant Human Interleukin-3 in Patients With Normal Hematopoiesis and in Patients with Bone Marrow Failure, Blood 76: 666 (1990).
Gething and Sambrook, Cell-surface expression of influenza haemagglutinin from a cloned DNA copy of the RNA gene, Nature, 293: 620-625 (1981).
Gillio, A. P., C. Gasparetto, J. Laver, M. Abboud, M. A. Bonilla, M. B. Garnick and R. J. O'Reilly. J. Clin. Invest. 85: 1560 (1990).
Gouy, M. and G. Gautier, Codon usage in bacteria: Correlation with gene expressivity, Nucleic Acids Research, 10: 7055-7074 (1982).
Greenfield, L., T. Boone, and G. Wilcox. DNA sequence of the araBAD promoter in Escherichia coli B/r. Proc. Natl. Acad. Sci. USA, 75: 4724-4728 (1978).
Higuchi, R, (1989) in PCR Technology, H. A. Erlich ed., Stockton Press, N.Y. chapter 2-6.
Hunkapiller, M. W., R. W. Hewick, R. J. Dreyer and L. E. Hood. High sensitivity sequencing with a gas-phase sequenator. Methods in Enzymology 153: 399-413 (1983).
Kaufman, et al., Coamplification and Coexpression of Human Tissue-Type Plasminogen Activator and Murine Dihydrofolate Reductase Sequences in Chinese Hamster Ovary Cells, Mol. Cell. Biol., 5(7): 1750-1759 (1985).
Kaufman, R. J. High level production of proteins in mammalian cells, in Genetic Engineering, Principles and Methods, Vol. 9, J. K. Setlow, editor, Plenum Press, New York (1987).
Kunkel, T. A. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc. Natl. Acad. Sci. USA, 82: 488-492 (1985).
Laemmli, U. K., Cleavage of structural proteins during assembly of the head of bacteriophage T4, Nature, 227:680-685 (1970).
Lange, B., M. Valtieri, D. Santoli, D. Caracciolo, F. Mavilio, I. Gemperlein, C. Griffin, B. Emanuel, J. Finan, P. Nowell, and G. Rovera. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-defendent cell lines. Blood 70: 192 (1987).
Mahler, H. R. and E. H. Cordes, in Biological Chemistry, p. 128, New York, Harper and Row (1966).
Maniatis, T., E. F. Fritsch and J. Sambrook, Molecular Cloning, A Laboratory Manual. Cold Spring Harbor Laboratory (1982).
Marinus, M. G. Location of DNA methylation genes on the Escherichia coli K-12 genetic map. Molec. Gen. Genet. 127: 47-55 (1973).
McBride, L. J. and Caruthers, M. H. An investigation of several deoxynucleoside phosphoramidites. Tetrahedron Lett., 24, 245-248 (1983).
Messing, J., A multipurpose cloning system based on the single-stranded DNA bacteriophage M13. Recombinant DNA Technical Bulletin, NIH Publication No. 79-99, Vol. 2, No. 2, pp. 43-48 (1979).
Neu, H. C. and L. A. Heppel. The release of enzymes from Escherichia coli by osmotic shock and during the formation of spheroplasts. J. Biol. Chem., 240: 3685-3692 (1965).
Obukowicz, M. G., Staten, N. R. and Krivi, G. G., Enhanced Heterologous Gene Expression in Novel rpoH Mutants of Escherichia coli. Applied and Environmental Microbology 58, No. 5, p. 1511-1523 (1992).
Olins, P. O., C. S. Devine, S. H. Rangwala and K. S. Kavka, The T7 phage gene 10 leader RNA, a ribosome-binding site that dramatically enhances the expression of foreign genes in Escherichia coli, Gene, 73:227-235 (1988).
Olins, P. O. and S. H. Rangwala, Vector for enhanced translation of foreign genes in Escherichia coli, Methods in Enzymology, 18: 115-119 (1990).
›REFERENCES · 2 of 2
Postmus, et al., Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study. J. Clin. Oncol., 10:1131-1140 (1992).
Prober, J. M., G. L. Trainor, R. J. Dam, F. W. Hobbst C. W. Robertson, R. J. Zagursky, A. J. Cocuzza, M. A. Jensen and K. Baumeister. A system for rapid DNA sequencing with fluorescent chain-terminating dideoxynucleotides. Science 283: 336-341 (1987).
Renart J., J. Reiser and G. R. Stark, Transfer of proteins from gels to diazobenzyloxymethyl-paper and detection with anti-sera: a method for studying antibody specificity and antigen structure, Proc. Natl. Acad. Sci. USA, 76:3116-3120 (1979).
Saiki, R. K., Schorf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A. and Arnheim, N., Enzymatic Amplification of β-Globin Genomic Sequences and Restriction Site Analysis for Diagnosis of Sickle Cell Anemia, Science, 230: 1350-1354 (1985).
Sambrook, J., et al., Molecular Cloning, A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory (1989).
Sancar, A., C. Stachelek, W. Konigsberg and W. D. Rupp, Sequences of the recA gene and protein, Proc. Natl. Acad. Sci., 77: 2611-2615 (1980).
Sanger, F., S. Nicklen and A. R. Coulson. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U. S. A. 74: 5463-5467 (1977).
Santoli, D., Y. Yang, S. C. Clark, B. L. Kreider, D. Caracciolo, and G. Rovera. Synergistic and antagonistic effects of recombinant human interleukin (IL-3), IL-1α, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139:348 (1987).
Smith, M. In vitro mutagenesis. Ann. Rev. Genet., 19:423-462 (1985).
Soberon, X., L. Covarrublas and F. Bolivar, Construction and characterization of new cloning vehicles. IV. Deletion derivatives of pBR322 and pBR325, Gene, 9: 211-223 (1980).
Stader, J. A. and T. J. Sulhavy. Engineering Escherichia coli to secrete heterologous gene products, Methods in Enzymology, 185: 166-87 (1990).
Summers, M. D. and G. E. Smith. A manual of methods for Baculovirus vectors and insect cell culture procedures. Texas Agricultural Experiment Station Bulletin No. 1555 (1987).
Taylor, J. W., Ott, J. and Eckstein, F.. The rapid generation of oligonucleotide-directed mutants at high frequency using phosphorothioate modified DNA. Nucl. Acids Res., 13:8764-8785 (1985).
Treco, D. A., in Current protocols in Molecular Biology, Seidman et al., eds. J Wiley N.Y., unit 2.1. (1989)
Valtieri, M., D. Santoli, D. Caracciolo, B. L. Kreider, S. W. Altmann, D. J. Tweardy, I. Gemperlein, F. Mavilio, B. J. Lange and G. Rovera. Establishment and characterization of an undifferentiated human T leukemia cell line which requires granulocyte-macrophage colony stimulating factor for growth. J. Immunol. 138:4042 (1987).
Voet, D., W. B. Gatzer, R. A. Cox, P. Doty. Absorption spectra of the common bases. Biopolymers 1: 193 (1963).
Wells, J. A., Vasser, M., and Powers, D. B. Cassette mutagenesis: an effective method for generation of multiple mutants at defined sites. Gene, 34:315-323 (1985).
Wong, E. Y., R. Seetharam, C. Kotts, R. A. Heeren, B. K. Klein, S. B. Braford, K. J. Mathis, B. F. Bishop, N. R. Siegel, C. E. Smith and W. C. Tacon. Expression of secreted IGF-1 in Escherichia coli. Gene, 68: 193-203 (1988).
Yang, Y., A. B. Clarletta, P. A. Temple, M. P. Chung, S., Koviacic, J. S. Witek-Giannotti, A. C. Leary, R. Kriz, R. E. Donahue, G. G. Wong and S. C. Clark. Human IL-3 (Multi-CSF): Identification by expression cloning of a novel hematopoietic growth factor related to murine IL-3. Cell 47: 3-10 (1985).
Yanisch-Perron, C., J. Viera and J. Messing. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33: 103-119 (1985).
Zoller, M. J. and Smith, M. Oligonucleotide-directed mutagenesis using M13-derived vectors: an efficient and general procedure for the production of point mutations in any fragment of DNA. Nucleic Acid Research, 10: 6487-6500 (1982).
Zoller, M. J. and Smith, M. Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors. Methods in Enzymology, 100:468-500 (1983).
Zoller, M. J. and Smith, M. Oligonucleotide-directed Mutagenesis: A simple method using two oligonucleotide primers and a single-stranded DNA template. DNA, 3: 479 (1984).
›Examples72
›EXAMPLE 1
Construction of pMON 5846 (FIG. 4) which Encodes [Met-(1-133) hIL-3 (Arg129)]
A plasmid containing the gene for the cDNA of hIL-3 cloned into pUC18 on an EcoRI to HindIII fragment was obtained from British Biotechnology Limited (Cambridge, England). This plasmid was designated pPO518. The purified plasmid DNA was cleaved by the restriction endonucleases NheI and BamHI. Approximately 0.5 micrograms of cleaved plasmid DNA was ligated to 1.0 picomoles of a pair of annealed oligonucleotides with the following sequence:
5′-CTAGCGATCTTTTAATAAGCTTG-3′ [SEQ ID NO: 1]
3′-GCTAGAAAATTATTCGAACCTAG-5′ [SEQ ID NO: 2]
The ligation mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked, and plasmid DNA was purified and subjected to restriction enzyme analysis. An isolate was identified in which the above oligonucleotide sequence had replaced the portion of the gene that encodes the extreme C-terminus. Within the new sequence was a new stop codon, TAA, and a recognition site for the enzyme HindIII. The new plasmid was designated pMON5846.
›EXAMPLE 2
(a) Construction of Expression Vector Plasmid pMON2341
The plasmid pMON2341 was used to supply the particular replicon and expression elements used for construction of many of the plasmids used to produce hIL-3 and hIL-3 muteins in E. coli. These expression elements are described in the materials and methods section. pMON2341 is derived from pMON5515 (Olins et al., 1988) and from pMON2429. pMON2429 consists of the phage mp18 (Yanisch-Perron et al., 1985) with a BclI fragment carrying the chloramphenicol acetyl transferase (cat) gene from pBR328 (Covarrubias et al., 1981) inserted into the BamHI site. The cat gene in pMON2429 has been altered from that in pBR328 by site directed mutagenesis (Kunkel, 1985). The recognition sites for NcoI and EcoRI which occur in the native gene were altered so that these two restriction enzymes no longer recognize these sites. The changes did not alter the protein specified by the gene. Also, an NcoI site was introduced at the N-terminus of the coding sequence so that it overlaps the codon for initiator methionine.
The steps involved in construction of pMON2341 are listed below:
(1) The DNAs of pMON5515 and pMON2429 were treated with NcoI and HindIII. The fragments were ligated and used to transform competent E. coli to ampicillin resistance. From these colonies, some were identified that were chloramphenicol resistant. From one of these colonies, plasmid DNA was isolated in which the rat atriopeptigen gene of pMON5515 had been replaced by the NcoI to HindIII fragment containing the cat gene from pMON2429. This fragment contains the recognition sites for several restriction enzymes in the portion derived, from the multilinker region of mp18. The new plasmid was designated pMON2412.
(2) pMON2412 was treated with the enzyme ClaI which cleaves at one location in the pBR327 derived portion of the DNA. The protruding ends were rendered blunt by treatment with Klenow in the presence of nucleotide precursors. This DNA was mixed with an isolated 514 bp RsaI fragment derived from pEMBL8 (Dente et al., 1983). This RsaI fragment contains the origin of replication of phage f1. This ligation mixture was used to transform competent E. coli cells to ampicillin resistance. Among the plasmid DNAs isolated from these cells was pMON5578. This plasmid has the structure of pMON2412 with the f1 origin region inserted into the ClaI site. This in illustrated in the Figures and in Olins and Rangwala (1990).
(3) The DNA of pMON5578 was treated with restriction enzymes HindIII and MstII. The DNA was then treated with Klenow enzyme in the presence of nucleotide precursors to render the ends blunt. This treated DNA was ligated and used to transform competent E. coli to ampicillin resistance. From the ampicillin resistant colonies, one plasmid was recovered from which the portion between HindIII and MstII was absent. This deletion resulted in the removal of sequences from the plasmid which are recognized by a number of restriction endonuclease sites. The new plasmid was designated pMON5582.
(4) The DNA of pMON5582 was treated with SstII and BclI and ligated in the presence of annealed oligonucleotides with the sequences shown below.
5′-GGCAACAATTTCTACAAAACACTTGATACTGTATGAGCAT-3′-CGCCGTTGTTAAAGATGTTTTGTGAACTATGACATACTCGTAACAGTATAATTGCTTCAACAGAACAGATC-3′ [SEQ ID NO:3]
TGTCATATTAACGAAGTTGTCTTGT-5′ [SEQ ID NO:4]
This sequence encodes the essential elements of the recA promoter of E. coli including the transcription start site and the lexA repressor binding site (the operator) (Sancar et al., 1980). The plasmid recovered from the ligation mixes contained this recA promoter in place of the one In pMON5582 (and in pMON5515). The functionality of the recA promoter was illustrated by Olins and Rangwala (1990). The new plasmid was designated pMON5594.
(5) To eliminate the single EcoRI site in pMON5594, the DNA was treated with EcoRI, then with Klenow in the presence of nucleotide precursors to render the ends blunt and then the DNA was ligated. From this ligation mix a plasmid was recovered whose DNA was not cleaved with EcoRI. This plasmid was designated pMON5630.
(6) To alter the single recognition site for PstI, plasmid pMON5630 was subjected to site directed mutagenesis (Kunkel, 1985). The oligonucleotide used in this procedure has the sequence shown below.
5′-CCATTGCTGCCGGCATCGTGGTC-3′ [SEQ ID NO:5]
The result of the procedure was to construct pMON2341 which differs from pMON5630 in that the PstI site in the beta-lactamase gene was altered so that PstI no longer recognizes the site. The single nucleotide change does not alter the amino acid sequence of the beta-lactamase protein.
(b) Construction of pMON5847 (FIG. 5) which Encodes [Met-(1-133) hIL-3(Arg 129 )]
Plasmid pMON2341 was used to supply the replicon, promotor, ribosome binding site, transcription terminator and antibiotic resistance marker for the plasmids used to produce hIL-3 in E. coli from cDNA derived hIL-3 genes.
Plasmid pMON2341 was treated with restriction enzymes NcoI and HindIII. The restriction fragment containing the replication origin was purified. The DNA of plasmid pMON5846 was treated with NcoI and HindIII. The restriction fragment containing the hIL-3 gene was gel purified. These purified restriction fragments were mixed and ligated. The ligation mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked, and plasmid DNA was purified and analyzed using restriction enzymes. pMON5847 was identified as a plasmid with the replicon of pMON2341 and the hIL-3 gene in place of the chloramphenicol acetyl transferase gene. JM101 cells harboring this plasmid were cultured in M9 medium and treated with nalidixic acid as described above. Samples of the culture were examined for protein content. It was found that this hIL-3 mutein was produced at about 6% of total cell protein as measured on Coomassie stained polyacrylamide gels.
›EXAMPLE 3
Construction of pMON5854 (FIG. 7) which Encodes [Met-(1-133) hIL-3(Arg 129 )]
To increase the accumulation of hIL-3 in E. coli, the coding sequence of the amino terminal portion of the protein was altered to more closely reflect the codon bias found in E. coli genes that produce high levels of proteins (Gouy and Gautier, 1982). To change the coding sequence for the amino terminal portion of the gene, a pair of synthetic oligonucleotides were inserted between the NcoI and HpaI sites within the coding sequence. About 0.5 micrograms of DNA of the plasmid pMON5847 (Example 2) was treated with NcoI and HpaI. This DNA was mixed with an annealed pair of oligonucleotides with the following sequence:
5′-CATGGCTCCAATGACTCAGACTACTTCTCTTAAGACT-3′-CGAGGTTACTGAGTCTGATGAAGAGAATTCTGATCTTGGGTT-3′ [SEQ ID NO:6]
AGAACCCAA-5′ [SEQ ID NO:7]
The fragments were ligated. The ligation mixture was used to transform competent JM101 to ampicillin resistance. Colonies were picked into broth. From the cultures plasmid DNA was made and examined for the presence of a DdeI site (CTNAG) which occurs in the synthetic sequence but not between the NcoI and HpaI sites in the sequence of pMON5847. The new recombinant plasmid was designated pMON5854. The nucleotide sequence of the DNA in the coding sequence of the amino terminal portion of the hIL-3 gene in pMON5854 was determined by DNA sequencing and found to be the same as that of the synthetic oligonucleotide used in ligation. Cultures of JM101 cells harboring this plasmid were grown and treated with nalidixic acid to induce production of the hIL-3 mutant protein. Analysis of the proteins on Coomassie gels showed that the accumulation of hIL-3 mutein was about 25% of total cell protein in cultures harboring pMON5854, significantly higher than it was in cultures harboring pMON5847.
›EXAMPLE 4
Construction of pMON5887 (FIG. 12) which Encodes [Met-(1-125) hIL-3]
The plasmid DNA of pMON5854 (Example 3) was treated with EcoRI and HindIII and the larger fragment was gel purified. About 0.5 mitrogram of this DNA was ligated to 1 picomole of an annealed pair of oligonucleotides which encode amino acids 107 through 125 of hIL-3. The sequences of these oligonucleotides are shown below. EcoRI to HindIII
5′-AATTCCGTCOTAAMCTGACCTTCTATCTGAAAA-3′-GGCAGCATTTGACTGGAAGATAGACTTTTCCTTGGAGAACGCGCAGGCTCAACAGTAATA-3′ [SEQ ID NO;8]
GGAACCTCTTGCGCGTCCGAGTTGTCATTATTCGA-5′ [SEQ ID NO:9]
After ligation, the DNA was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked into broth and plasmid DNA was isolated from each culture. Restriction analysis of the plasmid DNA showed the presence of an EcoRI to HindIII fragment smaller than that of pMON5854. The nucleotide sequence of the portion of the coding sequence between the EcoRI and HindIII sites was determined to confirm the accuracy of the replaced sequence. The new plasmid was designated pMON5887 encoding Met-(1-125) hIL-3 which has the following amino acid sequence:
[SEQ ID NO:10]
Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr
Ser Trp Val Asn Cys Ser Asn Met Ile Asp Glu Ile
Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu
Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile
Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu
Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala
Ser Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro
Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His
Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe
Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu
Asn Ala Gln Ala Gln Gln
›EXAMPLE 5
Construction of pMON5967 which Encodes [Met-Ala-(15-125) hIL-3]
Plasmid DNA of pMON5887 isolated from E. coli GM48 (dam-) was cleaved with NcoI and ClaI and ligated to 1 picomole of an annealed pair of oligonucleotides, Nco I and ClaI, encoding amino acids [Met Ala (15-20) hIL-3]. The sequence of these oligonucleotides is shown below.
5′-CATGGCTAACTGCTCTAACATGAT-3′[SEQ ID NO:11]
3′-CGATTGACGAGATTGTACTAGC-5′[SEQ ID NO:12]
The resulting ligation mix was used to transform competent E. coli JM101 cells to ampicillin resistant colonies. Plasmid DNA was isolated from these cells and the size of the inserted fragment was determined to be smaller than that of pMON5887 by restriction analysis using NcoI and NsiI. The nucleotide sequence of the region between NcoI and ClaI was determined and found to be that of the synthetic oligonucleotides. The new plasmid was designated pMON5967 and cells containing it were induced for protein production. Sonicated cell pellets and supernatants were used for protein purification and bio-assay.
›EXAMPLE 6
Construction of pMON5978 which Encodes [Met-Ala-(15-125) hIL-3]
Plasmid DNA of pMON5967 isolated from E. coli GM48(dam-) was cleaved with ClaI and NsiI and ligated to 1 picomole of an annealed assembly of six oligonucleotides encoding hIL-3 amino acids 20-70 (FIG. 2 ). This synthetic fragment encodes three unique restriction sites, EcoRV, XhoI and PstI. The sequence of these oligonucleotides is shown in FIG. 2 .
The resulting ligation mix was used to transform competent E. coli JM101 cells to ampicillin resistant colonies. Plasmid DNA was isolated and screened with XbaI and EcoRV for the presence of the new restriction site EcoRV. The DNA sequence of the region between ClaI and NsiI was determined and found to be the same as that of the synthetic oligonucleotides. The new plasmid was designated pMON5978, and cells containing it were induced for protein production. Sonicated cell pellets and supernatants were used for protein purification and bioassay.
Plasmid pMON5978 encodes [Met-Ala-(15-125) hIL-3] which has the following amino acid sequence:
[SEQ ID NO:13]
Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile
Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu Asp
Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu
Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala
Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser
Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro Cys
Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His Pro
Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg
Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn
Ala Gln Ala Gln Gln
›EXAMPLE 7
Construction of pMON5898
Plasmid pMON5851 DNA was digested with restriction enzymes HindIII and NcoI resulting in a 3695 base pair NcoI,HindIII fragment. The genetic elements derived from pMON5851 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, AraBAD promoter, g10L ribosome binding site and the lamB secretion leader. The AraBAD promoter is identical to that described in plasmid pMON6235 and the lamB signal peptide sequence used is that shown in FIG. 8 fused to hIL-3 at the NcoI recognition site. Plasmid pMON5873 DNA was digested with restriction enzymes HindIII and NcoI resulting in a 408 base pair NcoI,HindIII fragment. The genetic element derived from pMON5873 is the hIL-3 gene (1-133). Clones containing the hIL-3 (1-133) gene contained a 408 base pair NcoI, HindIII restriction fragment. This construct was designated pMON5898.
›EXAMPLE 8
Construction of pMON5987
Plasmid pMON6458 DNA was digested with restriction enzymes NcoI and HindIII, resulting in a 3940 base pair NcoI, HindIII fragment. The genetic elements derived from pMON6458 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, AraBAD promoter, g10L ribosome binding site and lamB secretion leader. Plasmid pMON5978 DNA was digested with NcoI and NsiI. The resulting 170 base pair NcoI, NsiI fragment encodes amino acids 15-71 of (15-125) hIL-3. Plasmid pMON5976 DNA was digested with NsiI and HindIII. The resulting 175 base pair NsiI, HindIII fragment encodes amino acids 72-125 of (15-125) hIL-3. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and screened for the restriction sites EcoRV and NheI and DNA sequenced to confirm the correct insert.
›EXAMPLE 9
Construction of pMON5988
The plasmid DNA of pMON5987 was digested with NheI and EcoRI, resulting in a 3903 base pair NheI, EcoRI fragment. The 3903 base pair NheI, EcoRI fragment was ligated to 1.0 picomoles of the following annealed oligonucleotides (oligo #3 and Oligo #4):
5′-CTAGCCACGGCCGCACCCACGCGACATCCAATCCATATCAA-3′-GGTGCCGGCGTGGGTGCGCTGTAGGTTAGGTATAGTTGGACGGTGACTGGAATG-3′ [SEQ ID NO:131]
CCTGCCACTGACCTTACAATT-5′ [SEQ ID NO:132]
The ligation reaction mixture was used to transform E. coli K-12 strain JM101 and transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and sequenced to confirm positive clones.
This plasmid was constructed to change alanine 101 to aspartic acid in the hIL-3 gene (15-125). The Ala 101 to Asp 101 change was confirmed by DNA sequencing. This plasmid was designated pMON5988 and encodes Peptide #1 [SEQ ID NO:65].
›EXAMPLE 10
Construction of pMON5873 which encodes [Met-(1-133) hIL-3]
The gene obtained from British Biotechnology, Ltd. specified arginine at codon position 129. The amino acid specified in the native hIL-3 cDNA is serine. To produce a protein with the native sequence at this position, the portion of the coding sequence between the EcoRI site at codons 106 and 107 and the NheI site at codons 129 and 130 was replaced. Plasmid DNA of pMON5854 (Example 3) and pMON5853 (Example 64) were treated with EcoRI and NheI. The larger fragments of each were gel purified. These were ligated to a pair of an annealed oligonucleotides with the following sequences:
5′-AATTCCGTCGTAAACTGACCTTCTATCTGAAAACC-3′-GGCAGCATTTGACTGGAAGATAGACTTTTGGTTGGAGAACGCGCAGGCTCAACAGACCACTCTGTCG-3′ [SEQ ID NO: 136]
AACCTCTTGCGCGTCCGAGTTGTCTGGTGAGACAGCGATC-5′ [SEQ ID NO:137]
The ligation reaction mixtures were used to transform competent JM101 cells to ampicillin resistance. Colonies were picked into broth and grown. Plasmid DNA was isolated and screened for the presence of a new StyI recognition site present in the synthetic DNA and not in pMON5854 and pMON5853. The nucleotide sequence of the gene in the region between EcoRI and NheI was determined and found to be that of the synthetic oligonucleotides. The new plasmids were designated pMON5873 encoding [Met-(1-133) hIL-3] and pMON5872 encoding [Met-(15-133) hIL-3].
The plasmid, pMON5873, encodes Met-(1-133) hIL-3 which has the following amino acid sequence:
[SEQ ID NO:128]
Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr
Ser Trp Val Asn Cys Ser Asn Met Ile Asp Glu Ile
Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu
Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile
Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu
Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala
Ser Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro
Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His
Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe
Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu
Asn Ala Gln Ala Gln Gln Thr Thr Leu Ser Leu Ala
Ile Phe
›EXAMPLE 11
Construction of pMON6458
Plasmid pMON6525 DNA was digested with restriction enzymes HindIII and SalI and the resulting 3172 base pair fragment was isolated from a 1% agarose gel by interception onto DEAE membrane. The genetic elements derived from pMON6525 are the beta-lactamase gene (AMP), pBR327 origin of replication, and phage f1 origin of replication as the transcription terminator. (The genetic elements derived from plasmid pMON6525 are identical to those in plasmid pMON2341 which could also be used to construct pMON6458.) Plasmid pMON6457 was, digested with restriction enzymes HindIII and SalI and the resulting 1117 base pair fragment was isolated by PAGE and crush and soak elution. The genetic elements derived from pMON6457 are the pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and the (15-125) hIL-3 gene. The restriction fragments were ligated and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Clones containing the hIL-3 gene (encoding amino acids 15-125) contained a 345 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6458. This plasmid was constructed to eliminate an EcoRI restriction site outside the hIL-3 gene coding region in plasmid pMON6457.
›EXAMPLE 12
Construction of pMON6455
Plasmid pMON5905 DNA was digested with restriction enzymes HindIII and NcoI resulting in a 3936 base pair fragment. The genetic elements derived from pMON5905 are the beta-lactamase gene (AMP), pBR327 origin of replication, pAraBAD promoter, g10L ribosome binding site, lamB secretion leader and phage f1 origin of replication as the transcription terminator. The following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, g10L ribosome binding site and phage f1 origin of replication as the transcription terminator, derived from plasmid pMON5905 are identical to those in plasmid pMON5594 which could also be used to construct pMON6455. The AraBAD promoter is identical to that described in pMON6235. The lamB signal peptide sequence used in pMON6455 is that shown in FIG. 8 fused to hIL-3 (15-125) at the NcoI site. Plasmid pMON5887 DNA was digested with restriction enzymes HindIII and NcoI, resulting in a 384 base pair NcoI, HindIII fragment. The restriction fragments were ligated, and the ligation reaction mixture was used to transform into E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Positive clones containing the hIL-3 gene (encoding amino acids 1-125) contained a 384 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6455.
›EXAMPLE 13
Construction of pMON6456
Plasmid pMON5905 DNA was digested with restriction enzymes HindIII and NcoI resulting in a 3936 base pair fragment. The genetic elements derived from pMONS905 are the beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, pAraBAD promoter, g10L ribosome binding site and the lamB secretion leader. Plasmid pMON5871 was digested with restriction enzymes HindIII and NcoI, resulting in a 330base pair NcoI, HindIII fragment. The genetic element derived from pMON5871 encompassed the bases encoding the (1-107) hIL-3 gene. The restriction fragments were ligated, and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes NcoI and HindIII in double digest. Clones containing the hIL-3 gene (encoding amino acids 1-107) contained a 330 base pair NcoI, HindIII restriction fragment. This construct was designated pMON6456.
›EXAMPLE 14
Construction of pMON6457
Plasmid pMON6455 DNA grown in E. coli strain GM48 (dam-)was digested with restriction enzymes NcoI and ClaI, resulting in a 4293 base pair NcoI, ClaI fragment. The restriction fragment was ligated to 1.0 picomoles of annealed oligonucleotides (Oligo #5 and Oligo #6) with the following sequence coding for Met Ala 14-20 hIL-3:
5′-CATGGCTAACTGCTCTAACATGAT-3′[SEQ ID NO:151]
3′-CGATTGACCAGATTGTACTAGC-5′[SEQ ID NO:152]
The resulting DNA was transformed into E. coli K-12 strain JM101 and transformant bacteria were selected on ampicillin-containing plates. Plasmid DNA was isolated and the size of the inserted fragment was determined by restriction analysis employing restriction enzymes XbaI and EcoRI in double digest. Positive clones containing the hIL-3 gene (encoding aa 15-125 of hIL-3) contained a 433 base pair XbaI, EcoRI restriction fragment and were DNA sequenced. This construct was designated pMON6457. This plasmid was constructed to delete the first 14 amino acids of hIL-3. The coding sequence of the resulting gene begins as follows:
The first two amino acids (Methionine, Alanine) create an NcoI restriction site and a signal peptidase cleavage site between the lamB signal peptide and (15-125) hIL-3. Plasmid pMON6457 encodes (15-125) hIL-3 which has the amino acid sequence designated SEQ ID NO 65.
›EXAMPLE 15
Construction of pMON6235
One of the DNA fragments used to create this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the following oligonucleotides, Oligo #51(A) [SEQ ID NO:155] and Oligo #52(A) [SEQ ID NO:156], were used as primers in this procedure. The template for the PCR reaction was E. coli strain W3110 chromosomal DNA, prepared as described in Maniatis (1982). The oligonucleotide primers were designed to amplify the AraBAD promoter (Greenfield et al., 1978). The resulting DNA product was digested with the restriction enzymes SacII and BglII. The reaction mixture was purified as described previously. Plasmid, pMON5594, DNA was digested with SacII and BglII, resulting in a 4416 base pair SacII,BglII restriction fragment which contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, G10L ribosome binding site, phage f1 origin of replication as the transcription terminator and the chloramphenicol acetyl transferase (cat) gene. The 4416 base pair SacII,BglII restriction fragment from pMON5594 was ligated to the PCR-generated SacII, BglII DNA fragment. The ligation mixture was used to transform E. coli K-12 strain JM101. Positive clones contained a 323 base pair SacII,BglII fragment and were DNA sequenced to confirm that the SacII,BglII fragment was the AraBAD promoter. This construct was designated pMON6235.
›EXAMPLE 16
Construction of pMON6460
One of the DNA fragments to construct this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the oligonucleotides, Oligo #7 [SEQ ID NO: 26] and Oligo #8 [SEQ ID NO: 27] as primers. The template for the PCR reaction was plasmid pMON6458 DNA. The resulting DNA product was digested with the restriction enzymes NcoI and EcoRI. Upon completion, the digest was heated at 70° C. for 15 minutes to inactivate the enzymes. The restriction fragment was purified by phenol/chloroform extraction and precipitation with equal volume isopropanol in the presence of 2M NH 4 OAc. The oligonucleotide, Oligo #8, introduces two stop codons (TAA) after amino acid 93 of hIL-3 and Creates a SalI restriction endonuclease recognition sequence. The NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones containing the above mentioned changes released a 1023 base pair SalI fragment. This construct was designated pMON6460. This plasmid was constructed to serve as the template for the creation of single amino acid substitution variants at positions 94, 95, 96 and 97 of hIL-3.
›EXAMPLE 17
Construction of pMON6461
One of the DNA fragments to create this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the following oligonucleotide, Oligo #7 [SEQ. ID NO: 26] and Oligo #9 [SEQ. ID NO: 28], as primers. The template for the PCR reaction was plasmid pMON6458 DNA. The resulting DNA product was digested with the restriction enzymes NcoI and EcoRI. The oligonucleotide, Oligo #9, introduces two stop codons (TAA) after amino acid 97 of hIL-3 and creates a SalI restriction endonuclease recognition sequence. The NcoI, EcoRI restriction fragment from pMON5458 was ligated to the PCR-generated NcoI, EcoRI DNA fragment. Positive clones containing the above mentioned changes released a 1035 base pair SalI fragment. This construct was designated pMON6461. This plasmid was constructed to serve as the template for the creation of single amino acid substitution variants at positions 98, 99, 100 and 101 of hIL-3.
›EXAMPLE 18
Construction of pMON6462
One of the DNA fragments to create this plasmid was generated by site-directed mutagenesis employing PCR techniques described previously using the following oligonucleotide, Oligo #7 [SEQ. ID NO: 26] and Oligo #10 [SEQ. ID NO: 31], as primers. The template for the PCR reaction was plasmid pMON6458 DNA. The resulting DNA product was digested with the restriction enzymes NcoI and EcoRI. The oligonucleotide, Oligo #10 [SEQ. ID NO: 31] introduces two stop codons (TAA) after amino acid 101 of hIL-3 and creates a SalI restriction endonuclease recognition sequence. The NcoI, EcoRI restriction fragment from pMON5458 was ligated to the PCR-generated NcoI, EcoRI DNA fragment. Positive clones containing the above mentioned changes released a 1047 base pair SalI fragment. This construct was designated pMON6462. This plasmid was constructed to serve as the template for the creation of single amino acid substitution variants at positions 102, 103, 104 and 105 of hIL-3.
›EXAMPLE 19
Construction of Single Amino Acid Substitution Libraries at Positions 94, 95, 96 and 97
One of the DNA fragments used to construct the plasmids containing single amino acid substitution at positions 94, 95, 96 and 97 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction plasmid pMON6460 DNA was the template and the oligonucleotide, Oligo #7 [SEQ. ID NO: 26], was used as the primer at the N-terminus, The degenerate oligonucleotides, Oligo #11 [SEQ. ID NO: 32], Oligo #12 [SEQ. ID NO: 33], Oligo #13 [SEQ. ID NO: 34] and Oligo #14 [SEQ. ID NO: 35], were the primers at the C-terminus. These oligonucleotides are 32-fold degenerate, with G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 94, 95, 96 and 97 of hIL-3 respectively. These degenerate oligonucleotide primers theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at a single position. The degenerate oligonucleotides (Oligo #11 [SEQ. ID NO: 32], Oligo #12 [SEQ. ID NO: 33], Oligo #13 [SEQ. ID NO: 34] and Oligo #14 [SEQ. ID NO: 35]) replace the twelve bases introduced into pMON6460, that encode the two stop codons (TAA) after amino acid 93 of hIL-3 and the SalI recognition sequence. At the other 9 bases the DNA sequence was restored to encode the native hIL-3 protein sequence. The resulting PCR-generated DNA products were digested with the restriction enzymes NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6460 was ligated to the PCR-generated NcoI, EcoRI DNA fragments. Plasmid DNA from individual colonies was isolated as described previously and screened by DNA dot blot differential hybridization using the oligonucleotide, Oligo #15 [SEQ. ID NO: 36], as the probe which had been labeled with P 32 . Clones shown to be positive by hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 20
Construction of Single Amino Acid Substitution Libraries at Positions 98. 99, 100 and 101
Single amino acid substitutions variants were constructed at position 98, 99, 100 and 101 as described previously, with the following changes. In the PCR reaction the template was plasmid pMON6461 DNA and the oligonucleotide, Oligo #7 [SEQ. ID NO: 26], was used as the primer at the N-terminus. The degenerate oligonucleotides, Oligo #16 [SEQ. ID NO: 37], Oligo #17 [SEQ. ID NO: 38], Oligo #18 [SEQ. ID NO: 39] and Oligo #19 [SEQ. ID NO: 40], were used as primers at the C-terminus. The resulting PCR-generated DNA products were purified and digested with restriction enzymes NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6461 was ligated to the PCR-generated DNA NcoI, EcoRI restriction fragment. Single colonies were screened by DNA dot blot differential hybridization using the oligonucleotide, Oligo #20 [SEQ. ID NO: 41], as the probe. Clones shown to be positive by hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 21
Construction of Single Amino Acid Substitution Libraries at Positions 102, 103, 104 and 105
Single amino acid substitutions variants were constructed at position 102, 103, 104 and 105 as described previously, with the following changes. The template was pMON6462 and the oligonucleotide, Oligo #7 [SEQ. ID NO: 26], was used as the primer at the N-terminus. The degenerate oligonucleotides, Oligo #21 [SEQ. ID NO: 42], Oligo #22 [SEQ. ID NO: 43], Oligo #23 [SEQ. ID NO: 44] and Oligo #24 [SEQ. ID NO: 45] were used as primers at the C-terminus. The resulting PCR-generated DNA products were purified and digested with restriction enzymes, NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6462 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Single colonies were screened by DNA dot blot differential hybridization using the oligonucleotide, Oligo #25 [SEQ. ID NO: 46], as the probe. Clones shown to be positive by hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 22
Construction of Plasmid pMON6464
Amino acids 17-22 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the PCR reaction using the oligonucleotides, Oligo #26 and Oligo #27 as primers. The resulting PCR-generated DNA products were purified and digested with NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment in which the bases encoding amino acids 17-22 of hIL-3 have been deleted. pMON6464 was made to serve as the template for the creation of single amino acid substitution variants at positions 17, 18, 19, 20, 21 and 22 of hIL-3.
›EXAMPLE 23
Construction of Plasmid pMON6465
Amino acids 23-28 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo # 26 and Oligo #28, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment in which the bases encoding amino acids 23-28 of hIL-3 have been deleted. pMON6465 was made to serve as the template for the creation of single amino acid substitution variants at positions 23, 24, 25, 26, 27 and 28 of hIL-3.
›EXAMPLE 24
Construction of Plasmid pMON6466
Amino acids 29-34 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #29 as the primers. The resulting PCR-generated DNA product was purified and digested with NcoI and EcoRI. The 4008 bp NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment in which the bases encoding amino acids 29-34 of hIL-3 have been deleted. pMON6466 was made to serve as the template for the creation of single amino acid substitution variants at positions 29, 30, 31, 32, 33 and 34 of hIL-3.
›EXAMPLE 25
Construction of Plasmid pMON6467
Amino acids 35-40 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #30, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and EcoRV. The NcoI, EcoRV restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, EcoRV restriction fragment. Positive clones contained a 81 base pair NcoI, EcoRV restriction fragment in which the bases encoding amino acids 35-40 of hIL-3 have been deleted. pMON6467 was made to serve as the template for the creation of single amino acid substitution variants at positions 35, 36, 37, 38, 39 and 40 of hIL-3.
›EXAMPLE 26
Construction of Plasmid pMON6468
Amino acids 41-46 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #31, as the primers. The resulting PCR-generated DNA product was purified and digested with NcoI and XhoI. The NcoI, XhoI restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, XhoI restriction fragment. Positive clones contained a 119 base pair NcoI, XhoI restriction fragment in which the bases encoding amino acids 41-46 of hIL-3 have been deleted. pMON6468 was made to serve as the template for the creation of single amino acid substitution variants at positions 41, 42, 43, 44, 45 and 46 of hIL-3.
›EXAMPLE 27
Construction of Plasmid pMON6469
Amino acids 47-52 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #32, as the primers. The resulting PCR-generated DNA product was purified and digested with NcoI and XhoI. The NcoI, XhoI restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, XhoI restriction fragment. Positive clones contained a 119 base pair NcoI, XhoI restriction fragment in which the bases encoding amino acids 47-52 of hIL-3 have been deleted. pMON6469 was made to serve as the template for the creation of single amino acid substitution variants at positions 47, 48, 49, 50, 51 and 52 of hIL-3.
›EXAMPLE 28
Construction of Plasmid pMON6470
Amino acids 53-58 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid, pMON5988, DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #33, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and NsiI. The NcoI, NsiI restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, NsiI restriction fragment. Positive clones contained a 152 base pair NcoI, NsiI restriction fragment in which the bases encoding amino acids 53-58 of hIL-3 have been deleted. pMON6470 was made to serve as the template for the creation of single amino acid substitution variants at positions 53, 54, 55, 56, 57 and 58 of hIL-3.
›EXAMPLE 29
Construction of Plasmid pMON6471
Amino acids 59-64 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #34, as the primers. The resulting PCR-generated DNA product was purified and digested with NcoI and NsiI. The NcoI, NsiI restriction fragment from pMON5988 was ligated to the PCR-generated NcoI, NsiI restriction fragment. Positive clones contained a 152 base pair NcoI, NsiI restriction fragment in which the bases encoding amino acids 59-64 of hIL-3 have been deleted. pMON6471 was made to serve as the template for the creation of single amino acid substitution variants at positions 59, 60, 61, 62, 63 and 64 of hIL-3.
›EXAMPLE 30
Construction of Plasmid pMON6472
Amino acids 65-70 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #35, as primers. The resulting PCR-generated DNA product was purified and digested with EcoRI and XhoI. The EcoRI, XhoI restriction fragment from pMON5988 was ligated to the PCR-generated EcoRI, XhoI restriction fragment. Positive clones contained a 126 base pair EcoRI, XhoI restriction fragment in which the bases encoding amino acids 65-70 of hIL-2 have been deleted. pMON6472 was made to serve as the template for the creation of single amino acid substitution variants at positions 65, 66, 67, 68, 69 and 70 of hIL-3.
›EXAMPLE 31
Construction of Plasmid pMON6473
Amino acids 71-76 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid, pMON5988, DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #36, as primers. The resulting PCR-generated DNA product was and digested with PstI and EcoRI. The PstI, EcoRI restriction fragment from pMON5988 was ligated to the PCR-generated PstI, EcoRI restriction fragment. Restriction analysis was with NcoI, NsiI and EcoRI in a triple digest. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment, in which the bases encoding amino acids 71-76 of hIL-3 have been deleted, and lost the NsiI restriction site. pMON6473 was made to serve as the template for the creation of single amino acid substitution variants at positions 71, 72, 73, 74, 75 and 76 of hIL-3.
›EXAMPLE 32
Construction of Plasmid pMON6474
Amino acids 77-82 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #37, as primers. The resulting PCR-generated DNA product was purified and digested with PstI and EcoRI. The PstI, EcoRI restriction fragment from pMON5988 was ligated to the PCR-generated PstI, EcoRI restriction fragment. Restriction analysis was with NcoI, NsiI and EcoRI in a triple digest. Positive clones contained a 170 base pair NcoI, NsiI restriction fragment and a 93 base pair NsiI, EcoRI restriction fragment in which the bases encoding amino acids 77-82 of hIL-3 have been deleted. pMON6474 was made to serve as the template for the creation of single amino acid substitution variants at positions 77, 78, 79, 80, 81 and 82 of hIL-3.
›EXAMPLE 33
Construction of Plasmid pMON6475
Amino acids 83-88 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON5988 DNA was the template in the reaction using the oligonucleotides, Oligo #26 and Oligo #38, as primers. The resulting PCR-generated DNA product was digested with PstI and EcoRI. The PstI, EcoRI restriction fragment from pMON5988 was ligated to the PCR-generated PstI, EcoRI restriction fragment. Restriction analysis was with NcoI, NsiI and EcoRI in a triple digest. Positive clones contained a 170 base pair NcoI, NsiI restriction fragment and a 93 base pair NsiI, EcoRI restriction fragment in which the bases encoding amino acids 83-88 of hIL-3 have been deleted. pMON6475 was made to serve as the template for the creation of single amino acid substitution variants at positions 83, 84, 85, 86, 87 and 88 of hIL-3.
›EXAMPLE 34
Construction of Plasmid pMON6476
Amino acids 88-93 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #39, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and EcoRI. The NcoI, EcoRI restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, EcoRI restriction fragment. Positive clones contained a 263 base pair NcoI, EcoRI restriction fragment in which the-bases encoding amino acids 88-93 of hIL-3 have been deleted. pMON6476 was made to serve as the template for the creation of single amino acid substitution variants at positions 88, 89, 90, 91, 92 and 93 of hIL-3.
›EXAMPLE 35
Construction of Plasmid pMON6477
Amino acids 106-111 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #40, as primers. The resulting PCR-generated DNA fragment was purified and digested with NcoI and HindIII. The NcoI, HindIII restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, HindIII restriction fragment. Positive clones contained a 327 base pair NcoI, HindIII restriction fragment in which the bases encoding amino acids 106-111 of hIL-3 have been deleted. pMON6477 was made to serve as the template for the creation of single amino acid substitution variants at positions 106, 107, 108, 109, 110 and 111 of hIL-3.
›EXAMPLE 36
Construction of Plasmid pMON6478
Amino acids 112-117 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, Oligo #7 and Oligo #41, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and HindIII. The 4008 bp NcoI, HindIII restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, HindIII restriction fragment. Positive clones contained a 327 base pair NcoI, HindIII restriction fragment in which the bases encoding amino acids 112-117 of hIL-3 have been deleted. pMON6478 was made to serve as the template for the creation of single amino acid substitution variants at positions 112, 113, 114, 115, 116 and 117 of hIL-3.
›EXAMPLE 37
Construction of Plasmid pMON6479
Amino acids 118-123 of hIL-3 were deleted using site-directed PCR mutagenesis methods described previously. Plasmid pMON6458 DNA was the template in the reaction using the oligonucleotides, oligo #7 and Oligo #42, as primers. The resulting PCR-generated DNA product was purified and digested with NcoI and HindIII. The NcoI, HindIII restriction fragment from pMON6458 was ligated to the PCR-generated NcoI, HindIII restriction fragment. Positive clones contained a 327 base pair NcoI, HindIII restriction fragment in which the bases encoding amino acids 118-123 of hIL-3 have been deleted. pMON6479 was made to serve as the template for the creation of single amino acid substitution variants at positions 118, 119, 120, 121, 122 and 123 of hIL-3.
›EXAMPLE 38
Construction of Single Amino Acid Substitution Libraries at Positions 17, 18, 19, 20, 21 and 22
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 17, 18, 19, 20, 21 and 22 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6464 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #43, Oligo #44, Oligo #45, Oligo #46, Oligo #47 and Oligo #48 were the primers at the C-terminus. The oligonucleotide, Oligo #26, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6464. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 17, 18, 19, 20, 21 and 22 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA product was digested with NcoI and EcoRV. Plasmid pMON6464 DNA was digested with restriction enzymes NcoI and EcoRV resulting in a 4190 base pair fragment which was ligated to the PCR-generated NcoI, EcoRV restriction fragments. Plasmid DNA was isolated and screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #139, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 39
Construction of Single Amino Acid Substitution Libraries at Positions 23, 24, 25, 26, 27 and 28
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 23, 24, 25, 26, 27 and 28 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6465 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #49, Oligo #50, Oligo #51, Oligo #52, Oligo #53 and Oligo #54 were the primers at the C-terminus. The oligonucleotide, Oligo #26, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6465. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 23, 24, 25, 26, 27 and 28 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with restriction enzymes NcoI and EcoRV. Plasmid pMON6465 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 4190 base pair fragment was ligated to the PCR-generated NcoI, EcoRV DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #140, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 40
Construction of Single Amino Acid Substitution Libraries at Positions 29, 30, 31, 32, 33 and 34
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 29, 30, 31, 32, 33 and 34 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6466 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #55, Oligo #56, Oligo #57, Oligo #58, Oligo #59 and Oligo #60 were the primers at the C-terminus. The oligonucleotide Oligo #26 was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6466. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 29, 30, 31, 32, 33 and 34 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and EcoRV. Plasmid pMON6466 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 4190 base pair fragment was ligated to the PCR-generated NcoI, EcoRV DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #141, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 41
Construction of Single Amino Acid Substitution Libraries at Positions 35, 36, 37, 38, 39 and 40
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 35, 36, 37, 38, 39 and 40 of hIL-3 were generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6467 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #61, Oligo #62, Oligo #63, Oligo #64, Oligo #65 and Oligo #66 were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6467. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 35, 36, 37, 38, 39 and 40 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored and at the other position, 32 different codons substitutions were created at positions independently. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and EcoRV. Plasmid pMON6467 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 4190 base pair fragment was ligated to the PCR-generated NcoI, EcoRV DNA fragments.
Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #142, which had been labeled with p32. Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 42
Construction of Single Amino Acid Substitution Libraries at Positions 41, 42, 43, 44, 45 and 46
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 41, 42, 43, 44, 45 and 46 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6468 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #67, Oligo #68, Oligo #69, Oligo #70, Oligo #71 and Oligo #72 were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6468. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 41, 42, 43, 44, 45 and 46 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and XhoI. Plasmid pMON6468 DNA was digested with restriction enzymes NcoI and XhoI and the resulting 4152 base pair fragment was ligated to the PCR-generated NcoI, XhoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #143, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 43
Construction of Single Amino Acid Substitution Libraries at Positions 47, 48, 49, 50, 51 and 52
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 47, 48, 49, 50, 51 and 52 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6469 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #73, Oligo #74, Oligo #75, Oligo #76, Oligo #77 and Oligo #78 , were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6469. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 47, 48, 49, 50, 51 and 52 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and XhoI. Plasmid pMON6469 DNA was digested with restriction enzymes NcoI and XhoI and the resulting 4152 base pair fragment was ligated to the PCR-generated NcoI, XhoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #143, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 44
Construction of Single Amino Acid Substitution Libraries at Positions 53, 54, 55, 56, 57 and 58
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 53, 54, 55, 56, 57 and 58 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6470 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #79, Oligo #80, Oligo #81, Oligo #82, Oligo #83 and Oligo #84 , were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6470. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 53, 54, 55, 56, 57 and 58 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and NsiI. Plasmid pMON6470 DNA was digested with restriction enzymes NcoI and NsiI and the resulting 4119 base pair fragment was ligated to the PCR-generated NcoI, NsiI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #145, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 45
Construction of Single Amino Acid Substitution Libraries at Positions 59, 60, 61, 62, 63 and 64
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 59, 60, 61, 62, 63 and 64 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6471 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #85, Oligo #86, Oligo #87, Oligo #88, Oligo #89 and Oligo #90 , were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6471. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 59, 60, 61, 62, 63 and 64 of hIL-3 respectively, These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes NcoI and NsiI. Plasmid pMON6471 DNA was digested with restriction enzymes NcoI and NsiI and the resulting 4119 base pair fragment was ligated to the PCR-generated NcoI, NsiI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #146, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 46
Construction of Single Amino Acid Substitution Libraries at Positions 65, 66, 67, 68, 69 and 70
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 65, 66, 67, 68, 69 and 70 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6472 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #91, Oligo #92, Oligo #93, Oligo #94, Oligo #95 and Oligo #96 , were the primers at the N-terminus. The oligonucleotide, Oligo 26, was used as the primer at the C-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6472. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 65, 66, 67, 68, 69 and 70 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes EcoRI and XhoI. Plasmid pMON6472 DNA was digested with restriction enzymes EcoRI and XhoI and the resulting 4145 base pair fragment was ligated to the PCR-generated EcoRI, XhoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #147, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 47
Construction of Single Amino Acid Substitution Libraries at Positions 71, 72, 73, 74, 75 and 76
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 71, 72, 73, 74, 75 and 76 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6473 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #97, Oligo #98, Oligo #99, Oligo #100, Oligo #101 and Oligo #102 , were the primers at the N-terminus. The oligonucleotide, Oligo #26, was used as the primer at the C-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6473. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 71, 72, 73, 74, 75 and 76 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA fragments were purified and digested with the restriction enzymes EcoRI and PstI. Plasmid pMON6473 DNA was digested with restriction enzymes EcoRI and PstI and the resulting 4171 base pair fragment was ligated to the PCR-generated EcoRI, PstI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #148, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 48
Construction of Single Amino Acid Substitution Libraries at Positions 77, 78, 79, 80, 81 and 82
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 77, 78, 79, 80, 81 and 82 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the reaction the plasmid pMON6474 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #103, Oligo #104, Oligo #105, Oligo #106, Oligo #107 and Oligo #108, were the primers at the N-terminus. The oligonucleotide, Oligo #26, was used as the primer at the C-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6474. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 77, 78, 79, 80, 81 and 82 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes EcoRI and PstI as described previosly. Plasmid pMON6474 DNA was digested with restriction enzymes EcoRI and PstI and the resulting 4171 base pair fragment was ligated to the PCR-generated EcoRI, PstI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #149, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 49
Construction of Single Amino Acid Substitution Libraries at Positions 83, 84, 85, 86, 87 and 88
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 83, 84, 85, 86, 87 and 88 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6475 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #109, Oligo #110, Oligo #111, Oligo #112, Oligo #113 and Oligo #114, were the primers at the N-terminus. The oligonucleotide, Oligo #26, was used an the primer at the C-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6475. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 83, 84, 85, 86, 87 and 88 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA producs were purified and digested with the restriction enzymes EcoRI and PstI. Plasmid pMON6475 DNA was digested with restriction enzymes EcoRI and PstI and the resulting 4171 base pair fragment was ligated to the PCR-generated EcoRI, PstI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #150, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 50
Construction of Single Amino Acid Substitution Libraries at Positions 88, 89, 90, 91, 92 and 93
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 88, 89, 90, 91, 92 and 93 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6476 DNA was the template and the following degenerate oligonucleotides, Oligo #114, Oligo #115, Oligo #116, Oligo #117, Oligo #118 and Oligo #119, were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6476. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 88, 89, 90, 91, 92 and 93 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes EcoRI and NcoI. Plasmid pMON6476 DNA was digested with restriction enzymes EcoRI and NcoI and the resulting 4008 base pair fragment was ligated to the PCR-generated EcoRI, NcoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #151, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 51
Construction of Single Amino Acid Substitution Libraries at Positions 106, 107, 108, 109, 110 and 111
One of the DNA fragments used to construct the plasmids containing the single amino acid substitutions at positions 106, 107, 108, 109, 110 and 111 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously in two sequential PCR reactions. In the first PCR reaction, plasmid pMON6477 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #120, Oligo #121, Oligo #122, Oligo #123, Oligo #124 and Oligo #125 were the primers at the C-terminus. The oligonucleotide, Oligo #7 was the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON9477. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 106, 107, 108, 109, 110 and 111 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The DNA generated in this PCR reaction was purified by phenol/chloroform extraction and precipitation with equal volume isopropanol in the presence of 2M NH 4 OAc to remove any primer that was not extended. This DNA was then used as a primer in the second PCR reaction.
In the second PCR reaction plasmid pMON6477 DNA was the template, the DNA product generated in the first PCR reaction (described above) was the primer at the N-terminus and the oligonucleotide, Oligo #126 (DNA sequence shown in Table 1), was the primer at the C-terminus. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes HindIII and NcoI. Plasmid pMON6477 was digested with restriction enzymes HindIII and NcoI and the resulting 3944 base pair fragment was ligated to the PCR-generated HindIII, NcoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #152, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 52
Construction of Single Amino Acid Substitution Libraries at Positions 112, 113, 114, 115, 116 and 117
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 112, 113, 114, 115, 116 and 117 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6478 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #127, Oligo #128, Oligo #129, Oligo #130, Oligo #131 and Oligo #132, were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus, The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6478. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 112, 113, 114, 115, 116 and 117 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes HindIII and NcoI. Plasmid pMON6478 was digested with restriction enzymes HindIII and NcoI and the resulting 3944 base pair fragment was ligated to the PCR-generated HindIII, NcoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #153, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 53
Construction of Single Amino Acid Substitution Libraries at Positions 118, 119, 120, 121, 122 and 123
One of the DNA fragments used to construct the plasmids containing single amino acid substitutions at positions 118, 119, 120, 121, 122 and 123 of hIL-3 was generated by site-directed mutagenesis employing PCR techniques described previously. In the PCR reaction the plasmid pMON6479 DNA was the template and the following 32 fold degenerate oligonucleotides, Oligo #133, Oligo #134, Oligo #135, oligo #136, Oligo #137 and Oligo #138, were the primers at the C-terminus. The oligonucleotide, Oligo #7, was used as the primer at the N-terminus. The degenerate oligonucleotides replace the eighteen bases, encoding six amino acids, deleted in pMON6479. The degenerate oligonucleotides have G, A, T or C in the first and second positions and G or C in the third position of a single codon at amino acid positions 118, 119, 120, 121, 122 and 123 of hIL-3 respectively. These degenerate oligonucleotide primers result in libraries which theoretically contain 32 different codons encoding all 20 amino acid substitutions and one translational stop codon at one position. At the other five amino acid positions the native hIL-3 DNA sequence was restored. The resulting PCR-generated DNA products were purified and digested with the restriction enzymes HindIII and NcoI. Plasmid pMON6479 DNA was digested with restriction enzymes HindIII and NcoI and the resulting 3944 base pair fragment was ligated to the PCR-generated HindIII, NcoI DNA fragments. Transformant bacteria were screened by DNA dot blot differential hybridization using the oligonucleotide probe, Oligo #154, which had been labeled with P 32 . Clones shown to be positive by colony hybridization were selected, plasmid DNA isolated and DNA sequenced to determine the amino acid substitution.
›EXAMPLE 54
Construction of pMON13358
Plasmid pMON5978 DNA (Example 6) was digested with restriction enzymes NsiI and EcoRI and the resulting 3853 base pair NsiI,EcoRI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-71 and 106-125 of (15-125) hIL-3. The 3853 base pair NsiI,EcoRI restriction fragment from pMON5978 was ligated to the following annealed complementary oligonucleotides.
Oligo #15(A) [SEQ ID NO: 29]
Oligo #16(A) [SEQ ID NO: 30]
In the resulting plasmid the 111 bases between the NsiI and EcoRI restriction sites in the (15-125) hIL-3 gene are replaced with 24 bases from the above mentioned oligonucleotides. This linker also creates a NdeI recognition sequence.
›EXAMPLE 55
Construction of pMON13304
Plasmid pMON13358 DNA is digested with restriction enzymes PstI and EcoRI and the resulting 3846 base pair PstI,EcoRI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-69 and 106-125 of (15-125) hIL-3. The 3846 base pair NsiI,EcoRI restriction fragment from pMON13358 is ligated to the following annealed complementary oligonucleotides.
When assembled, the oligonucleotides create PstI and EcoRI restriction ends and the DNA sequence that encodes amino acids 70-105 of (15-125) hIL-3 with the following amino acid substitutions; 98I and 100R. The codons encoding amino acids 70-105 of (15-125) hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13304, encodes the (15-125) hIL-3 variant with the following amino acid sequence:
Peptide #A1 [SEQ ID NO:66]
›EXAMPLE 56
Construction of pMON13305
Plasmid pMON13358 DNA is digested with restriction enzymes PstI and EcoRI and the resulting 3846 base pair PstI, EcoRI fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, recA promoter, g10L ribosome binding site and the bases encoding amino acids 15-69 and 106-125 of (15-125) hIL-3. The 3846 base pair NsiI,EcoRI restriction fragment from pMON13358 is ligated to the following annealed complementary oligonucleotides.
When assembled, the oligonucleotides create PstI and EcoRI restriction ends and the DNA sequence that encodes amino acids 70-105 of (15-125) hIL-3 with the following amino acid substitutions; 95R, 98I and 100R. The codons encoding amino acids 70-105 of (15-125) hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13305, encodes the (15-125) hIL-3 variant with the following amino acid sequence:
Peptide #A2 [SEQ ID NO:67]
›EXAMPLE 57
Construction of pMON13286
Plasmid pMON5978 DNA was digested with restriction enzymes NcoI and EcoRV and the resulting 3865 base pair NcoI,EcoRV fragment contains the following genetic elements; beta-lactamase gene (AMP), pBR327 origin of replication, phage f1 origin of replication as the transcription terminator, precA promoter, g10L ribosome binding site and the bases encoding amino acids 47-125 of (1-125) hIL-3. The 3865 base pair NcoI,EcoRV restriction fragment from pMON5978 was ligated to the following annealed complementary oligonucleotides.
When assembled, the oligonucleotides create NcoI and EcoRV restriction ends and the DNA sequence that encodes amino acids 15-46 of (15-125) hIL-3 with the following amino acid substitutions; 42D, 45M and 46S. The codons encoding amino acids 15-46 of (15-125) hIL-3 are those found in the hIL-3 cDNA sequence except at those positions where amino acid substitutions were made. The plasmid, pMON13286, encodes the (15-125) hIL-3 variant with the following amino acid sequence:
›EXAMPLE 58
Construction of pMON5853 (FIG. 6) which Encodes [Met-(15-133) hIL-3 (Arg129)]
Plasmid DNA of pMON5847 (Example 2) was treated with NcoI. The restriction enzyme was inactivated by heat treatment (65° C. for 10 minutes). The DNA was then treated with large fragment of DNA polymerase I (Klenow) in the presence of all four nucleotide precursors. This produces DNA termini with non-overlapping ends. After 5 minutes at 37° C., the polymerase was inactivated by heat treatment at 65° C. for 10 minutes. The DNA was then treated with HpaI, an enzyme which produces non-overlapping termini. The DNA was ethanol precipitated and ligated. The ligation reaction mixture was used to transform competent JM101 cells to ampicillin resistance. Colonies were picked and plasmid DNA was analyzed by restriction analysis. A plasmid designated pMON5853 was identified as one containing a deletion of the amino terminal 14 codons of the hIL-3 gene. The DNA sequence for the junction of the ribosome binding site to the (15-133) hIL-3 gene was determined to be the following:
The lower line contains the one-letter code for the amino acids specified by the coding sequence of the amino terminus of the 15-133 hIL-3 gene. These are methionine, asparagine, cysteine, serine and asparagine.
When cultures of JM101 cells harboring this plasmid were induced with nalidixic acid, it was found that hIL-3 (15-133) accumulated at levels higher than hIL-3 (pMON5847).
The plasmid, pMON5853, encodes Met-(15-133) hIL-3 (Arg 129 ) which has the following amino acid sequence:
Met Asn Cys Ser Asn Met Ile Asp Glu Ile Ile
Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu
Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile
Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu
Ala Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala
Ser Ala Ile Glu Ser Ile Leu Lys Asn Leu Leu Pro
Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His
Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe
Arg Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu
Asn Ala Gln Ala Gln Gln Thr Thr Leu Arg Leu Ala
Ile Phe [SEQ ID NO:135]
Formula XI shown below is a representation of a [(15-125) hIL-3 mutein] with numbers in bold type added above the amino acids to represent the position at which the amino acid below the bolded number appears in native (1-133) hIL-3 [e.g. the amino acid at position 1 of Formula XI corresponds to the Asn which appears at position 15 in native (1-133) hIL-3]. The number shown in bold indicates the amino acids that correspond to the native IL-3(1-133). The non-bold members below the amino acids sequences are for Seq Id reference numbers. When the muteins are expressed the initial amino acid may be preceded by Met- or Met-Ala-.
Table 6 shows (15-125) hIL-3 muteins of the present invention which have one (and in some cases two) amino acid substitutions in the (15-125) hIL-3 polypeptide and which were constructed as described in the Examples. The mutants in Table 6 were secreted into the periplasmic space in E. coli. The periplasmic content was released by osmotic shock and the material in the crude osmotic shock fraction was screened for growth promoting activity. Biological activity is the growth promoting activity of AML cells relative to (15-125) hIL-3 (pMON6458 or pMMON5988). The numbers in parentheses indicate the number of repeat assays. When a variant was assayed more than once the standard deviation is indicated. An “-” indicates that the hIL3 variant protein level was less than 1.0 μg/ml and was not screened for growth promoting activity.
The mutants in Table 6 were made as described in the Examples, particularly Examples 19, 20, 21 and 38 to 53.
It will be apparent to those skilled in the art that other codons besides those shown in Table 6 can also code for the substituted amino acids in the hIL-3 muteins. The present invention includes the DNAs encoding the mutant hIL-3 polypeptides of the invention including the various codons which can code for the parental and substituted amino acids of the hIL-3 muteins of the invention due to the degeneracy of the genetic code.
hIL-3 (15-125) variant genes encoding the variants listed in Table 6 can also be expressed from intracellular expression vectors to produce large quantities of the variant protein which can be purified and assayed for biological activity. The hIL-3 variant genes, from Table 6, can be excised from the secretion expression vector, as a 345 base pair NcoI/HindIII fragment and ligated into an appropriate intracellular expression vector, such as pMON2341 digested with NcoI and HindIII. Examples of variants transferred to pMON2341 in this manner are shown in Table 7. Two examples of such a transfer are described. in the construction of pMON13215 (EXAMPLE 64) and pMON13252 (EXAMPLE 65).
›EXAMPLE 64
Construction of pMON13215
Plasmid, pMON2341, DNA was digested with restriction enzymes NcoI and HindIII resulting in a 3619 base pair NcoI/HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication, F1 phage origin of replication as the transcription terminator, precA, g10L ribosome binding site. The plasmid encoding the hIL-3 (15-125) Trp (116) variant, from Table 6 wag digested with NcoT and HindIII resulting in a 345 base pair NcoI/HindIII fragment. The 345 Base pair NcoI/HindIII fragment was ligated with the 3619 base pair fragment from pMON2341 and the ligation reaction mixture was used to transform E.coli K-12 strain JM101. Plasmid DNA was isolated and screened by restriction anaylsis using NcoI and HindIII. Positive clones contained a 345 base pair NcoI/HindIII. This construct was designated PMON132I5. The plasmid, pMON13215, encodes the (15-125) hIL-3 variant with the following amino acid sequence:
PEPTIDE A9; (15-125)HIL-3 TRP (116) PMON13215
›EXAMPLE 65
Construction of pMON13252
Plasmid, pMON2341, DNA was digested with restriction enzymes NcoI and HindIII resulting in a 3619 base pair NcoI/HindIII fragment. The genetic elements derived from pMON2341 are the beta-lactamase gene (AMP), pBR327 origin of replication F1 phage origin of replication as the transcription terminator, precA, g10L ribosome binding site. The plasmid encoding the hIL-3 (15-125) Asp ( 50) variant, from Table 6, was digested with NcoI and HindIII resulting in a 345 base pair NcoI/HindIII fragment. This 345 Base pair NcoI/HindIII fragment was ligated with the 3619 base pair fragment from pMON2341 and the ligation reaction mixture was used to transform E. coli K-12 strain JM101. Plasmid DNA was isolated and screened by restriction analysis using NcoI and HindIII. Positive clones contained a 345 base pair NcoI/HindIII. This construct was designated pMON13252. The plasmid, pMON13252, encodes the (15-125) hIL-3 variant with the following amino acid sequence:
PEPTIDE A10; (15-125)HIL-3 ASP (50) pMON13252
Table 7 shows the biological activity of (15-125) hIL-3 mutant polypeptides of the present invention expressed from Intracellular expression vectors. Upon expression these muteins may have Met- or Met-Ala-preceding the initial (15-125) hIL-3 amino acid. The relative biological activity of IL-3 mutants is calculated by dividing the EC 50 (1-133) hIL-3 by the EC 50 of the mutant.
›EXAMPLE 66 · 1 of 12
The variants in Table 8 were constructed by cassette mutagenesis using methods described in the Materials and Methods and the Examples contained herein, particularly Examples 54-57. Parental plasmid DNA (Table 8), digested with the appropriate restriction enzymes (Table 8), was ligated with the indicated annealed pairs of complementary oligonucleotides (Table 8). The assembled oligonucleotides create appropriate restriction ends and a portion of the (15-125) hIL-3 gene sequence Individual isolates were screened by restriction analysis and DNA sequenced to confirm that the desired changes in the (15-125) hIL-3 variant gene were made. The oligonucleotides create change(s) in the (15-125) hIL-3 gene which enclode the corresponding amino acid substitution in the variant polypeptide (Table 8). The amino acids substitutions in polypeptide #1 (SEQ ID NO:65) are indicated in Table 8.
It will be apparent to those skilled in the art that other codons besides those shown in Table 8 can also code for the substituted amino acids in the hIL-3 muteins. The present invention includes the DNAs encoding the mutant hIL-3 polypeptides of the invention including the various codons which can code for the parental and substituted amino acids of the hIL-3 muteins of the invention due to the degeneracy of the genetic code.
hIL-3 (15-125) variant genes encoding the variants listed in Table 8 can also be expressed from intracellular expression vectors to produce large quantities of the variant protein which can be purified and assayed for biological activity. The hIL-3 variant genes, from Table 8, can be excised from the secretion expression vector, as a 345 base pair NcoI/HindIII fragment and ligated into an appropriate intrecellular expression vector, such as pMON2341 digested with NcoI and HindIII.
Table 9 shows the biological activity of (15-125) hIL-3 muteins of the present invention which have one amino acid substitutions in the (15-125) hIL-3 polypeptide and which were constructed as described in Example 66. The mutants in Table 9 were secreted into the periplasmic space in E. coli. The periplasmic content was released by osmotic shock and the material in the crude osmotic shock fraction was screened for growth promoting activity. Biological activity is the growth promoting activity of AML cells relative to (1-125) hIL-3 (pMON6458 or pMMON5988). The relative biological activity of IL-3 mutants is calculated by dividing the EC 50 (1-133) hIL-3 by the EC 50 of the mutant. The numbers in parentheses indicate the number of repeat assays. When a variant was assayed more than once the standard deviation is indicated. An “*” 0 indicates that the hIL3 variant protein level was less than 1.0 μg/ml and was not screened for growth promoting activity.
CTAGCGATCT TTTAATAAGC TTG 23
23 base pairs
nucleic acid
single
linear
DNA (synthetic)
2
GATCCAAGCT TATTAAAAGA TCG 23
69 base pairs
nucleic acid
single
linear
DNA (synthetic)
3
GGCAACAATT TCTACAAAAC ACTTGATACT GTATGAGCAT ACAGTATAAT TGCTTCAACA 60
GAACAGATC 69
67 base pairs
nucleic acid
single
linear
DNA (synthetic)
4
TGTTCTGTTG AAGCAATTAT ACTGTATGCT CATACAGTAT CAAGTGTTTT GTAGAAATTG 60
TTGCCGC 67
23 base pairs
nucleic acid
single
linear
DNA (synthetic)
5
CCATTGCTGC CGGCATCGTG GTC 23
46 base pairs
nucleic acid
single
linear
DNA (synthetic)
6
CATGGCTCCA ATGACTCAGA CTACTTCTCT TAAGACTTCT TGGGTT 46
42 base pairs
nucleic acid
single
linear
DNA (synthetic)
7
AACCCAAGAA GTCTTAAGAG AAGTAGTCTG AGTCATTGGA GC 42
64 base pairs
nucleic acid
single
linear
DNA (synthetic)
8
AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGT 60
AATA 64
64 base pairs
nucleic acid
single
linear
DNA (synthetic)
9
AGCTTATTAC TGTTGAGCCT GCGCGTTCTC CAAGGTTTTC AGATAGAAGG TCAGTTTACG 60
ACGG 64
126 amino acids
amino acid
linear
peptide
10
Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
1 5 10 15
Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro
20 25 30
Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile
35 40 45
Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg
50 55 60
Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu Lys
65 70 75 80
Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His
85 90 95
Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys Leu
100 105 110
Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln
115 120 125
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
11
CATGGCTAAC TGCTCTAACA TGAT 24
22 base pairs
nucleic acid
single
linear
DNA (synthetic)
12
CGATCATGTT AGAGCAGTTA GC 22
113 amino acids
amino acid
linear
peptide
13
Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
1 5 10 15
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp
20 25 30
Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala
35 40 45
Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser
50 55 60
Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro
65 70 75 80
Thr Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg
85 90 95
Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln
100 105 110
Gln
27 amino acids
amino acid
linear
peptide
14
Met Met Ile Thr Leu Arg Lys Leu Pro Leu Ala Val Ala Val Ala Ala
1 5 10 15
Gly Val Met Ser Ala Gln Ala Met Ala Asn Cys
20 25
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
85 90 95
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa Xaa Xaa
100 105 110
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu
115 120 125
Ser Leu Ala Ile Phe
130
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Xaa Xaa Xaa Xaa
›EXAMPLE 66 · 2 of 12
50 55 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa
65 70 75 80
Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg Xaa Xaa
85 90 95
Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Phe Xaa Xaa Lys Leu Xaa
100 105 110
Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu
115 120 125
Ser Leu Ala Ile Phe
130
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys
1 5 10 15
Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa Xaa Ile Leu
35 40 45
Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa Phe Xaa Xaa Xaa
50 55 60
Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu Xaa Xaa Leu Xaa Xaa
65 70 75 80
Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala Xaa Pro Xaa Arg Xaa Xaa
85 90 95
Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa Xaa Phe Xaa Xaa Lys Leu Xaa
100 105 110
Phe Xaa Xaa Xaa Xaa Leu Glu Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu
115 120 125
Ser Leu Ala Ile Phe
130
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys
1 5 10 15
Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa Xaa Pro Xaa
20 25 30
Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa Ile Leu
35 40 45
Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala Phe Xaa Arg Xaa
50 55 60
Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu Xaa Xaa Leu Xaa Xaa
65 70 75 80
Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala Xaa Pro Xaa Arg Xaa Pro
85 90 95
Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa Glu Phe Xaa Xaa Lys Leu Xaa
100 105 110
Phe Tyr Leu Xaa Xaa Leu Glu Xaa Xaa Xaa Xaa Gln Gln Thr Thr Leu
115 120 125
Ser Leu Ala Ile Phe
130
Asn Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Xaa Xaa Xaa
20 25 30
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Phe Xaa Xaa Xaa
85 90 95
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Gln
100 105 110
Asn Cys Xaa Xaa Xaa Xaa Xaa Glu Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Glu Xaa Xaa Xaa
20 25 30
Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Leu Xaa Xaa Xaa Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu
50 55 60
Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Arg
65 70 75 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Xaa Phe Xaa Xaa Lys
85 90 95
Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Gln Gln
100 105 110
Asn Cys Xaa Xaa Xaa Ile Xaa Glu Xaa Xaa Xaa Xaa Leu Lys Xaa Xaa
1 5 10 15
Xaa Xaa Xaa Xaa Xaa Asp Xaa Xaa Asn Leu Asn Xaa Glu Xaa Xaa Xaa
20 25 30
Ile Leu Met Xaa Xaa Asn Leu Xaa Xaa Xaa Asn Leu Glu Xaa Phe Xaa
35 40 45
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Xaa Xaa Xaa Ile Glu Xaa Xaa Leu
50 55 60
Xaa Xaa Leu Xaa Xaa Cys Xaa Pro Xaa Xaa Thr Ala Xaa Pro Xaa Arg
65 70 75 80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Asp Xaa Xaa Xaa Phe Xaa Xaa Lys
85 90 95
Leu Xaa Phe Xaa Xaa Xaa Xaa Leu Glu Xaa Xaa Xaa Xaa Gln Gln
100 105 110
Asn Cys Xaa Xaa Met Ile Asp Glu Xaa Ile Xaa Xaa Leu Lys Xaa Xaa
1 5 10 15
Pro Xaa Pro Xaa Xaa Asp Phe Xaa Asn Leu Asn Xaa Glu Asp Xaa Xaa
20 25 30
Ile Leu Met Xaa Xaa Asn Leu Arg Xaa Xaa Asn Leu Glu Ala Phe Xaa
35 40 45
Arg Xaa Xaa Lys Xaa Xaa Xaa Asn Ala Ser Ala Ile Glu Xaa Xaa Leu
50 55 60
Xaa Xaa Leu Xaa Pro Cys Leu Pro Xaa Xaa Thr Ala Xaa Pro Xaa Arg
65 70 75 80
Xaa Pro Ile Xaa Xaa Xaa Xaa Gly Asp Trp Xaa Glu Phe Xaa Xaa Lys
85 90 95
Leu Xaa Phe Tyr Leu Xaa Xaa Leu Glu Xaa Xaa Xaa Xaa Gln Gln
100 105 110
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro
1 5 10 15
Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp
20 25 30
Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn
35 40 45
Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu
50 55 60
Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg
65 70 75 80
His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys
85 90 95
Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln
100 105 110
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
24
CTAGCCACGG CCGCACCCAC GCGACATCCA ATCCATATCA AGGACGGTGA CTGGAATG 58
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
25
TTAACATTCC AGTCACCGTC CTTGATATGG ATTGGATGTC GCGTGGGTGC GGCCGTGG 58
20 base pairs
nucleic acid
single
linear
DNA (synthetic)
26
TGTCTGCTCA GGCCATGGCT 20
67 base pairs
nucleic acid
single
linear
DNA (synthetic)
27
GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGGTCGAC TTATTACGTG GGTGCGGCCG 60
TGGCTAG 67
55 base pairs
nucleic acid
single
linear
DNA (synthetic)
28
GCGCGAATTC ATTCCAGTCA CCGTCGACTT ATTAGATTGG ATGTCGCGTG GGTGC 55
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
29
TGAACCATAT GTCAGG 16
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
30
AATTCCTGAC ATATGGTTCA TGCA 24
43 base pairs
nucleic acid
single
linear
DNA (synthetic)
31
GCGCGAATTC GTCGACTTAT TAGTCCTTGA TATGGATTGG ATG 43
67 base pairs
nucleic acid
single
linear
DNA (synthetic)
32
GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGGATTGG ATGSNNCGTG GGTGCGGCCG 60
TGGCTAG 67
64 base pairs
nucleic acid
single
linear
DNA (synthetic)
33
GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGGATTGG SNNTCGCGTG GGTGCGGCCG 60
TGGC 64
61 base pairs
nucleic acid
single
linear
DNA (synthetic)
34
GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGGATSNN ATGTCGCGTG GGTGCGGCCG 60
T 61
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
35
GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TATGSNNTGG ATGTCGCGTG GGTGCGGC 58
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
36
GATATGGATT GGATGTCGCG TGGG 24
55 base pairs
nucleic acid
single
linear
DNA (synthetic)
37
GCGCGAATTC ATTCCAGTCA CCGTCCTTGA TSNNGATTGG ATGTCGCGTG GGTGC 55
52 base pairs
nucleic acid
single
linear
DNA (synthetic)
38
GCGCGAATTC ATTCCAGTCA CCGTCCTTSN NATGGATTGG ATGTCGCGTG GG 52
49 base pairs
nucleic acid
single
linear
DNA (synthetic)
39
GCGCGAATTC ATTCCAGTCA CCGTCSNNGA TATGGATTGG ATGTCGCGT 49
46 base pairs
nucleic acid
single
linear
DNA (synthetic)
40
GCGCGAATTC ATTCCAGTCA CCSNNCTTGA TATGGATTGG ATGTCG 46
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
41
GTCACCGTCC TTGATATGGA TTGG 24
43 base pairs
nucleic acid
single
›EXAMPLE 66 · 3 of 12
linear
DNA (synthetic)
42
GCGCGAATTC ATTCCAGTCS NNGTCCTTGA TATGGATTGG ATG 43
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
43
GCGCGAATTC ATTCCASNNA CCGTCCTTGA TATGGATTGG 40
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
44
GCGCGAATTC ATTSNNGTCA CCGTCCTTGA TATGGAT 37
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
45
GCGCGAATTC SNNCCAGTCA CCGTCCTTGA TATG 34
25 base pairs
nucleic acid
single
linear
DNA (synthetic)
46
GAATTCATTC CAGTCACCGT TCCTT 25
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
47
CGCGCGGAAT TCATTCCAGT CACCGT 26
42 base pairs
nucleic acid
single
linear
DNA (synthetic)
48
CGCGCGCCAT GGCTAACTGC ATTATAACAC ACACTTAAAG CA 42
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
49
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAACA GCCACCTTTG CCTTTGCT 58
76 base pairs
nucleic acid
single
linear
DNA (synthetic)
50
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCTGG 60
ACTTCAACAA CCTCAA 76
50 base pairs
nucleic acid
single
linear
DNA (synthetic)
51
GCGCGCGATA TCTTGGTCTT CTTCACCATT CAGCGGCAGC GGTGGCTGCT 50
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
52
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATGAGGT TGTTGAAGTC 60
CAGCA 65
47 base pairs
nucleic acid
single
linear
DNA (synthetic)
53
GCGCGCCTCG AGGTTTGGAC GACGAAGATC TTGGTCTTCA CCATTGA 47
68 base pairs
nucleic acid
single
linear
DNA (synthetic)
54
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGT TATTTTCCAT 60
CAGGATAT 68
50 base pairs
nucleic acid
single
linear
DNA (synthetic)
55
GCGCGCTGAT GCATTCTGCA GAGACTTGAC GAGGTTTGGA CGACGAAGGT 50
47 base pairs
nucleic acid
single
linear
DNA (synthetic)
56
GCGCGCCTCG AGGCATTCAA CCGTGCTGCA TCAGCAATTG AGAGCAT 47
35 base pairs
nucleic acid
single
linear
DNA (synthetic)
57
GCGCGCCTGC AGAATATTCT TAAAAATCTC CTGCC 35
53 base pairs
nucleic acid
single
linear
DNA (synthetic)
58
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCCCATGTC TGCCGCTAGC CAC 53
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
59
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GACGGCCGCA 60
CCCACGCGAC A 71
67 base pairs
nucleic acid
single
linear
DNA (synthetic)
60
CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCA GGGCAGACAT 60
GGCAGGA 67
78 base pairs
nucleic acid
single
linear
DNA (synthetic)
61
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGA TAGAAGGTAT 60
TCCAGTCACC GTCCTTGA 78
60 base pairs
nucleic acid
single
linear
DNA (synthetic)
62
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA CAGTTTACGA CGGAATTCAT 60
42 base pairs
nucleic acid
single
linear
DNA (synthetic)
63
CGCGCGAAGC TTATTACTGT TGGGTTTTCA GATAGAAGGT CA 42
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
64
CGCGCGCCAT GGCTAACTGC NNSAACATGA TCGATGAAAT TATAACACAC TTAAAGCA 58
111 amino acids
amino acid
linear
peptide
65
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro
1 5 10 15
Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp
20 25 30
Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn
35 40 45
Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu
50 55 60
Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg
65 70 75 80
His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys
85 90 95
Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln
100 105 110
113 amino acids
amino acid
linear
peptide
66
Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
1 5 10 15
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp
20 25 30
Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala
35 40 45
Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser
50 55 60
Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro
65 70 75 80
Thr Arg His Pro Ile Ile Ile Arg Asp Gly Asp Trp Asn Glu Phe Arg
85 90 95
Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln
100 105 110
Gln
113 amino acids
amino acid
linear
peptide
67
Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
1 5 10 15
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp
20 25 30
Gln Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala
35 40 45
Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser
50 55 60
Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro
65 70 75 80
Thr Arg Arg Pro Ile Ile Ile Arg Asp Gly Asp Trp Asn Glu Phe Arg
85 90 95
Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln
100 105 110
Gln
339 base pairs
nucleic acid
double
linear
DNA (genomic)
68
ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60
CCGCTGCTGG ACTTCAACAA CCTCAATGAC GAAGACATGT CTATCCTGAT GGAAAATAAC 120
CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA AGTCTCTGCA GAATGCATCA 180
GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240
ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300
TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAG 339
113 amino acids
amino acid
linear
peptide
69
Met Ala Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys
1 5 10 15
Gln Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Asp Glu Asp
20 25 30
Met Ser Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala
35 40 45
Phe Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser
50 55 60
Ile Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro
65 70 75 80
Thr Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg
85 90 95
Arg Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln
100 105 110
Gln
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
70
CTTTAAGTGT GTTATAATTT CGTTGATCAT GTTAGAGCAG TTAGC 45
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
71
CATGGCTAAC TGCTCTAACA TGATCCAAGA AATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
72
CTTTAAGTGT GTTATAATTT CTTGGATCAT GTTAGAGCAG TTAGC 45
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
73
CATGGCTAAC TGCTCTAACA TGATCGAAGA AATTATAACA 40
76 base pairs
nucleic acid
single
linear
DNA (synthetic)
74
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACANNS TTAAAGCAGC 60
CACCTTTGCC TTTGCT 76
76 base pairs
nucleic acid
single
linear
DNA (synthetic)
75
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC NNSAAGCAGC 60
CACCTTTGCC TTTGCT 76
76 base pairs
nucleic acid
single
linear
DNA (synthetic)
76
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTANNSCAGC 60
›EXAMPLE 66 · 4 of 12
CACCTTTGCC TTTGCT 76
94 base pairs
nucleic acid
single
linear
DNA (synthetic)
77
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGNNSC 60
CACCTTTGCC TTTGCTGGAC TTCAACAACC TCAA 94
94 base pairs
nucleic acid
single
linear
DNA (synthetic)
78
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGN 60
NSCCTTTGCC TTTGCTGGAC TTCAACAACC TCAA 94
94 base pairs
nucleic acid
single
linear
DNA (synthetic)
79
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGC 60
CANNSTTGCC TTTGCTGGAC TTCAACAACC TCAA 94
94 base pairs
nucleic acid
single
linear
DNA (synthetic)
80
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGC 60
CACCTNNSCC TTTGCTGGAC TTCAACAACC TCAA 94
94 base pairs
nucleic acid
single
linear
DNA (synthetic)
81
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGC 60
CACCTTTGNN STTGCTGGAC TTCAACAACC TCAA 94
94 base pairs
nucleic acid
single
linear
DNA (synthetic)
82
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATAACACAC TTAAAGCAGC 60
CACCTTTGCC TNNSCTGGAC TTCAACAACC TCAA 94
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
83
GCGCGCGATA TCTTGGTCTT CACCATTGAG GTTGTTGAAG TCSNNCAGCG GCAGCGGTGG 60
CTGCT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
84
GCGCGCGATA TCTTGGTCTT CACCATTGAG GTTGTTGAAS NNCAGCAGCG GCAGCGGTGG 60
CTGCT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
85
GCGCGCGATA TCTTGGTCTT CACCATTGAG GTTGTTSNNG TCCAGCAGCG GCAGCGGTGG 60
CTGCT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
86
GCGCGCGATA TCTTGGTCTT CACCATTGAG GTTSNNGAAG TCCAGCAGCG GCAGCGGTGG 60
CTGCT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
87
GCGCGCGATA TCTTGGTCTT CACCATTGAG SNNGTTGAAG TCCAGCAGCG GCAGCGGTGG 60
CTGCT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
88
GCGCGCGATA TCTTGGTCTT CACCATTSNN GTTGTTGAAG TCCAGCAGCG GCAGCGGTGG 60
CTGCT 65
83 base pairs
nucleic acid
single
linear
DNA (synthetic)
89
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCTT GGTCTTCACC 60
SNNGAGGTTG TTGAAGTCCA GCA 83
83 base pairs
nucleic acid
single
linear
DNA (synthetic)
90
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCTT GGTCTTCSNN 60
ATTGAGGTTG TTGAAGTCCA GCA 83
83 base pairs
nucleic acid
single
linear
DNA (synthetic)
91
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCTT GGTCSNNACC 60
ATTGAGGTTG TTGAAGTCCA GCA 83
83 base pairs
nucleic acid
single
linear
DNA (synthetic)
92
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCTT GSNNTTCACC 60
ATTGAGGTTG TTGAAGTCCA GCA 83
83 base pairs
nucleic acid
single
linear
DNA (synthetic)
93
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATATCSN NGTCTTCACC 60
ATTGAGGTTG TTGAAGTCCA GCA 83
83 base pairs
nucleic acid
single
linear
DNA (synthetic)
94
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGGATSNNTT GGTCTTCACC 60
ATTGAGGTTG TTGAAGTCCA GCA 83
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
95
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATC AGSNNATCTT GGTCTTCACC 60
ATTGA 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
96
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCCATS NNGATATCTT GGTCTTCACC 60
ATTGA 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
97
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTTTCSNNC AGGATATCTT GGTCTTCACC 60
ATTGA 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
98
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT ATTSNNCATC AGGATATCTT GGTCTTCACC 60
ATTGA 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
99
GCGCGCCTCG AGGTTTGGAC GACGAAGGTT SNNTTCCATC AGGATATCTT GGTCTTCACC 60
ATTGA 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
100
GCGCGCCTCG AGGTTTGGAC GACGAAGSNN ATTTTCCATC AGGATATCTT GGTCTTCACC 60
ATTGA 65
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
101
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GGTTTGGACG 60
ACGSNNGTTA TTTTCCATCA GGATAT 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
102
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GGTTTGGACG 60
SNNAAGGTTA TTTTCCATCA GGATAT 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
103
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GGTTTGGSNN 60
ACGAAGGTTA TTTTCCATCA GGATAT 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
104
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GGTTSNNACG 60
ACGAAGGTTA TTTTCCATCA GGATAT 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
105
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCGA GSNNTGGACG 60
ACGAAGGTTA TTTTCCATCA GGATAT 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
106
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCCTCSN NGTTTGGACG 60
ACGAAGGTTA TTTTCCATCA GGATAT 86
68 base pairs
nucleic acid
single
linear
DNA (synthetic)
107
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AATGCSNNGA GGTTTGGACG 60
ACGAAGGT 68
68 base pairs
nucleic acid
single
linear
DNA (synthetic)
108
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTG AASNNCTCGA GGTTTGGACG 60
ACGAAGGT 68
68 base pairs
nucleic acid
single
linear
DNA (synthetic)
109
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGGTTS NNTGCCTCGA GGTTTGGACG 60
ACGAAGGT 68
68 base pairs
nucleic acid
single
linear
DNA (synthetic)
110
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCACGSNNG AATGCCTCGA GGTTTGGACG 60
ACGAAGGT 68
68 base pairs
nucleic acid
single
linear
DNA (synthetic)
111
GCGCGCTGAT GCATTCTGCA GAGACTTGAC AGCSNNGTTG AATGCCTCGA GGTTTGGACG 60
ACGAAGGT 68
68 base pairs
nucleic acid
single
linear
DNA (synthetic)
112
GCGCGCTGAT GCATTCTGCA GAGACTTGAC SNNACGGTTG AATGCCTCGA GGTTTGGACG 60
ACGAAGGT 68
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
113
GCGCGCCTCG AGGCATTCAA CCGTGCTNNS AAGTCTCTGC AGAATGCATC AGCAATTGAG 60
AGCAT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
114
GCGCGCCTCG AGGCATTCAA CCGTGCTGTC NNSTCTCTGC AGAATGCATC AGCAATTGAG 60
AGCAT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
115
GCGCGCCTCG AGGCATTCAA CCGTGCTGTC AAGNNSCTGC AGAATGCATC AGCAATTGAG 60
AGCAT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
116
GCGCGCCTCG AGGCATTCAA CCGTGCTGTC AAGTCTNNSC AGAATGCATC AGCAATTGAG 60
AGCAT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
117
GCGCGCCTCG AGGCATTCAA CCGTGCTGTC AAGTCTCTGN NSAATGCATC AGCAATTGAG 60
AGCAT 65
65 base pairs
nucleic acid
single
linear
DNA (synthetic)
118
GCGCGCCTCG AGGCATTCAA CCGTGCTGTC AAGTCTCTGC AGNNSGCATC AGCAATTGAG 60
AGCAT 65
53 base pairs
nucleic acid
single
linear
›EXAMPLE 66 · 5 of 12
DNA (synthetic)
119
GCGCGCCTGC AGAATNNSTC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCC 53
53 base pairs
nucleic acid
single
linear
DNA (synthetic)
120
GCGCGCCTGC AGAATGCANN SGCAATTGAG AGCATTCTTA AAAATCTCCT GCC 53
53 base pairs
nucleic acid
single
linear
DNA (synthetic)
121
GCGCGCCTGC AGAATGCATC ANNSATTGAG AGCATTCTTA AAAATCTCCT GCC 53
53 base pairs
nucleic acid
single
linear
DNA (synthetic)
122
GCGCGCCTGC AGAATGCATC AGCANNSGAG AGCATTCTTA AAAATCTCCT GCC 53
53 base pairs
nucleic acid
single
linear
DNA (synthetic)
123
GCGCGCCTGC AGAATGCATC AGCAATTNNS AGCATTCTTA AAAATCTCCT GCC 53
53 base pairs
nucleic acid
single
linear
DNA (synthetic)
124
GCGCGCCTGC AGAATGCATC AGCAATTGAG NNSATTCTTA AAAATCTCCT GCC 53
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
125
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCNNSCTTA AAAATCTCCT GCCATGTCTG 60
CCGCTAGCCA C 71
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
126
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTNNSA AAAATCTCCT GCCATGTCTG 60
CCGCTAGCCA C 71
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
127
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTN NSAATCTCCT GCCATGTCTG 60
CCGCTAGCCA C 71
134 amino acids
amino acid
linear
peptide
128
Met Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn
1 5 10 15
Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro
20 25 30
Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile
35 40 45
Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg
50 55 60
Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu Lys
65 70 75 80
Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His
85 90 95
Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys Leu
100 105 110
Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr
115 120 125
Leu Ser Leu Ala Ile Phe
130
Ala Pro Met Thr Gln Thr Thr Ser Leu Lys Thr Ser Trp Val Asn Cys
1 5 10 15
Ser Xaa Met Ile Asp Glu Ile Ile Xaa His Leu Lys Xaa Pro Pro Xaa
20 25 30
Pro Leu Leu Asp Xaa Asn Asn Leu Asn Xaa Glu Asp Xaa Asp Ile Leu
35 40 45
Met Glu Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa Arg Ala
50 55 60
Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa Ile Leu Xaa Asn
65 70 75 80
Leu Xaa Pro Cys Leu Pro Xaa Ala Thr Ala Ala Pro Xaa Arg His Pro
85 90 95
Ile Xaa Ile Lys Xaa Gly Asp Trp Xaa Glu Phe Arg Xaa Lys Leu Thr
100 105 110
Phe Tyr Leu Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln Thr Thr Leu
115 120 125
Ser Leu Ala Ile Phe
130
Asn Cys Ser Xaa Met Ile Asp Glu Ile Ile Xaa His Leu Lys Xaa Pro
1 5 10 15
Pro Xaa Pro Leu Leu Asp Xaa Asn Asn Leu Asn Xaa Glu Asp Xaa Asp
20 25 30
Ile Leu Met Glu Xaa Asn Leu Arg Xaa Pro Asn Leu Xaa Xaa Phe Xaa
35 40 45
Arg Ala Val Lys Xaa Leu Xaa Asn Ala Ser Xaa Ile Glu Xaa Ile Leu
50 55 60
Xaa Asn Leu Xaa Pro Cys Leu Pro Xaa Ala Thr Ala Ala Pro Xaa Arg
65 70 75 80
His Pro Ile Xaa Ile Lys Xaa Gly Asp Trp Xaa Glu Phe Arg Xaa Lys
85 90 95
Leu Thr Phe Tyr Leu Xaa Thr Leu Glu Xaa Ala Gln Xaa Gln Gln
100 105 110
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
131
CTAGCCACGG CCGCACCCAC GCGACATCCA ATCCATATCA AGGACGGTGA CTGGAATG 58
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
132
TTAACATTCC AGTCACCGTC CTTGATATGG ATTGGATGTC GCGTGGGTGC GGCCGTGG 58
29 base pairs
nucleic acid
double
linear
DNA (genomic)
133
AAGGAGATAT ATCCATGAAC TGCTCTAAC 29
5 amino acids
amino acid
linear
peptide
134
Met Asn Cys Ser Asn
1 5
120 amino acids
amino acid
linear
peptide
135
Met Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln
1 5 10 15
Pro Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln
20 25 30
Asp Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe
35 40 45
Asn Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile
50 55 60
Leu Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr
65 70 75 80
Arg His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg
85 90 95
Lys Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln
100 105 110
Thr Thr Leu Arg Leu Ala Ile Phe
115 120
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
136
AATTCCGTCG TAAACTGACC TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAGA 60
CCACTCTGTC G 71
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
137
CTAGCGACAG AGTGGTCTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGA TAGAAGGTCA 60
GTTTACGACG G 71
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
138
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AANNSCTCCT GCCATGTCTG 60
CCGCTAGCCA C 71
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
139
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATNNSCT GCCATGTCTG 60
CCGCTAGCCA C 71
71 base pairs
nucleic acid
single
linear
DNA (synthetic)
140
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCNN SCCATGTCTG 60
CCGCTAGCCA C 71
89 base pairs
nucleic acid
single
linear
DNA (synthetic)
141
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GNNSTGTCTG 60
CCGCTAGCCA CGGCCGCACC CACGCGACA 89
89 base pairs
nucleic acid
single
linear
DNA (synthetic)
142
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCANNSCTG 60
CCGCTAGCCA CGGCCGCACC CACGCGACA 89
89 base pairs
nucleic acid
single
linear
DNA (synthetic)
143
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTNNS 60
CCGCTAGCCA CGGCCGCACC CACGCGACA 89
408 base pairs
nucleic acid
double
linear
DNA (genomic)
144
ATGGCTCCAA TGACTCAGAC TACTTCTCTT AAGACTTCTT GGGTTAACTG CTCTAACATG 60
ATCGATGAAA TTATAACACA CTTAAAGCAG CCACCTTTGC CTTTGCTGGA CTTCAACAAC 120
CTCAATGGGG AAGACCAAGA CATTCTGATG GAAAATAACC TTCGAAGGCC AAACCTGGAG 180
GCATTCAACA GGGCTGTCAA GAGTTTACAG AATGCATCAG CAATTGAGAG CATTCTTAAA 240
AATCTCCTGC CATGTCTGCC CCTGGCCACG GCCGCACCCA CGCGACATCC AATCCATATC 300
AAGGACGGTG ACTGGAATGA ATTCCGTCGT AAACTGACCT TCTATCTGAA AACCTTGGAG 360
AACGCGCAGG CTCAACAGAC CACTCTGTCG CTAGCGATCT TTTAATAA 408
ATC GAT GAA ATC ATC ACC CAC CTG AAG CAG CCA CCG CTG CCG CTG CTG 48
Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu
1 5 10 15
GAC TTC AAC AAC CTC AAT GGT GAA GAC CAA GAT ATC CTG ATG GAA AAT 96
Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn
20 25 30
AAC CTT CGT CGT CCA AAC CTC GAG GCA TTC AAC CGT GCT GTC AAG TCT 144
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala Val Lys Ser
35 40 45
CTG CAG AAT GCA T 157
Leu Gln Asn Ala
50
52 amino acids
amino acid
linear
protein
146
Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro Leu Pro Leu Leu
›EXAMPLE 66 · 6 of 12
1 5 10 15
Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu Met Glu Asn
20 25 30
Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala Val Lys Ser
35 40 45
Leu Gln Asn Ala
50
414 base pairs
nucleic acid
double
linear
DNA (genomic)
147
CCATGGCTCC AATGACTCAG ACTACTTCTC TTAAGACTTC TTGGGTTAAC TGCTCTAACA 60
TGATCGATGA AATTATAACA CACTTAAAGC AGCCACCTTT GCCTTTGCTG GACTTCAACA 120
ACCTCAATGG GGAAGACCAA GACATTCTGA TGGAAAATAA CCTTCGAAGG CCAAACCTGG 180
AGGCATTCAA CAGGGCTGTC AAGAGTTTAC AGAATGCATC AGCAATTGAG AGCATTCTTA 240
AAAATCTCCT GCCATGTCTG CCCCTGGCCA CGGCCGCACC CACGCGACAT CCAATCCATA 300
TCAAGGACGG TGACTGGAAT GAATTCCGTC GTAAACTGAC CTTCTATCTG AAAACCTTGG 360
AGAACGCGCA GGCTCAACAG ACCACTCTGT CGCTAGCGAT CTTTTAATAA GCTT 414
414 base pairs
nucleic acid
double
linear
DNA (genomic)
148
AAGCTTATTA AAAGATCGCT AGCGACAGAG TGGTCTGTTG AGCCTGCGCG TTCTCCAAGG 60
TTTTCAGATA GAAGGTCAGT TTACGACGGA ATTCATTCCA GTCACCGTCC TTGATATGGA 120
TTGGATGTCG CGTGGGTGCG GCCGTGGCCA GGGGCAGACA TGGCAGGAGA TTTTTAAGAA 180
TGCTCTCAAT TGCTGATGCA TTCTGTAAAC TCTTGACAGC CCTGTTGAAT GCCTCCAGGT 240
TTGGCCTTCG AAGGTTATTT TCCATCAGAA TGTCTTGGTC TTCCCCATTG AGGTTGTTGA 300
AGTCCAGCAA AGGCAAAGGT GGCTGCTTTA AGTGTGTTAT AATTTCATCG ATCATGTTAG 360
AGCAGTTAAC CCAAGAAGTC TTAAGAGAAG TAGTCTGAGT CATTGGAGCC ATGG 414
81 base pairs
nucleic acid
double
linear
DNA (genomic)
149
ATGATGATTA CTCTGCGCAA ACTTCCTCTG GCGGTTGCCG TCGCAGCGGG CGTAATGTCT 60
GCTCAGGCCA TGGCTAACTG C 81
81 base pairs
nucleic acid
double
linear
DNA (genomic)
150
GCAGTTAGCC ATGGCCTGAG CAGACATTAC GCCCGCTGCG ACGGCAACCG CCAGAGGAAG 60
TTTGCGCAGA GTAATCATCA T 81
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
151
CATGGCTAAC TGCTCTAACA TGAT 24
22 base pairs
nucleic acid
single
linear
DNA (synthetic)
152
CGATCATGTT AGAGCAGTTA GC 22
12 base pairs
nucleic acid
double
linear
DNA (genomic)
153
ATGGCTAACT GC 12
4 amino acids
amino acid
linear
peptide
154
Met Ala Asn Cys
1
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
155
GCCGATACCG CGGCATACTC CCACCATTCA GAGA 34
33 base pairs
nucleic acid
single
linear
DNA (synthetic)
156
GCCGATAAGA TCTAAAACGG GTATGGAGAA ACA 33
89 base pairs
nucleic acid
single
linear
DNA (synthetic)
157
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTCTG 60
NNSCTAGCCA CGGCCGCACC CACGCGACA 89
89 base pairs
nucleic acid
single
linear
DNA (synthetic)
158
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTCTG 60
CCGNNSGCCA CGGCCGCACC CACGCGACA 89
89 base pairs
nucleic acid
single
linear
DNA (synthetic)
159
GCGCGCCTGC AGAATGCATC AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTCTG 60
CCGCTANNSA CGGCCGCACC CACGCGACA 89
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
160
CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCG TGGGTGCGGC 60
SNNGGCCAGG GGCAGACATG GCAGGA 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
161
CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCG TGGGTGCSNN 60
CGTGGCCAGG GGCAGACATG GCAGGA 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
162
CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCG TGGGSNNGGC 60
CGTGGCCAGG GGCAGACATG GCAGGA 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
163
CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGCG TSNNTGCGGC 60
CGTGGCCAGG GGCAGACATG GCAGGA 86
86 base pairs
nucleic acid
single
linear
DNA (synthetic)
164
CGCGCGGAAT TCATTCCAGT CACCGTCCTT GATATGGATT GGATGTCGSN NGGGTGCGGC 60
CGTGGCCAGG GGCAGACATG GCAGGA 86
48 base pairs
nucleic acid
single
linear
DNA (synthetic)
165
TTTCAGATAG AAGGTCAGTT TACGACGGAA SNNATTCCAG TCACCGTC 48
48 base pairs
nucleic acid
single
linear
DNA (synthetic)
166
TTTCAGATAG AAGGTCAGTT TACGACGSNN TTCATTCCAG TCACCGTC 48
48 base pairs
nucleic acid
single
linear
DNA (synthetic)
167
TTTCAGATAG AAGGTCAGTT TACGSNNGAA TTCATTCCAG TCACCGTC 48
48 base pairs
nucleic acid
single
linear
DNA (synthetic)
168
TTTCAGATAG AAGGTCAGTT TSNNACGGAA TTCATTCCAG TCACCGTC 48
48 base pairs
nucleic acid
single
linear
DNA (synthetic)
169
TTTCAGATAG AAGGTCAGSN NACGACGGAA TTCATTCCAG TCACCGTC 48
48 base pairs
nucleic acid
single
linear
DNA (synthetic)
170
TTTCAGATAG AAGGTSNNTT TACGACGGAA TTCATTCCAG TCACCGTC 48
23 base pairs
nucleic acid
single
linear
DNA (synthetic)
171
CGCGCGAAGC TTATTACTGT TGA 23
78 base pairs
nucleic acid
single
linear
DNA (synthetic)
172
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGA TAGAASNNCA 60
GTTTACGACG GAATTCAT 78
78 base pairs
nucleic acid
single
linear
DNA (synthetic)
173
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGA TASNNGGTCA 60
GTTTACGACG GAATTCAT 78
78 base pairs
nucleic acid
single
linear
DNA (synthetic)
174
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTCAGS NNGAAGGTCA 60
GTTTACGACG GAATTCAT 78
78 base pairs
nucleic acid
single
linear
DNA (synthetic)
175
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTTTTSNNA TAGAAGGTCA 60
GTTTACGACG GAATTCAT 78
78 base pairs
nucleic acid
single
linear
DNA (synthetic)
176
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA GGTSNNCAGA TAGAAGGTCA 60
GTTTACGACG GAATTCAT 78
78 base pairs
nucleic acid
single
linear
DNA (synthetic)
177
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCCAA SNNTTTCAGA TAGAAGGTCA 60
GTTTACGACG GAATTCAT 78
60 base pairs
nucleic acid
single
linear
DNA (synthetic)
178
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTCTCSNN GGTTTTCAGA TAGAAGGTCA 60
60 base pairs
nucleic acid
single
linear
DNA (synthetic)
179
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CGTTSNNCAA GGTTTTCAGA TAGAAGGTCA 60
60 base pairs
nucleic acid
single
linear
DNA (synthetic)
180
CGCGCGAAGC TTATTACTGT TGAGCCTGCG CSNNCTCCAA GGTTTTCAGA TAGAAGGTCA 60
60 base pairs
nucleic acid
single
linear
DNA (synthetic)
181
CGCGCGAAGC TTATTACTGT TGAGCCTGSN NGTTCTCCAA GGTTTTCAGA TAGAAGGTCA 60
60 base pairs
nucleic acid
single
linear
DNA (synthetic)
182
CGCGCGAAGC TTATTACTGT TGAGCSNNCG CGTTCTCCAA GGTTTTCAGA TAGAAGGTCA 60
60 base pairs
nucleic acid
single
linear
DNA (synthetic)
183
CGCGCGAAGC TTATTACTGT TGSNNCTGCG CGTTCTCCAA GGTTTTCAGA TAGAAGGTCA 60
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
184
TGCTCTAACA TGATCGATGA AATT 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
185
GAAATTATAA CACACTTAAA GCAG 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
186
AAGCAGCCAC CTTTGCCTTT GCTG 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
187
AAGCAGCCAC CGCTGCCGCT GCTG 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
188
CTCAATGGTG AAGACCAAGA TATC 24
›EXAMPLE 66 · 7 of 12
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
189
GATATCCTGA TGGAAAATAA CCTT 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
190
AACCTTCGTC GTCCAAACCT CGAG 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
191
CTCGAGGCAT TCAACCGTGC TGTC 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
192
GCTGTCAAGT CTCTGCAGAA TGCA 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
193
AATGCATCAG CAATTGAGAG CATT 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
194
AGCATTCTTA AAAATCTCCT GCCA 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
195
CTGCCATGTC TGCCCCTGGC CACG 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
196
CTGGCCACGG CCGCACCCAC GCGA 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
197
AATGAATTCC GTCGTAAACT GACC 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
198
CTGACCTTCT ATCTGAAAAC CTTG 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
199
ACCTTGGAGA ACGCGCAGGC TCAA 24
22 base pairs
nucleic acid
single
linear
DNA (synthetic)
200
GAATGCATCA GCAATTGAGA GC 22
20 base pairs
nucleic acid
single
linear
DNA (synthetic)
201
AATTGCTGAT GCATTCTGCA 20
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
202
ATTCTTAAAA ATCTCCTGCC ATGT 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
203
CAGGAGATTT TTAAGAATGC TCTC 24
30 base pairs
nucleic acid
single
linear
DNA (synthetic)
204
CTGCCCCTGG CCACGGCCGC ACCCACGCGA 30
30 base pairs
nucleic acid
single
linear
DNA (synthetic)
205
GGGTGCGGCC GTGGCCAGGG GCAGACATGG 30
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
206
CATCCAATCA TCATCCGTGA CGGTGACTGG AATG 34
44 base pairs
nucleic acid
single
linear
DNA (synthetic)
207
AATTCATTCC AGTCACCGTC ACGGATGATG ATTGGATGTC GCGT 44
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
208
CGCCCAATCA TCATCCGTGA CGGTGACTGG AATG 34
44 base pairs
nucleic acid
single
linear
DNA (synthetic)
209
AATTCATTCC AGTCACCGTC ACGGATGATG ATTGGGCGTC GCGT 44
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
210
CATGGCTAAC TGCTCTAACA TGATCGATGA AATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
211
CTTTAAGTGT GTTATAATTT CATCGATCAT GTTAGAGCAG TTAGC 45
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
212
CACTTAAAGC AGCCACCTTT GCCTTTGCTG GACTTC 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
213
GAGGTTGTTG AAGTCCAGCA AAGGCAAAGG TGGCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
214
AACAACCTCA ATGACGAAGA CATGTCT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
215
AGACATGTCT TCGTCATT 18
339 base pairs
nucleic acid
double
linear
DNA (genomic)
216
ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60
CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC 120
CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA ACTCTCTGCA GAATGCATCA 180
GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240
ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300
TTCTATCTGA AAACCTTGGA GAACGCGCAG GCTCAACAG 339
111 amino acids
amino acid
linear
peptide
217
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro
1 5 10 15
Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp
20 25 30
Ile Leu Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn
35 40 45
Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu
50 55 60
Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg
65 70 75 80
His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys
85 90 95
Leu Thr Phe Tyr Leu Trp Thr Leu Glu Asn Ala Gln Ala Gln Gln
100 105 110
111 amino acids
amino acid
linear
peptide
218
Asn Cys Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro
1 5 10 15
Pro Leu Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp
20 25 30
Ile Leu Met Asp Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn
35 40 45
Arg Ala Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu
50 55 60
Lys Asn Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg
65 70 75 80
His Pro Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys
85 90 95
Leu Thr Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln
100 105 110
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
219
CTTTAAGTGT GTTATAATTT CTTCGATCAT GTTAGAGCAG TTAGC 45
339 base pairs
nucleic acid
double
linear
DNA (genomic)
220
ATGGCTAACT GCTCTAACAT GATCGATGAA ATCATCACCC ACCTGAAGCA GCCACCGCTG 60
CCGCTGCTGG ACTTCAACAA CCTCAATGGT GAAGACCAAG ATATCCTGAT GGAAAATAAC 120
CTTCGTCGTC CAAACCTCGA GGCATTCAAC CGTGCTGTCA ACTCTCTGCA GAATGCATCA 180
GCAATTGAGA GCATTCTTAA AAATCTCCTG CCATGTCTGC CCCTGGCCAC GGCCGCACCC 240
ACGCGACATC CAATCCATAT CAAGGACGGT GACTGGAATG AATTCCGTCG TAAACTGACC 300
TTCTATCTGT GGACCTTGGA GAACGCGCAG GCTCAACAG 339
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
221
CATGGCTAAC TGCTCTAACA TGATCAACGA AATTATAACA 40
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
222
CGCGCGCCAT GGCTAACTGC TCTNNSATGA TCGATGAAAT TATAACACAC TTAAAGCA 58
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
223
CGCGCGCCAT GGCTAACTGC TCTAACNNSA TCGATGAAAT TATAACACAC TTAAAGCA 58
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
224
CGCGCGCCAT GGCTAACTGC TCTAACATGN NSGATGAAAT TATAACACAC TTAAAGCA 58
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
225
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCNNSGAAAT TATAACACAC TTAAAGCA 58
58 base pairs
nucleic acid
single
linear
DNA (synthetic)
226
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATNNSAT TATAACACAC TTAAAGCA 58
76 base pairs
nucleic acid
single
linear
DNA (synthetic)
227
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAANN SATAACACAC TTAAAGCAGC 60
CACCTTTGCC TTTGCT 76
76 base pairs
nucleic acid
single
linear
DNA (synthetic)
228
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TNNSACACAC TTAAAGCAGC 60
CACCTTTGCC TTTGCT 76
76 base pairs
nucleic acid
single
linear
DNA (synthetic)
229
CGCGCGCCAT GGCTAACTGC TCTAACATGA TCGATGAAAT TATANNSCAC TTAAAGCAGC 60
CACCTTTGCC TTTGCT 76
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
230
CATGGCTAAC TGCTCTAACA TGATCAGCGA AATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
231
CTTTAAGTGT GTTATAATTT CGCTGATCAT GTTAGAGCAG TTAGC 45
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
232
CATGGCTAAC TGCTCTAACA TGATCACCGA AATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
233
CTTTAAGTGT GTTATAATTT CCGTGATCAT GTTAGAGCAG TTAGC 45
›EXAMPLE 66 · 8 of 12
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
234
CATGGCTAAC TGCTCTAACA TGATCGATAA CATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
235
CTTTAAGTGT GTTATAATGT TATCGATCAT GTTAGAGCAG TTAGC 45
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
236
CATGGCTAAC TGCTCTAACA TGATCGATGA CATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
237
CTTTAAGTGT GTTATAATGT CATCGATCAT GTTAGAGCAG TTAGC 45
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
238
CATGGCTAAC TGCTCTAACA TGATCGATCA GATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
239
CTTTAAGTGT GTTATAATCT GATCGATCAT GTTAGAGCAG TTAGC 45
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
240
CATGGCTAAC TGCTCTAACA TGATCGATCT GATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
241
CTTTAAGTGT GTTATAATCA GATCGATCAT GTTAGAGCAG TTAGC 45
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
242
CATGGCTAAC TGCTCTAACA TGATCGATGT TATTATAACA 40
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
243
CTTTAAGTGT GTTATAATAA CATCGATCAT GTTAGAGCAG TTAGC 45
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
244
CACTTAAAGC AGCCACCTTT GCCTGCTCTG GACTTC 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
245
GAGGTTGTTG AAGTCCAGAG CAGGCAAAGG TGGCTG 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
246
CACTTAAAGC AGCCACCTTT GCCTCGTCTG GACTTC 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
247
GAGGTTGTTG AAGTCCAGAC GAGGCAAAGG TGGCTG 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
248
CACTTAAAGC AGCCACCTTT GCCTCAGCTG GACTTC 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
249
GAGGTTGTTG AAGTCCAGCT GAGGCAAAGG TGGCTG 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
250
CACTTAAAGC AGCCACCTTT GCCTGAACTG GACTTC 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
251
GAGGTTGTTG AAGTCCAGCT CAGGCAAAGG TGGCTG 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
252
CACTTAAAGC AGCCACCTTT GCCTATCCTG GACTTC 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
253
GAGGTTGTTG AAGTCCAGGA TAGGCAAAGG TGGCTG 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
254
CACTTAAAGC AGCCACCTTT CCCTTTCCTG GACTTC 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
255
GAGGTTGTTG AAGTCCAGGA AAGGCAAAGG TGGCTG 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
256
CACTTAAAGC AGCCACCTTT GCCTACCCTG GACTTC 36
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
257
GAGGTTGTTG AAGTCCAGGG TAGGCAAAGG TGGCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
258
AACAACCTCA ATCGTGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
259
ATCTTGGTCT TCACGATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
260
AACAACCTCA ATAACGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
261
ATCTTGGTCT TCGTTATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
262
AACAACCTCA ATGAAGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
263
ATCTTGGTCT TCTTCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
264
AACAACCTCA ATATCGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
265
ATCTTGGTCT TCGATATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
266
AACAACCTCA ATCTGGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
267
ATCTTGGTCT TCCAGATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
268
AACAACCTCA ATAAAGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
269
ATCTTGGTCT TCTTTATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
270
AACAACCTCA ATATGGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
271
ATCTTGGTCT TCCATATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
272
AACAACCTCA ATTTCGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
273
ATCTTGGTCT TCGAAATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
274
AACAACCTCA ATACCGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
275
ATCTTGGTCT TCGGTATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
276
AACAACCTCA ATTACGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
277
ATCTTGGTCT TCGTAATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
278
AACAACCTCA ATGTTGAAGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
279
ATCTTGGTCT TCAACATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
280
AACAACCTCA ATGGGCGTGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
281
ATCTTGGTCT CGCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
282
AACAACCTCA ATGGGCAGGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
283
ATCTTGGTCC TGCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
284
AACAACCTCA ATGGGGGTGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
285
ATCTTGGTCA CCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
286
AACAACCTCA ATGGGACCGA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
287
ATCTTGGTCG GTCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
288
AACAACCTCA ATGGGGAAGC TCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
289
ATCTTGAGCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
290
AACAACCTCA ATGGGGAAAA CCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
291
ATCTTGGTTT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
292
AACAACCTCA ATGGGGAACA GCAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
293
ATCTTGCTGT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
294
AACAACCTCA ATGGGGAAGA ACAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
295
ATCTTGTTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
296
AACAACCTCA ATGGGGAAGA CGCTGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
297
ATCAGCGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
298
AACAACCTCA ATGGGGAAGA CCGTGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
299
ATCACGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
300
AACAACCTCA ATGGGGAAGA CAACGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
301
ATCGTTGTCT TCCCCATT 18
›EXAMPLE 66 · 9 of 12
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
302
AACAACCTCA ATGGGGAAGA CGACGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
303
ATCGTCGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
304
AACAACCTCA ATGGTGAAGA CGAAGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
305
ATCTTCGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
306
AACAACCTCA ATGGTGAAGA CCACGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
307
ATCGTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
308
AACAACCTCA ATGGGGAAGA CATCGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
309
ATCGATGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
310
AACAACCTCA ATGGGGAAGA CTCCGAT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
311
ATCGGAGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
312
AACAACCTCA ATGGGGAAGA CCAAGCT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
313
AGCTTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
314
AACAACCTCA ATGGGGAAGA CCAAAAC 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
315
GTTTTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
316
AACAACCTCA ATGGGGAAGA CCAACAG 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
317
CTGTTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
318
AACAACCTCA ATGGGGAAGA CCAAGAA 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
319
TTCTTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
320
AACAACCTCA ATGGGGAAGA CCAACAC 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
321
GTGTTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
322
AACAACCTCA ATGGGGAAGA CCAAATC 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
323
GATTTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
324
AACAACCTCA ATGGGGAAGA CCAACTG 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
325
CAGTTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
326
AACAACCTCA ATGGGGAAGA CCAAAAA 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
327
TTTTTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
328
AACAACCTCA ATGGGGAAGA CCAATAC 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
329
GTATTGGTCT TCCCCATT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
330
AACAACCTCA ATGGGGAAGA CCAAGTT 27
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
331
AACTTGGTCT TCCCCATT 18
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
332
ATCGCTATGG AAAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
333
CCTTCGAAGG TTATTTTCCA TAGCGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
334
ATCGAAATGG AAAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
335
CCTTCGAAGG TTATTTTCCA TTTCGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
336
ATCAAAATGG AAAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
337
CCTTCGAAGG TTATTTTCCA TTTTGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
338
ATCATGATGG AAAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
339
CCTTCGAAGG TTATTTTCCA TCATGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
340
ATCACCATGG AAAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
341
CCTTCGAAGG TTATTTTCCA TGGTGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
342
ATCGTTATGG AAAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
343
CCTTCGAAGG TTATTTTCCA TAACGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
344
ATCCTGATGC ACAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
345
CCTTCGAAGG TTATTGTGCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
346
ATCCTGATGA TGAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
347
CCTTCGAAGG TTATTCATCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
348
ATCCTGATGT TCAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
349
CCTTCGAAGG TTATTGAACA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
350
ATCCTGATGG CTAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
351
CCTTCGAAGG TTATTAGCCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
352
ATCCTGATGA ACAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
353
CCTTCGAAGG TTATTGTTCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
354
ATCCTGATGA TCAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
355
CCTTCGAAGG TTATTGATCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
356
ATCCTGATGA AAAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
357
CCTTCGAAGG TTATTTTTCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
358
ATCCTGATGT CCAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
359
CCTTCGAAGG TTATTGGACA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
360
ATCCTGATGG TTAATAACCT TCGAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
361
CCTTCGAAGG TTATTAACCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
362
ATCCTGATGG AAAATAACCT TGCTAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
363
CCTAGCAAGG TTATTTTCCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
364
ATCCTGATGG AAAATAACCT TAACAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
365
CCTGTTAAGG TTATTTTCCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
366
ATCCTGATGG AAAATAACCT TCACAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
367
CCTGTGAAGG TTATTTTCCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
368
ATCCTGATGG AAAATAACCT TAAAAGGCCA AACCTG 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
369
CCTTTTAAGG TTATTTTCCA TCAGGAT 27
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
›EXAMPLE 66 · 10 of 12
370
ATCCTGATGG AAAATAACCT TCGAAGGGCT AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
371
CCTGTTGAAT GCCTCCAGGT TAGC 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
372
ATCCTGATGG AAAATAACCT TCGAAGGCGT AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
373
CCTGTTGAAT GCCTCCAGGT TACG 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
374
ATCCTGATGG AAAATAACCT TCGAAGGAAC AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
375
CCTGTTGAAT GCCTCCAGGT TGTT 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
376
ATCCTGATGG AAAATAACCT TCGAAGGGAA AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
377
CCTGTTGAAT GCCTCCAGGT TTTC 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
378
ATCCTGATGG AAAATAACCT TCGAAGGCAC AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
379
CCTGTTGAAT GCCTCCAGGT TGTG 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
380
ATCCTGATGG AAAATAACCT TCGAAGGCTG AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
381
CCTGTTGAAT GCCTCCAGGT TCAG 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
382
ATCCTGATGG AAAATAACCT TCGAAGGTTC AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
383
CCTGTTGAAT GCCTCCAGGT TGAA 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
384
ATCCTGATGG AAAATAACCT TCGAAGGACC AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
385
CCTGTTGAAT GCCTCCAGGT TGGT 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
386
ATCCTGATGG AAAATAACCT TCGAAGGTAC AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
387
CCTGTTGAAT GCCTCCAGGT TGTA 24
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
388
ATCCTGATGG AAAATAACCT TCGAAGGGTT AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
389
CCTGTTGAAT GCCTCCAGGT TAAC 24
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
390
AAAAATCTCG CTCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
391
AGCGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
392
AAAAATCTCA ACCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
393
GTTGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
394
AAAAATCTCG AACCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
395
TTCGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
396
AAAAATCTCC ACCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
397
GTGGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
398
AAAAATCTCA TCCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
399
GATGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
400
AAAAATCTCA TGCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
401
CATGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
402
AAAAATCTCT TCCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
403
GAAGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
404
AAAAATCTCT CCCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
405
GGAGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
406
AAAAATCTCA CCCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
407
GGTGAGATTT TTAAGAAT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
408
AAAAATCTCT ACCCATGT 18
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
409
GTAGAGATTT TTAAGAAT 18
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
410
CTGCCCCTGG CCACGGCCGC AGCTACG 27
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
411
ATGGATTGGA TGTCGCGTAG CTGC 24
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
412
CTGCCCCTGG CCACGGCCGC AGGTACG 27
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
413
ATGGATTGGA TGTCGCGTAC CTGC 24
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
414
CTGCCCCTGG CCACGGCCGC AATCACG 27
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
415
ATGGATTGGA TGTCGCGTGA TTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
416
GCTCATCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
417
ATGGATTGGA TGAGCCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
418
CAGCATCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
419
ATGGATTGGA TGCTGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
420
CACCATCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
421
ATGGATTGGA TGGTGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
422
AAACATCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
423
ATGGATTGGA TGTTTCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
424
CGAGCTCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
425
ATGGATTGGA GCTCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
426
CGAAACCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
427
ATGGATTGGG TTTCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
428
CGAGACCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
429
ATGGATTGGG TCTCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
430
CGAATCCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
431
ATGGATTGGG ATTCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
432
CGAAAACCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
433
ATGGATTGGT TTTCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
434
CGAATGCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
435
ATGGATTGGC ATTCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
436
CGATTCCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
437
ATGGATTGGG AATCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
438
CGATCCCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
439
ATGGATTGGG GATCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
440
CGATGGCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
441
ATGGATTGGC CATCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
›EXAMPLE 66 · 11 of 12
442
CGATACCCAA TCCATATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
443
ATGGATTGGG TATCGCGTGG GTGC 24
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
444
CATCCAATCC AAATCAAGGA CGGTGACTGG AATG 34
44 base pairs
nucleic acid
single
linear
DNA (synthetic)
445
AATTCATTCC AGTCACCGTC CTTGATTTGG ATTGGATGTC GCGT 44
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
446
CATCCAATCG AAATCAAGGA CGGTGACTGG AATG 34
44 base pairs
nucleic acid
single
linear
DNA (synthetic)
447
AATTCATTCC AGTCACCGTC CTTGATTTCG ATTGGATGTC GCGT 44
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
448
CATCCAATCA TGATCAAGGA CGGTGACTGG AATG 34
44 base pairs
nucleic acid
single
linear
DNA (synthetic)
449
AATTCATTCC AGTCACCGTC CTTGATCATG ATTGGATGTC GCGT 44
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
450
CATCCAATCT TCATCAAGGA CGGTGACTGG AATG 34
44 base pairs
nucleic acid
single
linear
DNA (synthetic)
451
AATTCATTCC AGTCACCGTC CTTGATGAAG ATTGGATGTC GCGT 44
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
452
CATCCAATCT CCATCAAGGA CGGTGACTGG AATG 34
44 base pairs
nucleic acid
single
linear
DNA (synthetic)
453
AATTCATTCC AGTCACCGTC CTTGATGGAG ATTGGATGTC GCGT 44
34 base pairs
nucleic acid
single
linear
DNA (synthetic)
454
CATCCAATCG TAATCAAGGA CGGTGACTGG AATG 34
44 base pairs
nucleic acid
single
linear
DNA (synthetic)
455
AATTCATTCC AGTCACCGTC CTTGATTACG ATTGGATGTC GCGT 44
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
456
CGACATCCAA TCCGTATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
457
ACGGATTGGA TGTCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
458
CGACATCCAA TCAAAATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
459
TTTGATTGGA TGTCGCGTGG GTGC 24
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
460
CGACATCCAA TCTACATCAA G 21
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
461
GTAGATTGGA TGTCGCGTGG GTGC 24
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
462
GCTGGTGACT GGAATG 16
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
463
AATTCATTCC AGTCACCAGC CTTGAT 26
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
464
AACGGTGACT GGAATG 16
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
465
AATTCATTCC AGTCACCGTT CTTGAT 26
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
466
GAAGGTGACT GGAATG 16
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
467
AATTCATTCC AGTCACCTTC CTTGAT 26
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
468
GGTGGTGACT GGAATG 16
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
469
AATTCATTCC AGTCACCACC CTTGAT 26
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
470
ATCGGTGACT GGAATG 16
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
471
AATTCATTCC AGTCACCGAT CTTGAT 26
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
472
CTGGGTGACT GGAATG 16
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
473
AATTCATTCC AGTCACCCAG CTTGAT 26
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
474
TTCGGTGACT GGAATG 16
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
475
AATTCATTCC AGTCACCGAA CTTGAT 26
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
476
TCCGGTGACT GGAATG 16
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
477
AATTCATTCC AGTCACCGGA CTTGAT 26
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
478
AATTCGCTAG GAAACTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
479
CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTAGCG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
480
AATTCCAGAG GAAACTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
481
CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTCTGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
482
AATTCCACAG GAAACTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
483
CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTGTGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
484
AATTCTCCAG GAAACTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
485
CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTGGAG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
486
AATTCCGGAG GCGTCTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
487
CTCAAGGGTT TTCAGATAGA ACGTCAGACG CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
488
AATTCCGGAG GGAACTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
489
CTCAAGGGTT TTCAGATAGA ACGTCAGTTC CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
490
AATTCCGGAG GCACCTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
491
CTCAAGGGTT TTCAGATAGA ACGTCAGGTG CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
492
AATTCCGGAG GATCCTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
493
CTCAAGGGTT TTCAGATAGA ACGTCAGGAT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
494
AATTCCGGAG GTCCCTGACG TTCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
495
CTCAAGGGTT TTCAGATAGA ACGTCAGGGA CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
496
AATTCCGGAG GAAACTGACG GACTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
497
CTCAAGGGTT TTCAGATAGT CCGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
498
AATTCCGGAG GAAACTGACG ATCTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
499
CTCAAGGGTT TTCAGATAGA TCGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
500
AATTCCGGAG GAAACTGACG CTGTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
501
CTCAAGGGTT TTCAGATACA GCGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
502
AATTCCGGAG GAAACTGACG AAATATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
503
CTCAAGGGTT TTCAGATATT TCGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
504
AATTCCGGAG GAAACTGACG GTTTATCTGA AA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
505
CTCAAGGGTT TTCAGATAAA CCGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
506
AATTCCGGAG GAAACTGACG TTCTATCTGG CT 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
507
CTCAAGGGTA GCCAGATAGA ACGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
›EXAMPLE 66 · 12 of 12
DNA (synthetic)
508
AATTCCGGAG GAAACTGACG TTCTATCTGC GT 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
509
CTCAAGGGTA CGCAGATAGA ACGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
510
AATTCCGGAG GAAACTGACG TTCTATCTGA AC 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
511
CTCAAGGGTG TTCAGATAGA ACGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
512
AATTCCGGAG GAAACTGACG TTCTATCTGC AG 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
513
CTCAAGGGTC TGCAGATAGA ACGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
514
AATTCCGGAG GAAACTGACG TTCTATCTGC AC 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
515
CTCAAGGGTG TGCAGATAGA ACGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
516
AATTCCGGAG GAAACTGACG TTCTATCTGA TG 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
517
CTCAAGGGTC ATCAGATAGA ACGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
518
AATTCCGGAG GAAACTGACG TTCTATCTGT TC 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
519
CTCAAGGGTG AACAGATAGA ACGTCAGTTT CCTCCGG 37
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
520
AATTCCGGAG GAAACTGACG TTCTATCTGT AC 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
521
CTCAAGGGTG TACAGATAGA ACGTCAGTTT CCTCCGG 37
40 base pairs
nucleic acid
single
linear
DNA (synthetic)
522
CATGGCTAAC TGCTCTAACA TGATCGATGA AATTATAACA 40
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
523
CACTTAAAGC AGCCACCTTT GCCTTTGCTG GACTTC 36
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
524
AACAACCTCA ATGGGGAAGA CCAAGAT 27
45 base pairs
nucleic acid
single
linear
DNA (synthetic)
525
CTTTAAGTGT GTTATAATTT CATCGATCAT GTTAGAGCAG TTAGC 45
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
526
GAGGTTGTTG AAGTCCAGCA AAGGCAAAGG TGGCTG 36
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
527
ATCTTGGTCT TCCCCATT 18
36 base pairs
nucleic acid
single
linear
DNA (synthetic)
528
ATCCTGATGG AAAATAACCT TCGAAGGCCA AACCTG 36
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
529
GAGGCATTCA ACAGGGCTGT CAAG 24
15 base pairs
nucleic acid
single
linear
DNA (synthetic)
530
AGTTTACAGA ATGCA 15
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
531
CCTTCGAAGG TTATTTTCCA TCAGGAT 27
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
532
CCTGTTGAAT GCCTCCAGGT TTGG 24
20 base pairs
nucleic acid
single
linear
DNA (synthetic)
533
TTCTGTAAAC TCTTGACAGC 20
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
534
TCAGCAATTG AGAGCATTCT T 21
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
535
AAAAATCTCC TGCCATGT 18
48 base pairs
nucleic acid
single
linear
DNA (synthetic)
536
CTGCCCCTGG CCACGGCCGC ACCCACGCGA CATCCAATCC ATATCAAG 48
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
537
CTGCCCCTGG CCACGGCCGC ACCCACG 27
21 base pairs
nucleic acid
single
linear
DNA (synthetic)
538
CGACATCCAA TCCATATCAA G 21
16 base pairs
nucleic acid
single
linear
DNA (synthetic)
539
GACGGTGACT GGAATG 16
19 base pairs
nucleic acid
single
linear
DNA (synthetic)
540
GCTCTCAATT GCTGATGCA 19
18 base pairs
nucleic acid
single
linear
DNA (synthetic)
541
CAGGAGATTT TTAAGAAT 18
48 base pairs
nucleic acid
single
linear
DNA (synthetic)
542
ATGGATTGGA TGTCGCGTGG GTGCGGCCGT GGCCAGGGGC AGACATGG 48
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
543
GGCCGTGGCC AGGGGCAGAC ATGG 24
24 base pairs
nucleic acid
single
linear
DNA (synthetic)
544
ATGGATTGGA TGTCGCGTGG GTGC 24
26 base pairs
nucleic acid
single
linear
DNA (synthetic)
545
AATTCATTCC AGTCACCGTC CTTGAT 26
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
546
AATTCCGGAG GAAACTGACG TTCTATCTGA AA 32
32 base pairs
nucleic acid
single
linear
DNA (synthetic)
547
ACCCTTGAGA ATGCGCAGGC TCAACAGTAA TA 32
37 base pairs
nucleic acid
single
linear
DNA (synthetic)
548
CTCAAGGGTT TTCAGATAGA ACGTCAGTTT CCTCCGG 37
27 base pairs
nucleic acid
single
linear
DNA (synthetic)
549
AGCTTATTAC TGTTGAGCCT GCGCATT 27
›Tables in the description — 21
| Plasmid | Polypeptide | Biological |
|---|---|---|
| Code | Structure | Activity |
| Reference | (1-133)hIL-3 | 1.0 |
| pMON13286 | [SEO ID NO. 69] | 8.0 |
| pMON13304 | [SEO ID NO. 66] | 3.2 |
| Abbreviated Designation | Amino Acid | |
| A | Ala | Alanine |
| C | Cys | Cysteine |
| D | Asp | Aspartic acid |
| E | Glu | Glutamic acid |
| F | Phe | Phenylalanine |
| G | Gly | Glycine |
| H | His | Histidine |
| I | Ile | Isoleucine |
| K | Lys | Lysine |
| L | Leu | Leucine |
| M | Met | Methionine |
| N | Asn | Asparagine |
| P | Pro | Proline |
| Q | Gln | Glutamine |
| R | Arg | Arginine |
| S | Ser | Serine |
| T | Thr | Threonine |
| V | Val | Valine |
| W | Trp | Tryptophan |
| Y | Tyr | Tyrosine |
| 5′ | ATG GCT AAC TGC . . . | 3′ | [SEQ ID NO:153] |
| Met Ala Asn Cys . . . | [SEQ ID NO:154] | ||
| 15 |
| Oligo #155 | [SEQ ID NO:200] |
| Oligo #156 | [SEQ ID NO:201] |
| Oligo #157 | [SEQ ID NO:202] |
| Oligo #158 | [SEQ ID NO:203] |
| Oligo #159 | [SEQ ID NO:204] |
| Oligo #160 | [SEQ ID NO:205] |
| Oligo #161 | [SEQ ID NO:206] |
| Oligo #162 | [SEQ ID NO:207] |
| Oligo #155 | [SEQ ID NO:200] |
| Oligo #156 | [SEQ ID NO:201] |
| Oligo #157 | [SEQ ID NO:202] |
| Oligo #158 | [SEQ ID NO:203] |
| Oligo #159 | [SEQ ID NO:204] |
| Oligo #160 | [SEQ ID NO:205] |
| Oligo #163 | [SEQ ID NO:208] |
| Oligo #164 | [SEQ ID NO:209] |
| Oligo #165 | [SEQ ID NO:210] |
| Oligo #166 | [SEQ ID NO:211] |
| Oligo #167 | [SEQ ID NO: 212] |
| Oligo #168 | [SEQ ID NO:213] |
| Oligo #169 | [SEQ ID NO:214] |
| Oligo #170 | [SEQ ID NO:215] |
| 5′-AAGGAGATATATCCATGAACTGCTCTAAC-3′ | [SEQ ID NO:133] |
| M N C S N | [SEQ ID NO:134] |
| hIL-3 aa | PARENTAL | (15-125)hIL-3 MUTANT | ||||
| POSITION 1 | aa | CODON | aa | SEQ ID NO: | CODON | BIOL ACTIVITY |
| 17/3 1 | SER | TCT | LYS | 19 | AAG | <0.018 (1) |
| 17/3 | SER | TCT | GLY | 19 | GGG | 1.2 ± 1.1 (3) |
| 17/3 | SER | TCT | ASP | 19 | GAC | 1.0 ± 0.7 (3) |
| 17/3 | SER | TCT | MET | 19 | ATG | 0.50 (1) |
| 17/3 | SER | TCT | GLN | 19 | CAG | 1.2 ± 0.7 (3) |
| 17/3 | SER | TCT | ARG | 19 | AGG | <0.070 (1) |
| 18/4 | ASN | AAC | HIS | 19 | CAC | 1.2 ± 0.3 (3) |
| 18/4 | ASN | AAC | LEU | 19 | CTC | 0.45 ± 0.42 (4) |
| 18/4 | ASN | AAC | ILE | 19 | ATC | 1.5 ± 0.2 (2) |
| 18/4 | ASN | AAC | PHE | 19 | TTC | 0.19 ± 0.26 (2) |
| 18/4 | ASN | AAC | ARG | 19 | CGG | 0.10 (1) |
| 18/4 | ASN | AAC | GLN | 19 | CAA | 0.37 (1) |
| 19/5 | MET | ATG | PHE | 19 | TTC | 0.25 (1) |
| 19/5 | MET | ATG | ILE | 19 | ATG | 0.77 ± 0.70 (9) |
| 19/5 | MET | ATG | ARG | 19 | AGG | 0.17 (1) |
| 19/5 | MET | ATG | GLY | 19 | GGA | 0.06 (1) |
| 19/5 | MET | ATG | ALA | 19 | GCG | 0.19 (1) |
| 19/5 | MET | ATG | CYS | 19 | TGC | — |
| 20/6 | ILE | ATC | CYS | 19 | TGC | — |
| 20/6 | ILE | ATC | GLN | 19 | CAG | — |
| 20/6 | ILE | ATC | GLU | 19 | GAG | <0.025 (1) |
| 20/6 | ILE | ATC | ARG | 19 | CGC | <0.025 (1) |
| 20/6 | ILE | ATC | PRO | 19 | CCG | 0.29 ± 0.16 (3) |
| 20/6 | ILE | ATC | ALA | 19 | GCG | 0.18 (1) |
| 21/7 | ASP | GAT | PHE | 19 | TTC | <0.016 (1) |
| 21/7 | ASP | GAT | LYS | 19 | AAG | 0.027 ± 0.027 (2) |
| 21/7 | ASP | GAT | ARG | 19 | AGG | <0.008 (1) |
| 21/7 | ASP | GAT | ALA | 19 | GCG | 0.07 ± 0.06 (3) |
| 21/7 | ASP | GAT | GLY | 19 | GGG | 0.032 (1) |
| 21/7 | ASP | GAT | VAL | 19 | GTG | <0.008 (1) |
| 22/8 | GLU | GAA | TRP | 19 | TGG | — |
| 22/8 | GLU | GAA | PRO | 19 | CCG | <0.015 (1) |
| 22/8 | GLU | GAA | SER | 19 | TCG | <0.015 (1) |
| 22/8 | GLU | GAA | ALA | 19 | GCC | <0.015 (1) |
| 22/8 | GLU | GAA | HIS | 19 | CAC | <0.015 (1) |
| 22/8 | GLU | GAA | GLY | 19 | GGC | <0.008 (1) |
| 23/9 | ILE | ATT | VAL | 19 | GTG | 0.18 (1) |
| 23/9 | ILE | ATT | ALA 2 | 19 | GCG | 1.16 ± 0.16 (3) |
| 23/9 | ILE | ATT | LEU | 19 | TTG | 1.3 (1) |
| 23/9 | ILE | ATT | GLY 2 | 19 | GGG | 0.06 (1) |
| 23/9 | ILE | ATT | TRP | 19 | TGG | — |
| 23/9 | ILE | ATT | LYS 2 | 19 | AAG | — |
| 23/9 | ILE | ATT | PHE | 19 | TTC | — |
| 23/9 | ILE | ATT | LEU 2 | 19 | TTG | 3.0 ± 1.1 (3) |
| 23/9 | ILE | ATT | SER 2 | 19 | AGC | <0.005 (1) |
| 23/9 | ILE | ATT | ARG 2 | 19 | CGC | — |
| 24/10 | ILE | ATA | GLY | 19 | GGG | <0.004 (1) |
| 24/10 | ILE | ATA | VAL | 19 | GTC | 0.89 ± 0.23 (4) |
| 24/10 | ILE | ATA | ARG 3 | 19 | CGG | — |
| 24/10 | ILE | ATA | SER | 19 | AGC | <0.003 (1) |
| 24/10 | ILE | ATA | PHE | 19 | TTC | 0.29 ± 0.24 (2) |
| 24/10 | ILE | ATA | LEU | 19 | CTG | 0.52 ± 0.12 (3) |
| 25/11 | THR | ACA | HIS | 19 | CAC | 1.11 ± 0.2 (3) |
| 25/11 | THR | ACA | GLY | 19 | GGC | 0.48 ± 0.27 (4) |
| 25/11 | THR | ACA | GLN | 19 | CAG | 1.0 ± 0.8 (4) |
| 25/11 | THR | ACA | ARG | 19 | CGG | 0.26 ± 0.17 (2) |
| 25/11 | THR | ACA | PRO | 19 | CCG | 0.36 (1) |
| 31/17 | PRO | CCT | GLY | 19 | GGG | 0.79 ± 0.61 (2) |
| 31/17 | PRO | CCT | ALA | 19 | GCC | 0.49 (1) |
| 31/17 | PRO | CCT | ARG | 19 | CGC | 0.25 ± 0.20 (2) |
| 31/17 | PRO | CCT | LEU | 19 | CTG | 0.22 (1) |
| 31/17 | PRO | CCT | GLN | 19 | CAG | 0.62 ± 0.04 (2) |
| 31/17 | PRO | CCT | LEU 4 | 19 | CTG | 0.30 ± 0.20 (3) |
| 32/18 | LEU | TTG | VAL 2 | 19 | GTG | 0.01 (1) |
| 32/18 | LEU | TTG | ARG | 19 | CCC | 1.5 ± 1.0 (4) |
| 32/18 | LEU | TTG | CLN | 19 | CAG | 0.93 ± 0.18 (3) |
| 32/18 | LEU | TTG | ASN | 19 | AAC | 1.2 ± 0.5 (5) |
| 32/18 | LEU | TTG | GLY 5 | 19 | GGC | 0.84 ± 1.0 (3) |
| 32/18 | LEU | TTG | ALA | 19 | GCG | 1.4 ± 0.7 (5) |
| 32/18 | LEU | TTG | GLU | 19 | GAG | 0.88 ± 0.37 (2) |
| 33/19 | PRO | CC(T/C) | LEU | 19 | CTG | 0.13 (1) |
| 33/19 | PRO | CC(T/C) | GLN | 19 | CAG | 0.22 ± 0.20 (2) |
| 33/19 | PRO | CC(T/C) | ALA | 19 | GCG | 0.30 ± 0.14 (2) |
| 33/19 | PRO | CC(T/C) | THR | 19 | ACC | <0.018 (1) |
| 33/19 | PRO | CC(T/C) | GLU | 19 | GAG | 0.54 ± 0.43 (2) |
| 34/20 | LEU | TTG | VAL | 19 | GTG | 1.2 ± 0.6 (3) |
| 34/20 | LEU | TTG | GLY | 19 | GGG | 0.64 ± 0.74 (2) |
| 34/20 | LEU | TTG | SER | 19 | TCG | 1.5 ± 0.7 (4) |
| 34/20 | LEU | TTG | LYS | 19 | AAG | 0.97 ± 0.28 (2) |
| 34/20 | LEU | TTG | MET | 19 | ATG | 1.1 ± 0.5 (3) |
| 35/21 | LEU | CTG | ALA | 19 | GCC | 1.6 ± 0.5 (3) |
| 35/21 | LEU | CTG | GLY | 19 | GGC | <0.006 ± 0.002 (3) |
| 35/21 | LEU | CTG | ASN | 19 | AAC | 1.1 ± 1.7 (5) |
| 35/21 | LEU | CTG | PRO | 19 | CCC | 1.8 ± 2.0 (5) |
| 35/21 | LEU | CTG | GLN | 19 | CAA | 0.98 ± 1.1 (5) |
| 35/21 | LEU | CTG | VAL | 19 | GTG | 0.76 ± 0.86 (5) |
| 36/22 | ASP | GAC | LEU | 19 | CTC | 0.20 (1) |
| 25/11 | THR | ACA | ALA | 19 | GCC | 0.86 ± 0.27 (3) |
| 26/12 | HIS | CAC | THR | 19 | ACG | 0.010 (1) |
| 26/12 | HIS | CAC | PHE | 19 | TTC | 0.26 (1) |
| 26/12 | HIS | CAC | GLY | 19 | GGG | 0.19 (1) |
| 26/12 | HIS | CAC | ARG | 19 | CGG | 0.21 (1) |
| 26/12 | HIS | CAC | ALA | 19 | GCC | 0.56 ± 0.03 (2) |
| 26/12 | HIS | CAC | TRP | 19 | TGG | — |
| 27/13 | LEU | TTA | GLY | 19 | GGG | — |
| 27/13 | LEU | TTA | ARG | 19 | AGG | — |
| 27/13 | LEU | TTA | THR | 19 | ATC | 0.084 (1) |
| 27/13 | LEU | TTA | SER | 19 | TCC | — |
| 27/13 | LEU | TTA | ALA | 19 | GCG | 0.01 (1) |
| 28/14 | LYS | AAG | ARG | 19 | CGG | 0.42 ± 0.07 (2) |
| 28/14 | LYS | AAG | LEU | 19 | TTG | — |
| 28/14 | LYS | AAG | TRP | 19 | TGG | — |
| 29/14 | LYS | AAG | GLN | 19 | CAG | 0.27 (1) |
| 28/14 | LYS | AAG | GLY | 19 | GGC | 0.36 ± 0.07 (2) |
| 29/14 | LYS | AAG | PRO | 19 | CCC | 0.10 ± 0.04 (2) |
| 28/14 | LYS | AAG | VAL | 19 | GTG | 0.19 ± 0.12 (2) |
| 29/15 | GLN | CAG | ASN | 19 | AAC | 1.62 ± 1.7 (3) |
| 29/15 | GLN | CAG | LEU | 19 | CTG | 0.284 |
| 29/15 | GLN | CAG | PRO | 19 | CCG | — |
| 29/15 | ARG | CAG | ARG | 19 | AGG | 0.44 ± 0.16 (4) |
| 29/15 | GLN | CAG | VAL | 19 | GTG | 0.62 ± 0.40 (4) |
| 30/16 | PRO | CCA | HIS | 19 | CAC | 0.26 (1) |
| 30/16 | PRO | CCA | THR | 19 | ACG | 0.36 (1) |
| 30/16 | PRO | CCA | GLY | 19 | GGG | 1.2 ± 0.8 (3) |
| 30/16 | PRO | CCA | ASP | 19 | GAC | — |
| 30/16 | PRO | CCA | GLN | 19 | CAG | 0.61 ± 0.37 (3) |
| 30/16 | PRO | CCA | SER | 19 | TCG | — |
| 30/16 | PRO | CCA | LEU | 19 | TTC | — |
| 30/16 | PRO | CCA | LYS | 19 | AAG | — |
| 31/17 | PRO | CCT | ASP | 19 | GAC | 0.66 ± 0.71 (3) |
| 36/22 | ASP | GAC | VAL | 19 | GTG | — |
| 37/23 | PHE | TTC | SER | 19 | AGC | 0.62 ± 0.40 (4) |
| 37/23 | PHE | TTC | PRO | 19 | CCG | 0.65 ± 0.39 (4) |
| 37/23 | PHE | TTC | TRP | 19 | TGG | — |
| 37/23 | PHE | TTC | ILE | 19 | ATC | 0.1 (1) |
| 36/24 | ASN | AAC | ALA | 19 | GCN | 1.9 (1) |
| 40/26 | LEU | CTC | TRP | 19 | TGG | — |
| 40/26 | LEU | CTC | ARG | 19 | CGC | — |
| 41/27 | ASN | AAT | CYS | 19 | TGC | 0.18 (1) |
| 41/27 | ASN | AAT | ARG | 19 | CGC | 0.13 ± 0.13 (2) |
| 41/27 | ASN | AAT | LEU | 19 | CTG | 0.09 ± 0.07 (2) |
| 41/27 | ASN | AAT | HIS | 19 | CAC | 0.49 ± 0.26 (4) |
| 41/27 | ASN | AAT | MET | 19 | ATG | 0.30 ± 0.38 (4) |
| 41/27 | ASN | AAT | PRO | 19 | CCG | 0.12 (1) |
| 42/28 | GLY | GGG | ASP | 19 | GAC | 5.7 ± 5.7 (6) |
| 42/28 | GLY | GGG | SER | 19 | AGC | 4.3 ± 4.8 (7) |
| 42/28 | GLY | GGG | CYS | 19 | TGC | 0.53 (1) |
| 42/28 | GLY | GGG | ALA | 19 | GCC | 5.9 ± 4.1 (7) |
| 43/29 | GLU | GAA | ASN | 19 | AAC | 0.050 (1) |
| 43/29 | GLU | GAA | TYR | 19 | TAC | 0.010 (1) |
| 43/29 | GLU | GAA | LEU | 19 | CTC | <0.009 (1) |
| 43/29 | GLU | GAA | PHE | 19 | TTC | <0.009 (1) |
| 43/29 | GLU | GAA | ASP | 19 | GAC | 0.044 (1) |
| 43/29 | GLU | GAA | ALA | 19 | GCC | <0.009 (1) |
| 43/29 | GLU | GAA | CYS | 19 | TGC | <0.009 (1) |
| 43/29 | GLU | GAA | SER | 19 | AGC | <0.009 (1) |
| 44/30 | ASP | GAC | SER | 19 | TCA | 0.007 (1) |
| 44/30 | ASP | GAC | LEU | 19 | CTG | <0.007 (1) |
| 44/30 | ASP | GAC | ARG | 19 | AGG | <0.007 (1) |
| 44/30 | ASP | GAC | LYS | 19 | AAG | <0.007 (1) |
| 44/30 | ASP | GAC | THR | 19 | ACG | — |
| 44/30 | ASP | GAC | MET | 19 | ATG | <0.007 (1) |
| 44/30 | ASP | GAC | TRP | 19 | TGG | <0.007 (1) |
| 44/30 | ASP | GAC | PRO | 19 | CCC | <0.007 (1) |
| 45/31 | GLN | CAA | PRO | 19 | CCC | — |
| 45/31 | GLN | CAA | PHE | 19 | TTC | 0.007 (1) |
| 45/31 | GLN | CAA | VAL | 19 | GTC | 6.7 ± 6.1 (5) |
| 45/31 | GLN | CAA | MET | 19 | ATG | 3.4 ± 1.8 (5) |
| 45/31 | GLN | CAA | LEU | 19 | TTG | 1.1 ± 1.3 (2) |
| 45/31 | GLN | CAA | THR | 19 | ACG | 0.96 ± 1.5 (3) |
| 45/31 | GLN | CAA | LYS | 19 | AAG | 1.6 ± 2.2 (5) |
| 45/31 | GLN | CAA | TRP | 19 | TGG | 0.10 (1) |
| 46/32 | ASP | GAC | PHE | 19 | TTC | 1.2 ± 0.5 (3) |
| 46/32 | ASP | GAC | SER | 19 | TCC | 7.9 ± 6.4 (4) |
| 46/32 | ASP | GAC | THR | 19 | ACC | 1.8 ± 0.2 (2) |
| 46/32 | ASP | GAC | CYS | 19 | TGC | 0.80 (1) |
| 46/32 | ASP | GAC | GLY | 19 | GGC | 0.25 (1) |
| 47/33 | ILE | ATT | GLY | 19 | GGC | <0.015 (1) |
| 47/33 | ILE | ATT | VAL | 19 | GTG | 0.38 (1) |
| 47/33 | ILE | ATT | HIS | 19 | CAC | 0.10 (1) |
| 47/33 | ILE | ATT | SER | 19 | TCC | 0.03 (1) |
| 47/33 | ILE | ATT | ARG | 19 | AGG | 0.09 (1) |
| 47/33 | ILE | ATT | PRO | 19 | CCG | <0.015 (1) |
| 48/34 | LEU | CTG | SER | 19 | AGC | <0.009 (1) |
| 48/34 | LEU | CTG | CYS | 19 | TCG | — |
| 48/34 | LEU | CTG | ARG | 19 | CGC | <0.009 (1) |
| 48/34 | LEU | CTG | ILE | 19 | ATC | 0.036 (1) |
| 48/34 | LEU | CTG | HIS | 19 | CAC | <0.009 (1) |
| 48/34 | LEU | CTG | PHE | 19 | TTC | <0.009 (1) |
| 48/34 | LEU | CTG | ASN | 19 | AAC | <0.009 (1) |
| 49/35 | MET | ATG | ARG | 19 | CGC | 0.007 (1) |
| 49/35 | MET | ATG | ALA | 19 | GCC | 0.091 (1) |
| 49/35 | MET | ATG | GLY | 19 | GGC | 0.036 (1) |
| 49/35 | MET | ATG | PRO | 19 | CCC | <0.009 (1) |
| 49/35 | MET | ATG | ASN | 19 | AAC | 0.23 (1) |
| 49/35 | MET | ATG | HIS | 19 | CAC | <0.009 (1) |
| 49/35 | MET | ATG | ASP | 19 | GAC | 0.28 ± 0.48 (3) |
| 50/36 | GLU | GAA | LEU | 19 | CTC | 0.01 (1) |
| 50/36 | GLU | GAA | THR | 19 | ACC | 0.20 (1) |
| 50/36 | GLU | GAA | ASP | 19 | GAC | — |
| 50/36 | GLU | GAA | TYR | 19 | TAC | 0.09 (1) |
| 50/36 | GLU | GAA | GLN | 19 | CTG | 0.02 (1) |
| 51/37 | ASN | AAT | ARG | 19 | CGC | 2.0 ± 0.8 (3) |
| 51/37 | ASN | AAT | MET | 19 | ATG | 0.75 ± 0.50 (2) |
| 51/37 | ASN | AAT | PRO | 19 | CCG | 2.77 ± 1.6 (3) |
| 51/37 | ASN | AAT | SER | 19 | TCC | 0.87 ± 0.44 (3) |
| 51/37 | ASN | AAT | THR | 19 | ACG | 2.3 ± 1.6 (3) |
| 51/37 | ASN | AAT | HIS | 19 | CAC | 1.3 ± 0.9 (5) |
| 52/38 | ASN | AAC | HIS | 19 | CAC | 0.004 (1) |
| 52/39 | ASN | AAC | ARG | 19 | CGC | 0.004 (1) |
| 52/36 | ASN | AAC | LEU | 19 | TGG | 0.003 (1) |
| 52/38 | ASN | AAC | GLY | 19 | GGC | 0.22 (1) |
| 52/38 | ASN | AAC | SER | 19 | AGC | 0.07 (1) |
| 52/38 | ASN | AAC | THR | 19 | ACG | 0.44 ± 0.30 (3) |
| 53/39 | LEU | CTT | THR | 19 | ACC | <0.005 (1) |
| 53/39 | LEU | CTT | ALA | 19 | GCG | — |
| 53/39 | LEU | CTT | GLY | 19 | GGC | <0.005 (1) |
| 53/39 | LEU | CTT | GLU | 19 | GAG | <0.005 (1) |
| 53/39 | LEU | CTT | PRO | 19 | CCG | <0.005 (1) |
| 53/39 | LEU | CTT | LYS | 19 | AAG | <0.005 (1) |
| 53/39 | LEU | CTT | SER | 19 | AGC | 0.008 (1) |
| 53/39 | LEU | CTT | MET | 19 | ATG | 0.31 (1) |
| 54/40 | ARG | CGA | ASP | 19 | GAC | <0.005 (1) |
| 54/40 | ARG | CGA | ILE | 19 | ATC | 0.05 (1) |
| 54/40 | ARG | CGA | SER | 19 | TCC | 0.10 (1) |
| 54/40 | ARG | CGA | VAL | 19 | GTC | <0.005 (1) |
| 54/40 | ARG | CGA | THR | 19 | ACC | 0.015 (1) |
| 54/40 | ARG | CGA | GLN | 19 | CAG | 0.04 (1) |
| 54/40 | ARG | CGA | LEU | 19 | TTG | 0.03 (1) |
| 55/41 | ARG | AGC | THR | 19 | ACC | 0.65 ± 1.1 (4) |
| 55/41 | ARG | AGG | VAL | 19 | GTC | 0.96 ± 0.36 (3) |
| 55/41 | ARG | AGG | SER | 19 | TCG | 0.065 (1) |
| 55/41 | ARG | AGG | LEU | 19 | CTG | 1.1 ± 1.2 (4) |
| 55/41 | ARG | AGC | GLY | 19 | GGC | 1.0 ± 0.6 (4) |
| 56/42 | PRO | CCA | GLY | 19 | GGC | 1.1 ± 0.8 (3) |
| 56/42 | PRO | CCA | CYS | 19 | TGC | 0.21 (1) |
| 56/42 | PRO | CCA | SER | 19 | AGC | 1.4 ± 0.4 (2) |
| 56/42 | PRO | CCA | GLN | 19 | CAG | 1.8 (1) |
| 56/42 | PRO | CCA | LYS | 19 | AAG | 0.60 (1) |
| 57/43 | ASN | AAC | GLY 6 | 19 | GGC | — |
| 58/44 | LEU | CTG | SER | 19 | ACC | <0.041 (1) |
| 58/44 | LEU | CTG | ASP | 19 | GAC | <0.041 (1) |
| 58/44 | LEU | CTG | ARG | 19 | CGG | <0.041 (1) |
| 58/44 | LEU | CTG | GLN | 19 | CAG | <0.041 (1) |
| 58/44 | LEU | CTG | VAL | 19 | GTC | <0.041 (1) |
| 58/44 | LEU | CTG | CYS | 19 | TGC | — |
| 59/45 | GLU | GAG | TYR | 19 | TAC | 0.41 ± 0.37 (5) |
| 59/45 | GLU | GAG | HIS | 19 | CAC | 0.38 ± 0.31 (2) |
| 59/45 | GLU | GAG | LEU | 19 | CTC | 0.46 ± 0.36 (6) |
| 59/45 | GLU | GAG | PRO | 19 | CCC | — |
| 59/45 | GLU | GAG | ARG | 19 | CGC | 0.15 (1) |
| 60/46 | ALA | GCA | SER | 19 | AGC | 0.91 ± 0.55 (4) |
| 60/46 | ALA | GCA | PRO | 19 | CCC | — |
| 60/46 | ALA | GCA | TYR | 19 | TAC | <0.008 (1) |
| 60/46 | ALA | GCA | ASN | 19 | AAC | 0.38 (1) |
| 60/46 | ALA | GCA | THR | 19 | ACG | 0.21 (1) |
| 61/47 | PHE | TTC | ASN | 19 | AAC | — |
| 61/47 | PHE | TTC | GLU | 19 | GAG | <0.010 (1) |
| 61/47 | PHE | TTC | PRO | 19 | CCC | — |
| 61/47 | PHE | TTC | LYS | 19 | AAG | <0.010 (1) |
| 61/47 | PHE | TTC | ARG | 19 | CGC | 0.006 (1) |
| 61/47 | PHE | TTC | SER | 19 | TCG | 0.17 (1) |
| 62/48 | ASN | AAC | HIS | 19 | CAC | — |
| 62/48 | ASN | AAC | VAL | 19 | GTG | 0.37 ± 0.25 (4) |
| 62/48 | ASN | AAC | ARG | 19 | AGG | — |
| 62/48 | ASN | AAC | PRO 7 | 19 | CCG | 1.6 ± 0.4 (3) |
| 62/48 | ASN | AAC | PRO | 19 | CCG | 2.0 ± 0.3 (3) |
| 62/48 | ASN | AAC | THR 8 | 19 | ACG | 2.3 ± 1.1 (3) |
| 62/45 | ASN | AAC | ASP | 19 | GAC | — |
| 62/48 | ASN | AAC | ILE | 19 | ATC | 0.56 ± 0.24 (4) |
| 63/49 | ARG | A(G/A)G | TYR | 19 | TAC | 0.47 (1) |
| 63/49 | ARG | A(G/A)G | TRP | 19 | TGG | 0.09 (1) |
| 63/49 | ARG | A(G/A)G | LYS | 19 | AGG | 0.52 (1) |
| 63/49 | ARG | A(G/A)G | SER 9 | 19 | TCC | 0.13 (1) |
| 63/49 | ARG | A(G/A)G | HIS | 19 | CAC | 0.42 ± 0.25 (7) |
| 63/49 | ARG | A(G/A)G | PRO | 19 | CCG | <0.014 ± 0.013(2) |
| 63/49 | ARG | A(G/A)G | VAL | 19 | GTG | 0.39 ± 0.34 (3) |
| 64/50 | ALA | GCT | ASN | 19 | AAC | 1.5 ± 2.9 (4) |
| 64/50 | ALA | GCT | PRO | 19 | CCG | <0.023 (1) |
| 64/50 | ALA | GCT | SER | 19 | AGC | <0.023 (1) |
| 64/50 | ALA | GCT | LYS | 19 | AAG | <0.047 (1) |
| 65/51 | VAL | GTC | THR | 19 | ACC | 0.71 ± 0.64 (3) |
| 65/51 | VAL | GTC | PRO | 19 | CCG | <0.014 (1) |
| 65/51 | VAL | GTC | HIS | 19 | CAC | <0.014 (1) |
| 65/51 | VAL | GTC | LEU | 19 | CTC | 0.42 (1) |
| 65/51 | VAL | GTC | PHE | 19 | TTC | 0.061 (1) |
| 65/51 | VAL | GTC | SER | 19 | TCC | 0.34 (1) |
| 66/52 | LYS | AAG | ILE 10 | 19 | ATC | 0.42 (1) |
| 66/52 | LYS | AAG | ARG | 19 | AGG | 0.79 ± 0.18 (2) |
| 66/52 | LYS | AAG | VAL | 19 | GTC | 0.38 ± 0.17 (2) |
| 66/52 | LYS | AAG | ASN | 19 | AAC | 0.32 (1) |
| 66/52 | LYS | AAG | GLU | 19 | GAG | 0.14 (1) |
| 66/52 | LYS | AAG | SER | 19 | TCG | 0.31 (1) |
| 66/52 | LYS | AAG | VAL 11 | 19 | GTG | 0.055 (1) |
| 67/53 | SER | AGT | ALA | 19 | GCG | <0.014 (1) |
| 67/53 | SER | AGT | PHE | 19 | TTC | 1.2 ± 0.2 (2) |
| 67/53 | SER | AGT | VAL | 19 | GTG | 0.24 (1) |
| 67/53 | SER | AGT | GLY | 19 | GGG | 0.50 ± 0.29 (4) |
| 67/53 | SER | AGT | ASN | 19 | AAC | 0.52 ± 0.28 (7) |
| 67/53 | SER | AGT | ILE | 19 | ATC | 0.29 (1) |
| 67/53 | SER | AGT | PRO | 19 | CCG | 0.055 (1) |
| 67/53 | SER | AGT | HIS | 19 | CAC | 0.99 ± 0.62 (6) |
| 68/54 | LEU | TTA | VAL | 19 | GTC | 0.14 (1) |
| 68/54 | LEU | TTA | TRP | 19 | TGG | 0.07 (1) |
| 68/54 | LEU | TTA | SER | 19 | AGC | <0.003 (1) |
| 68/54 | LEU | TTA | ILE | 19 | ATC | 0.84 ± 0.47 (3) |
| 68/54 | LEU | TTA | PHE | 19 | TTC | 1.7 ± 0.3 (3) |
| 68/54 | LEU | TTA | THR | 19 | ACG | 0.011 (1) |
| 68/54 | LEU | TTA | HIS | 19 | CAC | 0.82 ± 0.45 (2) |
| 69/55 | GLN | CAG | ALA | 19 | GCG | 1.2 ± 0.8 (3) |
| 69/55 | GLN | CAG | PRO | 19 | CCA | 0.74 0.45 (4) |
| 69/55 | GLN | CAG | THR | 19 | ACG | 0.97 ± 0.46 (4) |
| 69/55 | GLN | CAG | TRP | 19 | TGG | — |
| 69/55 | GLN | CAG | GLU | 19 | GAG | 1.4 ± 0.7 (3) |
| 69/55 | GLN | CAG | ARG | 19 | CGG | 1.4 ± 1.1 (3) |
| 69/55 | GLN | CAG | GLY | 19 | GGG | 0.68 ± 0.02 (2) |
| 69/55 | GLN | CAG | LEU | 19 | CTC | — |
| 70/56 | ASN | AA(C/T) | LEU | 19 | TTG | 0.032 (1) |
| 70/56 | ASN | AA(C/T) | VAL | 19 | GTG | — |
| 70/56 | ASN | AA(C/T) | TRP | 19 | TGG | — |
| 70/56 | ASN | AA(C/T) | PRO 12 | 19 | CCG | 0.43 ± 0.29 (2) |
| 70/56 | ASN | AA(C/T) | ALA 13 | 19 | GCC | 0.03 (1) |
| 71/57 | ALA | GCA | MET | 19 | ATG | 0.23 (1) |
| 71/57 | ALA | GCA | LEU | 19 | CTG | <0.005 (1) |
| 71/57 | ALA | GCA | PRO | 19 | CCC | 0.58 (1) |
| 71/57 | ALA | GCA | ARG | 19 | AGG | 0.66 (1) |
| 71/57 | ALA | GCA | GLU | 19 | GAG | 0.46 ± 0.27 |
| 71/57 | ALA | GCA | THR | 19 | ACC | 0.34 ± 0.41 (3) |
| 71/57 | ALA | GCA | GLN | 19 | GGC | 0.42 ± 0.32 (3) |
| 71/57 | ALA | GCA | TRP | 19 | TGG | — |
| 71/57 | ALA | GCA | ASN | 19 | AAC | 0.09 (1) |
| 72/58 | SER | TCA | GLU | 19 | GAG | 0.62 ± 0.27 (3) |
| 72/56 | SER | TCA | MET | 19 | ATG | 0.45 ± 0.55 (3) |
| 72/58 | SER | TCA | ALA | 19 | GCC | 0.48 ± 0.33 (3) |
| 72/58 | SER | TCA | HIS | 19 | CAC | 0.10 (1) |
| 72/58 | SER | TCA | ASN | 19 | AAC | 0.38 ± 0.44 (3) |
| 72/58 | SER | TCA | ARG | 19 | CGG | 0.81 ± 0.43 (4) |
| 72/58 | SER | TCA | ASP | 19 | GAC | 0.58 ± 0.39 (3) |
| 73/59 | ALA | GCA | GLU | 19 | GAG | 0.49 ± 0.32 (3) |
| 73/59 | ALA | GCA | ASP | 19 | GAC | 0.27 (1) |
| 73/59 | ALA | GCA | LEU | 19 | CTG | 0.55 ± 0.45 (4) |
| 73/59 | ALA | GCA | SER | 19 | AGC | 0.37 ± 0.36 (2) |
| 73/59 | ALA | GCA | GLY | 19 | CGG | 0.38 ± 0.32 (3) |
| 73/59 | ALA | GCA | THR | 19 | ACC | 0.31 (1) |
| 73/59 | ALA | GCA | ARG | 19 | AGG | 0.40 ± 0.18 (3) |
| 74/60 | ILE | AT(T/C) | MET | 19 | ATG | <0.16 (1) |
| 74/60 | ILE | AT(T/C) | THR | 19 | ACG | — |
| 74/60 | ILE | AT(T/C) | PRO | 19 | CCG | — |
| 74/60 | ILE | AT(T/C) | ARG | 19 | AGG | — |
| 74/60 | ILE | AT(T/C) | GLY | 19 | GCG | 0.006 (1) |
| 74/60 | ILE | AT(T/C) | ALA | 19 | GCG | — |
| 75/61 | GLU | GAG | LYS | 19 | AAG | 0.07 ± 0.07 (2) |
| 75/61 | GLU | GAG | GLY | 19 | GGG | 0.27 ± 0.20 (2) |
| 75/61 | GLU | GAG | ASP | 19 | GAC | 0.18 (1) |
| 75/61 | GLU | GAG | PRO | 19 | CCG | — |
| 75/61 | GLU | GAG | TRP | 19 | TGG | — |
| 75/61 | GLU | GAG | ARG | 19 | CGG | — |
| 75/61 | GLU | GAG | SER | 19 | TCG | 0.27 ± 0.22 (3) |
| 75/61 | GLU | GAG | GLN | 19 | CAG | 0.40 ± 0.38 (3) |
| 75/61 | GLU | GAG | LEU | 19 | TTG | — |
| 76/62 | SER | AGC | VAL | 19 | GTG | 1.0 ± 0.2 (2) |
| 76/62 | SER | AGC | ALA | 19 | GCG | 0.94 ± 0.46 (2) |
| 76/62 | SER | AGC | ASN | 19 | AAC | 1.2 (1) |
| 76/62 | SER | AGC | TRP | 19 | TGG | — |
| 76/62 | SER | AGC | GLU | 19 | GAG | 0.90 ± 0.19 (2) |
| 76/62 | SER | AGC | PRO | 19 | CCG | 2.1 ± 0.8 (4) |
| 76/62 | SER | AGC | GLY | 19 | GGC | 1.3 ± 1.0 (4) |
| 76/62 | SER | AGC | ASP | 19 | GAC | 0.29 (1) |
| 77/63 | ILE | ATT | SER | 19 | AGC | 0.48 ± 0.38 (4) |
| 77/63 | ILE | ATT | ARG | 19 | CGC | 0.09 ± 0.04 (2) |
| 77/63 | ILE | ATT | THR | 19 | ACG | <0.008 (1) |
| 77/63 | ILE | ATT | LEU | 19 | TTG | 2.0 ± 0.1 (3) |
| 78/64 | LEU | CTT | ALA | 19 | GCG | — |
| 78/64 | LEU | CTT | SER | 19 | TCC | — |
| 78/64 | LEU | CTT | GLU | 19 | GAG | <0.006 (1) |
| 78/64 | LEU | CTT | PHE | 19 | TTC | — |
| 78/64 | LEU | CTT | GLY | 19 | GGG | — |
| 78/64 | LEU | CTT | ARG | 19 | AGG | — |
| 79/65 | LYS | AA(A/G) | THR | 19 | ACA | 0.77 ± 0.91 (6) |
| 79/65 | LYS | AA(A/G) | GLY | 19 | GGG | 1.1 ± 0.9 (6) |
| 79/65 | LYS | AA(A/G) | ASN | 19 | AAC | 1.0 ± 0.6 (6) |
| 79/65 | LYS | AA(A/G) | MET | 19 | ATG | 1.6 ± 0.7 (6) |
| 79/65 | LYS | AA(A/G) | ARG | 19 | CGC | 1.04 ± 0.7 (7) |
| 79/65 | LYS | AA(A/G) | ILE | 19 | ATC | 1.0 ± 0.6 (6) |
| 79/65 | LYS | AA(A/G) | GLY | 19 | GGG | 1.2 ± 0.4 (6) |
| 79/65 | LYS | AA(A/G) | ASP | 19 | GAC | 0.72 ± 0.38 (7) |
| 80/66 | ASN | AAT | TRP | 19 | TGG | — |
| 80/66 | ASN | AAT | VAL | 19 | GTC | 0.32 (1) |
| 80/66 | ASN | AAT | GLY | 19 | GGC | 1.5 ± 1.4 (4) |
| 80/66 | ASN | AAT | THR | 19 | ACG | 0.13 (1) |
| 80/66 | ASN | AAT | LEU | 19 | CTG | 0.33 ± 0.14 (2) |
| 80/66 | ASN | AAT | GLU | 19 | GAG | 1.1 ± 0.8 (4) |
| 80/66 | ASN | AAT | ARG | 19 | AGG | 1.0 ± 0.8 (4) |
| 81/67 | LEU | CTC | GLN | 19 | CAA | — |
| 81/67 | LEU | CTC | GLY | 19 | GGC | <0.023 (1) |
| 81/67 | LEU | CTC | ALA | 19 | GCG | <0.047 (1) |
| 81/67 | LEU | CTC | TRP | 19 | TGG | <0.005 (1) |
| 81/67 | LEU | CTC | ARG | 19 | CGG | — |
| 81/67 | LEU | CTC | VAL | 19 | GTG | 0.16 ± 0.18 (2) |
| 81/67 | LEU | CTC | LYS | 19 | AAG | — |
| 82/68 | LEU | C(TG/CC) | GLN | 19 | CAG | 1.8 ± 0.3 (3) |
| 82/68 | LEU | C(TG/CC) | LYS | 19 | AAG | 0.05 (1) |
| 82/68 | LEU | C(TG/CC) | TRP | 19 | TGG | 2.7 ± 1.3 (4) |
| 82/68 | LEU | C(TG/CC) | ARG | 19 | AGC | 1.1 ± 0.2 (3) |
| 82/68 | LEU | C(TG/CC) | ASP | 19 | GAC | 2.7 ± 1.3 (4) |
| 82/68 | LEU | C(TG/CC) | VAL | 19 | GTG | 1.5 ± 1.1 (5) |
| 83/69 | PRO | CCA | ALA | 19 | GCA | 0.41 (1) |
| 83/69 | PRO | CCA | THR | 19 | ACC | 0.66 ± 0.12 (3) |
| 83/69 | PRO | CCA | ARG | 19 | CGG | — |
| 83/69 | PRO | CCA | TRP | 19 | TGG | 0.29 (1) |
| 83/69 | PRO | CCA | MET | 19 | ATG | 0.43 ± 0.28 (3) |
| 84/70 | CYS | TG(T/C) | GLU | 19 | GAG | <0.014 (1) |
| 84/70 | CYS | TG(T/C) | GLY | 19 | GGG | <0.006 (1) |
| 84/70 | CYS | TG(T/C) | ARG | 19 | AGG | — |
| 84/70 | CYS | TG(T/C) | MET | 19 | ATG | — |
| 84/70 | CYS | TG(T/C) | VAL | 19 | GTG | — |
| 85/71 | LEU | CTG | ASN | 19 | AAC | — |
| 85/71 | LEU | CTG | VAL | 19 | GTG | 0.52 ± 0.21 (5) |
| 85/71 | LEU | CTG | GLN | 19 | CAG | — |
| 86/72 | PRO | CCC | CYS | 19 | TGC | — |
| 86/72 | PRO | CCC | ARG | 19 | AGG | — |
| 86/72 | PRO | CCC | ALA | 19 | GCG | — |
| 86/72 | PRO | CCC | LYS | 19 | AAG | — |
| 87/73 | LEU | (C/A)TG | SER | 19 | AGC | 1.5 ± 0.4 (3) |
| 87/73 | LEU | (C/A)TG | TRP | 19 | TGG | — |
| 87/73 | LEU | (C/A)TG | GLY | 19 | GGG | — |
| 88/74 | ALA | GCC | LYS | 19 | AAG | — |
| 88/74 | ALA | GCC | ARG | 19 | AGG | 0.11 ± 0.10 (2) |
| 88/74 | ALA | GCC | VAL | 19 | GTG | 0.09 ± 0.02 (2) |
| 88/74 | ALA | GCC | TRP | 19 | TGG | 1.8 ± 0.2 (2) |
| 89/75 | THR | AC(G/A) | ASP | 19 | GAC | 0.24 ± 0.10 (2) |
| 89/75 | THR | AC(G/A) | CYS | 19 | TGC | — |
| 89/75 | THR | AC(G/A) | LEU | 19 | CTC | 0.01 (1) |
| 89/75 | THR | AC(G/A) | VAL | 19 | GTG | 0.08 (1) |
| 69/75 | THR | AC(G/A) | GLU | 19 | GAG | 0.11 (1) |
| 89/75 | THR | AC(G/A) | HIS | 19 | CAC | 0.16 ± 0.06 (2) |
| 89/75 | THR | AC(G/A) | ASN | 19 | AAC | 0.21 ± 0.04 (2) |
| 89/75 | THR | AC(G/A) | SER | 19 | TCG | 0.25 ± 0.07 (2) |
| 90/76 | ALA | GCC | PRO | 19 | CCC | 0.03 (1) |
| 90/76 | ALA | GCC | SER | 19 | TCG | — |
| 90/76 | ALA | GCC | THR | 19 | ACC | 0.48 (1) |
| 90/76 | ALA | GCC | GLY | 19 | GGC | <0.006 (1) |
| 90/76 | ALA | GCC | ASP | 19 | GAC | 0.44 ± 0.29 (4) |
| 90/76 | ALA | GCC | ILE | 19 | ATC | — |
| 90/76 | ALA | GCC | MET | 19 | ATG | 0.25 ± 0.13 (2) |
| 91/77 | ALA | GCA | PRO | 19 | CCC | 1.9 ± 1.2 (3) |
| 91/77 | ALA | GCA | SER | 19 | TCC | 0.12 ± 0.07 (2) |
| 91/77 | ALA | GCA | THR | 19 | ACC | 0.48 ± 0.16 (2) |
| 91/77 | ALA | GCA | PHE | 19 | TTC | 0.44 ± 0.50 (3) |
| 91/77 | ALA | GCA | LEU | 19 | CTC | 0.43 ± 0.27 (S) |
| 91/77 | ALA | GCA | ASP | 19 | GAC | 0.55 ± 0.09 (2) |
| 91/77 | ALA | GCA | HIS | 19 | CAC | — |
| 92/76 | PRO | CCC | PHE | 19 | TTC | — |
| 92/78 | PRO | CCC | ARG | 19 | CGG | — |
| 92/78 | PRO | CCC | SER | 19 | AGC | 0.26 (1) |
| 92/78 | PRO | CCC | LYS | 19 | AAG | — |
| 92/78 | PRO | CCC | HIS | 19 | CAC | — |
| 92/78 | PRO | CCC | LEU | 19 | CTG | — |
| 93/79 | THR | ACG | ASP | 19 | GAC | 1.3 ± 0.7 (4) |
| 93/79 | THR | ACG | SER | 19 | TCG | 0.70 ± 0.56 (4) |
| 93/79 | THR | ACG | ASN | 19 | AAC | — |
| 93/79 | THR | ACG | PRO | 19 | CCC | 0.53 ± 0.36 (4) |
| 93/79 | ThR | ACG | ALA | 19 | GCG | 1.13 ± 0.2 (3) |
| 93/79 | THR | ACG | LEU | 19 | CTG | 0.69 ± 0.42 |
| 93/79 | THR | ACG | ARG | 19 | CGC | 0.93 ± 0.96 (4) |
| 94/80 | ARG | CGA | ILE | 19 | ATC | <0.020 (1) |
| 94/80 | ARG | CGA | SER | 19 | TCC | <0.100 (1) |
| 94/80 | ARG | CGA | GLU | 19 | GAG | <0.020 (1) |
| 94/90 | ARG | CGA | LEU | 19 | CTG | <0.020 (1) |
| 94/50 | ARG | CGA | VAL | 19 | GTG | <0.024 (1) |
| 94/80 | ARG | CGA | PRO | 19 | CCC | <0.024 (1) |
| 95/81 | HIS | CAT | GLN | 19 | CAG | <0.010 (1) |
| 95/81 | HIS | CAT | PRO | 19 | CCG | 1.6 ± 0.8 (3) |
| 95/81 | HIS | CAT | ARG | 19 | CGC | 4.7 ± 5.9 (2) |
| 95/81 | HIS | CAT | VAL | 19 | GTC | 1.2 ± 1.7 (2) |
| 95/81 | HIS | CAT | LEU | 19 | CTC | 0.7 (1) |
| 95/81 | HIS | CAT | GLY | 19 | GGC | 1.7 ± 2.4 (5) |
| 95/81 | HIS | CAT | THR | 19 | ACC | 2.9 ± 4.5 (4) |
| 95/81 | HIS | CAT | TYR | 19 | TAC | 0.07 (1) |
| 96/82 | PRO | CCA | LYS | 19 | AAG | <0.010 ± 0.001 (2) |
| 96/82 | PRO | CCA | TYR | 19 | TAC | 0.69 (1) |
| 96/82 | PRO | CCA | GLY | 19 | GGG | <0.040 (1) |
| 96/82 | PRO | CCA | ILE | 19 | ATC | <0.040 (1) |
| 96/82 | PRO | CCA | THR | 19 | ACC | <0.040 (1) |
| 97/83 | ILE | ATC | VAL | 19 | GTC | 0.91 ± 1.2 (8) |
| 97/83 | ILE | ATC | LYS | 19 | AAG | <0.024 |
| 97/83 | ILE | ATC | ALA | 19 | GCG | 0.15 (1) |
| 97/83 | ILE | ATC | ASN | 19 | AAT | <0.02 (1) |
| 98/84 | HIS | CAT | ILE | 19 | ATC | 5.0 ± 4.9 (12) |
| 98/84 | HIS | CAT | ASN | 19 | AAC | 1.4 ± 0.4 (2) |
| 98/84 | HIS | CAT | LEU | 19 | CTC | 2.4 ± 1.0 (2) |
| 98/84 | HIS | CAT | ASP | 19 | GAC | 0.38 ± 0.49 (5) |
| 98/84 | HIS | CAT | ALA | 19 | GCC | 2.0 ± 1.0 (3) |
| 98/84 | HIS | CAT | THR | 19 | ACG | 1.6 ± 0.3 (2) |
| 98/84 | HIS | CAT | LEU | 19 | TTG | 1.5 (1) |
| 98/84 | HIS | CAT | PRO | 19 | CCG | 0.55 (1) |
| 99/85 | ILE | ATC | LEU | 19 | CTG | 1.4 ± 1.4 (7) |
| 99/85 | ILE | ATC | ARG | 19 | CGC | <0.025 (1) |
| 99/85 | ILE | ATC | ASP | 19 | GAC | <0.025 (1) |
| 99/65 | ILE | ATC | VAL | 19 | GTC | 0.51 ± 0.59 (3) |
| 99/55 | ILE | ATC | PRO | 19 | CCG | <0.025 (1) |
| 99/85 | ILE | ATC | GLN | 19 | CAG | <0.018 ± 0.010 (2) |
| 99/85 | ILE | ATC | GLY | 19 | GGG | <0.018 ± 0.10 (2) |
| 99/85 | ILE | ATC | SER | 19 | TCG | <0.025 (1) |
| 99/85 | ILE | ATC | PHE | 19 | TTC | 0.45 (1) |
| 99/85 | ILE | ATC | HIS | 19 | CAC | <0.025 (1) |
| 100/86 | LYS | AAG | TYR | 19 | TAC | 0.03 (1) |
| 100/96 | LYS | AAG | LEU | 19 | TTG | 0.33 ± 0.31 (3) |
| 100/96 | LYS | AAG | HIS | 19 | CAC | 0.36 ± 0.22 (9) |
| 100/86 | LYS | AAG | ARG | 19 | AGC | 4.7 ± 5.9 (4) |
| 100/86 | LYS | AAG | ILE | 19 | ATC | 0.95 (1) |
| 100/86 | LYS | AAG | SER | 19 | AGC | 0.95 (1) |
| 100/86 | LYS | AAG | GLN | 19 | CAG | 0.78 ± 0.80 (7) |
| 100/86 | LYS | AAG | PRO | 19 | CCG | 0.70 (1) |
| 101/87 | ASP | GAC | PRO | 19 | CCC | 2.3 ± 3.1 (4) |
| 101/87 | ASP | GAC | MET | 19 | ATG | 1.8 ± 2.5 (6) |
| 101/87 | ASP | GAC | LYS | 19 | AAG | 1.2 ± 1.7 (3) |
| 101/87 | ASP | GAC | HIS | 19 | CAC | 2.5 (1) |
| 101/87 | ASP | GAC | THR | 19 | ACG | 0.90 ± 0.77 (3) |
| 101/87 | ASP | GAC | TYR | 19 | TAC | 0.59 (1) |
| 101/87 | ASP | GAC | VAL | 19 | GTC | 0.42 (1) |
| 101/87 | ASP | GAC | TYR | 19 | TAC | 1.0 ± 0.02 (2) |
| 101/87 | ASP | GAC | GLN | 19 | CAG | 0.07 (1) |
| 102/88 | GLY | GGT | LEU | 19 | CTC | <0.015 ± 0.007 (2) |
| 102/88 | GLY | GGT | GLU | 19 | GAG | 0.40 ± 0.07 (3) |
| 102/88 | GLY | GGT | LYS | 19 | AGG | 0.16 ± 0.14 (2) |
| 102/88 | GLY | GGT | SER | 19 | TCC | 0.29 (1) |
| 102/88 | GLY | GGT | TYR | 19 | TAC | 0.04 (1) |
| 102/88 | GLY | GGT | PRO | 19 | CCC | <0.011 (1) |
| 103/89 | ASP | GAC | SER | 19 | TCC | 0.02 (1) |
| 104/90 | TRP | TGG | VAL | 19 | GTG | 0.11 ± 0.06 (5) |
| 104/90 | TRP | TGG | CYS | 19 | AGC | 0.07 ± 0.03 (5) |
| 104/90 | TRP | TGG | TYR | 19 | TAC | 0.34 ± 0.42 (5) |
| 104/90 | TRP | TGG | THR | 19 | ACC | 0.04 ± 0.02 (2) |
| 104/90 | TRP | TGG | MET | 19 | ATG | 0.14 (1) |
| 104/90 | TRP | TGG | PRO | 19 | CCC | 0.02 ± 0.02 (2) |
| 104/90 | TRP | TGG | LEU | 19 | TTG | 0.65 ± 1.0 (3) |
| 104/90 | TRP | TGG | GLN | 19 | CAG | 0.008 (1) |
| 104/90 | TRP | TGG | LYS | 19 | AAG | — |
| 104/90 | TRP | TGG | GLY | 19 | GAG | — |
| 104/90 | TRP | TGG | ALA | 19 | GCC | — |
| 104/90 | TRP | TGG | PHE | 19 | TTC | — |
| 104/90 | TRP | TGG | GLY | 19 | GGC | — |
| 105/91 | ASN | AAT | PRO | 19 | CCG | 4.8 ± 8.5 (5) |
| 105/91 | ASN | AAT | ALA | 19 | GCC | 0.65 ± 0.30 (3) |
| 105/91 | ASN | AAT | PHE | 19 | TTC | 0.13 (1) |
| 105/91 | ASN | AAT | SER | 19 | TCC | 1.9 ± 2.7 (5) |
| 105/91 | ASN | AAT | TRP | 19 | TGG | 0.95 (1) |
| 105/91 | ASN | AAT | GLN | 19 | CAA | 0.57 ± 0.52 (3) |
| 105/91 | ASN | AAT | TYR | 19 | TAC | 0.66 ± 0.53 (4) |
| 105/91 | ASN | AAT | LEU | 19 | CTC | 0.87 ± 0.79 (2) |
| 105/91 | ASN | AAT | LYS | 19 | AAG | 0.70 (1) |
| 105/91 | ASN | AAT | ILE | 19 | ATC | 1.0 (1) |
| 105/91 | ASN | AAT | ASP | 19 | GAC | 1.0 ± 0.9 (4) |
| 105/91 | ASN | AAT | HIS | 19 | CAC | 0.71 ± 0.48 (2) |
| 106/92 | GLU | GAA | SER | 19 | TCC | 0.17 ± 0.21 (2) |
| 106/92 | GLU | GAA | ALA | 19 | GCG | 0.235 ± 0.26 (2) |
| 106/92 | GLU | GAA | LYS | 19 | AAG | — |
| 106/92 | GLU | GAA | THR | 19 | ACC | — |
| 106/92 | GLU | GAA | ILE | 19 | ATC | — |
| 106/92 | GLU | GAA | GLY | 19 | GGC | 0.70 ± 0.76 (4) |
| 106/92 | GLU | GAA | PRO | 19 | CCC | — |
| 108/94 | ARG | CGG | LYS | 19 | AAG | 0.11 ± 0.03 (2) |
| 108/94 | ARG | CGG | ASP | 19 | GAC | — |
| 108/94 | ARG | CGG | LEU | 19 | TTG | 0.01 (1) |
| 108/94 | ARG | CGG | THR | 19 | ACG | 0.08 (1) |
| 108/94 | ARG | CGG | ILE | 19 | ATC | <0.01 (1) |
| 108/94 | ARG | CGG | PRO | 19 | CCC | — |
| 109/95 | ARG | AGG | THR | 19 | ACC | 1.1 ± 0.2 (3) |
| 109/95 | ARG | AGG | PRO | 19 | CCC | — |
| 109/95 | ARG | AGG | GLU | 19 | GAG | 1.1 ± 0.1 (3) |
| 109/95 | ARG | AGG | TYR | 19 | TAC | <0.006 (1) |
| 109/95 | ARG | AGG | LEU | 19 | CTC | 1.2 ± 0.9 (4) |
| 109/95 | ARG | AGG | SER | 19 | TCG | 1.7 ± 0.8 (4) |
| 109/95 | ARG | AGG | GLY | 19 | GGG | 0.17 (1) |
| 110/96 | LYS | AAA | ALA | 19 | GCC | <0.08 (1) |
| 110/96 | LYS | AAA | ASN | 19 | AAC | — |
| 110/96 | LYS | AAA | THR | 19 | ACG | — |
| 110/96 | LYS | AAA | LEU | 19 | CTC | — |
| 110/96 | LYS | AAA | ARG | 19 | CGG | — |
| 110/96 | LYS | AAA | GLN | 19 | CAG | — |
| 110/96 | LYS | AAA | TRP | 19 | TGG | — |
| 111/97 | LEU | CTG | ILE | 19 | ATC | — |
| 111/97 | LEU | CTG | ARG | 19 | CGG | — |
| 111/97 | LEU | CTG | ASP | 19 | GAC | — |
| 111/97 | LEU | CTG | MET | 19 | ATG | — |
| 112/98 | THR | ACG | VAL | 19 | GTG | 0.55 ± 0.44 (3) |
| 112/98 | THR | ACG | GLN | 19 | CAG | 1.7 ± 1.0 (3) |
| 112/98 | THR | ACG | TYR | 19 | TAC | <0.018 (1) |
| 112/98 | THR | ACG | GLU | 19 | GAG | 0.12 (1) |
| 112/98 | THR | ACG | HIS | 19 | CAC | 0.25 ± 0.40 (3) |
| 112/99 | THR | ACG | SER | 19 | TCC | 0.17 ± 0.15 (2) |
| 112/98 | THR | ACG | PHE | 19 | TTC | — |
| 113/99 | PHE | TTC | SER | 19 | AGC | — |
| 113/99 | PHE | TTC | CYS | 19 | TGC | — |
| 113/99 | PHE | TTC | HIS | 19 | CAC | <0.009 (1) |
| 113/99 | PHE | TTC | GLY | 19 | GGC | — |
| 113/99 | PHE | TTC | TRP | 19 | TGG | — |
| 113/99 | PHE | TTC | TYR | 19 | TAC | 0.07 (1) |
| 113/99 | PHE | TTC | ASN | 19 | AAC | — |
| 114/100 | TYR | TAT | CYS | 19 | TGC | — |
| 114/100 | TYR | TAT | HIS | 19 | CAC | — |
| 114/100 | TYR | TAT | SER | 19 | AGC | — |
| 114/100 | TYR | TAT | TRP | 19 | TGG | 0.88 (1) |
| 114/100 | TYR | TAT | ARG | 19 | AGG | — |
| 114/100 | TYR | TAT | LEU | 19 | CTC | <0.018 (1) |
| 115/101 | LEU | CTG | ASN | 19 | AAC | <0.004 (1) |
| 115/101 | LEU | CTG | VAL | 19 | GTG | — |
| 115/101 | LEU | CTG | PRO | 19 | CCC | <0.004 (1) |
| 115/101 | LEU | CTG | ARG | 19 | AGG | <0.004 (1) |
| 115/101 | LEU | CTG | ALA | 19 | GCG | 0.50 (1) |
| 115/101 | LEU | CTG | HIS | 19 | CAC | — |
| 115/101 | LEU | CTG | THR | 19 | ACC | — |
| 115/101 | LEU | CTG | TRP | 19 | TGG | — |
| 115/101 | LEU | CTG | MET | 19 | ATG | <0.008 (1) |
| 116/102 | LYS | AAA | LEU 14 | 19 | TTG | — |
| 116/102 | LYS | AAA | PRO 14 | 19 | CCG | <0.004 (1) |
| 116/102 | LYS | AAA | THR 14 | 19 | ACC | 0.50 (1) |
| 116/102 | LYS | AAA | MET 14 | 19 | ATG | 0.13 (1) |
| 116/102 | LYS | AAA | ASP 14 | 19 | GAC | <0.018 (1) |
| 116/102 | LYS | AAA | VAL | 19 | GTG | 2.3 ± 1.2 (5) |
| 116/102 | LYS | AAA | GLU | 19 | GAG | 0.06 (1) |
| 116/102 | LYS | AAA | ARG | 19 | CGC | 0.06 (1) |
| 116/102 | LYS | AAA | TRP | 19 | TGG | 2.3 ± 1.0 (4) |
| 116/102 | LYS | AAA | SER | 19 | TCG | 0.69 ± 0.51 (5) |
| 116/102 | LYS | AAA | LEU | 19 | CTC | 0.14 ± 0.02 (2) |
| 116/102 | LYS | AAA | ILE | 19 | ATC | 1.3 ± 0.3 (3) |
| 116/102 | LYS | AAA | THR | 19 | ACG | 0.84 ± 0.30 (4) |
| 117/103 | THR | ACC | SER | 19 | AGC | 1.1 ± 0.2 (3) |
| 117/103 | THR | ACC | ASN | 19 | AAC | 0.31 ± 0.39 (3) |
| 117/103 | THR | ACC | ILE | 19 | ATC | — |
| 117/103 | THR | ACC | TRP | 19 | TGG | 0.02 (1) |
| 117/103 | THR | ACC | LYS | 19 | AAG | <0.005 (1) |
| 117/103 | THR | ACC | PRO | 19 | CCG | — |
| 118/104 | LEU | CTT | SER | 19 | TCA | — |
| 118/104 | LEU | CTT | PRO | 19 | CCC | — |
| 118/104 | LEU | CTT | ALA | 19 | GCC | — |
| 118/104 | LEU | CTT | GLU | 19 | GAG | — |
| 118/104 | LEU | CTT | CYS | 19 | TGC | — |
| 118/104 | LEU | CTT | ASP | 19 | GAC | — |
| 118/104 | LEU | CTT | TYR | 19 | TAC | — |
| 119/105 | GLU | GAG | SER | 19 | TCC | 0.26 ± 0.19 (2) |
| 119/105 | GLU | GAG | LYS | 19 | AAG | 0.04 (1) |
| 119/105 | GLU | GAG | PRO | 19 | CCG | 0.31 ± 0.27 (3) |
| 119/105 | GLU | GAG | LEU | 19 | CTG | 0.35 ± 0.35 (3) |
| 119/105 | GLU | GAG | THR | 19 | ACC | 0.25 ± 0.27 (3) |
| 119/105 | GLU | GAG | TYR | 19 | TAC | 0.30 ± 0.32 (3) |
| 119/105 | GLU | GAG | ARG | 19 | CGC | 0.06 (1) |
| 120/106 | ASN | AAT | ALA | 19 | GCC | <0.009 (1) |
| 120/106 | ASN | AAT | PRO | 19 | CCC | 1.7 ± 0.7 (3) |
| 120/106 | ASN | AAT | LEU | 19 | TTG | 1.2 ± 0.3 (3) |
| 120/106 | ASN | AAT | HIS | 19 | CAC | 1.0 ± 0.3 (2) |
| 120/106 | ASN | AAT | VAL | 19 | GTG | 1.7 ± 0.3 (3) |
| 120/106 | ASN | AAT | GLN | 19 | CAG | 0.85 ± 0.16 (2) |
| 121/107 | ALA | GCG | SER | 19 | AGC | 1.2 ± 0.2 (3) |
| 121/107 | ALA | GCG | ILE | 19 | ATC | 2.8 ± 2.5 (2) |
| 121/107 | ALA | GCG | ASN | 19 | AAC | 0.91 ± 0.77 (5) |
| 121/107 | ALA | GCG | PRO | 19 | CCG | 1.3 (1) |
| 121/107 | ALA | GCG | LYS | 19 | AAG | 0.26 ± 0.24 (2) |
| 121/107 | ALA | GCG | ASP | 19 | GAC | 1.8* ± 0.9 (3) |
| 121/107 | ALA | GCG | GLY | 19 | GGC | 0.69 (1) |
| 122/108 | GLN | GCG | SER | 19 | AGC | 0.9.6 ± 0.41 (3) |
| 122/108 | GLN | CA(G/A) | MET | 19 | ATG | 1.7 ± 0.5 (3) |
| 122/108 | GLN | CA(G/A) | TRP | 19 | TGG | 1.4 (1) |
| 122/108 | GLN | CA(G/A) | ARG | 19 | AGG | 0.78 (1) |
| 122/108 | GLN | CA(G/A) | PHE | 19 | TTC | 2.3 ± 1.1 (3) |
| 122/108 | GLN | CA(G/A) | PRO | 19 | CCG | 1.0 (1) |
| 122/108 | GLN | CA(G/A) | HIS | 19 | CAC | 1.4 (1) |
| 122/108 | GLN | CA(G/A) | ILE | 19 | ATC | 2.7 ± 0.8 (3) |
| 122/108 | GLN | CA(G/A) | TYR | 19 | TAC | 1.7 ± 0.3 (2) |
| 122/108 | GLN | CA(G/A) | CYS | 19 | TGC | 0.58 (1) |
| 123/109 | ALA | GCT | MET | 19 | ATG | 2.0 ± 0.2 (3) |
| 123/109 | ALA | GCT | GLU | 19 | GAG | 2.1 ± 1.0 (3) |
| 123/109 | ALA | GCT | HIS | 19 | CAC | 0.98 ± 0.72 (3) |
| 123/109 | ALA | GCT | SER | 19 | AGC | 1.4 ± 0.8 (3) |
| 123/109 | ALA | GCT | PRO | 19 | CCC | 0.64 ± 0.16 (2) |
| 123/109 | ALA | GCT | TYR | 19 | TAC | 0.51 ± 0.25 (2) |
| 123/109 | ALA | GCT | LEU | 19 | CTG | 1.2 ± 0.1 (2) |
| 1 The first position number representes the amino acid position in (1-133)hIL-3 and the second number represents the position in (15-125)hIL-3 in which the Asn at position 15 of native hIL-3 is position 1 in (15-125)hIL-3 (See the numbering for Formula XI) |
| mutant | NATIVE | SUBSTITUTION | RELATIVE | ||
| pMON number | (15-125) hiL-3 | amino acid | amino acid | SEQ ID NO: | POTENCY |
| pMON13201 | 45/31M | Gln | Met | 19 | 6.3 |
| pMON13202 | 51/37R | Asn | Arg | 19 | 1.58 |
| pMON13203 | 51/37P | Asn | Pro | 19 | 2.5 |
| pMON13204 | 51/37T | Asn | Thr | 19 | 3.16 |
| pMON13205 | 56/42S | Pro | Ser | 19 | 6.3 |
| pMON13206 | 98/84I | His | Ile | 19 | 6.3 |
| pMON13207 | 45/31V | Gln | Val | 19 | 4 |
| pMON13208 | 42/28D | Gly | Asp | 19 | 6.3 |
| pMON13209 | 42/28S | Gly | Ser | 19 | 12.6 |
| pMON13210 | 42/28A | Gly | Ala | 19 | 2.5 |
| pMON13211 | 46/32S | Asp | Ser | 19 | 16 |
| pMON13212 | 82/68W | Leu | Trp | 19 | 5 |
| pMON13213 | 82/68D | Leu | Asp | 19 | 4 |
| pMON13214 | 100/86R | Lys | Arg | 19 | 4 |
| pMON13215 | 116/102W | Lys | Trp | 19 | 31 |
| pMON13216 | 23/9L | Ile | Leu | 19 | 4 |
| pMON13217 | 32/18R | Leu | Arg | 19 | 7.9 |
| pMON13218 | 32/18N | Leu | Asn | 19 | 2 |
| pMON13219 | 32/18A | Leu | Ala | 19 | 1.58 |
| pMON13220 | 34/20S | Leu | Ser | 19 | 6.3 |
| pMON13221 | 34/20M | Leu | Met | 19 | 6.3 |
| pMON13222 | 50/36D | Glu | Asp | 19 | 7.9 |
| pMON13223 | 62/48I | Asn | Ile | 19 | * |
| pMON13224 | 166/52R | Lys | Arg | 19 | 4 |
| pMON13225 | 176/62P | Ser | Pro | 19 | 1.25 |
| pMON13226 | 77/63L | Ile | Leu | 19 | 1.58 |
| pMON13227 | 22/8G | Glu | Gly | 19 | 0.008 |
| pMON13228 | 115/101M | Leu | Met | 19 | 0.04 |
| pMON13229 | 122/108I | Gln | Ile | 19 | 1 |
| pMON13231 | 51/37H | Asn | His | 19 | 1.25 |
| pMON13232 | 59/45L | Glu | Leu | 19 | 1.99 |
| pMON13233 | 63/49H | Arg | His | 19 | * |
| pMON13234 | 64/50N | Ala | Asn | 19 | 0.03 |
| pMON13235 | 65/51T | Val | Thr | 19 | 1.58 |
| pMON13236 | 76/62V | Ser | Val | 19 | 2.5 |
| pMON13237 | 76/62A | Ser | Ala | 19 | 5 |
| pMON13238 | 91/77P | Ala | Pro | 19 | * |
| pMON13240 | 100/86Q | Lys | Gln | 19 | 2.5 |
| pMON13241 | 101/87M | Asp | Met | 19 | 6.3 |
| pMON13242 | 105/91N | Asn | Asn | 19 | * |
| pMON13243 | 116/102V | Lys | Val | 19 | 79 |
| pMON13244 | 122/108F | Gln | Phe | 19 | 6.3 |
| pMON13245 | 123/109E | Ala | Gln | 19 | 1.58 |
| position/ | |||||
| mutant | NATIVE | SUBSTITUTION | RELATVE | ||
| pMON number | (1-133) hiL-3 | amino acid | amino acid | SEQ ID NO: | POTENCY |
| pMON13246 | 42D | Gly | Asp | 15 | 20 |
| pMON13247 | 42S | Gly | Ser | 15 | * |
| pMON13248 | 42A | Gly | Ala | 15 | 16 |
| pMON13249 | 45V | Gln | Val | 15 | 5 |
| pMON13250 | 45M | Gln | Met | 15 | * |
| pMON13251 | 46S | Asp | Ser | 15 | 5 |
| pMON13252 | 50D | Glu | Asp | 15 | 5 |
| pMON13253 | 981 | His | Ile | 15 | * |
| pMON13264 | 97V | Ile | Val | 15 | 4 |
| pMON13266 | 75K | Glu | Lys | 15 | 0.25 |
| pMON13267 | 89N | Thr | Asn | 15 | 2.5 |
| PARENTAL | BIOL | |||||
| aa position | AA | codon | AA | SEQ ID NO: | codon | ACTIVITY |
| 21/7 | ASP | GAT | ASN | 19 | AAC | 0.01 |
| 21/7 | ASP | GAT | GLN | 19 | CAA | 0.07 |
| 21/7 | ASP | GAT | GLU | 19 | GAA | 0.5 |
| 21/7 | ASP | GAT | SER | 19 | AGC | 0.1 |
| 21/7 | ASP | GAT | THR | 19 | ACC | 0.1 |
| 22/8 | GLU | GAA | ASN | 19 | AAC | * |
| 22/8 | GLU | GAA | ASP | 19 | GAC | * |
| 22/8 | GLU | GAA | GLN | 19 | CAG | <0.01 |
| 22/8 | GLU | GAA | LEU | 19 | CTG | * |
| 22/8 | GLU | GAA | VAL | 19 | GTT | * |
| 34/20 | LEU | TTG | ALA | 19 | GCT | 2.2 |
| 34/20 | LEU | TTG | ARG | 19 | CGT | 2.2 |
| 34/20 | LEU | TTG | GLN | 19 | CAG | 1.1 |
| 34/20 | LEU | TTG | GLU | 19 | GAA | 1.5 |
| 34/20 | LEU | TTG | ILE | 19 | ATC | 1.3 |
| 34/20 | LEU | TTG | PHE | 19 | TTC | 1.8 |
| 34/20 | LEU | TTG | THR | 19 | ACC | 1.1 |
| 42/28 | GLY | GGG | ASN | 19 | AAC | 1.3 (3) 0.28 |
| 42/28 | GLY | GGG | ILE | 19 | ATC | 10 |
| 42/28 | GLY | GGG | LEU | 19 | CTG | 10.1 (3) 7.57 |
| 42/28 | GLY | GGG | MET | 19 | ATG | 2.2 (3) 1.14 |
| 42/28 | GLY | GGG | TYR | 19 | TAC | 11 (2) 8.9 |
| 42/28 | GLY | GGG | VAL | 19 | GTT | 0.33 |
| 43/29 | GLU | GAA | ARG | 19 | CGT | * |
| 43/29 | GLU | GAA | GLN | 19 | CAG | <0.004 |
| 43/29 | GLU | GAA | GLY | 19 | GGT | * |
| 43/29 | GLU | GAA | THR | 19 | ACC | 0.005 |
| 44/30 | ASP | GAC | ALA | 19 | GCT | * |
| 44/30 | ASP | GAC | ASN | 19 | AAC | * |
| 44/30 | ASP | GAC | GLN | 19 | CAG | * |
| 44/30 | ASP | GAC | GLU | 19 | GAA | 0.66 |
| 45/31 | GLN | CAA | ALA | 19 | GCT | 1 |
| 45/31 | GLN | CAA | ASN | 19 | AAC | 15.8 |
| 45/31 | GLN | CAA | GLU | 19 | GAA | 2.3 |
| 45/31 | GLN | CAA | ILE | 19 | ATC | 4.9 |
| 45/31 | GLN | CAA | SER | 19 | TCC | 0.7 |
| 46/32 | ASP | GAC | ALA | 19 | GCT | 6.3 |
| 46/32 | ASP | GAC | ASN | 19 | AAC | 0.66, 1.1 |
| 46/32 | ASP | GAC | GLN | 19 | CAG | 6.3 |
| 46/32 | ASP | GAC | GLU | 19 | GAA | 1.97 (3) 2.14 |
| 46/32 | ASP | GAC | HIS | 19 | CAC | 3.2, 1.4 |
| 46/32 | ASP | GAC | ILE | 19 | ATC | 0.5 |
| 46/32 | ASP | GAC | LYS | 19 | AAA | 0.5 |
| 46/32 | ASP | GAC | TYR | 19 | TAC | 0.66 |
| 46/32 | ASP | GAC | VAL | 19 | GTT | 6.3 |
| 48/34 | LEU | CTG | GLU | 19 | GAA | * |
| 48/34 | LEU | CTG | HIS | 19 | * | |
| 48/34 | LEU | CTG | LYS | 19 | AAA | * |
| 48/34 | LEU | CTG | THR | 19 | ACC | * |
| 48/34 | LEU | CTG | VAL | 19 | CAC | * |
| 50/36 | GLU | GAA | ALA | 19 | GCT | 0.5 |
| 50/36 | GLU | GAA | ASN | 19 | AAC | 1.7 |
| 50/36 | GLU | GAA | HIS | 19 | CAC | * |
| 50/36 | GLU | GAA | LYS | 19 | AAA | * |
| 50/36 | GLU | GAA | SER | 19 | TCC | 1.3 |
| 50/36 | GLU | GAA | VAL | 19 | GTT | * |
| 54/40 | ARG | CGA | ALA | 19 | GCT | 0.9 |
| 54/40 | AFG | CGA | ASN | 19 | AAC | * |
| 54/40 | ARG | CGA | HIS | 19 | CAC | 0.01 |
| 54/40 | ARG | CGA | LYS | 19 | AAA | 0.2 |
| 56/42 | PRO | CAA | ALA | 19 | GCT | 1.8 |
| 56/42 | PRO | CAA | ASN | 19 | 0.6 | |
| 56/42 | PRO | CAA | ARG | 19 | CGT | 1.2 |
| 56/42 | PRO | CAA | GLU | 19 | GAA | 0.9 |
| 56/42 | PRO | CAA | HIS | 19 | CAC | 0.4 |
| 56/42 | PRO | CAA | LEU | 19 | CTG | 1.2 |
| 56/42 | PRO | CAA | PHE | 19 | TTC | |
| 56/42 | PRO | CAA | THR | 19 | ACC | 0.6 |
| 56/42 | PRO | CAA | VAL | 19 | GTT | 1.1 |
| 82/68 | LEU | CTG | ALA | 19 | GCT | 0.5 |
| 82/68 | LEU | CTG | ASN | 19 | AAC | 2.9 |
| 82/68 | LEU | CTG | GLU | 19 | GAA | 4.57 (3) 5.0 |
| 82/68 | LEU | CTG | HIS | 19 | CAC | 2.2 |
| 82/68 | LEU | CTG | ILE | 19 | ATC | 0.8 |
| 82/68 | LEU | CTG | MET | 19 | ATG | 1.1 |
| 82/68 | LEU | CTG | PHE | 19 | TTC | 3.2 |
| 82/68 | LEU | CTG | SER | 19 | TCC | 2.2 |
| 82/68 | LEU | CTG | THR | 19 | ACC | 1.6 |
| 82/68 | LEU | CTG | TYR | 19 | TAC | 2.7 |
| 94/80 | ARG | CGA | GLN | 19 | CAG | 0.03 |
| 94/80 | ARG | CGA | HIS | 19 | CAC | 0.01 |
| 94/80 | ARG | CGA | LYS | 19 | AAA | * |
| 95/81 | HIS | CAT | ASN | 19 | AAC | 2.7 (2) 2.3 |
| 95/81 | HIS | CAT | ILE | 19 | ATC | 0.33 |
| 95/81 | HIS | CAT | LYS | 19 | AAA | 0.9 |
| 95/81 | HIS | CAT | MET | 19 | ATG | 1 |
| 95/81 | HIS | CAT | PHE | 19 | TTC | 0.66 |
| 95/81 | HIS | CAT | SER | 19 | TCC | 4 |
| 95/81 | HIS | CAT | TRP | 19 | TGG | * |
| 98/84 | HIS | CAT | ARG | 19 | CGT | 3.2 |
| 98/84 | HIS | CAT | GLN | 19 | CAA | 2.2 |
| 98/84 | HIS | CAT | GLU | 19 | GAA | 1.55 (2) 0.15 |
| 98/84 | HIS | CAT | LYS | 19 | AAA | 4 |
| 98/84 | HIS | CAT | MET | 19 | ATG | 2.2 |
| 98/84 | HIS | CAT | PHE | 19 | TTC | 1 |
| 98/84 | HIS | CAT | SER | 19 | TCC | 4 |
| 98/84 | HIS | CAT | THR | 19 | 2.2 | |
| 98/84 | HIS | CAT | VAL | 19 | GTA | 2.4 (2) 0.8 |
| 101/87 | ASP | GAC | ASN | 19 | AAC | 7 |
| 101/87 | ASP | GAC | GLU | 19 | GAA | * |
| 101/87 | ASP | GAC | ILE | 19 | ATC | 3.2 |
| 101/87 | ASP | GAC | LEU | 19 | CTG | 3.2 |
| 108/94 | ARG | CGG | ALA | 19 | GCT | 4 |
| 108/94 | ARG | CGG | GLN | 19 | CAG | 0.4 |
| 108/94 | ARG | CGG | HIS | 19 | CAC | * |
| 108/94 | ARG | CGG | SER | 19 | TCC | 3.7 |
| 110/96 | LYS | AAA | GLU | 19 | GAA | * |
| 110/96 | LYS | AAA | HIS | 19 | CAC | * |
| 110/96 | LYS | AAA | ILE | 19 | ATC | * |
| 113/99 | PHE | TTC | ASP | 19 | GAC | * |
| 113/99 | PHE | TTC | ILE | 19 | ATC | * |
| 113/99 | PHE | TTC | LEU | 19 | CTG | * |
| 113/99 | PHE | TTC | LYS | 19 | AAA | * |
| 116/102 | LYS | AAA | ALA | 19 | GCT | 5 |
| 116/102 | LYS | AAA | ARG | 19 | CGT | 0.03 |
| 116/102 | LYS | AAA | ASN | 19 | AAC | 0.22 |
| 116/102 | LYS | AAA | GLN | 19 | CAG | 0.33 |
| 116/102 | LYS | AAA | HIS | 19 | CAC | 3.2 |
| 116/102 | LYS | AAA | MET | 19 | ATG | 0.9 |
| 116/102 | LYS | AAA | PHE | 19 | TTC | 2.5 |
| 116/102 | LYS | AAA | TYR | 19 | TAC | 5.4 (2) 0.3 |
| 549 | ||||||
| 23 base pairs | nucleic acid | single | linear | |||
| DNA (synthetic) | ||||||
| 1 |
| 133 amino acids | amino acid | linear | ||
| peptide | ||||
| Modified-site | /note= “Met- may or may not precede the | amino acid in position 1” | ||
| Modified-site | 17 | /note= “Xaa at position 17 is Ser, | Lys, Gly, Asp, Met, Gln, or Arg” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Asn, | His, Leu, Ile, Phe, Arg, or Gln” | |
| Modified-site | 19 | /note= “Xaa at positiion 19 is Met, | Phe, Ile, Arg, Gly, Ala, or Cys” | |
| Modified-site | 20 | /note= “Xaa at position 20 is Ile, | Cys, Gln, Glu, Arg, Pro, or Ala” | |
| Modified-site | 21 | /note= “Xaa at position 21 is Asp, | Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser, | or Val” |
| Modified-site | 22 | /note= “Xaa at position 22 is Glu, | Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val, | or Gly” |
| Modified-site | 23 | /note= “Xaa at position 23 is Ile, | Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser, or | Arg” |
| Modified-site | 24 | /note= “Xaa at position 24 is Ile, | Gly, Val, Arg, Ser, Phe, or Leu” | |
| Modified-site | 25 | /note= “Xaa at position 25 is Thr, | His, Gly, Gln, Arg, Pro, or Ala” | |
| Modified-site | 26 | /note= “Xaa at position 26 is His, | Thr, Phe, Gly, Arg, Ala, or Trp” | |
| Modified-site | 27 | /note= “Xaa at position 27 is Leu, | Gly, Arg, Thr, Ser, or Ala” | |
| Modified-site | 28 | /note= “Xaa at position 28 is Lys, | Arg, Leu, Gln, Gly, Pro, Val, or Trp” | |
| Modified-site | 29 | /note= “Xaa at position 29 is Gln, | Asn, Leu, Pro, Arg, or Val” | |
| Modified-site | 30 | /note= “Xaa at position 30 is Pro, | His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys” | |
| Modified-site | 31 | /note= “Xaa at position 31 is Pro, | Asp, Gly, Ala, Arg, Leu, or Gln” | |
| Modified-site | 32 | /note= “Xaa at position 32 is Leu, | Val, Arg, Gln, Asn, Gly, Ala, or Glu” | |
| Modified-site | 33 | /note= “Xaa at position 33 is Pro, | Leu, Gln, Ala, Thr, or Glu” | |
| Modified-site | 34 | /note= “Xaa at position 34 is Leu, | Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, | Ile, or Met” |
| Modified-site | 35 | /note= “Xaa at position 35 is Leu, | Ala, Gly, Asn, Pro, Gln, or Val” | |
| Modified-site | 36 | /note= “Xaa at position 36 is Asp, | Leu, or Val” | |
| Modified-site | 37 | /note= “Xaa at position 37 is Phe, | Ser, Pro, Trp, or Ile” | |
| Modified-site | 38 | /note= “Xaa at position 38 is Asn, | or Ala” | |
| Modified-site | 40 | /note= “Xaa at position 40 is Leu, | Trp, or Arg” | |
| Modified-site | 41 | /note= “Xaa at position 41 is Asn, | Cys, Arg, Leu, His, Met, or Pro” | |
| Modified-site | 42 | /note= “Xaa at position 42 is Gly, | Asp, Ser, Cys, Asn, Lys, Thr, Leu, Val, Glu, Phe, Tyr, | Ile, Met, or Ala” |
| Modified-site | 43 | /note= “Xaa at position 43 is Glu, | Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, Gly, | or Ser” |
| Modified-site | 44 | /note= “Xaa at position 44 is Asp, | Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, Ala, | or Pro” |
| Modified-site | 45 | /note= “Xaa at position 45 is Gln, | Pro, Phe, Val, Met, Leu, Thr, Lys, Trp, Asp, Asn, Arg, | Ser, Ala, Ile, Glu, or His” |
| Modified-site | 46 | /note= “Xaa at position 46 is Asp, | Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, Tyr, | Ile, Val, or Gly” |
| Modified-site | 47 | /note= “Xaa at position 47 is Ile, | Gly, Val, Ser, Arg, Pro, or His” | |
| Modified-site | 48 | /note= “Xaa at position 48 is Leu, | Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, Met, | Val, or Asn” |
| Modified-site | 49 | /note= “Xaa at position 49 is Met, | Arg, Ala, Gly, Pro, Asn, His, or Asp” | |
| Modified-site | 50 | /note= “Xaa at position 50 is Glu, | Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, His, | Phe, Met, or Gln” |
| Modified-site | 51 | /note= “Xaa at position 51 is Asn, | Arg, Met, Pro, Ser, Thr, or His” | |
| Modified-site | 52 | /note= “Xaa at position 52 is Asn, | His, Arg, Leu, Gly, Ser, or Thr” | |
| Modified-site | 53 | /note= “Xaa at position 53 is | Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met” | |
| Modified-site | 54 | /note= “Xaa at position 54 is Arg, | Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, Ala, | or Leu” |
| Modified-site | 55 | /note= “Xaa at position 55 is Arg, | Thr, Val, Ser, Leu, or Gly” | |
| Modified-site | 56 | /note= “Xaa at position 56 is Pro, | Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, | Phe, Leu, Val, or Lys” |
| Modified-site | 57 | /note= “Xaa at position 57 is Asn | or Gly” | |
| Modified-site | 58 | /note= “Xaa at position 58 is Leu, | Ser, Asp, Arg, Gln, Val, or Cys” | |
| Modified-site | 59 | /note= “Xaa at position 59 is Glu, | Tyr, His, Leu, Pro, or Arg” | |
| Modified-site | 60 | /note= “Xaa at position 60 is Ala, | Ser, Pro, Tyr, Asn, or Thr” | |
| Modified-site | 61 | /note= “Xaa at position 61 is Phe, | Asn, Glu, Pro, Lys, Arg, or Ser” | |
| Modified-site | 62 | /note= “Xaa at position 62 is Asn, | His, Val, Arg, Pro, Thr, Asp, or Ile” | |
| Modified-site | 63 | /note= “Xaa at position 63 is Arg, | Tyr, Trp, Lys, Ser, His, Pro, or Val” | |
| Modified-site | 64 | /note= “Xaa at position 64 is Ala, | Asn, Pro, Ser, or Lys” | |
| Modified-site | 65 | /note= “Xaa at position 65 is Val, | Thr, Pro, His, Leu, Phe, or Ser” | |
| Modified-site | 66 | /note= “Xaa at position 66 is Lys, | Ile, Arg, Val, Asn, Glu, or Ser” | |
| Modified-site | 67 | /note= “Xaa at position 67 is Ser, | Ala, Phe, Val, Gly, Asn, Ile, Pro, or His” | |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu, | Val, Trp, Ser, Ile, Phe, Thr, or His” | |
| Modified-site | 69 | /note= “Xaa at position 69 is Gln, | Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu” | |
| Modified-site | 70 | /note= “Xaa at position 70 is Asn, | Leu, Val, Trp, Pro, or Ala” | |
| Modified-site | 71 | /note= “Xaa at position 71 is | Ala,Met,Leu,Pro,Arg,Glu,Thr,Gln,Trp,or Asn” | |
| Modified-site | 72 | /note= “Xaa at position 72 is Ser, | Glu, Met, Ala, His, Asn, Arg, or Asp” | |
| Modified-site | 73 | /note= “Xaa at position 73 is Ala, | Glu, Asp, Leu, Ser, Gly, Thr, or Arg” | |
| Modified-site | 74 | /note= “Xaa at position 74 is Ile, | Met, Thr, Pro, Arg, Gly, or Ala” | |
| Modified-site | 75 | /note= “Xaa at position 75 is | Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, | or Leu” |
| Modified-site | 76 | /note= “Xaa at position 76 is Ser, | Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp” | |
| Modified-site | 77 | /note= “Xaa at position 77 is Ile, | Ser, Arg, Thr, or Leu” | |
| Modified-site | 78 | /note= “Xaa at position 78 is Leu, | Ala, Ser, Glu, Phe, Gly, or Arg” | |
| Modified-site | 79 | /note= “Xaa at position 79 is Lys, Thr, | Asn, Met, Arg, Ile, Gly, or Asp” | |
| Modified-site | 80 | /note= “Xaa at position 80 is Asn, | Trp, Val, Gly, Thr, Leu, Glu, or Arg” | |
| Modified-site | 81 | /note= “Xaa at position 81 is Leu, | Gln, Gly, Ala, Trp, Arg, Val, or Lys” | |
| Modified-site | 82 | /note= “Xaa at position 82 is Leu, | Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, | Tyr, Phe, Ile, Met, or Val” |
| Modified-site | 83 | /note= “Xaa at position 83 is Pro, | Ala, Thr, Trp, Arg, or Met” | |
| Modified-site | 84 | /note= “Xaa at position 84 is Cys, | Glu, Gly, Arg, Met, or Val” | |
| Modified-site | 85 | /note= “Xaa at position 85 is Leu, | Asn, Val, or Gln” | |
| Modified-site | 86 | /note= “Xaa at position 86 is Pro, | Cys, Arg, Ala, or Lys” | |
| Modified-site | 87 | /note= “Xaa at position 87 is Leu, | Ser, Trp, or Gly” | |
| Modified-site | 88 | /note= “Xaa at position 88 is Ala, | Lys, Arg, Val, or Trp” | |
| Modified-site | 89 | /note= “Xaa at position 89 is Thr, | Asp, Cys, Leu, Val, Glu, His, Asn, or Ser” | |
| Modified-site | 90 | /note= “Xaa at position 90 is Ala, | Pro, Ser, Thr, Gly, Asp, Ile, or Met” | |
| Modified-site | 91 | /note= “Xaa at position 91 is Ala, | Pro, Ser, Thr, Phe, Leu, Asp, or His” | |
| Modified-site | 92 | /note= “Xaa at position 92 is Pro, | Phe, Arg, Ser, Lys, His, Ala, Gly, Ile, or Leu” | |
| Modified-site | 93 | /note= “Xaa at position 93 is Thr, | Asp, Ser, Asn, Pro, Ala, Leu, or Arg” | |
| Modified-site | 94 | /note= “Xaa at position 94 is Arg, | Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro” | |
| Modified-site | 95 | /note= “Xaa at position 95 is His, | Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, Ala, | Trp, Phe, Ile, or Tyr” |
| Modified-site | 96 | /note= “Xaa at position 96 is Pro, | Lys, Tyr, Gly, Ile, or Thr” | |
| Modified-site | 97 | /note= “Xaa at position 97 is Ile, | Val, Lys, Ala, or Asn” | |
| Modified-site | 98 | /note= “Xaa at position 98 is His, | Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, Phe, Met, | Val, Lys, Arg, Tyr, or Pro” |
| Modified-site | 99 | /note= “Xaa at position 99 is Ile, | Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, Phe, | or His” |
| Modified-site | 100 | /note= “Xaa at position 100 is | Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro” | |
| Modified-site | 101 | /note= “Xaa at position 101 is | Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, Ser, | Ala, Gly, Ile, Leu, or Gln” |
| Modified-site | 102 | /note= “Xaa at position 102 is Gly, | Leu, Glu, Lys, Ser, Tyr, or Pro” | |
| Modified-site | 103 | /note= “Xaa at position 103 is Asp, | or Ser” | |
| Modified-site | 104 | /note= “Xaa at position 104 is | Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, Ala, | Phe, or Gly” |
| Modified-site | 105 | /note= “Xaa at position 105 is | Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, | Asp, or His” |
| Modified-site | 106 | /note= “Xaa at position 106 is Glu, | Ser, Ala, Lys, Thr, Ile, Gly, or Pro” | |
| Modified-site | 108 | /note= “Xaa at position 108 is Arg, | Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro” | |
| Modified-site | 109 | /note= “Xaa at position 109 is Arg, | Thr, Pro, Glu, Tyr, Leu, Ser, or Gly” | |
| Modified-site | 110 | /note= “Xaa at position 110 is Lys, | Ala, Asn, Thr, Leu, Arg, Gln, His, Glu, Ser, Ala, | or Trp” |
| Modified-site | 111 | /note= “Xaa at position 111 is Leu, | Ile, Arg, Asp, or Met” | |
| Modified-site | 112 | /note= “Xaa at position 112 is Thr, | Val, Gln, Tyr, Glu, His, Ser, or Phe” | |
| Modified-site | 113 | /note= “Xaa at position 113 is Phe, | Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, Val, | or Asn” |
| Modified-site | 114 | /note= “Xaa at position 114 is Tyr, | Cys, His, Ser, Trp, Arg, or Leu” | |
| Modified-site | 115 | /note= “Xaa at position 115 is | Leu, Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or | Met” |
| Modified-site | 116 | /note= “Xaa at position 116 is Lys, | Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, Ser, | Asn, His, Ala, Tyr, Phe, Gln, or Ile” |
| Modified-site | 117 | /note= “Xaa at position 117 is Thr, | Ser, Asn, Ile, Trp, Lys, or Pro” | |
| Modified-site | 118 | /note= “Xaa at position 118 is Leu, | Ser, Pro, Ala, Glu, Cys, Asp, or Tyr” | |
| Modified-site | 119 | /note= “Xaa at position 119 is Glu, | Ser, Lys, Pro, Leu, Thr, Tyr, or Arg” | |
| Modified-site | 120 | /note= “Xaa at position 120 is Asn, | Ala, Pro, Leu, His, Val, or Gln” | |
| Modified-site | 121 | /note= “Xaa at position 121 is Ala, | Ser, Ile, Asn, Pro, Lys, Asp, or Gly” | |
| Modified-site | 122 | /note= “Xaa at position 122 is | Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, | or Cys” |
| Modified-site | 123 | /note= “Xaa at position 123 is Ala, | Met, Glu, His, Ser, Pro, Tyr, or Leu” | |
| 15 |
| 133 amino acids | amino acid | linear | ||
| peptide | ||||
| Modified-site | /note= “Met- may or may not precede | the amino acid in position 1” | ||
| Modified-site | 17 | /note= “Xaa at position 17 is Ser, | Gly, Asp, Met, or Gln” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Asn, | His, Leu, Ile, Phe, Arg, or Gln” | |
| Modified-site | 19 | /note= “Xaa at position 19 is Met, | Phe, Ile, Arg, or Ala” | |
| Modified-site | 20 | /note= “Xaa at position 20 is Ile | or Pro” | |
| Modified-site | 21 | /note; “Xaa at position 21 is Asp | or Glu” | |
| Modified-site | 23 | /note= “Xaa at position 23 is Ile, | Val, Ala, Leu, or Gly” | |
| Modified-site | 24 | /note= “Xaa at position 24 is Ile, | Val, Phe, or Leu” | |
| Modified-site | 25 | /note= “Xaa at position 25 is Thr, | His, Gly, Gln, Arg, Pro, or Ala” | |
| Modified-site | 26 | /note= “Xaa at position 26 is His, | Phe, Gly, Arg, or Ala” | |
| Modified-site | 28 | /note= “Xaa at position 28 is Lys, | Leu, Gln, Gly, Pro, or Val” | |
| Modified-site | 29 | /note= “Xaa at position 29 is Gln, | Asn, Leu, Arg, or Val” | |
| Modified-site | 30 | /note= “Xaa at position 30 is Pro, | His, Thr, Gly, or Gln” | |
| Modified-site | 31 | /note= “Xaa at position 31 is Pro, | Asp, Gly, Ala, Arg, Leu, or Gln” | |
| Modified-site | 32 | /note= “Xaa at position 32 Leu, | Arg, Gln, Asn, Gly, Ala, or Glu” | |
| Modified-site | 33 | /note= “Xaa at position 33 is Pro, | Leu, Gln, Ala, or Glu” | |
| Modified-site | 34 | /note= “Xaa at position 34 is Leu, | Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, | Thr, or Met” |
| Modified-site | 35 | /note= “Xaa at position 35 is Leu, | Ala, Asn, Pro, Gln, or Val” | |
| Modified-site | 36 | /note= “Xaa at position 36 is Asp | or Leu” | |
| Modified-site | 37 | /note= “Xaa at position 37 is Phe, | Ser, Pro, Trp, or Ile” | |
| Modified-site | 38 | /note= “Xaa at position 38 is Asn | or Ala” | |
| Modified-site | 41 | /note= “Xaa at position 41 is Asn, | Cys, Arg, His, Met, or Pro” | |
| Modified-site | 42 | /note= “Xaa at position 42 is Gly, | Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, Val, | or Arg” |
| Modified-site | 44 | /note=“Xaa at position 44 is Asp or | Glu” | |
| Modified-site | 45 | /note= “Xaa at position 45 is Gln, | Val, Met, Leu, Thr, Lys, Ala, Asn, Glu, Ser, or Trp” | |
| Modified-site | 46 | /note= “Xaa at position 46 is Asp, | Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, Lys, | Tyr, Val, or Gly” |
| Modified-site | 47 | /note= “Xaa at position 47 is Ile, Val, | or His” | |
| Modified-site | 49 | /note= “Xaa at position 49 is Met, | Asn, or Asp” | |
| Modified-site | 50 | /note= “Xaa at position 50 is Glu, | Thr, Ala, Asn, Ser, or Asp” | |
| Modified-site | 51 | /note= “Xaa at position 51 is Asn, | Arg, Met, Pro, Ser, Thr, or His” | |
| Modified-site | 52 | /note= “Xaa at position 52 is Asn | or Gly” | |
| Modified-site | 53 | /note= “Xaa at position 53 is Leu, | Met, or Phe” | |
| Modified-site | 54 | /note= “Xaa at position 54 is Arg | Ala, or Ser” | |
| Modified-site | 55 | /note= “Xaa at position 55 is Arg, | Thr, Val, Leu, or Gly” | |
| Modified-site | 56 | /note= “Xaa at position 56 is Pro, | Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, Thr, | Val, or Lys” |
| Modified-site | 59 | /note= “Xaa at position 59 is Glu, | Tyr, His, Leu, or Arg” | |
| Modified-site | 60 | /note= “Xaa at position 60 is Ala, | Ser, Asn, or Thr” | |
| Modified-site | 61 | /note= “Xaa at position 61 is Phe | or Ser” | |
| Modified-site | 62 | /note= “Xaa at position 62 is Asn, | Val, Pro, Thr, or Ile” | |
| Modified-site | 63 | /note= “Xaa at position 63 is Arg, | Tyr, Lys, Ser, His, or Val” | |
| Modified-site | 64 | /note= “Xaa at position 64 is Ala | or Asn” | |
| Modified-site | 65 | /note= “Xaa at position 65 is Val, | Thr, Leu, or Ser” | |
| Modified-site | 66 | /note= “Xaa at position 66 is Lys, | Ile, Arg, Val, Asn, Glu, or Ser” | |
| Modified-site | 67 | /note= “Xaa at position 67 is Ser, | Phe, Val, Gly, Asn, Ile, or His” | |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu, | Val, Ile, Phe, or His” | |
| Modified-site | 69 | /note= “Xaa at position 69 is Gln, | Ala, Pro, Thr, Glu, Arg, or Gly” | |
| Modified-site | 70 | /note= “Xaa at position 70 is Asn | or Pro” | |
| Modified-site | 71 | /note= “Xaa at position 71 is Ala, | Met, Pro, Arg, Glu, Thr, or Gln” | |
| Modified-site | 72 | /note= “Xaa at position 72 is Ser, | Glu, Met, Ala, His, Asn, Arg, or Asp” | |
| Modified-site | 73 | /note= “Xaa at position 73 is Ala, | Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro” | |
| Modified-site | 74 | /note= “Xaa at position 74 is Ile | or Met” | |
| Modified-site | 75 | /note= “Xaa at position 75 is Glu, | Gly, Asp, Ser, or Gln” | |
| Modified-site | 76 | /note= “Xaa at position 76 is Ser, | Val, Ala, Asn, Glu, Pro, Gly, or Asp” | |
| Modified-site | 77 | /note= “Xaa at position 77 is Ile, | Ser, or Leu” | |
| Modified-site | 79 | /note= “Xaa at position 79 is Lys, | Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp” | |
| Modified-site | 80 | /note= “Xaa at position 80 is Asn, | Val, Gly, Thr, Leu, Glu, or Arg” | |
| Modified-site | 81 | /note= “Xaa at position 81 is Leu | or Val” | |
| Modified-site | 82 | /note= “Xaa at position 82 is Leu, | Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, | Ser, Thr, Tyr, or Val” |
| Modified-site | 83 | /note= “Xaa at position 83 is Pro, | Ala, Thr, Trp, or Met” | |
| Modified-site | 85 | /note= “Xaa at position 85 is Leu | or Val” | |
| Modified-site | 87 | /note= “Xaa at position 87 is Leu | or Ser” | |
| Modified-site | 88 | /note= “Xaa at position 88 is Ala, | Arg, or Trp” | |
| Modified-site | 89 | /note= “Xaa at position 89 is Thr, | Asp, Glu, His, Asn, or Ser” | |
| Modified-site | 90 | /note= “Xaa at position 90 is Ala, | Asp, or Met” | |
| Modified-site | 91 | /note= “Xaa at position 91 is Ala, | Pro, Ser, Thr, Phe, Leu, or Asp” | |
| Modified-site | 92 | /note= “Xaa at position 92 is Pro | or Ser” | |
| Modified-site | 93 | /note= “Xaa at position 93 is Thr, | Asp, Ser, Pro, Ala, Leu, or Arg” | |
| Modified-site | 95 | /note= “Xaa at position 95 is His, | Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser, | or Thr” |
| Modified-site | 96 | /note= “Xaa at position 96 is Pro | or Tyr” | |
| Modified-site | 97 | /note= “Xaa at position 97 is Ile, | Val, or Ala” | |
| Modified-site | 98 | /note= “Xaa at position 98 is His, | Ile, Asn, Leu, Asp, Ala, Thr, Leu, Arg, Gln, Glu, | Lys, Met, Ser, Tyr, Val, or Pro” |
| Modified-site | 99 | /note= “Xaa at position 99 is Ile, | Leu, Val, or Phe” | |
| Modified-site | 100 | /note= “Xaa at position 100 is Lys, | Leu, His, Arg, Ile, Gln, Pro, or Ser” | |
| Modified-site | 101 | /note= “Xaa at position 101 is Asp, | Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu, or Tyr” | |
| Modified-site | 102 | /note= “Xaa at position 102 is Gly, | Glu, Lys, or Ser” | |
| Modified-site | 104 | /note= “Xaa at position 104 is Trp, | Val, Tyr, Met, or Leu” | |
| Modified-site | 105 | /note= “Xaa at position 105 is | Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, | Ile, Asp or His” |
| Modified-site | 106 | /note= “Xaa at position 106 is Glu, | Ser, Ala, or Gly” | |
| Modified-site | 108 | /note= “Xaa at position 108 is Arg, | Ala, Gln, Ser, or Lys” | |
| Modified-site | 109 | /note= “Xaa at position 109 is Arg, | Thr, Glu, Leu, Ser, or Gly” | |
| Modified-site | 112 | /note= “Xaa at position 112 is Thr, | Val, Gln, Glu, His, or Ser” | |
| Modified-site | 114 | /note= “Xaa at position 114 is Tyr | or Trp” | |
| Modified-site | 115 | /note= “Xaa at position 115 is Leu | or Ala” | |
| Modified-site | 116 | /note= “Xaa at position 116 is Lys, | Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, Met, | Phe, Tyr, or Ile” |
| Modified-site | 117 | /note= “Xaa at position 117 is Thr, | Ser, or Asn” | |
| Modified-site | 119 | /note= “Xaa at position 119 is | Glu, Ser, Pro, Leu, Thr, or Tyr” | |
| Modified-site | 120 | /note= “Xaa at position 120 is Asn, | Pro, Leu, His, Val, or Gln” | |
| Modified-site | 121 | /note= “Xaa at position 121 is Ala, | Ser, Ile, Asn, Pro, Lys, Asp, or Gly” | |
| Modified-site | 122 | /note= “Xaa at position 122 is | Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, | or Cys” |
| Modified-site | 123 | /note= “Xaa at position 123 is Ala, | Met, Glu, His, Ser, Pro, Tyr, or Leu” | |
| 16 |
| 133 amino acids | amino acid | linear | ||
| peptide | ||||
| Modified-site | /note= “Met- may or may not precede | the amino acid in position 1” | ||
| Modified-site | 17 | /note= “Xaa at position 17 is Ser, | Gly, Asp, Met, or Gln” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Asn, | His, or Ile” | |
| Modified-site | 19 | /note= “Xaa at position 19 is Met | or Ile” | |
| Modified-site | 21 | /note= “Xaa at position 21 is Asp | or Glu” | |
| Modified-site | 23 | /note= “Xaa at position 23 is Ile, | Ala, Leu, or Gly” | |
| Modified-site | 24 | /note= “Xaa at position 24 is Ile, | Val, or Leu” | |
| Modified-site | 25 | /note= “Xaa at position 25 is Thr, | His, Gln, or Ala” | |
| Modified-site | 26 | /note= “Xaa at position 26 is His | or Ala” | |
| Modified-site | 29 | /note= “Xaa at position 29 is Gln, | Asn, or Val” | |
| Modified-site | 30 | /note= “Xaa at position 30 is Pro, | Gly, or Gln” | |
| Modified-site | 31 | /note= “Xaa at position 31 is Pro, | Asp, Gly, or Gln” | |
| Modified-site | 32 | /note= “Xaa at position 32 is Leu, | Arg, Gln, Asn, Gly, Ala, or Glu” | |
| Modified-site | 33 | /note= “Xaa at position 33 is Pro | or Glu” | |
| Modified-site | 34 | /note= “Xaa at position 34 is Leu, | Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe | Thr, or Met” |
| Modified-site | 35 | /note= “Xaa at position 35 is Leu, | Ala, Asn, Pro, Gln, or Val” | |
| Modified-site | 37 | /note= “Xaa at position 37 is Phe, | Ser, Pro, or Trp” | |
| Modified-site | 38 | /note= “Xaa at position 38 is Asn | or Ala” | |
| Modified-site | 42 | /note= “Xaa at position 42 is Gly, | Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg” | |
| Modified-site | 45 | /note= “Xaa at position 45 is Gln, | Val, Met, Leu, Thr, Ala, Asn, Glu, Ser, or Lys” | |
| Modified-site | 46 | /note= “Xaa at position 46 is Asp, | Phe, Ser, Thr, Ala, Asn, Gln, Glu, His, Ile, Lys, | Tyr, Val, or Cys” |
| Modified-site | 50 | /note= “Xaa at position 50 is Glu, | Ala, Asn, Ser, or Asp” | |
| Modified-site | 51 | /note= “Xaa at position 51 is Asn, | Arg, Met, Pro, Ser, Thr, or His” | |
| Modified-site | 54 | /note= “Xaa at position 54 is Arg | or Ala” | |
| Modified-site | 55 | /note= “Xaa at position 55 is Arg, | Thr, Val, Leu, or Gly” | |
| Modified-site | 56 | /note= “Xaa at position 56 is Pro, | Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val, | or Lys” |
| Modified-site | 60 | /note= “Xaa at position 60 is Ala | or Ser” | |
| Modified-site | 62 | /note= “Xaa at position 62 is Asn, | Pro, Thr, or Ile” | |
| Modified-site | 63 | /note= “Xaa at position 63 is Arg | or Lys” | |
| Modified-site | 64 | /note= “Xaa at position 64 is Ala | or Asn” | |
| Modified-site | 65 | /note= “Xaa at position 65 is Val | or Thr” | |
| Modified-site | 66 | /note= “Xaa at position 66 is Lys | or Arg” | |
| Modified-site | 67 | /note= “Xaa at position 67 is Ser | Phe or His” | |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu, | Ile, Phe, or His” | |
| Modified-site | 69 | /note= “Xaa at position 69 is Gln, | Ala, Pro, Thr, Glu, Arg, or Gly” | |
| Modified-site | 71 | /note= “Xaa at position 71 is Ala, | Pro, or Arg” | |
| Modified-site | 72 | /note= “Xaa at position 72 is Ser, | Glu, Arg, or Asp” | |
| Modified-site | 73 | /note= “Xaa at position 73 is Ala | or Leu” | |
| Modified-site | 76 | /note= “Xaa at position 76 is Ser, | Val, Ala, Asn, Glu, Pro, or Gly” | |
| Modified-site | 77 | /note= “Xaa at position 77 is Ile | or Leu” | |
| Modified-site | 79 | /note= “Xaa at position 79 is | Lys, Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp” | |
| Modified-site | 80 | /note= “Xaa at position 80 is Asn, | Gly, Glu, or Arg” | |
| Modified-site | 82 | /note= “Xaa at position 82 is Leu, | Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, | Phe, Ser, Thr, Tyr, or Val” |
| Modified-site | 83 | /note= “Xaa at position 83 is Pro | or Thr” | |
| Modified-site | 85 | /note= “Xaa at position 85 is Leu | or Val” | |
| Modified-site | 87 | /note= “Xaa at position 87 is Leu | or Ser” | |
| Modified-site | 88 | /note= “Xaa at position 88 is Ala | or Trp” | |
| Modified-site | 91 | /note= “Xaa at position 91 is Ala | or Pro” | |
| Modified-site | 93 | /note= “Xaa at position 93 is Thr, | Asp, Ser, Pro, Ala, Leu, or Arg” | |
| Modified-site | 95 | /note= “Xaa at position 95 is His, | Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser, or Thr” | |
| Modified-site | 96 | /note= “Xaa at position 96 is Pro | or Tyr” | |
| Modified-site | 97 | /note= “Xaa at position 97 is Ile | or Val” | |
| Modified-site | 98 | /note= “Xaa at position 98 is His, | Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln, Leu, Lys, | Met, Ser, Tyr, Val, or Pro” |
| Modified-site | 99 | /note= “Xaa at position 99 is Ile, | Leu, or Val” | |
| Modified-site | 100 | /note= “Xaa at position 100 is Lys, | Arg, Ile, Gln, Pro, or Ser” | |
| Modified-site | 101 | /note= “Xaa at position 101 is Asp, | Pro, Met, Lys, His, Thr, Pro, Asn, Ile, Leu, or Tyr” | |
| Modified-site | 104 | /note= “Xaa at position 104 is Trp | or Leu” | |
| Modified-site | 105 | /note= “Xaa at position 105 is | Asn, Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, | Asp, or His” |
| Modified-site | 106 | /note= “Xaa at position 106 is Glu | or Gly” | |
| Modified-site | 109 | /note= “Xaa at position 109 is Arg, | Thr, Glu, Leu, or Ser” | |
| Modified-site | 112 | /note= “Xaa at position 112 is Thr, | Val, or Gln” | |
| Modified-site | 114 | /note= “Xaa at position 114 is Tyr | or Trp” | |
| Modified-site | 115 | /note= “Xaa at position 115 is Leu | or Ala” | |
| Modified-site | 116 | /note= “Xaa at position 116 is Lys, | Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr, or Ile” | |
| Modified-site | 117 | /note= “Xaa at position 117 is Thr | or Ser” | |
| Modified-site | 120 | /note= “Xaa at position 120 is Asn, | Pro, Leu, His, Val, or Gln” | |
| Modified-site | 121 | /note= “Xaa at position 121 is Ala, | Ser, Ile, Asn, Pro, Asp, or Gly” | |
| Modified-site | 122 | /note= “Xaa at position 122 is | Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, | or Cys” |
| Modified-site | 123 | /note= “Xaa at position 123 is Ala, | Met, Glu, His, Ser, Pro, Tyr, or Leu” | |
| 17 |
| 133 amino acids | amino acid | linear | ||
| peptide | ||||
| Modified-site | /note= “Met- may or may not precede | the amino acid in position 1” | ||
| Modified-site | 17 | /note= “Xaa at position 17 is Ser, | Gly, Asp, or Gln” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Asn, | His, or Ile” | |
| Modified-site | 23 | /note= “Xaa at position 23 is Ile, | Ala, Leu, or Gly” | |
| Modified-site | 25 | /note= “Xaa at position 25 is Thr, | His, or Gln” | |
| Modified-site | 26 | /note= “Xaa at position 26 is His | or Ala” | |
| Modified-site | 29 | /note=“Xaa at position 29 is Gln | or Asn” | |
| Modified-site | 30 | /note= “Xaa at position 30 is Pro | or Gly” | |
| Modified-site | 32 | /note= “Xaa at position 32 is Leu, | Arg, Asn, or Ala” | |
| Modified-site | 34 | /note= “Xaa at position 34 is Leu, | Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr, or Met” | |
| Modified-site | 35 | /note= “Xaa at position 35 is Leu, | Ala, Asn, or Pro” | |
| Modified-site | 38 | /note= “Xaa at position 38 is Asn | or Ala” | |
| Modified-site | 42 | /note= “Xaa at position 42 is Gly, | Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr, or Arg” | |
| Modified-site | 45 | /note= “Xaa at position 45 is Gln, | Val, Met, Leu, Ala, Asn, Glu, or Lys” | |
| Modified-site | 46 | /note= “Xaa at position 46 is Asp, | Phe, Ser, Ala, Gln, Glu, His, Val, or Thr” | |
| Modified-site | 50 | /note= “Xaa at position 50 is Glu, | Asn, Ser, or Asp” | |
| Modified-site | 51 | /note= “Xaa at position 51 is Asn, | Arg, Pro, Thr, or His” | |
| Modified-site | 55 | /note= “Xaa at position 55 is Arg, | Leu, or Gly” | |
| Modified-site | 56 | /note= “Xaa at position 56 is Pro, | Gly, Ser, Ala, Asn, Val, Leu, or Gln” | |
| Modified-site | 62 | /note= “Xaa at position 62 is Asn, | Pro, or Thr” | |
| Modified-site | 64 | /note= “Xaa at position 64 is Ala | or Asn” | |
| Modified-site | 65 | /note= “Xaa at position 65 is Val | or Thr” | |
| Modified-site | 67 | /note= “Xaa at position 67 is Ser | or Phe” | |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu | or Phe” | |
| Modified-site | 69 | /note= “Xaa at position 69 is Gln, | Ala, Glu, or Arg” | |
| Modified-site | 76 | /note= “Xaa at position 76 is Ser, | Val, Asn, Pro, or Gly” | |
| Modified-site | 77 | /note= “Xaa at position 77 is Ile | or Leu” | |
| Modified-site | 79 | /note= “Xaa at position 79 is Lys, | Gly, Asn, Met, Arg, Ile, or Gly” | |
| Modified-site | 80 | /note= “Xaa at position 80 is Asn, | Gly, Glu, or Arg” | |
| Modified-site | 82 | /note= “Xaa at position 82 is Leu, | Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, | Thr, Tyr, or Val” |
| Modified-site | 87 | /note= “Xaa at position 87 is Leu | or Ser” | |
| Modified-site | 88 | /note= “Xaa at position 88 is Ala | or Trp” | |
| Modified-site | 91 | /note= “Xaa at position 91 is Ala | or Pro” | |
| Modified-site | 93 | /note= “Xaa at position 93 is Thr, | Asp, or Ala” | |
| Modified-site | 95 | /note= “Xaa at position 95 is His, | Pro, Arg, Val, Gly, Asn, Ser, or Thr” | |
| Modified-site | 98 | /note= “Xaa at position 98 is His, | Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, Ser, | Tyr, Val, or Leu” |
| Modified-site | 99 | /note= “Xaa at position 99 is Ile | or Leu” | |
| Modified-site | 100 | /note= “Xaa at position 100 is Lys | or Arg” | |
| Modified-site | 101 | /note= “Xaa at position 101 is Asp, | Pro, Met, Lys, Thr, His, Pro, Asn, Ile, Leu, or Tyr” | |
| Modified-site | 105 | /note= “Xaa at position 105 is Asn, | Pro, Ser, Ile, or Asp” | |
| Modified-site | 108 | /note= “Xaa at position 108 is Arg, | Ala, or Ser” | |
| Modified-site | 109 | /note= “Xaa at position 109 is Arg, | Thr, Glu, Leu, or Ser” | |
| Modified-site | 112 | /note= “Xaa at position 112 is Thr | or Gln” | |
| Modified-site | 116 | /note= “Xaa at position 116 is Lys, | Val, Trp, Ala, His, Phe, Tyr, or Ile” | |
| Modified-site | 117 | /note= “Xaa at position 117 is Thr | or Ser” | |
| Modified-site | 120 | /note= “Xaa at position 120 is Asn, | Pro, Leu, His, Val, or Gln” | |
| Modified-site | 121 | /note= “Xaa at position 121 is Ala, | Ser, Ile, Pro, or Asp” | |
| Modified-site | 122 | /note= “Xaa at position 122 is Gln, | Met, Trp, Phe, Pro, His, Ile, or Tyr” | |
| Modified-site | 123 | /note= “Xaa at position 123 is Ala, | Met, Glu, Ser, or Leu” | |
| 18 |
| 111 amino acids | amino acid | linear | ||
| peptide | ||||
| Modified-site | /note= “Met- or Met-Ala- may or may | not precede the amino acid in position 1” | ||
| Modified-site | /note= “Xaa at position 3 is Ser, | Lys, Gly, Asp, Met, Gln, or Arg” | ||
| Modified-site | /note= “Xaa at position 4 is Asn, | His, Leu, Ile, Phe, Arg, or Gln” | ||
| Modified-site | /note= “Xaa at position 5 is Met, | Phe, Ile, Arg, Gly, Ala, or Cys” | ||
| Modified-site | /note= “Xaa at position 6 is Ile, | Cys, Gln, Glu, Arg, Pro, or Ala” | ||
| Modified-site | /note= “Xaa at position 7 is Asp, | Phe, Lys, Arg, Ala, Gly, Glu, Gln, Asn, Thr, Ser, | or Val” | |
| Modified-site | /note= “Xaa at position 8 is Glu, | Trp, Pro, Ser, Ala, His, Asp, Asn, Gln, Leu, Val, | or Gly” | |
| Modified-site | /note= “Xaa at position 9 is | Ile, Val, Ala, Leu, Gly, Trp, Lys, Phe, Leu, Ser | or Arg” | |
| Modified-site | 10 | /note= “Xaa at position 10 is Ile, | Gly, Val, Arg, Ser, Phe, or Leu” | |
| Modified-site | 11 | /note= “Xaa at position 11 is Thr, | His, Gly, Gln, Arg, Pro, or Ala” | |
| Modified-site | 12 | /note= “Xaa at position 12 is His, | Thr, Phe, Gly, Arg, Ala, or Trp” | |
| Modified-site | 13 | /note= “Xaa at position 13 is Leu, | Gly, Arg, Thr, Ser, or Ala” | |
| Modified-site | 14 | /note= “Xaa at position 14 is Lys, | Arg, Leu, Gln, Gly, Pro, Val, or Trp” | |
| Modified-site | 15 | /note= “Xaa at position 15 is Gln, | Asn, Leu, Pro, Arg, or Val” | |
| Modified-site | 16 | /note= “Xaa at position 16 is Pro, | His, Thr, Gly, Asp, Gln, Ser, Leu, or Lys” | |
| Modified-site | 17 | /note= “Xaa at position 17 is Pro, | Asp, Gly, Ala, Arg, Leu, or Gln” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Leu, | Val, Arg, Gln, Asn, Gly, Ala, or Glu” | |
| Modified-site | 19 | /note= “Xaa at position 19 is Pro, | Leu, Gln, Ala, Thr, or Glu” | |
| Modified-site | 20 | /note= “Xaa at position 20 is Leu, | Val, Gly, Ser, Lys, Glu, Gln, Thr, Arg, Ala, Phe, | Ile, or Met” |
| Modified-site | 21 | /note= “Xaa at position 21 is Leu, | Ala, Gly, Asn, Pro, Gln, or Val” | |
| Modified-site | 22 | /note= “Xaa at position 22 is Asp, | Leu, or Val” | |
| Modified-site | 23 | /note= “Xaa at position 23 is Phe, | Ser, Pro, Trp, or Ile” | |
| Modified-site | 24 | /note= “Xaa at position 24 is Asn | or Ala” | |
| Modified-site | 26 | /note= “Xaa at position 26 is Leu, | Trp, or Arg” | |
| Modified-site | 27 | /note= “Xaa at position 27 is Asn, | Cys, Arg, Leu, His, Met, or Pro” | |
| Modified-site | 28 | /note= “Xaa at position 28 is Gly, | Asp, Ser, Cys, Ala, Lys, Asn, Thr, Leu, Val, Glu, | Phe, Tyr, Ile, or Met” |
| Modified-site | 29 | /note= “Xaa at position 29 is Glu, | Asn, Tyr, Leu, Phe, Asp, Ala, Cys, Gln, Arg, Thr, | Gly, or Ser” |
| Modified-site | 30 | /note= “Xaa at position 30 is Asp, | Ser, Leu, Arg, Lys, Thr, Met, Trp, Glu, Asn, Gln, | Ala, or Pro” |
| Modified-site | 31 | /note= “Xaa at position 31 is Gln, | Pro, Phe, Val, Met, Leu, Thr, Lys, Asp, Asn, Arg, | Ser, Ala, Ile, Glu, His, or Trp” |
| Modified-site | 32 | /note= “Xaa at position 32 is Asp, | Phe, Ser, Thr, Cys, Glu, Asn, Gln, Lys, His, Ala, | Tyr, Ile, Val, or Gly” |
| Modified-site | 33 | /note= “Xaa at position 33 is Ile, | Gly, Val, Ser, Arg, Pro, or His” | |
| Modified-site | 34 | /note= “Xaa at position 34 is Leu, | Ser, Cys, Arg, Ile, His, Phe, Glu, Lys, Thr, Ala, | Met, Val, or Asn” |
| Modified-site | 35 | /note= “Xaa at position 35 is Met, | Arg, Ala, Gly, Pro, Asn, His, or Asp” | |
| Modified-site | 36 | /note= “Xaa at position 36 is Glu, | Leu, Thr, Asp, Tyr, Lys, Asn, Ser, Ala, Ile, Val, | His, Phe, Met, or Gln” |
| Modified-site | 37 | /note= “Xaa at position 37 is Asn, | Arg, Met, Pro, Ser, Thr, or His” | |
| Modified-site | 38 | /note= “Xaa at position 38 is Asn, | His, Arg, Leu, Gly, Ser, or Thr” | |
| Modified-site | 39 | /note= “Xaa at position 39 is | Leu, Thr, Ala, Gly, Glu, Pro, Lys, Ser, or Met” | |
| Modified-site | 40 | /note= “Xaa at position 40 is Arg, | Asp, Ile, Ser, Val, Thr, Gln, Asn, Lys, His, | Ala, or Leu” |
| Modified-site | 41 | /note= “Xaa at position 41 is Arg, | Thr, Val, Ser, Leu, or Gly” | |
| Modified-site | 42 | /note= “Xaa at position 42 is Pro, | Gly, Cys, Ser, Gln, Glu, Arg, His, Thr, Ala, Tyr, | Phe, Leu, Val, or Lys” |
| Modified-site | 43 | /note= “Xaa at position 43 is Asn | or Gly” | |
| Modified-site | 44 | /note= “Xaa at position 44 is Leu, | Ser, Asp, Arg, Gln, Val, or Cys” | |
| Modified-site | 45 | /note= “Xaa at position 45 is Glu, | Tyr, His, Leu, Pro, or Arg” | |
| Modified-site | 46 | /note= “Xaa at position 46 is Ala, | Ser, Pro, Tyr, Asn, or Thr” | |
| Modified-site | 47 | /note= “Xaa at position 47 is Phe, | Asn, Glu, Pro, Lys, Arg, or Ser” | |
| Modified-site | 48 | /note= “Xaa at position 48 is Asn, | His, Val, Arg, Pro, Thr, Asp, or Ile” | |
| Modified-site | 49 | /note= “Xaa at position 49 is Arg, | Tyr, Trp, Lys, Ser, His, Pro, or Val” | |
| Modified-site | 50 | /note= “Xaa at position 50 is Ala, | Asn, Pro, Ser, or Lys” | |
| Modified-site | 51 | /note= “Xaa at position 51 is Val, | Thr, Pro, His, Leu, Phe, or Ser” | |
| Modified-site | 52 | /note= “Xaa at position 52 is Lys, | Ile, Arg, Val, Asn, Glu, or Ser” | |
| Modified-site | 53 | /note= “Xaa at position 53 is Ser, | Ala, Phe, Val, Gly, Asn, Ile, Pro, or His” | |
| Modified-site | 54 | /note= “Xaa at position 54 is Leu, | Val, Trp, Ser, Ile, Phe, Thr, or His” | |
| Modified-site | 55 | /note= “Xaa at position 55 is Gln, | Ala, Pro, Thr, Glu, Arg, Trp, Gly, or Leu” | |
| Modified-site | 56 | /note= “Xaa at position 56 is Asn, | Leu, Val, Trp, Pro, or Ala” | |
| Modified-site | 57 | /note= “Xaa at position 57 is Ala, | Met, Leu, Pro, Arg, Glu, Thr, Gln, Trp, or Asn” | |
| Modified-site | 58 | /note= “Xaa at position 58 is Ser, | Glu, Met, Ala, His, Asn, Arg, or Asp” | |
| Modified-site | 59 | /note= “Xaa at position 59 is Ala, | Glu, Asp, Leu, Ser, Gly, Thr, or Arg” | |
| Modified-site | 60 | /note= “Xaa at position 60 is Ile, | Met, Thr, Pro, Arg, Gly, Ala” | |
| Modified-site | 61 | /note= “Xaa at position 61 is | Glu, Lys, Gly, Asp, Pro, Trp, Arg, Ser, Gln, | or Leu” |
| Modified-site | 62 | /note= “Xaa at position 62 is Ser, | Val, Ala, Asn, Trp, Glu, Pro, Gly, or Asp” | |
| Modified-site | 63 | /note= “Xaa at position 63 is Ile, | Ser, Arg, Thr, or Leu” | |
| Modified-site | 64 | /note= “Xaa at position 64 is Leu, | Ala, Ser, Glu, Phe, Gly, or Arg” | |
| Modified-site | 65 | /note= “Xaa at position 65 is Lys, | Thr, Gly, Asn, Met, Arg, Ile, or Asp” | |
| Modified-site | 66 | /note= “Xaa at position 66 is Asn, | Trp, Val, Gly, Thr, Leu, Glu, or Arg” | |
| Modified-site | 67 | /note= “Xaa at position 67 is Leu, | Gln, Gly, Ala, Trp, Arg, Val, or Lys” | |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu, | Gln, Lys, Trp, Arg, Asp, Glu, Asn, His, Thr, Ser, Ala, | Tyr, Phe, Ile, Met, or Val” |
| Modified-site | 69 | /note= “Xaa at position 69 is Pro, | Ala, Thr, Trp, Arg, or Met” | |
| Modified-site | 70 | /note= “Xaa at position 70 is Cys, | Glu, Gly, Arg, Met, or Val” | |
| Modified-site | 71 | /note= “Xaa at position 71 is Leu, | Asn, Val, or Gln” | |
| Modified-site | 72 | /note= “Xaa at position 72 is Pro, | Cys, Arg, Ala, or Lys” | |
| Modified-site | 73 | /note= “Xaa at position 73 is Leu, | Ser, Trp, or Gly” | |
| Modified-site | 74 | /note= “Xaa at position 74 is Ala, | Lys, Arg, Val, or Trp” | |
| Modified-site | 75 | /note= “Xaa at position 75 is Thr, | Asp, Cys, Leu, Val, Glu, His, Asn, or Ser” | |
| Modified-site | 76 | /note= “Xaa at position 76 is Ala, | Pro, Ser, Thr, Gly, Asp, Ile, or Met” | |
| Modified-site | 77 | /note= “Xaa at position 77 is Ala, | Pro, Ser, Thr, Phe, Leu, Asp, or His” | |
| Modified-site | 78 | /note= “Xaa at position 78 is Pro, | Phe, Arg, Ser, Lys, His, Ala, Gly, Ile, or Leu” | |
| Modified-site | 79 | /note= “Xaa at position 79 is Thr, | Asp, Ser, Asn, Pro, Ala, Leu, or Arg” | |
| Modified-site | 80 | /note= “Xaa at position 80 is Arg, | Ile, Ser, Glu, Leu, Val, Gln, Lys, His, Ala, or Pro” | |
| Modified-site | 81 | /note= “Xaa at position 81 is His, | Gln, Pro, Arg, Val, Leu, Gly, Thr, Asn, Lys, Ser, | Ala, Trp, Phe, Ile, or Tyr” |
| Modified-site | 82 | /note= “Xaa at position 82 is Pro, | Lys, Tyr, Gly, Ile, or Thr” | |
| Modified-site | 83 | /note= “Xaa at position 83 is Ile, | Val, Lys, Ala, or Asn” | |
| Modified-site | 84 | /note= “Xaa at position 84 is His, | Ile, Asn, Leu, Asp, Ala, Thr, Glu, Gln, Ser, | Phe, Met, Val, Lys, Arg, Tyr, or Pro” |
| Modified-site | 85 | /note= “Xaa at position 85 is | Ile, Leu, Arg, Asp, Val, Pro, Gln, Gly, Ser, | Phe, or His” |
| Modified-site | 86 | /note= “Xaa at position 86 is | Lys, Tyr, Leu, His, Arg, Ile, Ser, Gln, or Pro” | |
| Modified-site | 87 | /note= “Xaa at position 87 is | Asp, Pro, Met, Lys, His, Thr, Val, Tyr, Glu, Asn, | Ser, Ala, Gly, Ile, Leu, or Gln” |
| Modified-site | 88 | /note= “Xaa at position 88 Gly, | Leu, Glu, Lys, Ser, Tyr, or Pro” | |
| Modified-site | 89 | /note= “Xaa at position 89 is Asp | or Ser” | |
| Modified-site | 90 | /note= “Xaa at position 90 is | Trp, Val, Cys, Tyr, Thr, Met, Pro, Leu, Gln, Lys, | Ala, Phe, or Gly” |
| Modified-site | 91 | /note= “Xaa at position 91 is | Asn, Pro, Ala, Phe, Ser, Trp, Gln, Tyr, Leu, Lys, | Ile, Asp, or His” |
| Modified-site | 92 | /note= “Xaa at position 92 is Glu, | Ser, Ala, Lys, Thr, Ile, Gly, or Pro” | |
| Modified-site | 94 | /note= “Xaa at position 94 is Arg, | Lys, Asp, Leu, Thr, Ile, Gln, His, Ser, Ala, or Pro” | |
| Modified-site | 95 | /note= “Xaa at position 95 is Arg, | Thr, Pro, Glu, Tyr, Leu, Ser, or Gly” | |
| Modified-site | 96 | /note= “Xaa at position 96 is Lys, | Asn, Thr, Leu, Gln, Arg, His, Glu, Ser, Ala, | or Trp” |
| Modified-site | 97 | /note= “Xaa at position 97 is Leu, | Ile, Arg, Asp, or Met” | |
| Modified-site | 98 | /note= “Xaa at position 98 is Thr, | Val, Gln, Tyr, Glu, His, Ser, or Phe” | |
| Modified-site | 99 | /note= “Xaa at position 99 is Phe, | Ser, Cys, His, Gly, Trp, Tyr, Asp, Lys, Leu, Ile, | Val, or Asn” |
| Modified-site | 100 | /note= “Xaa at position 100 is Tyr, | Cys, His, Ser, Trp, Arg, or Leu” | |
| Modified-site | 101 | /note= “Xaa at position 101 is Leu, | Asn, Val, Pro, Arg, Ala, His, Thr, Trp, or Met” | |
| Modified-site | 102 | /note= “Xaa at position 102 is | Lys, Leu, Pro, Thr, Met, Asp, Val, Glu, Arg, Trp, | Ser, Asn, His, Ala, Tyr, Phe, Gln, or Ile” |
| Modified-site | 103 | /note= “Xaa at position 103 is Thr, | Ser, Asn, Ile, Trp, Lys, or Pro” | |
| Modified-site | 104 | /note= “Xaa at position 104 is Leu, | Ser, Pro, Ala, Glu, Cys, Asp, or Tyr” | |
| Modified-site | 105 | /note= “Xaa at position 105 is Glu, | Ser, Lys, Pro, Leu, Thr, Tyr, or Arg” | |
| Modified-site | 106 | /note= “Xaa at position 106 is Asn, | Ala, Pro, Leu, His, Val or Gln” | |
| Modified-site | 107 | /note= “Xaa at position 107 is Ala, | Ser, Ile, Asn, Pro, Lys, Asp, or Gly” | |
| Modified-site | 108 | /note= “Xaa at position 108 is | Gln, Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, | or Cys” |
| Modified-site | 109 | /note= “Xaa at position 109 is Ala, | Met, Glu, His, Ser, Pro, Tyr, or Leu” | |
| 19 |
| 111 amino acids | amino acid | linear | ||
| peptide | ||||
| Modified-site | /note= “Met- or Met-Ala- may or may | not precede the amino acid in position 1” | ||
| Modified-site | /note= “Xaa at position 3 is Ser, | Gly, Asp, Met, or Gln” | ||
| Modified-site | /note= “Xaa at position 4 is Asn, | His, Leu, Ile, Phe, Arg, or Gln” | ||
| Modified-site | /note= “Xaa at position 5 is Met, | Phe, Ile, Arg, or Ala” | ||
| Modified-site | /note= “Xaa at position 6 is Ile or | Pro” | ||
| Modified-site | /note= “Xaa at position 7 is Asp or | Glu” | ||
| Modified-site | /note= “Xaa at position 9 is Ile, | Val, Ala, Leu, or Gly” | ||
| Modified-site | 10 | /note= “Xaa at position 10 is Ile, | Val, Phe, or Leu” | |
| Modified-site | 11 | /note= “Xaa at position 11 is Thr, | His, Gly, Gln, Arg, Pro, or Ala” | |
| Modified-site | 12 | /note= “Xaa at position 12 is His, | Phe, Gly, Arg, or Ala” | |
| Modified-site | 14 | /note= “Xaa at position 14 is Lys, | Leu, Gln, Gly, Pro, or Val” | |
| Modified-site | 15 | /note= “Xaa at position 15 is Gln, | Asn, Leu, Arg, or Val” | |
| Modified-site | 16 | /note= “Xaa at position 16 is Pro, | His, Thr, Gly, or Gln” | |
| Modified-site | 17 | /note= “Xaa at position 17 is Pro, | Asp, Gly, Ala, Arg, Leu, or Gln” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Leu, | Arg, Gln, Asn, Gly, Ala or Glu” | |
| Modified-site | 19 | /note= “Xaa at poisiton 19 is Pro, | Leu, Gln, Ala, or Glu” | |
| Modified-site | 20 | /note= “Xaa at positon 20 is Leu, | Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, | Thr, or Met” |
| Modified-site | 21 | /note= “Xaa at position 21 is Leu, | Ala, Asn, Pro, Gln, or Val” | |
| Modified-site | 22 | /note= “Xaa at position 22 is Asp | or Leu” | |
| Modified-site | 23 | /note= “Xaa at position 23 is Phe, | Ser, Pro, Trp, or Ile” | |
| Modified-site | 24 | /note= “Xaa at position 24 is Asn | or Ala” | |
| Modified-site | 27 | /note= “Xaa at position 27 is Asn, | Cys, Arg, His, Met, or Pro” | |
| Modified-site | 28 | /note= “Xaa at position 28 is Gly, | Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg” | |
| Modified-site | 30 | /note= “Xaa at position 30 is Asp | or Glu” | |
| Modified-site | 31 | /note= “Xaa at position 31 is Gln, | Val, Met, Leu, Thr, Lys, Ala, Asn, Glu, Ser, or Trp” | |
| Modified-site | 32 | /note= “Xaa at position 32 is Asp, | Phe, Ser, Thr, Cys, Ala, Asn, Gln, Glu, His, Ile, | Lys, Tyr, Val, or Gly” |
| Modified-site | 33 | /note= “Xaa at position 33 is Ile, | Val, or His” | |
| Modified-site | 35 | /note= “Xaa at position 35 is Met, | Asn, or Asp” | |
| Modified-site | 36 | /note= “Xaa at position 36 is Glu, | Thr, Ala, Asn, Ser, or Asp” | |
| Modified-site | 37 | /note= “Xaa at position 37 is Asn, | Arg, Met, Pro, Ser, Thr, or His” | |
| Modified-site | 38 | /note= “Xaa at position 38 is Asn | or Gly” | |
| Modified-site | 39 | /note= “Xaa at position 39 is Leu, | Met, or Phe” | |
| Modified-site | 40 | /note= “Xaa at position 40 is Arg, | Ala, or Ser” | |
| Modified-site | 41 | /note= “Xaa at position 41 is Arg, | Thr, Val, Leu, or Gly” | |
| Modified-site | 42 | /note= “Xaa at position 42 is Pro, | Gly, Cys, Ser, Gln, Ala, Arg, Asn, Glu, His, Leu, | Thr, Val, or Lys” |
| Modified-site | 45 | /note= “Xaa at position 45 is Glu, | Tyr, His, Leu, or Arg” | |
| Modified-site | 46 | /note= “Xaa at position 46 is Ala, | Ser, Asn, or Thr” | |
| Modified-site | 47 | /note= “Xaa at position 47 is Phe | or Ser” | |
| Modified-site | 48 | /note= “Xaa at position 48 is Asn, | Val, Pro, Thr, or Ile” | |
| Modified-site | 49 | /note= “Xaa at position 49 is Arg, | Tyr, Lys, Ser, His, or Val” | |
| Modified-site | 50 | /note= “Xaa at position 50 is Ala | or Asn” | |
| Modified-site | 51 | /note= “Xaa at position 51 is Val, | Thr, Leu, or Ser” | |
| Modified-site | 52 | /note= “Xaa at position 52 is Lys, | Ile, Arg, Val, Asn, Glu, or Ser” | |
| Modified-site | 53 | /note= “Xaa at position 53 is Ser, | Phe, Val, Gly, Asn, Ile, or His” | |
| Modified-site | 54 | /note= “Xaa at position 54 is Leu, | Val, Ile, Phe, or His” | |
| Modified-site | 55 | /note= “Xaa at position 55 is Gln, | Ala, Pro, Thr, Glu, Arg, or Gly” | |
| Modified-site | 56 | /note= “Xaa at position 56 is Asn | or Pro” | |
| Modified-site | 57 | /note= “Xaa at position 57 is Ala, | Met, Pro, Arg, Glu, Thr, or Gln” | |
| Modified-site | 58 | /note= “Xaa at position 58 is Ser, | Glu, Met, Ala, His, Asn, Arg, or Asp” | |
| Modified-site | 59 | /note= “Xaa at position 59 is Ala, | Glu, Asp, Leu, Ser, Gly, Thr, Arg, or Pro” | |
| Modified-site | 60 | /note= “Xaa at position 60 is Ile | or Met” | |
| Modified-site | 61 | /note= “Xaa at position 61 is Glu, | Gly, Asp, Ser, or Gln” | |
| Modified-site | 62 | /note= “Xaa at position 62 is Ser, | Val, Ala, Asn, Glu, Pro, Gly, or Asp” | |
| Modified-site | 63 | /note= “Xaa at position 63 is Ile, | Ser, or Leu” | |
| Modified-site | 65 | /note= “Xaa at position 65 is Lys, | Thr, Gly, Asn, Met, Arg, Ile, or Asp” | |
| Modified-site | 66 | /note= “Xaa at position 66 is Asn, | Val, Gly, Thr, Leu, Glu, or Arg” | |
| Modified-site | 67 | /note= “Xaa at position 67 is Leu | or Val” | |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu, | Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Met, Phe, | Ser, Thr, Tyr, or Val” |
| Modified-site | 69 | /note= “Xaa at position 69 is Pro, | Ala, Thr, Trp, or Met” | |
| Modified-site | 71 | /note= “Xaa at position 71 is Leu | or Val” | |
| Modified-site | 73 | /note= “Xaa at position 73 is Leu | or Ser” | |
| Modified-site | 74 | /note= “Xaa at position 74 is Ala, | Arg, or Trp” | |
| Modified-site | 75 | /note= “Xaa at position 75 is Thr, | Asp, Glu, His, Asn, or Ser” | |
| Modified-site | 76 | /note= “Xaa at position 76 is Ala, | Asp, or Met” | |
| Modified-site | 77 | /note= “Xaa at position 77 is Ala, | Pro, Ser, Thr, Phe, Leu, or Asp” | |
| Modified-site | 78 | /note= “Xaa at position 78 is Pro | or Ser” | |
| Modified-site | 79 | /note= “Xaa at position 79 is Thr, | Asp, Ser, Pro, Ala, Leu, or Arg” | |
| Modified-site | 81 | /note= “Xaa at position 81 is His, | Pro, Arg, Val, Leu, Gly, Asn, Ile, Phe, Ser, or Thr” | |
| Modified-site | 82 | /note= “Xaa at position 82 is Pro | or Tyr” | |
| Modified-site | 83 | /note= “Xaa at position 83 is Ile, | Val, or Ala” | |
| Modified-site | 84 | /note= “Xaa at position 84 is His, | Ile, Asn, Leu, Asp, Ala, Thr, Arg, Gln, Glu, Lys, | Met, Ser, Tyr, Val, or Pro” |
| Modified-site | 85 | /note= “Xaa at position 85 is Ile, | Leu, Val, or Phe” | |
| Modified-site | 86 | /note= “Xaa at position 86 is Lys, | Leu, His, Arg, Ile, Gln, Pro, or Ser” | |
| Modified-site | 87 | /note= “Xaa at position 87 is Asp, | Pro, Met, Lys, His, Thr, Val, Asn, Ile, Leu, or Tyr” | |
| Modified-site | 88 | /note= “Xaa at position 88 is Gly, | Glu, Lys, or Ser” | |
| Modified-site | 90 | /note= “Xaa at position 90 is Trp, | Val, Tyr, Met, or Leu” | |
| Modified-site | 91 | /note= | “Xaa at position 91 is Asn, Pro, Ala, Phe, Ser, | Trp, Gln, Tyr, Leu, Lys, Ile, Asp, or His” |
| Modified-site | 92 | /note= “Xaa at position 92 is Glu, | Ser, Ala, or Gly” | |
| Modified-site | 94 | /note= “Xaa at position 94 is Arg, | Ala, Gln, Ser, or Lys” | |
| Modified-site | 95 | /note= “Xaa at position 95 Arg, | Thr, Glu, Leu, Ser, or Gly” | |
| Modified-site | 98 | /note= “Xaa at position 98 is Thr, | Val, Gln, Glu, His, or Ser” | |
| Modified-site | 100 | /note= “Xaa at position 100 is Tyr | or Trp” | |
| Modified-site | 101 | /note= “Xaa at position 101 is Leu | or Ala” | |
| Modified-site | 102 | /note= “Xaa at position 102 is Lys, | Thr, Met, Val, Trp, Ser, Leu, Ala, Asn, Gln, His, | Met, Phe, Tyr, or Ile” |
| Modified-site | 103 | /note= “Xaa at position 103 is Thr, | Ser, or Asn” | |
| Modified-site | 105 | /note= “Xaa at position 105 is Glu, | Ser, Pro, Leu, Thr, or Tyr” | |
| Modified-site | 106 | /note= “Xaa at position 106 is Asn, | Pro, Leu, His, Val, or Gln” | |
| Modified-site | 107 | /note= “Xaa at position 107 is Ala, | Ser, Ile, Asn, Pro, Lys, Asp, or Gly” | |
| Modified-site | 108 | /note= | “Xaa at position 108 is Gln, Ser, Met, Trp, Arg, Phe, | Pro, His, Ile, Tyr, or Cys” |
| Modified-site | 109 | /note= “Xaa at position 109 is Ala, | Met, Glu, His, Ser, Pro, Tyr, or Leu” | |
| 20 |
| 111 amino acids | amino acid | linear | ||
| peptide | ||||
| Modified-site | /note= “Met- or Met-Ala- may or may | not precede the amino acid in position 1” | ||
| Modified-site | /note= “Xaa at position 3 is Ser, | Gly, Asp, Met, or Gln” | ||
| Modified-site | /note= “Xaa at position 4 is Asn, | His, or Ile” | ||
| Modified-site | /note= “Xaa at position 5 is Met | or Ile” | ||
| Modified-site | /note= “Xaa at position 7 is Asp or | Glu” | ||
| Modified-site | /note= “Xaa at position 9 is Ile, | Ala, Leu, or Gly” | ||
| Modified-site | 10 | /note= “Xaa at position 10 is Ile, | Val, or Leu” | |
| Modified-site | 11 | /note= “Xaa at position 11 is Thr, | His, Gln, or Ala” | |
| Modified-site | 12 | /note= “Xaa at position 12 is His | or Ala” | |
| Modified-site | 15 | /note= “Xaa at position 15 is Gln, | Asn, or Val” | |
| Modified-site | 16 | /note= “Xaa at position 16 is Pro, | Gly, or Gln” | |
| Modified-site | 17 | /note= “Xaa at position 17 is Pro, | Asp, Gly, or Gln” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Leu, | Arg, Gln, Asn, Gly, Ala, or Glu” | |
| Modified-site | 19 | /note= “Xaa at position 19 is Pro | or Glu” | |
| Modified-site | 20 | /note= “Xaa at position 20 is Leu, | Val, Gly, Ser, Lys, Ala, Arg, Gln, Glu, Ile, Phe, | Thr, or Met” |
| Modified-site | 21 | /note= “Xaa at position 21 is Leu, | Ala, Asn, Pro, Gln, or Val” | |
| Modified-site | 23 | /note= “Xaa at position 23 is Phe, | Ser, Pro, or Trp” | |
| Modified-site | 24 | /note= “Xaa at position 24 is Asn | or Ala” | |
| Modified-site | 28 | /note= “Xaa at position 28 is Gly, | Asp, Ser, Cys, Ala, Asn, Ile, Leu, Met, Tyr, or Arg” | |
| Modified-site | 30 | /note= “Xaa at position 30 is Asp | or Glu” | |
| Modified-site | 31 | /note= “Xaa at position 31 is Gln, | Val, Met, Leu, Thr, Ala, Asn, Glu, Ser, or Lys” | |
| Modified-site | 32 | /note= “Xaa at position 32 is Asp, | Phe, Ser, Thr, Ala, Asn, Gln, Glu, His, Ile, Lys, | Tyr, Val, or Cys” |
| Modified-site | 36 | /note= “Xaa at position 36 is Glu, | Ala, Asn, Ser, or Asp” | |
| Modified-site | 37 | /note= “Xaa at position 37 is Asn, | Arg, Met, Pro, Ser, Thr, or His” | |
| Modified-site | 40 | /note= “Xaa at position 40 is Arg | or Ala” | |
| Modified-site | 41 | /note= “Xaa at position 41 is Arg, | Thr, Val, Leu, or Gly” | |
| Modified-site | 42 | /note= “Xaa at position 42 is Pro, | Gly, Ser, Gln, Ala, Arg, Asn, Glu, Leu, Thr, Val, | or Lys” |
| Modified-site | 46 | /note= “Xaa at position 46 is Ala | or Ser” | |
| Modified-site | 48 | /note= “Xaa at position 48 is Asn, | Pro, Thr, or Ile” | |
| Modified-site | 49 | /note= “Xaa at position 49 is Arg | or Lys” | |
| Modified-site | 50 | /note= “Xaa at position 50 is Ala | or Asn” | |
| Modified-site | 51 | /note= “Xaa at position 51 is Val | or Thr” | |
| Modified-site | 52 | /note= “Xaa at position 52 is Lys | or Arg” | |
| Modified-site | 53 | /note= “Xaa at position 53 is Ser, | Phe, or His” | |
| Modified-site | 54 | /note= “Xaa at position 54 is Leu, | Ile, Phe, or His” | |
| Modified-site | 55 | /note= “Xaa at position 55 is Gln, | Ala, Pro, Thr, Glu, Arg, or Gly” | |
| Modified-site | 57 | /note= “Xaa at position 57 is Ala, | Pro, or Arg” | |
| Modified-site | 58 | /note= “Xaa at position 58 is Ser, | Glu, Arg, or Asp” | |
| Modified-site | 59 | /note= “Xaa at position 59 is Ala | or Leu” | |
| Modified-site | 62 | /note= “Xaa at position 62 is Ser, | Val, Ala, Asn, Glu, Pro, or Gly” | |
| Modified-site | 63 | /note= “Xaa at position 63 is Ile | or Leu” | |
| Modified-site | 65 | /note= “Xaa at position 65 is Lys, | Thr, Gly, Asn, Met, Arg, Ile, Gly, or Asp” | |
| Modified-site | 66 | /note= “Xaa at position 66 is Asn, | Gly, Glu, or Arg” | |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu, | Gln, Trp, Arg, Asp, Ala, Asn, Glu, His, Ile, Met, | Phe, Ser, Thr, Tyr, or Val” |
| Modified-site | 69 | /note= “Xaa at position 69 is Pro | or Thr” | |
| Modified-site | 71 | /note= “Xaa at position 71 is Leu | or Val” | |
| Modified-site | 73 | /note= “Xaa at position 73 is Leu | or Ser” | |
| Modified-site | 74 | /note= “Xaa at position 74 is Ala | or Trp” | |
| Modified-site | 77 | /note= “Xaa at position 77 is Ala | or Pro” | |
| Modified-site | 79 | /note= “Xaa at position 79 is Thr, | Asp, Ser, Pro, Ala, Leu, or Arg” | |
| Modified-site | 81 | /note= “Xaa at position 81 is His, | Pro, Arg, Val, Leu, Gly, Asn, Phe, Ser, or Thr” | |
| Modified-site | 82 | /note= “Xaa at position 82 is Pro | or Tyr” | |
| Modified-site | 83 | /note= “Xaa at position 83 is Ile | or Val” | |
| Modified-site | 84 | /note= “Xaa at position 84 is His, | Ile, Asn, Leu, Ala, Thr, Leu, Arg, Gln, Leu, Lys, | Met, Ser, Tyr, Val, or Pro” |
| Modified-site | 85 | /note= “Xaa at position 85 is Ile, | Leu, or Val” | |
| Modified-site | 86 | /note= “Xaa at position 86 is Lys, | Arg, Ile, Gln, Pro, or Ser” | |
| Modified-site | 87 | /note= “Xaa at position 87 is Asp, | Pro, Met, Lys, His, Thr, Asn, Ile, Leu, or Tyr” | |
| Modified-site | 90 | /note= “Xaa at position 90 is Trp | or Leu” | |
| Modified-site | 91 | /note=“Xaa at position 91 is Asn, | Pro, Ala, Ser, Trp, Gln, Tyr, Leu, Lys, Ile, Asp, | or His” |
| Modified-site | 92 | /note= “Xaa at position 92 is Glu | or Gly” | |
| Modified-site | 94 | /note= “Xaa at position 94 is Arg, | Ala, or Ser” | |
| Modified-site | 95 | /note= “Xaa at position 95 is Arg, | Thr, Glu, Leu, or Ser” | |
| Modified-site | 98 | /note= “Xaa at position 98 is Thr, | Val, or Gln” | |
| Modified-site | 100 | /note= “Xaa at position 100 is Tyr | or Trp” | |
| Modified-site | 101 | /note= “Xaa at position 101 is Leu | or Ala” | |
| Modified-site | 102 | /note= “Xaa at position 102 is Lys, | Thr, Val, Trp, Ser, Ala, His, Met, Phe, Tyr, or Ile” | |
| Modified-site | 103 | /note= “Xaa at position 103 is Thr | or Ser” | |
| Modified-site | 106 | /note= “Xaa at position 106 is Asn, | Pro, Leu, His, Val, or Gln” | |
| Modified-site | 107 | /note= “Xaa at position 107 is Ala, | Ser, Ile, Asn, Pro, Asp, or Gly” | |
| Modified-site | 108 | /note= “Xaa at position 108 is Gln, | Ser, Met, Trp, Arg, Phe, Pro, His, Ile, Tyr, or Cys” | |
| Modified-site | 109 | /note= “Xaa at position 109 is Ala, | Met, Glu, His, Ser, Pro, Tyr, or Leu” | |
| 21 |
| 111 amino acids | amino acid | linear | ||
| peptide | ||||
| Modified-site | /note= “Met- or Met-Ala- may or may | not precede the amino acid in position 1” | ||
| Modified-site | /note= “Xaa at position 3 is Ser, | Gly, Asp, or Gln” | ||
| Modified-site | /note= “Xaa at position 4 is Asn, | His, or Ile” | ||
| Modified-site | /note= “Xaa at position 9 is Ile, | Ala, Leu, or Gly” | ||
| Modified-site | 11 | /note= “Xaa at position 11 is Thr, | His, or Gln” | |
| Modified-site | 12 | /note= “Xaa at position 12 is His | or Ala” | |
| Modified-site | 15 | /note= “Xaa at position 15 is Gln | or Asn” | |
| Modified-site | 16 | /note= “Xaa at position 16 is Pro | or Gly” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Leu, | Arg, Asn, or Ala” | |
| Modified-site | 20 | /note= “Xaa at position 20 is Leu, | Val, Ser, Ala, Arg, Gln, Glu, Ile, Phe, Thr, or Met” | |
| Modified-site | 21 | /note= “Xaa at position 21 is Leu, | Ala, Asn, or Pro” | |
| Modified-site | 24 | /note= “Xaa at position 24 is Asn | or Ala” | |
| Modified-site | 28 | /note= “Xaa at position 28 is Gly, | Asp, Ser, Ala, Asn, Ile, Leu, Met, Tyr, or Arg” | |
| Modified-site | 31 | /note= “Xaa at position 31 is Gln, | Val, Met, Leu, Ala, Asn, Glu, or Lys” | |
| Modified-site | 32 | /note= “Xaa at position 32 is Asp, | Phe, Ser, Ala, Gln, Glu, His, Val, or Thr” | |
| Modified-site | 36 | /note= “Xaa at position 36 is Glu, | Asn, Ser, or Asp” | |
| Modified-site | 37 | /note= “Xaa at position 37 is Asn, | Arg, Pro, Thr, or His” | |
| Modified-site | 41 | /note= “Xaa at position 41 is Arg, | Leu, or Gly” | |
| Modified-site | 42 | /note= “Xaa at position 42 is Pro, | Gly, Ser, Ala, Asn, Val, Leu, or Gln” | |
| Modified-site | 48 | /note= “Xaa at position 48 is Asn, | Pro, or Thr” | |
| Modified-site | 50 | /note= “Xaa at position 50 is Ala | or Asn” | |
| Modified-site | 51 | /note= “Xaa at position 51 is Val | or Thr” | |
| Modified-site | 53 | /note= “Xaa at position 53 is Ser | or Phe” | |
| Modified-site | 54 | /note= “Xaa at position 54 is Leu | or Phe” | |
| Modified-site | 55 | /note= “Xaa at position 55 is Gln, | Ala, Glu, or Arg” | |
| Modified-site | 62 | /note= “Xaa at position 62 is Ser, | Val, Asn, Pro, or Gly” | |
| Modified-site | 63 | /note= “Xaa at position 63 is Ile | or Leu” | |
| Modified-site | 65 | /note= “Xaa at position 65 is Lys, | Asn, Met, Arg, Ile, or Gly” | |
| Modified-site | 66 | /note= “Xaa at position 66 is Asn, | Gly, Glu, or Arg” | |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu, | Gln, Trp, Arg, Asp, Asn, Glu, His, Met, Phe, Ser, | Thr, Tyr, or Val” |
| Modified-site | 73 | /note= “Xaa at position 73 is Leu | or Ser” | |
| Modified-site | 74 | /note= “Xaa at position 74 is Ala | or Trp” | |
| Modified-site | 77 | /note= “Xaa at position 77 is Ala | or Pro” | |
| Modified-site | 79 | /note= “Xaa at position 79 is Thr, | Asp, or Ala” | |
| Modified-site | 81 | /note= “Xaa at position 81 is His, | Pro, Arg, Val, Gly, Asn, Ser, or Thr” | |
| Modified-site | 84 | /note= “Xaa at position 84 is His, | Ile, Asn, Ala, Thr, Arg, Gln, Glu, Lys, Met, | Ser, Tyr, Val, or Leu” |
| Modified-site | 85 | /note= “Xaa at position 85 is Ile | or Leu” | |
| Modified-site | 86 | /note= “Xaa at position 86 is Lys | or Arg” | |
| Modified-site | 87 | /note= “Xaa at position 87 is Asp, | Pro, Met, Lys, His, Pro, Asn, Ile, Leu, or Tyr” | |
| Modified-site | 91 | /note= “Xaa at position 91 is Asn, | Pro, Ser, Ile, or Asp” | |
| Modified-site | 94 | /note= “Xaa at position 94 is Arg, | Ala, or Ser” | |
| Modified-site | 95 | /note= “Xaa at position 95 is Arg, | Thr, Glu, Leu, or Ser” | |
| Modified-site | 98 | /note= “Xaa at position 98 is Thr | or Gln” | |
| Modified-site | 102 | /note= “Xaa at position 102 is Lys, | Val, Trp, or Ile” | |
| Modified-site | 103 | /note= “Xaa at position 103 is Thr, | Ala, His, Phe, Tyr, or Ser” | |
| Modified-site | 106 | /note= “Xaa at position 106 is Asn, | Pro, Leu, His, Val, or Gln” | |
| Modified-site | 107 | /note= “Xaa at position 107 is Ala, | Ser, Ile, Pro, or Asp” | |
| Modified-site | 108 | /note= “Xaa at position 108 is Gln, | Met, Trp, Phe, Pro, His, Ile, or Tyr” | |
| Modified-site | 109 | /note= “Xaa at position 109 is Ala, | Met, Glu, Ser, or Leu” | |
| 22 |
| 111 amino acids | amino acid | linear |
| peptide | ||
| Modified-site | /note= “Met- or Met-Ala- may or may | not precede the amino acid in position 1” |
| 23 |
| 133 amino acids | amino acid | linear | |
| peptide | |||
| Modified-site | /note= “Met- may or may not precede | the amino acid in position 1” | |
| Modified-site | 18 | /note= “Xaa at position 18 is Asn | or Ile” |
| Modified-site | 25 | /note= “Xaa at position 25 is Thr | or His” |
| Modified-site | 29 | /note= “Xaa at position 29 is Gln, | Arg, or Val” |
| Modified-site | 32 | /note= “Xaa at position 32 is Leu, | Ala, or Asn” |
| Modified-site | 37 | /note= “Xaa at position 37 is Phe, | Pro, or Ser” |
| Modified-site | 42 | /note= “Xaa at position 42 is Glu, | Ala, or Ser” |
| Modified-site | 45 | /note= “Xaa at position 45 is Gln, | Val, or Met” |
| Modified-site | 51 | /note= “Xaa at position 51 is Asn | or Arg” |
| Modified-site | 55 | /note= “Xaa at position 55 is Arg, | Leu, or Thr” |
| Modified-site | 59 | /note= “Xaa at position 59 is Glu | or Leu” |
| Modified-site | 60 | /note= “Xaa at position 60 is Ala | or Ser” |
| Modified-site | 62 | /note= “Xaa at position 62 is Asn | or Val” |
| Modified-site | 67 | /note= “Xaa at position 67 is Ser, | Asn, or His” |
| Modified-site | 69 | /note= “Xaa at position 69 is Gln | or Glu” |
| Modified-site | 73 | /note= “Xaa at position 73 is Ala | or Gly” |
| Modified-site | 76 | /note= “Xaa at position 76 is Ser | or Ala” |
| Modified-site | 79 | /note= “Xaa at position 79 is Lys | or Arg” |
| Modified-site | 82 | /note= “Xaa at position 82 is Leu, | Glu, or Val” |
| Modified-site | 87 | /note= “Xaa at position 87 is Leu | or Ser” |
| Modified-site | 93 | /note= “Xaa at position 93 is Pro | or Ser” |
| Modified-site | 98 | /note= “Xaa at position 98 is His, | Ile, or Thr” |
| Modified-site | 101 | /note= “Xaa at position 101 is Asp | or Ala” |
| Modified-site | 105 | /note= “Xaa at position 105 is Asn | or Glu” |
| Modified-site | 109 | /note= “Xaa at position 109 is Arg | or Glu” |
| Modified-site | 116 | /note= “Xaa at position 116 is Lys | or Val” |
| Modified-site | 120 | /note= “Xaa at position 120 is Asn, | Gln, or His” |
| Modified-site | 123 | /note= “Xaa at position 123 is Ala | or Glu” |
| 129 |
| 111 amino acids | amino acid | linear | |
| peptide | |||
| Modified-site | /note= “Met- or Met-Ala may or may | not precede the amino acid in position 1” | |
| Modified-site | /note= “Xaa at position 4 is Asn or | Ile” | |
| Modified-site | 11 | /note= “Xaa at position 11 is Thr | or His” |
| Modified-site | 15 | /note= “Xaa at position 15 is Gln, | Arg, or Val” |
| Modified-site | 18 | /note= “Xaa at position 18 is Leu, | Ala, or Asn” |
| Modified-site | 23 | /note= “Xaa at position 23 is Phe, | Pro, or Ser” |
| Modified-site | 28 | /note= “Xaa at position 28 is Glu, | Ala, or Ser” |
| Modified-site | 31 | /note= “Xaa at position 31 is Gln, | Val, or Met” |
| Modified-site | 37 | /note= “Xaa at position 37 is Asn | or Arg” |
| Modified-site | 41 | /note= “Xaa at position 41 is Arg, | Leu, or Thr” |
| Modified-site | 45 | /note= “Xaa at position 45 is Glu | or Leu” |
| Modified-site | 46 | /note= “Xaa at position 46 is Ala | or Ser” |
| Modified-site | 48 | /note= “Xaa at position 48 is Asn | or Val” |
| Modified-site | 53 | /note= “Xaa at position 53 is Ser, | Asn, or His” |
| Modified-site | 55 | /note= “Xaa at position 55 is Gln | or Glu” |
| Modified-site | 59 | /note= “Xaa at position 59 is Ala | or Gly” |
| Modified-site | 62 | /note= “Xaa at position 62 is Ser | or Ala” |
| Modified-site | 65 | /note= “Xaa at position 65 is Lys | or Arg” |
| Modified-site | 68 | /note= “Xaa at position 68 is Leu, | Glu, or Val” |
| Modified-site | 73 | /note= “Xaa at position 73 is Leu | or Ser” |
| Modified-site | 79 | /note= “Xaa at position 79 is Pro | or Ser” |
| Modified-site | 84 | /note= “Xaa at position 84 is His, | Ile, or Thr” |
| Modified-site | 87 | /note= “Xaa at position 87 is Asp | or Ala” |
| Modified-site | 91 | /note= “Xaa at position 91 is Asn | or Glu” |
| Modified-site | 95 | /note= “Xaa at position 95 is Arg | or Glu” |
| Modified-site | 102 | /note= “Xaa at position 102 is Lys | or Val” |
| Modified-site | 106 | /note= “Xaa at position 106 is Asn, | Gln, or His” |
| Modified-site | 109 | /note= “Xaa at position 109 is Ala | or Glu” |
| 130 |
Claims as granted
22 claimsLog in to read the claims of this application.
Log in to unlockClassifications
24 codes- A61K45/00
- A61K38/20
- A61K38/00
- A61P43/00
- A61P7/00
- C07K1/00
- C12P21/04
- C07K17/00
- C07K14/00
- C12N15/24
- C12P21/02
- C12N1/19
- C07K14/54
- C12R1/19
- C07H21/04
- C12N1/21
- C12N5/10
- C12N1/15
- C12N15/09
- C12N5/08
- C12N15/61
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this application are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockDocuments
Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.
Log in to unlockChain of title
No assignments have been recorded for this application yet.